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ABSTRACT 
Author: Geetinder Kaur 
Thesis title: Recruitment to randomised controlled trials with children 
Recruitment to randomised controlled trials is known to be difficult. Poor 
recruitment has several adverse consequences. It affects the validity of study 
findings, is a common cause of trial extensions and may result in premature 
termination of trials, which is a huge loss in terms of invested funds, resources 
and lost knowledge. Non-completion or delayed completion of studies maintains 
the uncertainty about the efficacy and safety of interventions, thereby delaying or 
preventing the use of effective interventions and prolonging the use of ineffective 
or potentially harmful treatments. Recruitment of children to randomised 
controlled trials is thought to be more challenging due to the vulnerability of the 
population and the fact that consent is provided by another person usually parents. 
This thesis aims to review the recruitment performance, i.e. comparison of 
achieved to anticipated recruitment, of randomised controlled trials with children 
and identify the factors associated with good or poor recruitment.  
We undertook a pilot systematic review of recruitment and retention in 
randomised controlled trials with children, in published literature, and found that 
few studies report recruitment information but those that do, report very high rates 
of percentage total recruitment achieved (%TR) and consent. It was not possible 
to obtain unbiased estimates of recruitment performance and consent rate due to 
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the likelihood of selective reporting and/or non-publication of trials with 
unsuccessful recruitment.  
We subsequently conducted a review of recruitment of children to randomised 
controlled trials in the National Institute of Health Research (NIHR) Clinical 
Research Network (CRN) portfolio and found that under-recruitment and delayed 
recruitment are common problems in paediatric trials. Having a trial manager or 
coordinator was found to be significantly associated with successful recruitment. 
Other factors such as being an IMP (Investigational Medicinal Product) vs. non-
IMP trial, trial of acute vs. chronic illness, having CTU (Clinical Trials Unit) 
involvement, pilot/feasibility study and additional trial demands had no 
statistically significant association with recruitment success.  
Since recruitment to a clinical trial can be affected by a number of internal and 
external factors, we conducted a survey with the clinical teams of a multi-centre 
randomised controlled trial with children, the MAGNETIC trial, to understand the 
various facilitators and barriers to recruitment. In order to identify the facilitators 
and barriers to recruitment and establish the recruitment experience of clinical 
teams in a systematic manner, we developed an evidence based recruitment 
survey tool. The survey tool is an online questionnaire that presents a 
comprehensive evidence based list of facilitators and barriers and free text space 
for responders to record the strategies applied to overcome these barriers and 
suggestions for change in organisation of trials to boost recruitment.   
The survey of clinical teams recruiting to the MAGNETIC trial found that a 
motivated clinical team with effective communication skills, effective 
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coordination between study team members at site and between sites and CTU, 
trial management support, research experience of PI, presence of a research nurse 
and availability of a designated research team were imperative for trial 
recruitment success. Heavy clinical workload, shift patterns of work, lack of 
trained staff particularly out of hours, GCP training, local clinical arrangements 
and parental anxiety about the safety of experimental treatment were recognised 
as important barriers to recruitment. A trial specific barrier was difficulty faced by 
the clinicians in seeking consent from the parents of an acutely ill child in the 
emergency setting and suggestions were made for consideration of deferred 
consent.  
We concluded that recruitment to randomised controlled trials with children is 
challenging and poor recruitment and recruitment delays are a common problem. 
Reporting of recruitment and consent in paediatric trials is poor and needs 
improvement. Presence of a dedicated trial manager is significantly associated 
with successful recruitment and the various generic and trial specific facilitators 
and barriers to recruitment that have been identified can be used by trialists in 
planning and conducting future clinical trials with children.  
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Chapter 1 
INTRODUCTION 
1.1 BACKGROUND 
High quality clinical research is needed to develop the evidence base required to 
support decision-making by health care professionals, policymakers and patients. 
Randomised controlled trials (RCTs) and systematic reviews of RCTs are the 
‘gold standard’ and provide the highest level of evidence for the evaluation of 
health care technologies. The randomised controlled trial is one of the most 
powerful study designs that allows a reliable estimate of the effect of an 
intervention with minimal effect from other factors that could influence the course 
of the study participants or outcomes (Vader 1998). It has the potential to detect 
moderate benefits that would otherwise be obscured by bias and random effects 
(Yusuf, Collins & Peto 1984) and confirm the value of effective treatments and 
prevent the propagation of worthless treatments (Kerridge, Lowe & Henry 1998). 
However, successful completion of a randomised controlled trial depends on 
recruitment of an adequate number of eligible participants in the stipulated time 
frame and budget.   
1.2 RECRUITMENT TO CLINICAL TRIALS 
Recruitment to a clinical trial involves enrolment of participants who fulfil the 
eligibility criteria in accordance with the study protocol (Gul, Ali 2010).  Poor 
recruitment can have several adverse scientific, economic and ethical 
consequences (Hunninghake, Darby & Probstfield 1987, Watson & Torgerson 
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2006). Recruitment of a sufficient number of participants is crucial to reach the 
target sample size so that the study is adequately powered to test the study 
hypothesis, detect a true treatment effect and avoid a type II error (Drew et al. 
2002, Gul, Ali 2010).  
Poor recruitment is an important shortcoming that prevents a study from reaching 
the target sample size (McDonald et al. 2006, Watson & Torgerson 2006, Relton 
et al. 2010). This limits the statistical power of a study to detect a treatment effect 
(Altman 1991), thereby reducing the chances of obtaining a statistically 
significant result when a true difference exists between treatments and decreasing 
the likelihood of finding evidence of effect for an intervention (Watson & 
Torgerson 2006, Treweek et al. 2010, Sully, Julious & Nicholl 2013).  Slow 
recruitment results in time or cost extensions thereby increasing the direct and 
indirect costs of a trial. Poor recruitment may result in premature termination of 
trials, which is a huge loss in terms of invested funds, resources and lost 
knowledge. Non-completion or delayed completion of studies maintains the 
uncertainty about the effectiveness or safety of treatment interventions thereby 
delaying or preventing the uptake of potentially effective treatments and 
increasing the risk of people being exposed to ineffective or dangerous treatments 
(Watson & Torgerson 2006). Studies that terminate prematurely or fail to reach 
adequate statistical power raise ethical concerns as trialists have exposed the 
participants to an intervention with uncertain benefit and may still be unable to 
determine whether the intervention does more harm than good at trial completion 
(Treweek et al. 2010).  
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Review of existing literature 
Recruiting patients to randomised controlled trials is known to be challenging. A 
review of literature was conducted on Medline and Scopus using the search terms 
‘recruitment’, ‘enrolment’ combined with the AND connector to search terms 
‘clinical trials’, ‘multicentre studies’, ‘randomised controlled trials’ and ‘rct’ to 
look for existing evidence on recruitment to clinical trials.  
Several studies have examined recruitment to clinical trials from a number of 
perspectives. There are reviews of literature exploring issues around recruitment 
and summarising the recruitment experience in clinical trials (Hunninghake, 
Darby & Probstfield 1987, Lovato et al. 1997); reports of recruitment to specific 
trials (Vollmer, Hertert & Allison 1992, Childhood Asthma Management Program 
Research Group 1999, Mihrshashi et al. 2002, Vickers, Meade & Darbyshire 
2002, Wynn et al. 2010) and surveys and interviews reporting modifiers and 
barriers to participation from the health care provider (Hjorth et al. 1996, 
Goodwin et al. 2000, Maslin-Prothero 2000, Baum 2002, Ehrlich et al. 2002, 
Spaar et al. 2009). Systematic reviews of literature have identified barriers to 
participation of patients and clinicians in clinical trials (Prescott et al. 1999, 
Fayter, McDaid & Eastwood 2007), barriers to recruitment of patients in cancer 
clinical trials (Tournoux et al. 2006, Mills et al. 2006) and reasons for non-entry 
of eligible patients into surgical randomised controlled trials (Abraham, Young & 
Solomon 2006). Systematic reviews have also been conducted to identify 
strategies for increasing recruitment to randomised controlled trials (Mc Daid et 
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al. 2006, Judith M Watson and David J Torgerson 2006, Mapstone, Elbourne & 
Roberts 2007, Caldwell et al. 2010, Treweek et al. 2010). 
1.2.1 Magnitude of the problem 
Poor recruitment to randomised controlled trials is a widespread problem. 
Previous studies conducted to assess the extent of the problem indicate that 
recruitment to randomised controlled trials is difficult. Puffer and Torgerson 
conducted a survey with the lead authors of individually randomised trials 
published in the British Medical Journal (BMJ) and Lancet in the years 2000 and 
2001. They showed that 51% of multicentre randomised controlled trials reported 
difficulties with recruitment (Puffer, Torgerson 2003). Haidich and Ioannidis 
(Haidich, Ioannidis 2001) studied the pattern of enrolment in a cohort of RCTs 
initiated by the AIDS (Acquired Immunodeficiency Syndrome) Clinical Trials 
Group between 1986 and 1996 and reported that more than 17% of the included 
RCTs recruited to less than 50% of target.  
An epidemiological review (Campbell et al. 2007) of a cohort of multicentre 
randomised controlled trials funded by the UK MRC (Medical Research Council) 
and the UK NHS HTA (National Health Service Health Technology Assessment) 
program, between January 1994 and December 2002, found that only 38 (31%) of 
the 114 included trials recruited to 100% of the original target. A further 29 (24%) 
trials recruited to 80% of target but less than 100%. The recruitment target had to 
be revised in 42 (34%) trials; of which only 19 (45%) could recruit to 100% of the 
revised target. Sixty-six (54%) trials requested an extension to the trial grant; a 
time and cost extension in 42 (64%), time-only extension in 15 (23%) and a cost-
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only extension in 8 (12%) trials. The overall start to recruitment was delayed in 47 
(41%) trials, early recruitment problems were identified in 77 (63%) and late 
recruitment problems in 46 (38%) trials.  
An update to the review conducted by Campbell et al examined the recruitment 
performance of multicentre RCTs funded by the UK HTA program and UK MRC 
between 2002 and 2008 (Sully, Julious & Nicholl 2013). The original target was 
achieved in 40 (55%) of the 73 included trials, which was a significant 
improvement compared to trials that recruited between 1994 and 2002 (p-value 
0.002). 17 (23%) trials recruited to 80% but less than 100% target. The target had 
to be revised in significantly fewer numbers of trials, 19% compared to 34% in 
previous years (p-value 0.036) and 71% of the trials recruited to 100% of the 
revised target, which was another improvement noted compared to the previous 
review. An extension was requested in 33 (47%) trials; time-only extension in 22 
(30%), time and cost extension in 10 (14%) and cost-only extension in 1 (1%).  
These studies indicate an improving trend in recruitment to multicentre RCTs 
with an increased number of trials recruiting to target and lesser numbers needing 
revision of target. However, the problem persists and recruitment rates continue to 
be low with about half the trials failing to meet targets and one-third needing an 
extension.  
1.2.2 Factors affecting recruitment to clinical trials 
The factors affecting recruitment to clinical trials can be described as facilitators 
or barriers from the patients’ and health care providers’ or clinical teams’ 
perspectives. Prescott et al undertook a systematic review of literature covering 
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the period from 1986-1996 to determine the factors that limit the quality, number 
and progress of RCTs. They identified clinician and patient participation as 
important issues and reported on the barriers to clinician and patient participation 
in clinical trials (Prescott et al. 1999). Other reviews of literature have reported 
issues pertaining to participation of physicians and patients in clinical trials (Ellis 
2000), and explored the factors that influence participation or non-participation of 
patients (Cox, McGarry 2003). Fayter et al conducted a systematic review of 
literature from 1996 to 2004 to identify barriers, modifiers and benefits to cancer 
trial participation from the health care providers’ and patients’ perspectives and 
assessed the included studies for methodological quality (Fayter, McDaid & 
Eastwood 2007).  
Tournoux et al undertook a systematic review of published clinical trials and 
prospective and retrospective cohort studies up to August 2004 that reported 
barriers to recruitment of patients to trials in onco-haematology (Tournoux et al. 
2006). They identified 75 papers; 33 (44%) reported factors related to patient and 
28 (37%) reported clinicians’ factors to be important in influencing the inclusion 
of patients in a clinical trial. 37 (49%) reported influence of other factors such as 
age of patients, minority populations and advanced stage of disease (30 papers) 
with the effect of cost of RCTs and influence of an important person and/or 
legislation reported in 17 papers. Mills et al conducted a systematic review of 
literature until 2005 to define the nature and extent of barriers identified in 
quantitative and qualitative studies, which were thought to hinder participation in 
cancer clinical trials (Mills et al. 2006). Abraham et al systematically reviewed the 
reasons for non-entry of eligible patients in surgical randomised trials to ascertain 
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characteristics of eligible patients who are likely to refuse participation and made 
recommendations to improve recruitment (Abraham, Young & Solomon 2006).  
Prescott et al reported the most comprehensive systematic review of barriers to 
participation by patients and clinical teams in clinical trials of cancer and other 
illnesses. The findings of other systematic reviews are similar to those described 
by Prescott et al. Fayter additionally assessed the included studies for 
methodological quality and found that many studies were of poor quality with 
threats to internal validity in the form of potential for selection bias, poor 
reporting of recruitment methods, problems with data collection and lack of 
reliability and validity of research instrument (Fayter, McDaid & Eastwood 2007). 
1.2.2.1 Facilitators for trial participation 
Patient perspective 
Patient willingness to participate is crucial for successful recruitment to a trial. 
Several factors have been described that influence a patient’s decision to enrol in 
a clinical trial. The most commonly reported motivator for participation is 
altruism (Siminoff, Fetting & Abeloff 1989, Larson, McGuire 1990, Lynoe et al. 
1991, Newburg, Holland & Pearce 1992, Sutherland et al. 1993, Jensen et al. 
1993, Ross, Jeffords & Gold 1994, DeLuca et al. 1995, Slevin et al. 1995, Jenkins, 
Fallowfield 2000). Benefitting others and contributing to medical knowledge are 
important reasons mentioned for participating in clinical trials (Cassileth BR, 
Lusk EJ, Miller DS, Hurwitz S. 1982, Ross, Jeffords & Gold 1994, Slevin et al. 
1995, Paskett et al. 1996). However, patients also participate in trials because of 
the perception that trial participation will be beneficial, will offer better treatment 
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and provide cure for their ailment (Huizinga et al. 1999, Moritz et al. 2002, 
Kemeny et al. 2003) and in the hope of receiving extra monitoring, better care and 
treatment from doctors and nursing staff (Mingus et al. 1996, Schaeffer et al. 
1996, Madsen et al. 2002). Patients have been known to participate for reasons of 
perceived benefit of future generations (Jenkins et al. 1999, Hietanen et al. 2000, 
Ellis et al. 2001, Madsen et al. 2002), whereas some agree to trial participation to 
please their physicians (Grunfeld et al. 2002) and to help with a doctor’s research 
(Moritz et al. 2002). Incentives such as compensation for extra expenses related to 
parking or childcare were found to facilitate participation. Certain demographic 
characteristics such as being male, an older patient, less educated or from a lower 
socio-economic background appear to be associated with a greater willingness to 
participate in randomised clinical trials (Bevan et al. 1993, Henzlova et al. 1994, 
Verheggen, Nieman & Jonkers 1998).  Media coverage and increasing exposure 
to the internet in recent times has increased patients’ awareness about trials and 
interest in participation. There is evidence that patients are keen to participate and 
want the option of trial participation to be offered to them (Grunfeld et al. 2002, 
Shilling et al. 2011).  
It is important to bear in mind that literature dating back to 80’s and 90’s is 
unlikely to reflect the culture change in recent times; decreased medical 
paternalism, patients being better informed about their condition and potentially 
reduced trust in clinicians and health care practitioners. Recent advances in 
technology and increased access to internet has led to patients being better 
informed, engaged and empowered for decision-making about participation in 
clinical trials.  
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Clinical team perspective 
The STEPS study (Campbell et al. 2007) reported case studies of four trials that 
had recruited successfully and had interesting lessons for recruitment. Interviews 
were conducted with a range of people with different responsibilities and 
perspectives to gain role specific and location specific insights into the four 
included trials. They identified four key stages of a trial that may affect 
recruitment: foundation work involving engagement of collaborators, establishing 
scientific rigour and funding and financial considerations; recruitment processes; 
delivery of care and delivery of research. The authors reported common factors in 
the success of these trials based on analysis of themes identified in these key 
stages and from the responses of the interviewees. The factors identified by the 
interviewees for successful recruitment in the different trials were: an important or 
interesting research question, good trial design, good protocol, clinicians keen to 
recruit to the trial, drugs tested already so easier to explain to patients, no extra 
demands on patients, no competing trials for centres/patients, drugs not available 
outside the trial, excellent trial management, good communication between trial 
team and clinicians, helpful trials unit, centre accreditation, annual meetings and 
good public relations. Other factors identified by interviewees were flexibility of 
trial teams, involvement of GPs in trial design, adequate numbers and willingness 
of practices to take part, pragmatic study design, good funding, trial teams with 
good communication and responsiveness to problems, good infrastructure, 
minimal impact on practice running and costs, minimising work for health 
professionals, prior screening to ensure patients were eligible, presence of 
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research nurses and teams working hard at explaining the trial to patients 
(Campbell et al. 2007).     
1.2.2.2 Barriers to trial participation 
Patient perspective 
Treatment preference for or against a particular treatment was identified as a 
common reason for declining participation (Spiro et al. 2000, Ringberg, Moller 
2000, Fleissig, Jenkins & Fallowfield 2001, Lara et al. 2001, Ellis et al. 2001, 
Kemeny et al. 2003, Westcombe et al. 2003). Patients have been known to be 
averse to randomisation and treatment choice by random allocation (Jack, Chetty 
& Rodger 1990, Llewellyn-Thomas et al. 1991, Schwartz, Fox 1995, Fallowfield 
et al. 1998, Featherstone, Donovan 1998). Participants worry about 
experimentation and receiving treatment of unproven efficacy (Tripathy, Patel & 
Brown 1998, Wiley et al. 1999, Jenkins et al. 1999, Ellis et al. 1999, Kemeny et 
al. 2003). They have concerns about side effects of treatment and may not want to 
take an experimental medicine or placebo (Bowen, Hirsch 1992, Stone et al. 1994, 
Slevin et al. 1995, Yeomans-Kinney et al. 1995). Trials with larger differences in 
the treatments offered with regards to adverse effects or the possibility of 
receiving a placebo have been known to experience difficulties with recruitment 
(Kemp, Skinner & Toms 1984, Yeomans-Kinney et al. 1995, Welton et al. 1999). 
Additional trial demands such as extra procedures, clinic appointments, in-patient 
hospital stay and extra travel causing discomfort, inconvenience and additional 
expense were recognised as barriers (Harth, Thong 1990, Bowen, Hirsch 1992, 
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Autret et al. 1993, Cunny, Miller 1994, Richardson et al. 1998, Camerini et al. 
1999, Maslin-Prothero 2000, Westcombe et al. 2003).  
The influence of the physician (Tripathy, Patel & Brown 1998, Richardson et al. 
1998, Maslin-Prothero 2000, Westcombe et al. 2003) and family members 
(Paskett et al. 1996, Motzer, Moseley & Lewis 1997, Tripathy, Patel & Brown 
1998, Spiro et al. 2000) was recognised as significant factors affecting trial 
participation.  
Patients’ knowledge and understanding  
Poor understanding of the rationale for random allocation of treatment (Snowdon, 
Garcia & Elbourne 1997, Featherstone, Donovan 1998) and lack of knowledge 
about trial participation (Cunny, Miller 1994) have been acknowledged as major 
deterrents for patient recruitment. Patients are known to experience problems with 
the concept of equipoise (Jenkins et al. 1999). Studies show that providing 
‘enough trial information’ (Jenkins, Fallowfield 2000) and informing patients 
about the treatment arms, equipoise and option of leaving the trial at any time 
encourages people to be more willing to participate (Fallowfield et al. 1998). 
However, problems with understanding trial information and ‘information 
overload’ have been linked to trial refusal (Stevens, Ahmedzai 2004). Long and 
complex patient information leaflets have been criticised and the need for simple 
and easy to understand trial information is well recognised by both patients and 
practitioners (Shilling et al. 2011).  
Clinical team perspective 
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The clinical teams undoubtedly play a key role in recruitment of participants to a 
clinical trial.  Time constraints have been identified as an important barrier to 
clinician participation due to heavy clinical workload and managerial 
responsibilities (Foley, Moertel 1991, Dickinson 1994, Smyth et al. 1994, 
Aaronson et al. 1996), extra work due to the trial (Hjorth et al. 1996, Fallowfield, 
Ratcliffe & Souhami 1997) and additional demands of recruitment and follow up 
in clinical trials (Taylor, Margolese & Soskolne 1984, Taylor 1985, Foley, 
Moertel 1991, Benson et al. 1991, Langley et al. 2000, Wright et al. 2002, 
Grunfeld et al. 2002). Other system related barriers are cost of trial participation 
(Hjorth et al. 1996, Langley et al. 2000), strict timelines and lack of resources. 
The importance of trial regulation in safeguarding patients has been 
acknowledged but excessive regulation and unnecessary documentation are 
regarded as barriers (Grunfeld et al. 2002). 
Lack of research experience (Winn et al. 1984, Wadland et al. 1990, Dickinson 
1994) and training (Shea et al. 1992), non-availability of additional support staff 
such as research nurses to help with recruitment (Penn, Steer 1990, Foley, Moertel 
1991, Shea et al. 1992, Smyth et al. 1994, Morse et al. 1995) and lack of a stable 
research team (Henzlova et al. 1994) are thought to hinder recruitment. The 
importance of infrastructure to support research and appropriate communication 
between trial organisers and clinicians has been emphasized (Langley et al. 2000). 
Cook et al highlighted the importance of engaging and motivating all members of 
the research team involved in recruitment to the trial (Cook, Finlay & Butler-
Keating 2002).  
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The decision by a clinician to not offer a patient the option of participation in a 
clinical trial is thought to be a major contributory factor to poor accrual (Hunter et 
al. 1987). A clinician’s reluctance to offer participation to a patient may stem due 
to concerns about side effects of treatment (Winn et al. 1984, Foley, Moertel 
1991), additional demands on the patient due to the trial (Siminoff, Fetting & 
Abeloff 1989, Smyth et al. 1994, Aaronson et al. 1996) and hesitation to enrol 
severely ill patients (Antman et al. 1985, Aaronson et al. 1996). The potential 
conflict in their role as a clinician and researcher (Taylor, Kelner 1987, Siminoff, 
Fetting & Abeloff 1989, Penn, Steer 1990, Taylor 1992), loss of clinical 
autonomy (Taylor, Margolese & Soskolne 1984, Taylor 1985, Taylor, Kelner 
1987, Fisher et al. 1991, Taylor 1992, Taylor et al. 1994), difficulty in admitting 
that they do not know which treatment was better (Taylor, Margolese & Soskolne 
1984, Taylor 1985, Taylor, Kelner 1987, Benson et al. 1991) and fear of the 
resulting impact on their relationship with patients may prevent clinicians from 
recruiting patients into trials (Taylor, Margolese & Soskolne 1984, Taylor 1985, 
Taylor, Kelner 1987, Chang et al. 1990, Tognoni et al. 1991). Many doctors 
expressed difficulty in acknowledging uncertainty and discussing treatment 
choices including participation in trials (Benson et al. 1991, Fallowfield, Ratcliffe 
& Souhami 1997). 
Clinicians may have a personal preference for a particular treatment (Siminoff, 
Fetting & Abeloff 1989, Klein et al. 1995), may be unwilling to recruit to trials 
with ‘no treatment’ arm (Fisher et al. 1991), have problems in complying with the 
research protocol (Hjorth et al. 1996) and may demand pragmatic trials (Siminoff 
et al. 2000, Baum 2002). They may be less likely to engage with the trial if it is 
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perceived to be irrelevant to their clinical practice (Skeel, Taylor & Harrington 
1998) and are more willing to participate if the research question is felt to be 
important and likely to enhance existing knowledge (Taylor, Margolese & 
Soskolne 1984, Tognoni et al. 1991). Seeking an informed consent was thought to 
be problematic and a hindrance to recruitment due to lack of time and availability 
of trained staff to obtain consent (Taylor 1985, Langley et al. 1987, Benson et al. 
1991).  
1.2.3 Association of trial features with recruitment success 
Campbell et al (2007) tested the association of pre-specified trial features with 
recruitment success (≥ 100% of original recruitment target). The pre-specified 
trial features included simple design, good level of funding, multidisciplinary 
input, consumer input, intervention available only in the trial, pilot phase, 
dedicated trial manager, local recruitment coordinators, support from a trials unit, 
being a cancer trial, being a drug trial and funded by the MRC. They found a 
marginally statistically significant association with the trial being funded by the 
MRC (OR 2.31, p-value 0.048), being a cancer trial (OR 2.77, p-value 0.026) and 
not having local paid coordinators (OR 0.34, p-value 0.017). Paid local 
recruitment coordinators were expected to boost recruitment but the authors 
discuss that the apparent negative association may be explained by the 
confounding effect of other factors such as trial complexity and the years in which 
these trials were undertaken. Some factors such as intervention being available 
only in the trial, having a dedicated trial manager and being a drug trial were seen 
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more commonly in trials that recruited successfully but the confidence intervals 
were wide and the results were not statistically significant (Campbell et al. 2007).  
Sully et al (2013) found that trials funded by the MRC appeared to recruit 
successfully more often than HTA funded trials (61% vs. 45%) but this was not 
statistically significant (p-value 0.270). Involvement of a clinical trials unit (CTU) 
was found to have a positive impact on recruitment; 65% of trials with CTU 
support recruited successfully compared to 48% with no CTU involvement but 
this was not statistically significant (p-value 0.235). The clinical area was found to 
be important with 65% of mental health trials recruiting successfully compared to 
23% primary care trials. However, the authors report that the sample sizes in the 
categories were too small for a meaningful statistical analysis. A small negative 
effect was noted with planned sample size and studies that planned for 80% power 
were found to be less likely to recruit successfully than studies that aimed for 90% 
power (Sully, Julious & Nicholl 2013).    
1.2.4 Strategies to improve recruitment 
Several studies have tried to identify methods to improve recruitment to clinical 
trials. Systematic reviews of effectiveness of recruitment interventions in 
randomised controlled trials have found strategies such as personalised letters, 
making trial material culturally sensitive, telephonic reminders and monetary 
incentives to be effective. Trials with an open design appeared to benefit 
recruitment (Watson, Torgerson 2006). A Cochrane systematic review aiming to 
quantify the effects of recruitment strategies found telephone reminders to non-
responders (OR 1.95, 95% CI 1.04, 3.66), use of opt-out procedures for contacting 
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trial participants (RR 1.39, 95% CI 1.06, 1.84) and open trial design (RR 1.22, 
95% CI 1.09, 1.36) to be effective in increasing recruitment (Treweek et al. 2013). 
Caldwell et al (2010) found that interventions which increased people’s awareness 
of the health problem being studied along with its impact on their health and 
increasing people’s engagement in the learning process improved recruitment. An 
interactive computer program (RR 1.48, 95% CI 1.00, 2.18), attendance at an 
education session (RR 1.14, 95% CI 1.01, 1.28), addition of a health questionnaire 
(RR 1.37, 95% CI 1.14, 1.66) or a video on the health condition (RR 1.75, 95% CI 
1.11, 2.74) and monetary incentives were found to be effective (Caldwell et al. 
2010).  
With greater access to internet and advances in technology in recent times, the 
role of social media in recruitment of participants to clinical trials is being 
increasingly recognised.  It has been shown to be a viable recruitment method for 
clinical research studies (Frandsen et al 2013, Tweet et al 2011). Social 
intelligence is seen to offer a faster and less expensive way to identify appropriate 
potential participants. Social media can be effectively used to provide trial 
information, engage with potential participants and invite active involvement and 
input into trial design, thereby improving participant experience and reducing 
barriers to trial participation. Social media can also be used to enhance trial 
recruitment via online patient communities and support groups and by the use of 
social networking sites that can match eligible patients to appropriate trials 
(Thompson 2014, #trial: clinical research in the age of social media, 2014).  
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1.3 CLINICAL RESEARCH WITH CHILDREN 
1.3.1 Need for conducting clinical research with children 
Evidence based medicine is fundamental in bringing about significant 
improvements in clinical care and achieving better health outcomes in children.  
The importance of conducting well-designed clinical studies in children is well 
recognised as is the danger in relying on evidence generated from studies 
conducted in the adult population (Smyth, Weindling 1999, Smyth 2001, Klassen 
et al. 2008). Clinical trials have been a key tool in bringing about a significant 
improvement in the care and survival of children particularly in preterm infants 
(Liggins, Howie 1972, Crowley 2000), children with malignant disease (Chessells 
1992) and chronic diseases, such as sickle cell disease (Quinn, Rogers & 
Buchanan 2004). Clinical trials have played an important role in the development 
of vaccines (Waddington et al. 2010, Snape et al. 2010) and important treatments 
that have led to prevention of childhood diseases and reduction in associated 
morbidity and mortality (MRC Vitamin Study Research Group 1991, Centers for 
Disease Control and Prevention (CDC) 2004). Smyth highlighted the top ten cited 
clinical trials in children that have made a huge impact on paediatric practice and 
benefitted children world-wide (Smyth 2007).  
However, it is recognised that fewer, high quality clinical trials are conducted 
with children as compared to adults.  A review of randomised controlled trials 
with children published in Archives of Diseases in Childhood from January 1982 
to December 1996 identified only 249 studies; most of which were single centre 
studies with approximately half recruiting fewer than 40 children (Campbell, 
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Surry & Royle 1998). A review of therapeutic paediatric trials worldwide between 
1996 and 2002 reported that majority of the trials were single centre (75%) and 
the number of children recruited to each trial was less than 50 in 38%, between 50 
and 100 in 24% and more than 100 in 34% of the included trials (Sammons, 
Choonara 2005). A review of selected journals found that adult studies were three 
times more likely to be RCTs than studies recruiting children (Martinez-Castaldi, 
Silverstein & Bauchner 2008). 
There is evidence to show that the gap between the number of adult and paediatric 
trials is widening. The number of annual adult trials published in high impact 
journals was found to double from 1985-2004, with no change in the number of 
paediatric trials (Cohen et al. 2007). Cohen et al examined 43, 326 RCTs with age 
specific categorisation published in paediatric specialist journals, general internal 
medicine journals, journals for each specialty and general paediatric journals with 
highest impact factors. Adult RCTs were found to increase by 90.5 RCTs per year 
(95% CI 78-103) which was significantly higher than the rise in the number of 
paediatric RCTs (16.9 per year, 95% CI 12-22) and RCTs involving both children 
and adults (22.7 RCTs per year, 95% CI 10-35) (Cohen et al. 2010). Rudolf et al 
(2010) investigated the research evidence that existed to support clinical decisions 
in community paediatric practice and found that only 40% decisions were based 
on good quality evidence (Rudolf et al. 1999). 
Lack of evidence can result in delay or non-implementation of treatments that are 
effective and use of therapies that are ineffective or which may even lead to 
unintended harm (Roberts R, Rodriguez W, Murphy D,Crescenzi T. 2003, 
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Klassen et al. 2008). In the absence of direct evidence from trials in children, 
health care providers are forced to extrapolate results from adult studies and base 
their clinical decisions on research conducted in adults, which is inappropriate. 
This is because many childhood diseases are different from adult diseases and the 
effect of treatments in children may be different from that in adults. The 
pharmacokinetics and pharmacodynamics of drugs vary with age and children 
metabolise drugs differently from adults (Wilson 1996, Smyth, Weindling 1999, 
Steinbrook 2002). Certain treatments may not be tolerated, may be unsafe to use 
or difficult to administer in children.  
The majority of the medicines used in children are off-label and unlicensed 
(Turner et al. 1998, Smyth, Weindling 1999, Conroy et al. 2000, 't Jong et al. 
2000). Use of off-label medications may benefit, have no therapeutic effect or 
may even result in harm. A lack of therapeutic effect or adverse effects may result 
from use of an inappropriate dose or to a lack of understanding of the drug’s 
pharmacokinetic and pharmacodynamics profile (Roberts, Lipman 2009).  
Research in children is necessary to ascertain the safety and effectiveness of 
treatments and for promotion of their health and well-being. Paediatric research 
also has implications for adult medicine. Many adult diseases are thought to have 
their origin early in life and research in early childhood may form the basis of 
preventative strategies to control adult diseases (Smyth, Weindling 1999). It is 
therefore extremely important to conduct high quality clinical trials with children.  
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1.3.2 Research infrastructure for clinical research with children 
In view of increasing recognition of the need for safe and effective treatments for 
children, legal provisions and regulations were enforced in the US and Europe. 
The European Paediatric Regulation came into force on the 26
th
 January 2007.  
The objective was to improve the health of the children in Europe by facilitating 
the development and availability of high quality, ethically researched and 
authorised medicines for children (European Medicines Agency).  
In the UK, in preparation for the European Regulation that requires 
pharmaceutical companies to conduct studies with children and a mandatory 
Paediatric Investigation Plan (PIP), the Department of Health, England working 
with the Medicines and Healthcare products Regulatory Agency (MHRA), 
developed a strategy on Medicines for Children in 2004. This included the 
development of the National Institute of Health Research (NIHR) Medicines for 
Children’s Research Network (MCRN) in 2005 to facilitate the conduct of 
randomised controlled trials and other well designed studies of medicines for 
children in the UK.   
1.3.3 Conducting randomised controlled trials with children 
Ethical issues 
Conducting clinical research with children is fraught with several methodological 
and ethical challenges (Smyth, Weindling 1999). They are perceived as a 
vulnerable population (Kipnis 2003) with a need to protect them from potential 
risks from participation in research and to respect their autonomy by seeking an 
34 
 
informed consent from parents or legal guardians and children themselves, when 
possible (Code of Human Research Ethics).  Historically, children have been 
excluded from participation in research and deprived of the benefits and resulting 
advancements in medical knowledge, therefore described as the ‘therapeutic 
orphans’ (Shirkey 1968).  
However, it is evident that children are not small adults and while it is important 
to protect them from harm, it is equally important that they receive the best 
treatments which are based on ethically conducted research in children. The risks 
of participation should be weighed against the benefits keeping the child’s 
interests above those of society and science (Sammons 2009). The potential risks 
could be due to physical, emotional and/or psychological harm or discomfort 
and/or stress resulting due to trial participation and can be immediate or delayed. 
Issues that are important to consider specifically in clinical trials with children are 
discomfort, pain, fear, unfamiliar surroundings, separation from parents and 
effects on developing organs and size or volume of biological samples (American 
Academy of Paediatrics 2010). The counterpoint to risks is the benefit of trial 
participation, both for the children participating in research and those who may 
benefit in the future. A well designed clinical trial should offer the optimum 
treatment approach with the control arm receiving the current best standard 
treatment and intervention being as good as or better than standard treatment, as 
required by the Declaration of Helsinki (World Medical Association ). Studies 
have shown improved survival for all participants in trials, both in the intervention 
and control arm, which may be attributable to the Hawthorne effect (Smyth, 
Weindling 1999, Vist et al. 2001). This may also be due to better care and closer 
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monitoring of trial participants or due to the fact that physicians involved in 
clinical trials are more likely to incorporate trial findings and published evidence 
into clinical practice (Ellis et al. 1999).  
It is suggested that paediatric trials should be designed by professionals with 
experience in clinical trials and children’s medicines, in consultation with parents 
and patients from appropriate age groups. Study design should be optimised to 
answer the research question with the smallest number of patients while making 
efforts to limit the invasiveness of methods used (Sammons 2009). The General 
Medical Council advises that risk vs. benefits of participation should be carefully 
assessed at all stages of a trial and it must be ensured that the ‘research is not 
contrary to the child participant’s interests’ and ‘the potential benefits from the 
development of treatment and furthering of knowledge must outweigh any 
foreseeable risks’ (Medical Research Council 2004, General Medical Council. 
2007).  
Informed consent 
There are then the issues relating to consent and respecting the autonomy of 
children. The Nuremberg Code 1947 requires that consent be sought from all 
participants and the Declaration of Helsinki 2013 allows for proxy consent from 
parents or legal representatives along with assent from the child. The Royal 
College of Paediatrics and Child Health states that “where children have 
‘sufficient understanding and intelligence to understand what is proposed’ (Gillick 
vs. West Norfolk), it is they and not their parents whose consent is required by 
law” (McIntosh et al. 2000).   
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Researchers should ensure that parents or legal guardians and children are 
informed about the nature of the study and given the option to withdraw their 
child at any stage. The children should be actively included in the decision 
making process and their assent should be monitored on an on-going basis by 
sensitive attention to verbal and non-verbal cues (Code of Human Research 
Ethics). Practical considerations in seeking consent from parents include the level 
of information provided and the extent to which the information is received and 
understood by the parents. Another consideration is the setting and available time 
in which parents take the decision, especially for acutely unwell children (Smyth, 
Weindling 1999). Concepts such as equipoise and randomisation may be 
confusing and difficult for parents to understand in stressful circumstances (Modi 
1994, Mason 1997, Snowdon, Garcia & Elbourne 1997).  
Methodological issues 
There are also methodological problems in recruiting children to randomised 
clinical trials. The population pool is smaller and more heterogeneous as 
compared to adults and there is a need to study different age groups. The number 
of children affected by a disease may be too small, making it difficult to recruit an 
adequate sample size to be able to detect a treatment effect (Smyth, Weindling 
1999).  
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1.4 RECRUITMENT TO RANDOMISED CONTROLLED TRIALS WITH 
CHILDREN  
There is limited research on factors that influence recruitment of children to 
clinical trials. It is thought to be complex (Walterspiel 1990, Macrae 2009, 
Chamberlain et al. 2009) and more difficult than recruitment to adult trials (Collet 
et al. 1991). The issues pertaining to recruitment of children in trials have been 
described in relation to parents, children, doctors and trial related factors 
(Caldwell et al. 2004).  
1.4.1 Parent factors 
The children are considered vulnerable as they cannot consent for themselves and 
therefore parents are entrusted with the responsibility of providing consent for 
their children to participate in a clinical trial. A study of parents’ attitudes to 
randomised controlled trials involving children showed that although parents 
understand the importance of conducting research with children, they feel 
uncomfortable with the responsibility of taking this decision and some parents 
acknowledged that they would be more reluctant to consent for their child’s 
participation in a trial than if they were being asked to consent for their own 
participation (Caldwell, Butow & Craig 2003).  
Studies show that parents weigh risks against benefits of trial participation 
(Zupancic et al. 1997, Tait, Voepel-Lewis & Malviya 2003, Caldwell, Butow & 
Craig 2003), the perceived benefits being access to new and better treatments, 
greater access to health care professionals and health information, better care and 
opportunity to meet others in similar circumstances. Some parents had altruistic 
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motivation for trial participation whereas some viewed trial participation as a 
treatment option and a ‘source of hope’ (Caldwell, Butow & Craig 2003). The 
major reason for participation cited by parents in another study was to know about 
their child’s illness and to help advance medical knowledge (Rothmier, Lasley & 
Shapiro 2003). Many parents were found to be willing to enrol their child in a trial 
that had minimal risk even if it was not directly beneficial to the child (Wendler D 
2008). However, parents do worry about the side effects of experimental 
treatment, the chance of their child being randomised to an ineffective treatment 
and perceive these as potential risks. An additional consideration is the 
inconvenience of trial participation resulting from additional blood tests, hospital 
visits, time demands, travel costs and long waiting periods etc. (Harth, Thong 
1995, Zupancic et al. 1997, Langley et al. 1998, Hayman et al. 2001) and this can 
be a major reason for refusal to participate (Hayman et al. 2001). 
A qualitative study exploring parents’ and practitioners’ experiences of 
recruitment to a clinical trial reported that parents’ decision to participate was 
influenced by factors such as their child’s safety and well-being, potential benefit 
to their child and family, benefit to others and practical aspects of participation. 
The prime consideration for them was their child’s safety and parents stated that 
they would not consent if they had doubts about safety of treatment (Shilling et al. 
2011).    
Focus group discussions with paediatricians identified certain parent 
characteristics that were associated with greater likelihood of trial participation. 
Middle class, educated, internet information seekers were thought to be more 
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likely to participate than people from low socioeconomic, non-English speaking 
background (Caldwell, Butow & Craig 2002). 
1.4.2 Child related factors 
Children are thought to view trial participation as a positive experience. The key 
benefit of participation is to learn more about their disease (Cain, McGuinness 
2005) and help other children (Wolthers 2006, Cherrill et al. 2007). Other reasons 
cited for participation in trials are to advance scientific knowledge, age-
appropriate incentives and seeking a fun or unique experience (Johnson et al. 
1999). They appreciate simple, easy to use trial documents and the adolescent 
population are keen to use technology to control their disease. The major 
motivation for trial participation for children is to help themselves and others and 
parental influence is not a major factor (Cain, McGuinness 2005). However, not 
surprisingly they dislike blood tests, needles, dietary restrictions, bad tasting 
medicines and interruption to their normal routine (Johnson et al. 1999). Cherrill 
(2007) found that children have an understanding of the risks involved in 
participation in clinical trials. The most common reasons provided by adolescents 
for refusal to participate in a study of IDDM therapy were increased clinic visits, 
increased injections and blood glucose monitoring and transportation difficulties 
(Tercyak et al. 1998).  
1.4.3 Clinical team related factors 
Caldwell et al reported that paediatricians acknowledge concerns similar to 
physician related barriers reported in adult studies, such as time constraints, extra 
work involved for physicians, lack of resources, financial constraints, concern for 
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patients and about doctor patient relationship, conflict between clinicians’ roles as 
caregivers and researchers, discomfort with randomisation, personal treatment 
preference and discomfort with discussions about uncertainty and seeking 
informed consent (Caldwell, Butow & Craig 2002).  
Paediatricians believe that parents are reluctant to enrol children to clinical trials 
because of parental protectiveness, apprehension about experimentation on 
children and fear of harming or hurting them. Parents are perceived to lack 
understanding of concepts such as equipoise, placebo use and random allocation 
and paediatricians sense fear and mistrust of researchers in parents, which affects 
their willingness to enrol children in a clinical trial. Paediatricians report difficulty 
in recruiting to placebo-controlled trials. They felt that parents’ decision for trial 
participation is influenced by their opinion and parents are more willing to 
participate if the trial was considered to be important either because of media 
promotion or doctors’ recommendation. The severity of the child’s condition was 
also felt to be important; parents of children with a poor prognosis were thought to 
be less likely to agree to participate except for specialities with a research culture 
such as paediatric oncology (Caldwell, Butow & Craig 2002).  
It is evident that physicians worry about the adverse effects of experimental 
treatment and additional trial demands on parents and families. Shilling et al 
highlighted a disparity between parents’ willingness to be approached about their 
children’s participation in clinical trials and physicians’ discomfort in 
approaching families for recruiting children into trials (Shilling et al. 2011). 
Physicians felt anxious about asking parents for trial participation particularly if 
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the children were severely or critically ill, whereas parents accepted and 
understood the need for research and did not mind being approached even in the 
most difficult circumstances, provided it was done in a considerate manner. 
Parents felt positive about trial discussions and practitioners’ communication even 
if they did not contribute much to these discussions. This study suggested the need 
for mentoring and support for recruiting practitioners to improve their experience 
of recruiting children in a trial, particularly for less experienced practitioners and 
in specialities where families and children are perceived to be particularly 
vulnerable.  
1.4.4 Trial related factors 
The trial design of clinical trials with children needs to be acceptable to parents, 
children and paediatricians to ensure adequate recruitment of participants. Parents 
prefer superiority trials, and pragmatic trial designs with minimal trial demands 
such as hospital visits or additional blood tests etc. (Caldwell et al. 2004). The use 
of placebo is perceived as a barrier to trial participation and its use is considered 
unethical for life threatening illnesses (Caldwell, Butow & Craig 2002, Caldwell, 
Butow & Craig 2003). The EU guidance on clinical trials with children states that 
placebo should not be used in trials with children when this implies that an 
effective treatment will be withheld (Directive 2001/20/EC of the European 
Parliament and of the Council 2001). Parents have been found to have a limited 
understanding of the informed consent process (Harth, Thong 1995, Snowdon, 
Garcia & Elbourne 1997, van Stuijvenberg et al. 1998, Wiley et al. 1999) and find 
the consent forms difficult to read and complex (Caldwell, Butow & Craig 2003). 
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Improving the clarity and readability of the consent forms could help parents’ 
understanding of the process. The length and complexity of patient information 
leaflets have been found to be damaging to families’ understanding and have been 
criticised by both parents and practitioners (Beardsley, Jefford & Mileshkin 2007, 
Freer et al. 2009, Shilling et al. 2011).  
1.5 GAPS IN EXISTING KNOWLEDGE AND RATIONALE FOR THE 
RESEARCH DESCRIBED IN THIS THESIS 
Recruitment to randomised controlled trials is challenging and a common 
problem. Under-recruitment is a common cause of delays, increased cost and may 
result in failure to complete trials. It is important to identify the predictors of good 
or poor accrual to a clinical trial so that appropriate strategies can be put in place 
to over-ride these problems and facilitate successful completion of a trial.  
Although, a lot is known about recruitment of adults to clinical trials, there is very 
little knowledge about recruitment of children to clinical trials. It is perceived to 
have additional challenges but empirical evidence is lacking and the scale and 
magnitude of the problem is not known. The number of randomised controlled 
trials with children in previous reviews of recruitment performance (Campbell et 
al. 2007) was limited to ten; three neonatal and seven paediatric trials. There is 
limited research on the factors that influence recruitment to randomised clinical 
trials with children.  
With increasing recognition and widespread consensus about the need for clinical 
trials with children and young people, it is imperative to understand the trends in 
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recruitment to randomised clinical trials with children and identify the facilitators 
and barriers to recruitment. This will be helpful in developing effective strategies 
and channelling resources appropriately to counter the problem of under-
recruitment in paediatric research. To the best of our knowledge, there is paucity 
of data with no quantitative research and published evidence on the extent of the 
problem in children. The aim of this thesis is to review recruitment to randomised 
controlled trials with children and identify the factors associated with good or 
poor recruitment.  
1.6 STRUCTURE OF THIS THESIS 
The thesis is organised in six chapters. Introduction to the topic, a review of 
literature and rationale for the research described in the thesis have been presented 
in this chapter (Chapter 1). 
In Chapter 2, a pilot systematic review of recruitment and retention in randomised 
controlled trials with children in published literature is described. The purpose of 
this review was to estimate the percentage of target recruitment achieved, consent 
rate and rate of retention of children in randomised controlled trials and assess the 
feasibility of obtaining this data from published trial reports. 
However, we found that very few studies reported data on recruitment and 
consent and it was not possible to obtain unbiased estimates of recruitment 
performance from published trial reports. A review of recruitment to randomised 
controlled trials with children in the NIHR portfolio was then conducted which is 
described in Chapter 3. The purpose of this review was to compare achieved to 
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anticipated recruitment and identify the factors associated with good or poor 
recruitment.  
In Chapter 4, the method of developing a web based recruitment survey tool is 
described. Since recruitment to a trial is governed by various external and internal 
influences, understanding the motivators and barriers to recruitment in individual 
trials can generate useful information that can form the basis of strategies to 
overcome recruitment problems in future trials. The purpose of this survey tool is 
to systematically establish and monitor the recruitment experience of clinical 
teams with regard to the perceived facilitators and barriers to recruitment, to 
identify strategies applied to overcome the barriers and to obtain suggestions for 
change in organisation of future trials.  
In Chapter 5, a survey of recruitment experience of clinical teams recruiting to a 
large multicentre randomised controlled trial with children, the MAGNETIC trial 
is described, using the recruitment survey tool described previously. The purpose 
of this study was to understand the various facilitators and barriers to recruitment 
experienced by the clinical teams along with the strategies that were implemented 
to overcome the hurdles.  
The discussion is presented in Chapter 6 which summarises the key findings in 
relation to the research objectives, describes the contribution to existing literature, 
implications for practice and future research direction.  
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Chapter 2 
METHODS TO EVALUATE RECRUITMENT AND 
RETENTION OF CHILDREN IN RANDOMISED 
CONTROLLED TRIALS IN THE PUBLISHED LITERATURE 
2.1 BACKGROUND   
The success of a clinical research project depends heavily on the research team’s 
ability to recruit an adequate number of research participants. ‘Recruitment’ is the 
act of enlisting people for a cause, which in this context is participation in a 
research project (SAGE Publications, Haboush 2010). It involves the process of 
screening and selection of appropriate participants, seeking informed consent for 
participation and enrolment in the study. ‘Retention’ refers to the participant 
remaining in the study until it is completed. Effective recruitment and retention of 
participants through all stages is essential for successful completion of the trial 
and generation of valid results.   
Poor recruitment and retention of participants in clinical trials are serious 
methodological concerns. Recruitment and retention of children in clinical trials 
have additional challenges because of the vulnerable nature of the population and 
the fact that decision to participate is taken by another person, usually a parent. 
However, there is a paucity of data for paediatric trials and the scale and 
magnitude of recruitment and retention problems in trials with children is not 
clearly known. We planned to conduct a systematic review of recruitment and 
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retention of children to randomised clinical trials reported in the published 
literature.  
2.2 A PILOT SYSTEMATIC REVIEW OF REC RUITMENT AND 
RETENTION OF CHILDREN IN RANDOMISED CONTROLLED 
TRIALS  
A pilot study was conducted on a small sample of trial reports published between 
2006 and 2010. This was done to assess the feasibility of conducting a systematic 
review of recruitment, consent and retention of children in randomised controlled 
trials in the published literature. The trial reports were selected from 2006 
onwards as reporting was expected to be better in this period than earlier years.  
2.2.1 Aims and objectives 
The aims of this pilot study were: 
 To estimate the percentage of target recruitment achieved (%TR), consent 
rate and rate of retention of children in randomised controlled trials  
 To review the reporting of flow diagram, sample size calculation, target 
sample size, number of patients who declined to participate and number 
included in the analysis of primary outcome 
 To assess the feasibility of extracting these data from published trial 
reports. 
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2.2.2 Methods 
2.2.2.1 Identification of relevant studies 
Ten published reports of randomised controlled trials were identified for each year 
from 2006-2010. This was a sample size of convenience. The trials were 
identified from the Cochrane Central Register of Controlled Trials (CENTRAL) 
using a list of random numbers generated through statistical software ‘R’. 
CENTRAL is a bibliographic database developed by ‘The Cochrane 
Collaboration’ and is published as a part of ‘The Cochrane Library’.  It is 
considered to be the most comprehensive source of reports of randomised 
controlled trials. CENTRAL includes records identified through systematic 
searches of MEDLINE and EMBASE, Specialized Registers maintained by the 
Cochrane groups and records retrieved through manual searching of journals and 
conference proceedings to identify all reports of randomised controlled trials and 
controlled clinical trials (Cochrane Central Register of Controlled Trials).   
2.2.2.2 Inclusion and exclusion criteria 
Individually randomised controlled trials of any health care intervention, in 
children up to 18 years of age, were eligible for inclusion in the review. Non- 
randomised or cluster randomised trials were excluded. 
2.2.2.3 Search strategy 
The Cochrane Central Register of Controlled Trials was searched for all reports of 
randomised controlled trials published between January 2006 and December 
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2010. A ‘Child search filter’ (Boluyt et al. 2008) developed by the Cochrane 
Child Health Field was used to limit the results to trials with children only. The 
search strategy is shown in Appendix 1.  
2.2.2.4 Selection of studies to be included in the pilot 
The titles and abstracts of the identified studies were independently screened for 
eligibility by two reviewers (GK,MB) and full texts were obtained for all 
potentially relevant reports. The trials were excluded by mutual agreement; where 
consensus could not be reached, advice was sought from a senior member of the 
project team (PW). 
2.2.2.5 Data extraction  
The data from each trial report was extracted independently by both reviewers, 
using a standard data extraction form (Appendix 2). Disagreements were resolved 
by discussion; however, where consensus could not be reached, advice was sought 
from a senior member of the project team (PW). Where data was missing from the 
trial reports or not reported clearly, the authors were contacted for obtaining 
missing information or further clarification. 
Data was extracted for: 
1. Presence of participant flow diagram  
2. Reporting of sample size calculation 
3. Target sample size  
4. Number of participants randomised 
5. Number of participants declining to participate 
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6. Number of participants analysed for primary outcome variable 
2.2.2.6 Outcomes 
The outcomes of interest were:  
 Percentage of target recruitment achieved (%TR), consent rate and overall 
retention rate of children in randomised controlled trials included in the 
review.  
 proportion of trials that reported a participant flow diagram, sample size 
calculation, target sample size, number randomised, number declining to 
participate and number of participants analysed for primary outcome 
variable  
 proportion of trial reports where it was possible to estimate the percentage 
of target recruitment achieved, retention rate and consent rate 
2.2.2.7 Data analysis 
Percentage of target recruitment achieved (%TR) was calculated as below: 
 Total number randomised/recruitment target x100 
Retention rate was calculated as below: 
Number included in analysis of primary outcome/number randomised x100 
Consent rate was calculated as below: 
  Numbers giving consent/total approached x100 
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2.2.2.8 Contact with authors 
The lead author was contacted by email if information on the parameters of 
interest was missing.  
2.2.3 Results 
2.2.3.1 Selection of eligible studies 
The initial search on CENTRAL identified 43,450 reports related to clinical trials 
involving children from 2006 to 2010. The number of trial reports for each year 
from 2006-2010 are shown in Table 1.  10 trials were selected randomly from 
each year resulting in a total of 50 trials. The titles and abstracts of the trial reports 
were independently screened by each reviewer and one trial report was excluded 
at this stage. The full text of the article was obtained for the remaining 49 trial 
reports. 10 further trial reports were excluded by agreement between reviewers.  
Table 1: Number of trial reports per year from 2006-2010 identified from 
CENTRAL 
Year Number of controlled trials 
2006 8414 
2007 8308 
2008 8756 
2009 8920 
2010 9052 
 
2.2.3.2 Reasons for exclusion 
Eleven trials were excluded from the review. Five trials were non-randomised 
(O’Kearney 2009, Powell 2008 Chen 2008, Knott 2007, Jurg 2006); one was 
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pseudo-randomised (Boivin 2008); three studies were secondary publications of 
previously conducted randomised controlled trials (Mamtani 2009, Manger 2008, 
Bellinger 2007); and the participants were more than 18 years of age in two trials 
(Ladas 2010, Berrak 2007). The excluded trials are listed and referenced in 
Appendix 3.   
2.2.3.3 Description of included studies 
39 trial reports of randomised controlled trials of health care interventions, with 
children up to 18 years of age, were included in the pilot review. A summary of 
included studies is presented in Appendix 4.  
2.2.3.4 Outcome data 
The percentage of target recruitment achieved (%TR), consent rate and retention 
rate for children in randomised controlled trials included in the review are listed in 
Table 2.  The blank spaces indicate the gaps in information in the trial reports. 
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Table 2: Reporting of information and rates of recruitment, consent and retention in the included trial reports 
 
Study Flow 
diagram 
Sample 
size 
calculation 
Target 
sample 
size  
Number 
randomised 
Number 
refusing 
consent 
Number 
analysed for 
primary 
outcome 
variable 
Recruitment 
rate  
(%) 
Consent 
rate 
(%) 
Retention 
rate 
(%) 
Akbay 2010 No Yes 34 40 - - 118 - - 
Bojang 2010 Yes Yes 1009 1200 - 1008 119 - 84 
Boots 2010 No Yes 183 200 - 200 109 - 100 
Diez-Domingo 2010 Yes Yes 452 389 - 374 86 - 96 
Okan 2010 No Yes 108 108 - 107 100 92* 99 
Schuttelar 2010 Yes Yes 160 160 54 152 100 75 95 
Swadi 2010 Yes No - 22 2 22 - 92 100 
Waling 2010 Yes Yes 82 105 0 66 128 100 63 
Zampieri 2010 No No - 428 - 428 - - 100 
Bassiouny 2009 Yes No - 80 9 75 - 90 94 
Berrard 2009 Yes Yes 124 124 7 124 100 95 100 
Gelotte 2009 Yes Yes 256 318 - 291 124 - 92 
Kadan-Lottick 2009 No Yes** - 92 52 92 - 64 100 
Morita 2009 No Yes 26 28 - 28 108 - 100 
Haas 2009 Yes Yes 159 160 2 158 101 99 99 
Parker 2009 Yes Yes 60 79 12 70 132 87 89 
Turk 2009 Yes No - 34 - 24 - - 71 
Beaumont 2008 No No - 49 - - - - - 
Greenberg 2008 Yes Yes 1400 167 - 89 12 - 53 
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Lee 2008 No No - 40 - 40 - - 100 
Lynch 2008 No Yes 100 101 - - 101 - - 
Patrizi 2008 No No - 60 - 57 - - 95 
Szmuk 2008 No Yes 200 200 - 200 100 - 100 
Channon 2007 Yes Yes 60 80 43 47 133 65 59 
Dewan 2007 No No 60 80 - 68 133 - 85 
Ghazal 2007 No Yes 194 201 - 201 104 - 100 
Lewis 2007 No No - 14 - 14 - - 100 
Lottmann 2007 Yes Yes 180 221  210 123  95 
Manzoni 2007 Yes Yes 354 336 12 322 95 97 96 
Millar 2007 No Yes 181 181 - 179 100 - 99 
Ahonen 2006 Yes Yes 150 147 - 96 98 - 65 
Berens 2006 No No - 43 - 37 - - 86 
Boo 2006 No Yes 94 106 6 106 113 95 100 
Hayden 2006 Yes No - 28 - 26 - - 93 
Ng 2006 No Yes 48 48 5 48 100 91 100 
Luhmann 2006 No Yes 100 102 - 102 102 - 100 
Mathai 2006 No No - 104 - - - - - 
Mulenga 2006 Yes Yes 640 255 - 223 40 - 87 
Galli 2006 No No - 125 - 125 - - 100 
*Numbers refusing consent not reported, consent rate reported in trial report 
** This study assessed a subset of patients randomised in a larger trial. A retrospective sample size calculation was reported for the subset. 
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Percentage of total recruitment achieved (%TR) 
21/26 (81%) trials recruited to or above 100% of the target sample size.   
Consent rate 
9/13 (69%) trials had consent rates of 90% or more. 
Retention rate 
25/35 (71%) trials had a retention rate of more than 90%. 
2.2.3.4 Reporting of data  
A summary of information provided in the included studies: reporting a flow 
diagram, sample size calculation, target sample size, number randomised, number 
of participants who refused consent and number included in the analysis of 
primary outcome variable, is provided in Table 2.  
Flow diagram  
A flow diagram outlining the progress of participants through the study was 
reported in 18/39 (46%) of trial reports.  
Sample size calculation and target sample size  
A prospective sample size calculation was reported in 25/39 (64%) trials. Kadan-
Lottick 2009 assessed an outcome in a subset of patients randomised in a larger 
trial and provided a retrospective sample size calculation for this subset. The 
target sample size was reported in 26/39 (67%) of trial reports. Dewan 2007 
reported the sample size estimate without a power calculation.  
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Number of randomised patients 
39/39 (100%) reports provided information on the number of patients who were 
randomised to these studies. Lynch 2008 reported the ‘numbers completing the 
study’. This study was excluded from retention statistics since the numbers 
randomised were not clearly specified. The number of participants randomised 
and analysed for primary outcome variable in the trial was not reported clearly in 
another study (Bojang 2010). As per the flow diagram, 1200 participants were 
screened and 1008 were enrolled. However, text in the results section mentioned 
that “1200 children were screened and allocated to receive the treatments. 1008, 
that were enrolled, treated and followed up for at least one visit were included in 
the primary analysis.” For purpose of the our study, the number of participants 
randomised was taken as 1200 and the numbers retained till the end of follow up 
for primary outcome data was taken as 1008. 
Consent refusals 
Information on number of participants who refused consent was provided in 12/39 
(31%) studies. Okan 2010 did not provide the number of patients who refused 
consent but reported the consent rate. One study did not specify the exact number 
of participants refusing consent but reported the numbers excluded collectively 
with one reason for exclusion being consent refusal. This study was not included 
in consent rate calculations (Berens 2006).  
Analysis of primary outcome variable 
The number of patients included in the analysis of primary outcome variable was 
reported in 35/39 (90%) studies.  
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2.2.3.5 Feasibility of calculation of percentage of total recruitment achieved, 
consent and retention rates 
Percentage of total recruitment achieved 
The percentage of total recruitment achieved (%TR) could be calculated for 26/39 
(67%) studies as the target sample size was reported in 26 studies.  
Consent rate 
The consent rate could be calculated for 13/39 (33%) studies only as data on 
number of patients who refused consent was available for 12 studies only and one 
study reported the consent rate.  
Retention rate 
The retention rate could be calculated for 35/39 (90%) studies as information on 
number of patients included in the analysis of primary outcome variable was 
reported for 35 studies.  
2.2.4 Contact with Authors 
A summary of missing or unclear information in trial reports and information 
obtained on contacting authors is presented in Appendix 5. 
Target sample size  
Information on target sample size was missing in 13 trial reports. Dewan 2007 had 
provided a target but no sample size calculation. Another author (Manzoni 2007) 
had reported both a prospective and a retrospective sample size calculation. The 
authors of these trial reports were contacted. Usable information was obtained 
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from 4 authors who confirmed that sample size calculations were not done and a 
sample size of convenience was used. One of these four authors provided a 
definite target sample size (sample size of convenience) that had been used in the 
trial. Using this information, recruitment rate could be calculated in 27/39 (69%) 
trial reports. However, there was no information on target sample size in 12/39 
(31%) trial reports. Of the trial reports where recruitment rate could be calculated, 
22/27 (81%) had recruitment rates of 100% and above. 
Consent Refusal 
Contact with authors of the 26 trial reports with missing information on consent 
refusal resulted in 11 responses. Usable information was obtained from 10 (38%). 
In one response, the author wanted the query to be sent formally to their ethics 
committee for review and decision. Of the 10 usable responses, 3 authors gave 
information on numbers refusing consent and 7 authors confirmed that this 
information was not recorded at the time.  
Using the information obtained from contact with authors, the consent rate could 
be calculated for 16/39 (41%) trial reports as compared to 13/39 (33%) 
previously. Information on number of consent refusals was not recorded in 7/39 
(18%) trial reports. 12/16 (75%) trials reported a consent rate of 90% and above. 
All of the three trial reports for which the numbers refusing participation were 
obtained by contacting the authors, the consent rate was higher than 95%.  
Clarification on numbers randomised  
Two authors were contacted for clarification on the numbers randomised but they 
did not respond.  
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Information on the number included in primary outcome analysis 
Information on the number included in the primary outcome analysis was missing 
from four reports and unclear in two. These six authors were contacted for 
missing information or clarification of numbers reported, but no responses were 
received. 
2.2.5 Discussion 
The results of the pilot study demonstrated that a limited proportion of paediatric 
trial reports present data on recruitment and consent. Efforts to contact authors of 
these trial reports did not add much information to existing data. It became 
evident that this method could not be used to obtain true estimates of recruitment 
and consent rates of children in randomised controlled trials.  
This method had some limitations. Few studies reported the percentage total 
recruitment achieved and consent rates, but those that did, reported very high rates 
of recruitment and consent.  It was difficult to establish whether the high rates of 
percentage of total recruitment achieved and consent were representative or a 
result of selective reporting or non-publication of trials with unsuccessful 
recruitment. Studies that recruit well and have good consent rates may be more 
likely to report on the same than studies that have poor recruitment and consent 
rates. Studies with recruitment problems may be more likely to be terminated 
prematurely or fail to complete and be published. It was evident that a review of 
published literature alone would give falsely high rates of recruitment.  
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2.3 ALTERNATIVE METHOD TO REVIEW RECRUITMENT OF 
CHILDREN IN PUBLISHED RANDOMISED CONTROLLED TRIALS 
We tried to explore other methods to review recruitment of children to 
randomised clinical trials. Alternative sources for data on target sample size such 
as trial registers were considered. We planned to compare the target sample size in 
randomised controlled trials using trial registers as the source to numbers 
randomised in the trial using published trial reports as the source. However, 
further exploration revealed that this approach would not be feasible either and 
had its own set of limitations.  
2.3.1 Trial registers as source of data on target sample size 
Using trial registers as the source of target sample size, relied on the premise that 
all trials be registered and report data transparently. The International Committee 
of Medical Journal editors (ICMJE) introduced the policy on trial registration in 
2004 (De Angelis et al. 2004) and stated that all trials that began after July 2005 
must register in a public trials registry at or before the onset of enrolment. Trials 
that began enrolment before this date, must register before Sept 13, 2005 to be 
considered for publication in ICMJE member journals. ICJME updated their 
statement in 2007 (Laine et al. 2007) to call for prospective registration of trials. 
In November 2004, the World Health Organisation (WHO) called for members to 
"establish a voluntary platform to link clinical trials registers in order to ensure a 
single point of access and the unambiguous identification of trials with a view to 
enhancing access to information by patients, families, patient groups and others" 
(World Health Organisation ). The World Medical Association announced in the 
revised Declaration of Helsinki, in 2008, “Every clinical trial must be registered 
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in a publicly accessible database before recruitment of the first subject” (World 
Medical Association Declaration of Helsinki).  The number of trial registrations 
increased dramatically after these initiatives but there were doubts about universal 
trial registration and data transparency (Bian, Wu 2010). 
A review of reporting of sample size calculation in randomised controlled trials 
(Charles et al. 2009) found that 53% (113/215) of randomised controlled trials 
included in their review, reported registration in an online database. In 85% 
(96/113) of these studies, an expected sample size was mentioned in the online 
trial register. Of these 85%, the expected sample size matched the target sample 
size in the published trial reports in only 48% (46/96); the relative difference 
between sample size mentioned in the trial register and published report 
exceeding 10% in 18 articles (19%) and 20% in 5 articles (5%). 
Contact with researchers undertaking similar work with surgical trials revealed the 
problem of retrospective registration. Rosenthal et al (2013) compared 
randomised controlled trial registry entries with published reports in three surgical 
journals in 2010. They found that 56.9% trials had been registered retrospectively, 
33.3% registered during trial conduct and only 9.8% were prospectively 
registered. However, no discrepancy was found in in target sample size for 72.5% 
trial reports (Rosenthal, Dwan 2013).   
The population of studies in trial registers was expected to be different from the 
population of studies represented in the published literature. The published 
literature included studies from all countries and the recruitment issues were 
anticipated to be different, with recruitment being potentially easier in the 
developing countries due to factors relating to doctor patient relationships and 
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patients likely to be less informed and less demanding than patients in the 
developed world.  
2.3.2 Limitations of this approach 
From the point of view of adopting this method to review recruitment of children 
to randomised controlled trials, we realised that there were some major 
limitations: 
1 Trials that registered prospectively and started recruitment after 2007 would not 
have been completed and published by 2010-2011. Thus, it was not feasible to 
compare trial registers to published reports to get true estimates of recruitment 
performance. 
2. These reviews indicated that a considerable proportion of trials had been 
registered retrospectively even in the years 2009 and 2010 and we were likely to 
face similar problems. 
3. Selective reporting of target sample sizes in trial registers could not be ruled out 
completely.   
2.4 CONCLUSION 
The pilot review of recruitment, consent and retention demonstrated that reporting 
of paediatric trials was poor. It was difficult to determine whether the high rates of 
%TR, consent and retention obtained in the pilot study were valid or whether they 
occurred as a result of selective reporting within published trials, non-publication 
of trials with unsuccessful recruitment or a combination of both. Other methods 
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were considered to review recruitment of children to randomised controlled trials 
but did not prove to be feasible and had some major drawbacks.  
It became evident that we needed a prospective approach to review recruitment of 
children to randomised controlled trials and an actively monitored, objective 
source of recruitment targets to assess recruitment performance and compare 
achieved to target sample size. We then proceeded to plan and conduct a review 
of recruitment of children to randomised controlled trials in the National Institute 
of Health Research Clinical Research Network (NIHR CRN) portfolio. 
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Chapter 3 
A REVIEW OF RECRUITMENT OF CHILDREN TO 
CLINICAL TRIALS ON THE NATIONAL INSTITUTE OF 
HEALTH RESEARCH CLINICAL RESEARCH NETWORK 
(NIHR CRN) PORTFOLIO                                     
3.1 BACKGROUND   
High quality paediatric research is crucial for improving the clinical care and 
health outcomes of children. Successful completion of a trial and application of its 
results in clinical practice depends on recruitment of adequate numbers of eligible 
participants in a given time frame. Recruitment to randomised controlled trials is 
known to be difficult and a common problem. Previous reviews of recruitment to 
a cohort of trials funded by the MRC and HTA (Campbell et al. 2007, Sully, 
Julious & Nicholl 2013) showed that majority of trials failed to recruit to target 
with over a half needing trial extensions. However, the number of paediatric trials 
included in these reviews was limited and the degree and extent of the problem is 
not clearly known for randomised clinical trials with children. It is of vital 
importance to study the issues around recruitment of children to clinical trials, so 
that good quality paediatric clinical research can be carried out to address specific 
child health needs and paediatric clinical care to be more evidence based.   
The pilot study showed that a systematic review of recruitment to randomised 
controlled trials with children in published literature will not provide accurate 
estimates of recruitment performance, as discussed in Chapter 2. We then 
proceeded to undertake a review of recruitment to randomised controlled trials 
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with children in the National Institute of Health Research (NIHR) Clinical 
Research Network (CRN) portfolio. 
National Institute of Health Research Clinical Research Network (NIHR 
CRN)  
The National Institute of Health Research was established by the Department of 
Health in 2006, to create a ‘world-class health research system’ within the 
National Health Service (NHS), under the 2005 Government strategy: Best 
Research for Best Health (NIHR Clinical Research Network). It was created with 
an aim to establish the NHS as an internationally recognised centre of research 
excellence, by providing ‘world class facilities’ to ‘outstanding individuals’, 
conducting ‘leading edge research focussed on the needs of patients and the 
public’ (The National Institute for Health Research). 
The NIHR Clinical Research Network (CRN) is the research delivery arm of the 
NHS, which supports a portfolio of over 5000 clinical research studies. It provides 
the infrastructure for set up and timely delivery of commercial and non-
commercial studies in England. It advises researchers on study feasibility, runs 
streamlined systems for obtaining NHS permission and provides funding to meet 
the costs of NHS equipment and facilities used during a study. It provides 
practical help in identifying and recruiting patients to portfolio studies; monitors 
the number of patients recruited and offers services to help studies in recruiting to 
time and target (NIHR Clinical Research Network).                                         
The NIHR CRN comprised of eight clinical research networks prior to April 
2014; six topic specific research networks, including Cancer, Dementia and 
Neurodegenerative Diseases, Diabetes, Medicines for Children, Mental Health 
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and Stroke; and Primary Care Research Network and Comprehensive Clinical 
Research Network, covering other disease areas (NIHR CRN). The NIHR 
Medicines for Children Research Network (MCRN) was established in 2005 to 
improve the coordination and quality of randomised controlled trials and other 
well designed studies of medicines for children and adolescents. The NIHR 
MCRN works in partnership with NIHR CRN. It operates through six local 
research networks that work in partnership with comprehensive local research 
networks, thirteen clinical study groups, neonatal network and a coordinating 
centre that also administers the paediatric (non-medicines) speciality group 
(NIHR MCRN).  
NIHR CRN portfolio 
The NIHR CRN portfolio is a collection of studies eligible for consideration for 
support by the Clinical Research Network in England and consists of randomised 
controlled trials and other well designed studies. The NIHR CRN portfolio is a 
part of the UK CRN portfolio and is held on the UK CRN portfolio database 
along with network portfolios for Northern Ireland, Scotland and Wales.  
The portfolio database records the research activity data to facilitate the active 
management of included studies. Anonymised recruitment data is collected for 
each participant who is recruited to a study. The collected data includes details on 
the recruitment site, date of recruitment, whether the participant was ‘registered’ 
or ‘randomised’ based on study type and if the participant was a healthy control or 
suffering from disease (National Institute of Health Research).  The recruitment 
data is submitted by the study teams on a monthly basis, by uploading an excel 
spread-sheet in a prescribed format, using a secure online tool.  The study teams 
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are mandated to submit monthly recruitment data, which is a condition for 
continued support from the Clinical Research Network and inclusion in the NIHR 
CRN portfolio. The recruitment data are used to monitor the studies to ensure that 
recruitment targets are met.  
We conducted a review of recruitment to randomised controlled trials with 
children on the NIHR CRN portfolio. The portfolio database provided a 
comprehensive list of commercial and non-commercial randomised controlled 
trials conducted with children and a rich source of actively monitored and 
reported recruitment data. This provided the opportunity to examine recruitment 
performance of these trials in great detail and to assess the factors that influence 
the recruitment of children.  
3.2 AIMS & OBJECTIVES 
The aims and objectives of the review were: 
1 To compare achieved to anticipated recruitment in terms of numbers and time 
frame  
2 To identify factors that affect recruitment of children to randomised clinical 
trials  
3.3 METHODS 
The trials were identified from the NIHR CRN portfolio database: Medicines for 
Children Research Network (MCRN) studies, paediatric (non-medicinal) studies 
adopted by the Comprehensive Clinical Research Network (CCRN) and paediatric 
oncology studies adopted by the National Cancer Research Network (NCRN).  
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3.3.1 Inclusion and exclusion criteria  
Types of studies 
Individually randomised controlled trials with children were selected which 
started recruiting on or after 01/04/2006 and closed to recruitment by 31/03/2013. 
This cut-off for start date was selected to coincide with the establishment of the 
NIHR Medicines for Children’s Research Network. 
Types of participants 
Study participants were children ≤18yrs age. Mixed studies with adults and 
children as research participants, were excluded. 
Types of interventions 
Any health care intervention  
Exclusion criteria: 
Non-randomised and cluster randomised trials were excluded.  
3.3.2 Access to information 
Formal permission was sought from the NIHR CRN coordinating centre. 
Reporting request was made to the NIHR CRN and MCRN coordinating centres 
and study lists and recruitment data were requested. Email correspondence with 
the NIHR coordinating centre is included in Appendix 6.  
3.3.3 Identification of relevant studies 
The NIHR CRN coordinating centre were asked for a list of studies and 
recruitment data for paediatric studies which included studies adopted by the 
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Medicines for Children’s Research Network, Paediatric non-medicines speciality 
group and paediatric oncology studies adopted by the National Cancer Research 
Network (NCRN). The format of existing data and changes made to extract 
relevant data from these reports, for the purpose of this analysis, is described in 
Appendix 7.  
MCRN studies 
The studies were identified from the NIHR CRN portfolio database using the 
‘Topic Study Summary’ report May 2013. The following filters were applied in 
the report: 
Main Network or supporting network: Medicines for Children 
Randomisation: randomised  
Active status: Closed – in follow up  
                       Closed – follow up complete 
Actual opening date: April 2006 and beyond 
Actual closure date: Up to March 2013 
Paediatric Non-medicinal studies 
The studies were identified from the study list requested from the NIHR CRN 
coordinating centre. The following filters were applied in the report: 
Shortname: Generic Relevance and Cross Cutting Themes 
Randomisation: randomised  
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Active status: Closed – in follow up  
                       Closed – follow up complete 
Actual opening date: April 2006 and beyond 
Actual closure date: Up to March 2013 
The selected list of studies was cross checked with the NIHR Paediatrics (Non-
meds) study information and recruitment report May 2013.  
National Cancer Research Network (NCRN) studies 
A list of paediatric oncology studies was requested from the NCRN coordinating 
centre. The following filters were applied: 
Subtopic: Paediatric oncology 
Randomisation: randomised 
Active status: Closed – in follow up  
                       Closed – follow up complete 
Actual opening date: April 2006 and beyond 
Actual closure date: Up to March 2013 
3.3.4 Selection of studies to be included in the review 
The studies were included in the review if they met the inclusion criteria. 
Individually randomised controlled trials of any health care intervention, with 
70 
 
participants 18 years or younger, which started recruiting after 01/04/2006 and 
closed to recruitment by 31/03/2013, were identified.  
After initial identification from the NIHR reports, the randomisation status and 
age of the participants was checked. The online study details provided on the 
UKCRN Portfolio were used to verify that the studies were randomised controlled 
studies and age of the participants were 18 years or younger. Additionally, the 
Medicines for Children’s Research Network coordinating centre was requested for 
permission to access protocols for identified studies. Protocols for Paediatric non-
medicines studies were not available and corresponding study teams were emailed 
to request for a copy of the study protocol. For international studies, the study 
start and recruitment closure date were checked on the Clinical Trials Register 
(ClinicalTrials.gov). Information on inclusion criteria was confirmed from a 
mixture of sources based on availability; study protocol if available, email 
confirmation from the Chief Investigator or study co-ordinator, and study details 
provided on the UKCRN Portfolio. 
3.3.5 Data extraction 
3.3.5.1 Types of data 
Recruitment data  
The following recruitment data were extracted: 
 Target sample size 
 Numbers recruited  
 Target recruitment period 
 Actual recruitment period 
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Factors affecting recruitment  
Hypotheses of factors to be tested for association with recruitment success in 
clinical trials with children were generated. The factors were decided a priori to 
avoid being data driven in the exploration of factors and avoid the chance of 
finding an apparent relationship between variables by chance in absence of a real 
association.  
The factors were limited in number to avoid data dredging and getting spurious 
results due to multiple testing and showing an association between variables due 
to random error. It was anticipated that factors affecting recruitment are 
potentially correlated and a suitably powered multivariable analysis would be 
required to look for significant associations with recruitment success. It was 
estimated that the number of randomised controlled trials with children on the 
portfolio was 150. Assuming a 50% probability of recruitment success (binary 
outcome), six factors were selected in the a priori hypothesis, to achieve an ‘event 
per variable ratio’ of 10 or more (Peduzzi 1996).  
The hypotheses were guided by a review of existing literature on the subject and 
selected based on the experience of senior members of the research team. An 
evidence based list of factors affecting recruitment was made and the factors were 
selected if they were objective, measurable within the scope of the current review 
and were either amenable to intervention or useful for trialists to be aware of, in 
conducting future clinical trials with children. The factors tested for association 
with recruitment success in previous studies were considered in four categories: 
nature of participant, nature of intervention, trial management and logistical 
burden of the trial. Factors to be tested in this review were selected from these 
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categories and clear operational definitions were assigned in advance. The six 
hypotheses are listed below: 
1. ‘IMP (Investigational medicinal product) trials recruit better than non-IMP 
trials.  
IMP trial was defined as ‘any investigation in human subjects intended to discover 
or verify the clinical, pharmacological and/or other pharmacodynamic effects of 
one or more investigational medicinal product(s), and /or to identify any adverse 
reactions to one or more investigational medicinal product(s) and/or to study the 
absorption, distribution, metabolism and excretion of one or more investigational 
medicinal products with the object of ascertaining its safety and/or efficacy’. 
IMP was defined as ‘a pharmaceutical form of an active substance or placebo 
being tested or used as a reference in a clinical trial, including products already 
with a marketing authorisation but used or assembled (formulated or packaged) in 
a way different from the authorised form, or when used for an unauthorised 
indication, or when used to gain further information about the authorised form’ 
(Directive 2001/20/EC). The included studies were classified as IMP or non-IMP 
trial based on this definition.  
2. ‘Trials of chronic illnesses recruit better than trials of acute illnesses’ 
Chronic illness was defined as a condition which usually lasts 6 months or longer,   
results in the child and family having increased contact with health care services 
and produces limitation of function, activities or social role and dependency on 
either medication, special diet, medical technology, assistive device, or personal 
assistance (Stein, Silver 1999). An acute illness was defined as conditions with an 
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abrupt onset and/or a short duration. This included acute minor and major 
illnesses and acute presentation of a new or existing chronic illness (Jones et al. 
2010). The included trials were classified into ‘acute’ and ‘chronic’ illness 
categories based on the above definitions. Trials enrolling healthy participants 
were classified as the ‘healthy’ category.  
3. ‘Trials with a pilot phase or feasibility assessment recruit better than trials that 
do not have a pilot phase or feasibility assessment’ 
Pilot phase/feasibility study was defined as elements of any prior assessment to 
establish potential recruitment to the trial. This could include questionnaires to 
parents to assess willingness to enrol in the trial, assessments of numbers eligible 
to participate in the study and willing to be randomised, survey of clinician 
willingness to recruit, establishing the source of patients and choice of recruitment 
setting, identification of other trials that could potentially compete for patients 
and/or resources or conducting a miniature version of the trial prior to starting the 
main study with a view to assess the processes around recruitment.   
The trials were classified into three categories- ‘yes’ ‘no’ and ‘NA’ based on if 
they had a pilot/feasibility assessment prior to starting the trial. The category 
‘NA’ included trials which were pilot studies or feasibility assessments 
themselves. This information was obtained from the online questionnaire 
responses from the Chief investigator. The commercial studies were included in 
the ‘yes’ category for the purpose of this review, as industry sponsored studies 
have a feasibility assessment conducted by the companies. 
4. ‘Trials with CTU (Clinical trials unit) involvement recruit better than trials 
without CTU involvement 
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The trials were classified into two categories, depending on if they had CTU 
support or not. This was based on information obtained from the Chief 
Investigators. This analysis was not conducted for commercial studies; as industry 
sponsored studies have Contract Research Organisations (CROs) and no CTU 
involvement. 
5. ‘Trials with a trial manager or coordinator recruit better than trials without a 
trial manager or coordinator’ 
The trials were classified into two categories, based on if it had a trial manager or 
coordinator. This information was obtained from the Chief Investigators. The 
commercial studies were considered to have trial manager support as industry led 
studies have trial management support provided by the CRO.  
6. ‘Trials with additional trial demands in comparison to standard practice 
recruit less well than trials without additional trial demands’ 
The trials were classified into the following categories, based on additional 
demand on children, young people and families, resulting due to the trial: 
 Additional tests or procedures 
 Additional/prolonged hospital/clinic visits or extended hospital stay 
 Additional travel distance and/or time and/or associated costs 
 Extra days off work, school and/or change in lifestyle of the family 
 Extra paperwork for child/young adult and/or family 
 None 
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3.3.5.2 Data sources 
3.3.5.2.1. NIHR study reports 
Recruitment data were collected from various sources. The study reports obtained 
from NIHR CRN coordinating centre provided data about 
 Global sample size 
 Original sample size UK 
 Planned sample size UK 
 UK recruitment 
 Original opening and closing dates 
 Planned opening and closing dates 
 Actual opening and closing dates 
The global sample size was taken as the recruitment target (numbers) for 
international studies. Original sample size UK reflected the originally planned 
sample size for studies in the UK, whereas planned sample size reflected the 
revised sample size. The original sample size UK was taken as the recruitment 
target (numbers) for UK single and multicentre studies. However, if the revision 
of target was for reasons other than recruitment difficulties i.e. the drop-out rate 
was less than expected, the planned sample size was accepted as target. Each 
study was considered on a separate case basis, depending on the information 
available from various sources, as shown in Appendix 8. UK recruitment data was 
used for UK studies, whereas global targets and recruitment data were used to 
assess the recruitment performance of international studies. Original opening and 
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closing dates were used to calculate the target recruitment period and actual 
opening and closing dates for actual recruitment period.  
3.3.5.2.2. Online questionnaire sent to Chief Investigators 
The Chief investigator of each included study was sent an online questionnaire 
enquiring about the study characteristics, recruitment data, logistical burden of the 
trial, details of Clinical Trials Unit (CTU) involvement and pilot or feasibility 
assessment, if applicable.  
Design 
The questionnaire was developed using the online survey software 
www.surveygizmo.com. In the design stage, comments were sought on the 
content, from staff in the NIHR MCRN Clinical Trials Unit. The questionnaire 
content and style was modified after discussions with senior members of the 
research team. The online version was drafted and tested within the research team 
before it was piloted with Chief Investigators of two trials. Feedback was sought 
on the content, time taken and ease of completion.  
An initial email with the link to the questionnaire was sent to the Chief 
Investigators of the trials along with a covering letter. The questionnaire and the 
covering letter are presented in Appendices 9 and 10 respectively. Three 
additional email reminders were sent to non-responders. Efforts were also made to 
contact the Chief Investigators by telephone, if no response was received despite 
the three additional email reminders. 
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Content and presentation 
The first section was designed to elicit information on trial characteristics. The 
initial questions asked about the name of the trial and the name and role of the 
responder. These two questions were made compulsory, so the responder had to 
answer these to move on to the next section. Further questions in this section 
asked about the randomisation status. The responders were provided options to 
select if the trial was individually or cluster randomised. An ‘other’ option was 
provided with a free text space for details. The survey was designed in a manner 
that responders who selected ‘cluster randomised’ were led directly to the end of 
the questionnaire, whereas responders who selected ‘individually randomised’ or 
‘other’ were directed to the next page. 
The second page of the questionnaire asked about clinical setting of recruitment. 
A preformed list of options was provided for the responders to select. The survey 
settings allowed responders to select multiple options, if needed. Responders were 
then asked if blinding was implemented. The ‘yes’ responders were provided a list 
of options to specify who was blinded; the others were directed to the next 
question. Multiple options could be selected and the ‘other’ option was given with 
a textbox for responders to provide details. The next question asked if the primary 
outcome measure was available from routinely collected data such as patient notes 
or electronic records. The ‘yes’ responders were directed to the next section; the 
‘no’ responders were asked about the method of data collection. 
The second section was designed to gather recruitment data. Information was 
requested on the total number of participants recruited to the trial, target sample 
size in originally approved protocol, and if the target was revised during the 
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course of the trial. Trialists who answered ‘yes’ were asked to provide details of 
the number of revisions, final recruitment target and reasons for revision. Further 
questions enquired about the planned duration of recruitment in originally 
approved protocol and if recruitment to the study was discontinued earlier than 
planned with reasons, if applicable. The next question asked if a trial extension 
was requested. The ‘yes’ responders were asked to specify the type of extension 
request and if it was granted. A free text box was provided for trialists to give 
additional comments on recruitment to the trial, if applicable. 
The third section was designed to enquire about the additional burden on trial 
participants or parents/carers, resulting due to the study, which was outside of 
routine clinical practice. A preformed list of options was provided.  Responders 
were asked to select single or multiple responses and the ‘none’ and ‘other’ option 
were provided with free text space for responders to provide specific details, as 
applicable.  
The fourth section requested information about Clinical Trials Unit (CTU) 
support. The initial question asked if the trial had CTU support. The responders 
who answered ‘yes’ were asked about the name of the CTU and if it was 
registered with the UK Clinical Research Collaboration (UKCRC). A preformed 
list of options, was provided to gather information on the nature and degree of 
support provided by the CTU. The ‘other’ option was given with free text space 
for responders to give relevant details.  
Further questions enquired about trial management. The initial question asked if 
the trial had a trial coordinator or manager. Details of trial coordinator or manager 
were sought and if the trial coordinator was full time equivalent or less than full 
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time. The final section was designed to ask if a pilot or feasibility assessment was 
conducted prior to starting the trial. Questions were designed to gather 
information on the design, aims and methods of the pilot or feasibility study and if 
it led to any change in the recruitment target or recruitment strategy.  
3.3.5.2.3. UK CRN portfolio  
The study details provided in the UK CRN portfolio were used to obtain 
information on  
i. type of intervention: Investigational Medicinal Product (IMP) or non-IMP.  
ii. type of participants: acute illness vs. chronic illness vs. healthy 
participants 
3.3.5.2.4 Clinical Trials Register 
Global recruitment data was used to analyse the recruitment performance of 
international studies. The global target sample size was recorded on the NIHR 
CRN portfolio but no data was available on the global recruitment numbers. This 
data was accessed from Clinical Trials Registers (Clinicaltrials.gov). The numbers 
recruited to the trial were obtained from the study details provided on the register 
and study results, wherever available. The study start date was provided in study 
details and ‘history of changes’ section was used to identify the recruitment 
closure date.   
3.3.5.3 Recruitment data from different sources 
The recruitment data was obtained from different sources. The target sample size, 
numbers recruited to the study, planned and actual recruitment period were taken 
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from the study reports obtained from the NIHR CRN portal. Information on target 
sample size, numbers recruited and planned recruitment period were also 
requested from the Chief Investigators.  
3.3.5.4 Discrepancies in data  
There were a number of discrepancies in recruitment data obtained from the 
NIHR reports and that obtained from the questionnaires completed by the Chief 
Investigators and the study teams. Efforts were made to resolve these and the 
Chief Investigators were emailed to ask about the various discrepancies and the 
NIHR CRN coordinating centre was contacted. The MCRN coordinating centre 
was requested for granting access to study protocols to confirm the original 
sample size. Information from study files was requested to clarify discrepancies in 
target sample size and numbers recruited to the study.  
3.3.5.5 Resolution of discrepancies 
Information from the various sources was collated and efforts were made to 
resolve discrepancies based on all available information. Each study was 
considered on a separate case basis based on the information available from 
various sources. A set of decision rules was laid to help in the resolution process. 
The decision rules are presented in the textbox below.  
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Textbox 1: Decision rules for resolution of discrepancies 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 
 
 
 
The list of studies with recruitment discrepancies and collated recruitment 
information from all available sources for UK studies are presented in Appendix 
8. The global recruitment data for international studies is presented in Appendix 
11. 
3.3.6 Data analysis          
3.3.6.1 Definition of recruitment success 
The primary outcome was ‘recruitment success’. A study was classified to have 
recruited successfully, if the study recruited to or above 100% of the original 
target. The secondary outcome was ‘successful recruitment’ if a trial recruited to 
or above 100% of the original target in a period not exceeding 10% beyond the 
originally planned recruitment period.  
3.3.6.2 Recruitment data 
A quantitative assessment of recruitment performance was conducted and the 
studies were classified as ‘successful’ or ‘unsuccessful’ based on definitions 
described previously. The primary and secondary outcomes could be calculated 
Rule 1: Accept value where two out of three data sources match; if not,  
             accept value provided by CI 
Rule 2: Discrepancies clarified with the CI or study team 
Rule 3: Accept NIHR data where the CI has not responded            
questionnaire  
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for UK based studies but for international studies, only the primary outcome could 
be calculated as data on planned recruitment period was not available.  
3.3.6.3 Factors affecting recruitment 
The hypotheses of factors affecting recruitment were tested for association with 
recruitment success (outcome variable) with the various hypothesised factors 
being the explanatory variables. 
3.3.6.4 Statistical Analysis 
The data was extracted from various sources and stored in Microsoft Excel 2010. 
Analysis was performed using SPSS (version 20). The trial characteristics were 
summarised in frequency tables. The associations between a-priori factors and 
recruitment success, was presented in 2x2 tables and chi-square test was applied 
to determine the statistical level of association.  
3.4 RESULTS 
3.4.1 Study selection 
A total of 159 randomised studies (107 MCRN and 52 Paediatric non-medicines) 
that started recruiting after April 2006 and completed recruitment by March 2013, 
were initially identified from the study list requested form NIHR CRN 
coordinating centre. No randomised controlled trial for children <18 years could 
be identified from the NCRN portfolio. The list of identified MCRN and 
Paediatric non-medicines studies are presented in Appendices 12 and 13 
respectively.  
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3.4.2 Reasons for exclusion 
These studies were then screened for eligibility for inclusion in the review. Non-
randomised and cluster randomised studies were excluded. Studies with adult 
participants were excluded. Mixed studies with children and adults participants 
were also excluded as separate recruitment targets were not specified for children 
and it would not have been possible to examine the recruitment of children into 
these studies. Three MCRN studies were initially included where the upper age 
limit of participants was higher than 18 years; 19 years in 2 studies and 20 years 
in 1 study. These studies were included as majority of the population was in the 
under 18 age group.  
75 MCRN and 25 Paediatric non-medicinal studies were found to be eligible for 
inclusion in the review after initial screening. Recruitment data were extracted 
from the study reports obtained from the NIHR CRN coordinating centre and 
online questionnaires were emailed to the Chief investigators of these studies. 4 
MCRN and 1 Paediatric non-med studies were identified to be cluster randomised 
at this stage and excluded from the review. Another MCRN study was excluded at 
this stage as it was a pilot study with no defined recruitment target number.  
Six international MCRN studies had to be excluded; the global recruitment period 
of two studies extended beyond the census date for inclusion in the review, two 
studies had been terminated and global recruitment data were not available for 
two studies. The list of excluded studies with reasons for exclusion is presented in 
Appendix 14. The number of trials that were identified, excluded and included in 
the review is presented in the flow diagram below:  
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Figure 1: Flow Diagram 
  
 
 
 
 
 
 
 
 
Assessed for eligibility (n=159) 
MCRN studies (n=107) 
Cluster randomised (n=7) 
Mixed methods study (n=1) 
Mixed participants (n=25) 
Adult participants (n=2) 
Extension study (n=1) 
Pilot study, no definite recruitment 
target  (n=1) 
 
 
 
Paediatric non-medicines studies (n=52) 
Cluster randomised (n=5) 
Observational studies (n=8) 
Non-randomised (n=1) 
Mixed participants (n=4) 
Adult participants (n=8) 
Follow up study (n=2) 
 
 
 
International studies 
Study terminated (n=2) 
Global recruitment data not available 
(n=2) 
Global recruitment period extended 
beyond cut off period (n=2) 
 
 
Included (n=88) 
(64 MCRN studies and 24 Paediatric Non-medicines studies) 
UK based 57: Commercial 4 Non-commercial 53 
International 31: Commercial 28 Non-commercial 3 
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3.4.3 Included Studies 
A total of 88 studies were finally included in the review, 64 of which were MCRN 
studies and 24 were paediatric non-medicines studies. 57 of the 88 studies were 
UK based and 31 were international studies. Majority of the UK based studies 
(93%) were non-commercial and most international studies (90%) were 
commercial. 72 studies were multicentre, 41 UK based and 31 international. 16 
studies were UK single centre studies. A list of included studies with study 
characteristics is presented in Appendix 15. 
3.4.4 Trial characteristics  
Information on trial characteristics was obtained through the online questionnaires 
sent to the Chief investigators. 76 complete and 2 partial responses were included; 
partial responses with no information and duplicate responses were deleted.  The 
trial characteristics for the 78 trials are described below.   
3.4.4.1 Study Design 
The study design was ‘parallel’ in 63 (80.7%) of the 78 studies. Of the 63 studies 
with a parallel design, 37 (59%) were UK based multicentre studies, 33 non-
commercial and 4 commercial. 21 (33%) studies were international studies, 18 
commercial and 3 non-commercial and 5 (8%) studies were UK single centre 
studies. Studies with parallel design were generally interventions for chronic 
conditions (64%), more commonly medicinal products than non-medicinal 
interventions.  
Six studies had a crossover design. Four studies were UK based non-commercial 
studies; two single-centre and two multicentre. The other two studies were 
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international commercial studies. Five of the six studies were of chronic 
interventions. Two studies had a factorial design and these were UK based single 
centre, non-commercial studies for chronic interventions. The study design was 
not described adequately for seven studies.    
3.4.4.2 Clinical setting of recruitment 
Information on the clinical setting of recruitment was available for 77 studies.    
51 (66%) studies recruited from a single clinical setting: 26 from the outpatient 
clinic, five from the paediatric ward, one from accident & emergency department, 
nine from intensive care unit, one from postnatal ward, one from general practice, 
two from community clinics and one from school, three from Child health 
departments and one from wheel chair services.  
19 (25%) studies recruited from multiple clinical settings and seven (9%) studies 
recruited through other settings. This is presented in Table 3.   
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Table 3: Clinical Setting of recruitment for included studies 
Clinical setting of recruitment n 
Single Clinical Setting 51 
Outpatient clinic 26 
Paediatric Ward 5 
Accident & Emergency 1 
Intensive Care Unit 9 
Postnatal ward 1 
General practice 1 
Community clinic 2 
School 1 
Clinical research facility 1 
Wheelchair services 1 
Child Health Departments 3 
Multiple Clinical settings 19 
Outpatient clinic and paediatric Ward 5 
Outpatient clinic and community clinic 3 
Outpatient clinic, paediatric ward and community clinic 1 
Outpatient clinic, accident & emergency and general practice 1 
Outpatient clinic, paediatric Ward, accident & emergency, intensive 
Care Unit, general practice 
1 
Outpatient clinic, school and contacting help groups 1 
Paediatric ward and accident & emergency 2 
Paediatric ward and intensive Care Unit 1 
Intensive Care Unit and community clinic 1 
General practice, community clinic, sure start children’s centres and 
other relevant community venues  
1 
General practice, clinical research facilities and patients’ homes 1 
Child Health Departments, media and emails 1 
Other settings 7 
Participant’s homes 3 
Recruitment via open Exeter database 1 
The National Autistic Society (parent referral) 1 
Nurseries 1 
Help groups 1 
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3.4.4.3 Blinding 
52 (67%) of the 78 included trials observed blinding of one or more of the groups 
involved and 26 (33%) did not. All the groups were blinded in 17 (33%) studies. 
Different groups of individuals were blinded in different studies and this is 
presented in Table 4 below. 
 
Table 4: Blinding in included trials 
Blinding n (%) 
           Yes 
           No  
        Missing  
52 (59) 
26 (30) 
10 (11) 
Who was Blinded? n (%) 
          Patients 
          Health care providers 
          Patients and health care providers 
          Data collectors 
          Outcome adjudicators 
          Data analysts 
43 (83) 
38 (73) 
36 (69) 
43 (83) 
32 (62) 
28 (54) 
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3.4.5 Risk factors 
3.4.5.1 Investigational Medicinal Product (IMP) vs. non IMP trial 
Of the included 88 studies, 61 (69%) were IMP studies and 27 (31%) were non 
IMP studies. Of the 57 UK studies, 30 (53%) were IMP studies and 27 (47%) 
were non-IMP studies. All the international studies were IMP studies. The 
classification of studies is shown in Appendix 16. 
3.4.5.2 Acute vs. chronic illness vs. healthy participants 
14 (16%) studies were categorised as ‘acute’, 61 (69%) studies as ‘chronic’ and 
13 (15%) studies enrolled ‘healthy’ participants. Of the 57 UK studies, 12 (21%) 
were ‘acute’, 36 (63%) were ‘chronic’ and 9 (16%) were in the ‘healthy’ category. 
The classification of studies is shown in Appendix 16. 
3.4.5.3 Pilot or feasibility assessment 
Of the 56 non-commercial studies included in the review, a pilot or feasibility 
assessment was conducted in 15 (27%) studies, pilot study in 8 and a feasibility 
assessment in 7 studies. The details of these studies, as described by the trialists 
are presented in Table 3. 27 (48%) studies had no pilot or feasibility assessment 
conducted prior to starting the study. 9 (16%) studies were pilot or feasibility 
studies themselves. This information was not available for 5 (9%) non-
commercial studies.  
Of the 32 commercial studies, two studies were pilot/feasibility studies 
themselves. The other 30 commercial studies were included in the ‘yes’ category 
for pilot or feasibility assessment, for the purpose of this review, based on the 
90 
 
premise that industry led studies have a feasibility assessment conducted by the 
pharmaceutical companies. However, being mindful of the fact that feasibility 
assessment for commercial studies may be different from that conducted in non-
commercial studies and that all commercial studies may not have the same level 
of feasibility assessment, the analysis of association between pilot/feasibility 
study and recruitment success was conducted both with and without commercial 
studies to avoid artificial skewing of data (i.e. higher number of studies with a 
pilot/feasibility assessment) and the possibility of introducing a bias. 
Trials that were pilot or feasibility studies themselves were not included in the 
analysis of association with recruitment success. This analysis was to assess the 
association between prior pilot or feasibility assessment and potential recruitment 
to a trial, the hypothesis being that studies with a prior pilot or feasibility 
assessment were more likely recruit successfully. Therefore, by definition, studies 
that were pilot/feasibility assessments were excluded.  
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Table 5: Pilot or feasibility assessment in included studies 
Pilot studies  
1. Waiting list control study - subjects randomised to active intervention immediately or 
after 12 months. This design was suboptimal for paediatric population - parents and 
young people wanted to take part immediately and struggled to commit 12 months in 
advance. 
2. Recruited 30 patients locally to show that parents would consent within the 20 minute 
time limit and to check that the protocol (especially the administration of the drugs and 
the outcomes) worked. 
3. Design: An open pragmatic study of effectiveness and cost effectiveness of autoinflation 
for OME. An RCT using telephone randomised allocation and objective outcomes in a 
pragmatic sample of 28 patients and 4 practices based in Southampton and Oxford areas.  
Analysis is by child and on and intention to treat basis. 
4. The pilot study was an open trial with a small n, to evaluate feasibility and likely success 
of telephone cognitive behaviour therapy with an adolescent population.  Participants 
with a primary diagnosis of OCD were offered treatment by telephone, and repeated 
measures were given at fixed time points to evaluate outcome 
5. Parallel group double blind RCT to test the impact of slower growth in very early infancy 
on long-term risk of obesity. 
6. Similar design 
7. Small open label study of peanut oral immunotherapy to assess safety 
8. case-series (N = 8)  testing feasibility and acceptability  of intervention and measurement 
Feasibility assessments  
1. We performed two studies - the first to look at safety aspects of potential early discharge 
and how infants are identified who may deteriorate with bronchiolitis. The second looked 
at potential reduction in hospital length of stay for helping understand health benefits of 
the study. 
2. Each potential centre was contacted for information on the number of children either 
commencing or receiving steroids form rheumatic diseases. They were asked on the basis 
of this data to estimate how many children they felt they could recruit to the POPS study. 
3. To determine the feasibility of recruitment and conduct of a community based trial 
(speaking to parents and staff at local Sure Start Children's Centres) and to determine 
current levels of dental decay. Focus groups, dental assessment and informal discussions. 
4. Pilot RCT to assess feasibility of blinding, recruitment and logistics.  
5. Parent questionnaire to assess validity of inclusion criteria (eczema/egg allergy) and 
willingness to take part in study 
6. Assessed numbers of eligible participants across the region over the previous 12 months 
7. No details provided  
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3.4.5.4 CTU involvement 
Of the 56 non-commercial studies, 28 (50%) studies had CTU involvement and 23 
(41%) did not. This information was not available for 5 (9%) non-commercial 
studies, all of which were UK based. The commercial studies were excluded from 
this analysis since industry sponsored studies have Contact Research 
Organisations (CROs) and no CTU involvement.  
The CTU in all the 28 studies were registered with the UK Clinical Research 
Collaboration (UKCRC). The nature of trial support provided by the CTUs is 
summarised in Table 6. 
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Table 5: Nature of support provided by CTU 
Nature of support n (%) 
Advice on trial design 22 (79) 
Costing of the trial and planning of staffing required to develop and 
manage the trial 
18 (64) 
Communication with the Clinical Research Networks regarding 
feasibility and levels of interest 
11 (39) 
Management of the trial 19 (68) 
Liaising with potential centres, identifying and initiating participating 
centres, and maintaining good communication with each centre 
18 (64) 
Liaising with potential centres, identifying and initiating participating 
centres, and maintaining good communication with each centre 
11 (39) 
Recruiting clinical sites in order to identify and recruit eligible trial 
patients and allocating a trial entry number and treatment to trial 
patients 
11 (39) 
Data management: central coordination and management of essential 
trial documents and patient data collected from participating clinical 
sites 
25 (89) 
Trial monitoring 16 (57) 
Conducting interim and final analyses 22 (79) 
Others 
Whole trial designed and conducted by OVG 
Great motivator and moral supporter (a fantastic CTU) 
Telephone randomisation 
 
1 
1 
1 
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3.4.5.5 Trial Management 
41 of 56 (73%) non-commercial studies had a trial manager but 10 (18%) did not. 
This information was not available for 5 (9%) non-commercial studies. For the 
purpose of this analysis, the commercial studies were assumed to have trial 
management support, as industry led studies have management provided by the 
CROs. However, keeping in mind that the trial management support for 
commercial studies may be different from non-commercial studies and that all 
commercial studies may not have a uniform level of trial management support, 
analysis for association of recruitment success with presence of a dedicated trial 
manager was conducted both with and without commercial studies. This was done 
to avoid the possibility of introducing bias due to an artificial higher number of 
studies with trial management support.  
Details of trial manager or coordinator for the non-commercial studies were 
present for 40 studies, from the questionnaire received from the Chief 
Investigators. 15 studies had a professional trial manager; who was full time 
equivalent in 8 studies. For the remaining seven studies, it was initially 100% and 
later reduced to 50% in one, variable based on the stage of the trial but overall 
70% in another and 40%, 60% and 20% respectively in three others. No 
information was available for the remaining two trials.  
The Chief Investigator provided trial management for four studies, full time 
equivalent in one, 50% in two and 25% in one. Research fellows were full time 
equivalent trial managers in five trials. The trial managers were described in the 
‘other’ category for the remaining 16 trials and the details are presented in Table 
7.  
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Table 6: ‘Other’ responses for trial management in non-commercial studies 
Trial Manager Full time equivalent 
(FTE) 
% of 
FTE 
Yes No 
Research nurse 1 2 10% 
40% 
Research associate 1   
Administrative person supported by DRN staff  1 50% 
Clinical trial coordinator 1   
Co-applicant  1  
Employed for trial 1 2 80% 
50% 
Masters graduate 1   
Neurobiologist  1 40-50% 
Shared post between research fellow, research 
nurse and dedicated trial coordinator 
 1 40% 
Trial manager in centre 1   
Senior lecturer  1 10% 
Not mentioned  1 40% 
 
3.4.5.6 Additional Trial Demands 
The primary outcome measure was available from routinely collected data only in 
19 included studies (22%) and other methods of data collection were reported in 
59 (67%) studies. No information was available for 10 (11%) studies. Information 
on additional demands on patient, carer or families due to participation in the trial, 
was reported for 76 studies. 57 (75%) studies had an additional test or procedure 
performed as a part of the trial which was outside of routine clinical practice.  35 
(49%) studies had an additional and/or prolonged hospital or clinic visit or 
extended hospital stay. 29 (38%) studies were associated with burden on families 
resulting due to additional travel distance or time and associated costs. The trial 
resulted in extra days off work or school and a change in the lifestyle of families 
in 28 (37%) studies and extra paperwork for the child/young adult and families 
was noted in 32 (42%) studies. Two trials were associated with no additional trial 
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demands. The classification of additional trial demands in various categories is 
shown in Table 8.  
 
Table 7: Additional Trial Demands 
Category 
Additional tests or procedures 
1. Additional painful/invasive procedure for trial that would not happen 
otherwise  
2. Extra blood tests i.e. additional venepuncture event that would otherwise not 
be necessary 
3. Extra blood taken with routine bloods 
4. Any other extra tests/procedure 
Additional/prolonged hospital/clinic visits or extended hospital stay 
5. Additional hospital/clinic visit for protocol defined follow up 
6. Prolonged clinic visits 
7. Extended hospital stay 
Additional travel distance/time and/or associated costs   
8. Extra travel cost 
9. Extra travel distance/ time 
Extra days off work,  school and/or change in the lifestyle of the family 
10. Extra days off work for family/young adult 
11. Extra days off school 
12. Change in lifestyle of child/young adult/family 
Extra paperwork for child/young adult/family 
13. Extra paperwork for child/young adult/family e.g. questionnaires, 
treatment diaries etc. 
None 
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3.4.6 Outcome data 
3.4.6.1 Recruitment success 
3.4.6.1.1 Primary outcome 
Overall, 61 of 88 (69%) included studies recruited successfully i.e. recruited to 
100% target irrespective of time period. Of the 57 UK studies, 36 (63%) recruited 
successfully. 
3.4.6.1.2 Secondary Outcome 
20 of 57 (35%) UK studies recruited successfully, i.e. recruited to 100% target in 
the planned time frame or time period not exceeding 10% of the planned 
recruitment period. The secondary outcome could be calculated only for the 57 
UK studies as global data on planned recruitment period was not available for 
international studies.  
3.4.6.2 Revision of target 
The original recruitment target was revised in 13 (23%) UK based studies. The 
recruitment target was not revised in 39 (68%) studies and this information was 
not available for five studies. The recruitment target was revised downwards in 12 
studies and upwards in 1 study. 11 (85%) studies recruited to 100% of the revised 
target. The details and reasons for revision of target were provided for 12 studies. 
The recruitment target was lowered in four studies, in view of trial progress and 
reduced drop-out rate. Three studies experienced problems with recruitment; 
recruitment was found to be challenging in two; repeated staff shortages and 
cancellation of clinics in another study led to loss of patients who had initially 
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consented to participate in the study. The original recruitment target was arbitrary 
in one study as no existing data was available to estimate the likely effect size. 
The target was revised in two studies after interim analysis; a planned reduction in 
target based on available data in one and adequate numbers recruited for a pilot 
study in another. One study reported replacing two patients due to not meeting 
timing of primary endpoint. The recruitment target was revised upwards in one 
study as the initial powering of the study was reported to be potentially 
compromised.  
Information on recruitment target was available for 24 international studies. The 
questionnaire requesting study information was not completed by five study teams 
and information on recruitment target was missing in two responses. Of these 24 
studies, information on global recruitment target was provided for 16 studies. The 
recruitment target had been revised in three studies and all the three studies 
recruited to 100% of revised target. 13 studies did not need a revision of target.  
3.4.6.3 Recruitment discontinued earlier than planned 
The recruitment was discontinued earlier than planned in 6 (11%) UK based 
studies. Of the 6 studies with early discontinuation of recruitment, 4 were due to 
recruitment difficulties. The results and reasons for early discontinuation of 
studies are presented in Table 9. Of the 16 international studies with available 
global recruitment data, the recruitment was discontinued early in one study as 
recruitment had successfully completed.  
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Table 8: Recruitment discontinued earlier than planned in included UK 
based studies 
Recruitment discontinued earlier than planned n (%) 
Yes 6 (10) 
No 46 (81) 
Missing 5 (9) 
Reasons for early discontinuation n 
DMC recommended to the TSC that recruitment should cease because a 
meta-analysis of the on-going trials showed a highly significant and 
unexpected difference in mortality  
1 
Funders not willing to continue  1 
Reached recruitment target early 1 
Poor recruitment 3 
 
3.4.6.4 Trial extension 
A trial extension was requested in 28 (49%) UK based studies. 17 (61%) requests 
were for a ‘no cost extension’ and 10 (36%) were for both; ‘cost extension’ and 
‘no cost extension’. Information on the type of extension request was not provided 
for one study. The trial extension was granted in 27 (96%) studies and rejected in 
only one study. The reasons for requesting trial extension were provided for 27 
studies. Each study had multiple reasons for requesting extension and the major 
themes are summarised below.  
20 studies (71%) reported issues with recruitment; a slower than anticipated 
recruitment rate was reported in twelve studies. Two studies described recruitment 
difficulties arising due to factors such as changes in prescribing policies, rapid 
turnover of research nurses, a competing trial and inadequate referral of patients 
for recruitment to the trial. One study reported staggered recruitment at sites, 
resulting due to factors such as delays in local R&D approval, NHS structural 
changes and local staff health issues. Another study mentioned the effect of 
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seasonal variation; underestimation of recruitment period was described by 
another. External factors such as H1N1 epidemic and Olympics were reported to 
affect recruitment in two studies.  Three studies also reported a delay in start of 
the trial. A delay in receiving the Investigational Medicinal Product (IMP) was 
also reported in one study. Two studies requested for extension to ensure data 
capture and preparation of materials related to Good Clinical Practice. A time 
extension was requested in two studies to enable follow up of children, to 
complete final study visits in one and because of limited capacity to undertake 
research on the ward in another. One study reported a time extension for a slow 
early recruitment and a cost extension to support an add-on genetic study.  
Of the 16 international studies where information was available on global 
recruitment targets, one study requested for a ‘no cost extension’ as the 
recruitment target had been increased and an additional follow up visit had been 
added.  
3.4.6.5 Association of risk factors with outcome 
The a-priori factors were tested for association with recruitment success (primary 
outcome). Having a trial manager or coordinator was significantly associated with 
successful recruitment. Other factors such as being an IMP trial, trial of chronic 
illness, having CTU support, pilot or feasibility assessment and additional trial 
demands did not show a statistically significant association with successful 
recruitment. These results are presented in Table 10. The commercial studies were 
further excluded from analysis of pilot/feasibility assessment and dedicated trial 
manager, for association with recruitment success, as shown in Table 11.  
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For UK non-commercial studies, having a trial manager/coordinator showed a 
statistically significant association with recruitment success (primary outcome). 
None of the factors were found to be associated with recruitment success 
(secondary outcome). The results for the association of factors affecting 
recruitment with recruitment success (primary and secondary outcome) for UK 
non-commercial studies are presented in Table 12. 
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Table 9: Association of factors affecting recruitment with recruitment 
success (primary outcome) for all studies 
 Trial with factor 
that recruited 
successfully n (%) 
p-
value 
Type of trial 
IMP 
nonIMP 
 
44/61 (72.1) 
17/27 (63) 
 
0.390 
Type of illness 
Acute  
Chronic 
Healthy 
 
8/14 (57.1) 
44/61 (72.1) 
9/13 (69.2) 
 
0.548 
Pilot/Feasibility assessment prior to main trial* 
Yes 
No 
Missing 
 
37/45 (82.2) 
17/27 (63) 
5 
 
0.068 
CTU involvement** 
Yes 
No 
Missing 
 
20/28 (71.4) 
15/23 (65.2) 
5 
 
0.634 
Trial Management 
Dedicated Trial manager 
No Dedicated trial manager 
Missing 
 
56/73 (76.7) 
4/10 (40) 
5 
 
0.015 
Additional Trial Demand 
Routine data collection for primary outcome*** 
Yes 
No 
Missing 
Additional test or procedure 
Yes  
No 
Missing 
Additional/prolonged hospital/clinic visit or extended 
hospital stay 
Yes                                                                
No 
Missing 
Additional travel distance/time and/or associated costs 
Yes 
No 
Missing 
Extra days off work/school and/or change in lifestyle of the 
family 
Yes 
No 
Missing 
Extra paperwork for child/young adult/family 
Yes 
No 
Missing 
 
 
15/19 (78.9) 
41/59 (69.5) 
10 
 
43/57 (75.4) 
11/19 (57.9) 
12 
 
 
24/35 (68.6) 
30/41 (73.2) 
12 
 
           21/29 (72.4) 
33/47 (70.2) 
12 
 
 
21/28 (75) 
33/48 (68.8) 
12 
 
24/32 (75) 
30/44 (68.2) 
12 
 
 
0.426 
 
 
 
0.144 
 
 
 
 
0.659 
 
 
 
0.837 
 
 
 
 
0.562 
 
 
 
0.518 
*11 studies were pilot/feasibility studies, **32 commercial studies excluded from analysis of this factor, ***n=78, 2 partial 
responses included in this analysis 
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Table 10: Association of factors affecting recruitment with recruitment 
success for non-commercial studies 
 Trial with factor that 
recruited successfully n 
(%) 
p-value 
Pilot/Feasibility assessment prior to main 
trial* 
Yes 
No 
Missing 
 
 
13/15 (86.6) 
17/27 (62.9) 
5 
 
 
0.103 
Trial Management 
Dedicated Trial manager 
No Dedicated trial manager 
Missing 
 
31/41 (75.6) 
4/10 (40) 
5 
 
0.03 
*9 studies were pilot/feasibility studies 
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Table 11: Association of factors affecting recruitment with recruitment 
success for UK non-commercial studies  
 Trial with 
factor that 
recruited 
successfully 
(PO)* n (%)  
p-
value 
Trial with 
factor that 
recruited 
successfully 
(SO)* n (%) 
p-
value 
Type of trial 
IMP 
nonIMP 
 
16/26 (61.5) 
17/27 (63.0) 
 
0.915 
 
9/26 (34.6) 
9/27 (33.3) 
 
0.992 
Type of illness 
Acute  
Chronic 
Healthy 
 
6/12 (50.0) 
23/36 (63.9) 
4/5 (80) 
 
0.478 
 
3/12 (25.0) 
11/36 (30.6) 
4/5 (80.0) 
 
0.069 
Pilot/Feasibility prior to main trial** 
Yes 
No 
Missing  
 
13/15 (86.7) 
14/24 (58.3) 
5 
 
0.062 
 
5/15 (33.3) 
10/24 (41.7) 
5 
 
0.603 
CTU involvement 
Yes 
No 
Missing 
 
18/26 (69.2) 
14/22 (63.6) 
5 
 
0.682 
 
10/26 (38.5) 
8/22 (36.4) 
5 
 
0.881 
Trial Management 
Dedicated Trial manager 
No Dedicated trial manager 
Missing 
 
29/39 (74.4) 
3/9 (33.3) 
5 
 
0.019 
 
16/39 (41.0) 
2/9 (22.2) 
5 
 
0.294 
Additional Trial Demand 
Routine data collection for PO 
Yes 
No 
Missing 
Additional test or procedure 
Yes  
No 
Missing 
Additional hospital visit or ext. hospital stay 
Yes 
No 
Missing 
Additional travel distance/time and/or 
associated costs 
Yes 
No 
Missing 
Extra days off work/school and/or change in 
lifestyle of the family 
Yes 
No 
Missing 
Extra paperwork for child/young adult/family 
Yes 
No 
Missing 
 
 
7/10 (70.0) 
25/38 (65.8) 
5 
 
24/33 (72.7) 
8/15 (53.3) 
5 
 
11/19 (57.9) 
21/29 (72.4) 
5 
 
 
10/15 (66.7) 
22/33 (66.7) 
5 
 
 
8/12 (66.7) 
24/36 (66.7) 
5 
 
14/19 (73.7) 
18/29 (62.1) 
5 
 
 
0.802 
 
 
 
0.186 
 
 
 
0.297 
 
 
 
 
1.00 
 
 
 
 
1.00 
 
 
 
0.404 
 
 
4/10 (40.0) 
14/38 (36.8) 
 
 
14/33 (42.4) 
4/15 (26.7) 
 
 
4/19 (21.1) 
14/29 (48.3) 
 
 
 
6/15 (40) 
12/33 (36.4) 
 
 
 
3/12 (25) 
15/36 (41.7) 
 
 
10/19 (52.6) 
8/29 (27.6) 
 
 
0.854 
 
 
 
0.296 
 
 
 
0.057 
 
 
 
 
0.809 
 
 
 
 
0.302 
 
 
 
0.08 
 
*PO primary outcome, *SO secondary outcome, **9 studies were pilot/feasibility assessments 
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3.5 DISCUSSION 
This study reviewed the recruitment performance of randomised controlled trials 
with children. The results show that 69% of the trials recruited to 100% target but 
only 35% recruited to target in the stipulated time frame or in a period not 
exceeding 10% of the planned recruitment period. The target was revised in 23% 
of the UK based trials and extension was requested in 49%.   
Analyses to test association with a- priori factors, that were thought to affect 
recruitment, showed a significant association between trial management and 
successful recruitment. There was no significant association between recruitment 
success and being an IMP or non-IMP trial, trial of acute or chronic illness, CTU 
involvement, having a pilot or feasibility assessment prior to the study and 
additional trial demands on children, young people and/or families.  
The strengths of the study were that it examined the recruitment performance of a 
comprehensive set of exclusively paediatric trials. The included trials were 
identified from the NIHR CRN portfolio implying these were well designed 
randomised controlled trials, eligible for research support from the NIHR Clinical 
Research Network.  The cohort was a mix of publicly funded and commercial 
trials and included both international and UK studies. The trials covered a wide 
range of clinical areas and settings, different geographical centres and study teams 
and included small single centre to large multicentre trials. A previous review 
examined recruitment to a cohort of trials funded by the Medical Research 
Council (MRC) and National Health Service Health Technology Assessment 
(NHS HTA) programme between 1994 and 2002 (Campbell et al. 2007), but the 
number of paediatric trials in the review were limited to seven along with three 
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neonatal trials. To the best of our knowledge, this is the first study to review the 
recruitment performance of randomised controlled trials with children.  
The study findings show that recruitment to randomised controlled trials with 
children is challenging. Under-recruitment and recruitment delays are a common 
problem, with trials needing revision of recruitment targets in a quarter and 
extensions in about half of the paediatric randomised controlled trials in the UK. 
In the previous review conducted by Campbell et al, 31% of trials recruited to 
100% target and 54% recruited to 80% target (McDonald et al. 2006, Campbell et 
al. 2007). The recruitment target was revised in 34% of the trials and trial 
extension was requested in 54%. An update to this review assessed recruitment to 
a similar cohort of randomised controlled trials funded by the MRC and HTA 
between 2002 and 2008, which showed some improvement with 55% of the trials 
recruiting to target and 78% recruiting to 80% of target (Sully, Julious & Nicholl 
2013). The recruitment target was revised in 19% and trial extension was 
requested in 47% of the trials. Our study shows that a higher proportion of 
randomised controlled trials recruited to 100% target, though a vast majority of 
trials had recruitment delays.  
The reviews by Campbell et al and Sully et al looked at the percentage of studies 
that recruited to 100% target, irrespective of time frame. Additionally, they looked 
at studies that recruited to 80% of target but less than 100%.  Our study defined 
recruitment success as recruiting to 100% target irrespective of time period but 
also adopted a stricter definition by defining recruitment success as recruiting to 
target in a period not exceeding 10% of the planned time period. This outcome is 
107 
 
likely to be more meaningful to trialists, clinicians and funding bodies, since it 
implies trial completion without a significant time delay.  
The primary source of data was the NIHR CRN portfolio database, which is an 
actively monitored source of recruitment activity in the included trials. The 
recruitment data is uploaded on a monthly basis by the study teams through a 
secure online system. The data was also confirmed by contacting the Chief 
Investigators and study teams and verified from other sources such as Medicines 
for Children’s Research Network (MCRN) coordinating centre to improve the 
accuracy and confirm the validity of collected data. The strength of the review 
was very little missing data. Our study defined recruitment success with reference 
to the originally planned recruitment target but a pragmatic approach was adopted. 
Each trial was considered on a case basis and the revised sample size accepted as 
target, if the reduction was due to reasons other than difficulties with recruitment 
such as a reduced drop-out rate.  
The hypotheses of factors tested for association with recruitment success were 
generated a-priori to avoid being data driven. The initial sample size estimation of 
150 randomised controlled trials on the NIHR CRN portfolio allowed for six 
factors to be tested. However, only 88 studies fulfilled the inclusion criteria for 
the review of which 61 recruited successfully, which was a reasonable number for 
six factors to be investigated based on an event per variable ratio of 10.  
Our study showed that ‘having a dedicated trial manager’ was significantly 
associated with successful recruitment. Previous studies have reported the 
importance of good trial management to the successful conduct of a study (Menon 
et al. 2008, Farrell, Kenyon & Shakur 2010). In the review conducted by 
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Campbell et al, trials with a dedicated trial manager were more likely to recruit 
successfully, however the confidence intervals were wide and the result was not 
statistically significant at the 5% level (OR 3.8, CI 0.79-36.14, p 0.087). Other 
factors tested for association with recruitment success in this review were trial 
design, funding, dedicated trial management, multidisciplinary input, consumer 
involvement, pilot phase, nature of trial (drug vs. non drug, cancer trials) and 
intervention being available only in the trial. They found marginally significant 
association between recruitment success and being funded by MRC, being a 
cancer trial and not having paid local trial coordinators. However, the authors 
discuss that analyses performed to look at association between these factors and 
recruitment success were of limited value because of the choice of outcome and 
exposure variables and because of imprecision around estimates of association 
(McDonald et al. 2006, Campbell et al. 2007). There was some evidence that 
factors such as intervention being available only in the trial, having a dedicated 
trial manager and being a cancer or a drug trial may be associated with successful 
recruitment but the results were inconsistent and the authors report insufficient 
power to undertake a multivariable analysis.  
Sully et al (2013) found that MRC funded trials appeared to recruit better than 
HTA funded trials but the results were not statistically significant. The clinical 
area of the trial appeared to affect recruitment success but the authors reported 
that the numbers were too small for a meaningful statistical analysis. CTU 
involvement was reported to be associated with improved recruitment to trials.  
Our study found no statistically significant association between recruitment 
success and having a pilot/feasibility assessment and CTU support though trials 
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with these factors were more likely to recruit successfully. A potential explanation 
may be the confounding effect of trial complexity. Simple trials may be less likely 
to have a pilot/feasibility assessment or CTU involvement than more complex and 
difficult to recruit trials. Another possible explanation is that the services provided 
by a CTU other than a dedicated trial manager, may be less likely to affect trial 
recruitment.  
The numbers were too small to draw conclusions with regards to the effect of 
additional trial demands on recruitment success but some interesting observations 
were made which can be investigated in future studies. Trials were more likely to 
recruit well if routine data collection was carried out or if a trial offered an 
additional test or procedure and less well if an additional or prolonged clinic visit 
or extended hospital stay was involved. Travel distance or time and associated 
costs and extra days off work or school for the family did not have any effect on 
recruitment success for non-commercial studies in the UK.  
This review has some limitations. It tested some important factors for association 
with recruitment success but could not test factors that may affect parental 
consent. The study teams’ perspective of additional trial demands on the family 
were tested for association with recruitment success but this is indirect evidence 
and the numbers were too small to derive any meaningful conclusion. It was 
difficult to measure the effect of patient and public involvement and as such this 
factor could not be tested.  
Another limitation of the study was the presence of discrepancies in data obtained 
from the NIHR CRN portfolio and corresponding data obtained from the Chief 
Investigators/study teams. A huge amount of time and effort was invested in 
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collecting information from various sources, to be able to resolve these 
discrepancies. It was originally intended to calculate the recruitment rate to 
analyse achieved to anticipated recruitment, but the quality of the data did not 
permit this analysis. Global recruitment data had to be used to analyse the 
recruitment success of international studies as the discrepancies in data could not 
be resolved for these studies. The recruitment success of international studies 
could only be analysed for the primary outcome; data for calculation of secondary 
outcome was not reliably available. For the UK based studies, difficulties arising 
due to data discrepancies were overcome by obtaining information from various 
other sources and treating each trial on a separate case basis but adopting a 
uniform set of rules to resolve these discrepancies.  
This review presents the collective picture of recruitment to paediatric trials. 
Recruitment to a clinical trial is affected by various intrinsic and extrinsic factors, 
relating to the study itself, clinical teams, patients, trial planning and conduct and 
the effect of media, publicity or external policies, to name a few. To understand 
the various factors that operate within a trial and their effect on recruitment, we 
planned to conduct a survey with the clinical teams of a multicentre randomised 
controlled trial with children, the MAGNETIC trial, to elicit their views on 
facilitators and barriers to recruitment to the trial. An evidence based recruitment 
survey tool was developed to capture the recruitment experience of clinical teams 
recruiting to a clinical trial.  
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Chapter 4 
DEVELOPING A SURVEY OF BARRIERS AND 
FACILITATORS TO RECRUITMENT IN RANDOMISED 
CONTROLLED TRIALS                                     
4.1 BACKGROUND 
Recruitment to randomised controlled trials is known to be challenging. 
Prolonged or inefficient recruitment can have several adverse consequences (Gul, 
Ali 2010). Failure to achieve the target sample size can lead to a reduction in the 
statistical power of a study. An underpowered study may report clinically 
important effects to be statistically non-significant and result in delay or non-
implementation of a clinically effective intervention and delay in identification of 
non-effective interventions.  Prolonged recruitment results in increased time or 
cost extensions and may result in premature termination of trials. It is ethically 
unacceptable to conduct studies that terminate prematurely or fail to reach 
adequate statistical power (Treweek et al. 2013).  It is important to understand and 
identify the predictors of good or poor accrual to a clinical trial so that appropriate 
strategies can be put in place to overcome these problems and facilitate successful 
trial completion. 
Recruitment experience in existing studies 
Several studies have examined recruitment experience from a number of 
perspectives. There are reports by trialists describing their recruitment experience, 
methods and strategies applied to increase recruitment (Baines 1984, Vollmer, 
Hertert & Allison 1992b, Strunk et al. 1999, Bailey et al. 2004, Heinrichs et al. 
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2005, Galbreath et al. 2008, Finne et al. 2009, Wardle et al. 2010). There are 
reports on recruitment and participation of under-represented populations such as 
minorities (Baquet et al. 2006, Nicholson et al. 2011) and adolescents and young 
adults in cancer trials (Fern, Whelan 2010). Studies have tried to assess parents’ 
or families’ reasons for participation or non-participation in trials (Peden et al. 
2000, Mihrshashi et al. 2002, Wynn et al. 2010) and there are several reports of 
surveys and interviews with parents or patients investigating the same (Weintraub 
et al. 1980, Eiser et al. 2005, Cain, McGuinness 2005, Sharp et al. 2006, Dolan et 
al. 2008, Smyth et al. 2009, Driscoll et al. 2011, Nabulsi, Khalil & Makhoul 
2011).  
Surveys and interviews with clinical teams have investigated reasons for 
considering patients unsuitable for a trial (Hunt, Shepherd & Andrews 2001), 
reasons for not entering eligible patients (Taylor, Margolese & Soskolne 1984) 
and have explored difficulties with recruitment to the trial (Fairhurst, Dowrick 
1996, Brooker et al. 1999). Caldwell et al (2002) conducted focus group 
discussions with sixteen paediatricians and five trainees from a paediatric teaching 
hospital to evaluate paediatrician’s attitudes towards participation of children in 
randomised controlled trials and identify potential barriers to participation.  
A number of studies have explored barriers to trial participation from patients and 
clinicians perspectives. Systematic reviews of studies (Ellis 2000, Cox, McGarry 
2003, Tournoux et al. 2006) reporting barriers to participation in cancer trials have 
identified various patient and clinician related barriers. Fayter et al (2007) 
conducted a systematic review to investigate the barriers, modifiers and benefits 
of participation in randomised controlled trials of cancer therapies as perceived by 
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health care providers or patients and identified system-related or organisational 
barriers, trial design related and health care provider barriers. Twenty five 
included studies explored barriers to participation from the health care perspective 
with eight investigating recruitment to specific trials and seventeen studies 
investigating attitudes to trials in general. However, the authors concluded that the 
studies were of poor methodological quality and identified threats to internal 
validity in terms of potential for selection bias, non- justification of sample size, 
lack of reliability and validity of research instrument and problems of data 
collection. None of the included surveys in this systematic review provided a 
comprehensive list of facilitators and barriers to recruitment (Fayter, McDaid & 
Eastwood 2007). 
Cook et al (2008) conducted a survey to explore the experiences, beliefs and 
practices of Critical Care Trials Groups regarding the effectiveness, feasibility and 
ethics of strategies to enhance enrolment and views on co-enrolment of critically 
ill children and adults into one or more clinical studies. Fernandez et al (2001) 
conducted a trial specific survey to explore the physicians’ and parents’ barriers to 
enrolment in the Children’s Oncology Group’s study of very low risk Wilm’s 
tumour. Spaar et al (2009) conducted a postal survey among recruiting physicians 
in a multi-centre trial of respiratory rehabilitation in patients with chronic 
obstructive pulmonary disease to identify and weigh barriers to recruitment to the 
trial. The survey questionnaire comprised of barriers identified in literature which 
were applicable to the trial and concerns raised by recruiting physicians during the 
recruitment process.  
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Studies (Taylor, Margolese & Soskolne 1984, Fairhurst, Dowrick 1996, Brooker 
et al. 1999, Hunt, Shepherd & Andrews 2001, Fernandez et al. 2011) have 
examined barriers to recruitment in the context of a specific trial or a specific 
population and the survey questionnaires have been developed as trial or 
speciality specific (Cook et al. 2008). Spaar et al (2009) investigated some general 
barriers to recruitment as well but not comprehensively and recruitment 
facilitators were not identified.  
We developed a survey instrument which can be used to investigate the 
experience of clinical teams with regards to both facilitators and barriers to 
recruitment to a single/multicentre clinical trial in any clinical setting or 
speciality. The survey questionnaire is evidence based and has the potential to 
explore the generic factors affecting recruitment to a clinical trial with the scope 
of adding trial/speciality specific questions, thus providing a reliable tool and 
systematic approach to the recognition and management of recruitment problems.  
To the best of our knowledge, there is no such existing recruitment survey tool 
and we describe here the method of developing this survey questionnaire.  
4.2 METHODS 
4.2.1 Survey Design 
The survey has been designed as an online questionnaire to be completed by study 
teams involved with recruitment to a trial. The process of developing the 
questionnaire is illustrated in Figure 2.  
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Figure 2: Process of developing the questionnaire  
 
  
• Define the aims and scope of the survey and 
population of interest 
• Compile content of the questionnaire using evidence 
based list of potential factors affecting recruitment and 
provide a mix of open and closed questions  
• Pilot the survey on a small sample of the population of 
interest: make modifications based on feedback 
• Pretest modified version with senior members of the 
project team: make further changes if needed 
• Test and launch final version of the survey 
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The survey is divided into four main sections to collect information about the site 
and study role of the responders, the perceived facilitators and barriers to 
recruitment, strategies applied to overcome the problems and suggestions for 
changes in organisation of future trials.  
Free text space is provided for participants to enter information on their site/centre 
of recruitment, their role in the study and their duration and period of involvement 
if they were not involved for the whole trial recruitment period. It is possible to 
add questions for collecting information on if the centre was ever open to 
recruitment, the number of eligible patients for recruitment, numbers expected to 
be randomised and trust policy on recruitment to the study. Skip logic can be 
applied to direct questions selectively to responders depending on their response 
to past questions or skip questions if it does not apply to them.  
The second section provides the survey participants with preformed lists of 
potential factors which could act as facilitators or barriers to recruitment, to be 
rated from -3 to +3, depending on whether the factor was perceived to be a strong 
(-3), intermediate (-2) or weak barrier (-1), 0 if thought to be not applicable and 
weak (+1), intermediate (+2), or strong facilitator (+3). Each factor could be 
assigned only one score. This question was designed in this format to enable us to 
deduce the most commonly identified strong barriers and facilitators and also 
calculate average scores for each factor.   
The last section had open ended questions to gain information on the interventions 
applied and collate reflective experiences and suggestions of the study team to 
improve recruitment with space for additional comments. A copy of the survey 
questionnaire is presented in Appendix 17.  
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4.2.2 Writing the questionnaire 
A list of potential facilitators and barriers affecting recruitment to randomised 
controlled trials was made from a review of existing literature on the subject. A 
literature search on Medline using the search terms ‘recruitment’, ‘enrolment’ 
combined with the AND connector to search terms for ‘clinical trials’ and 
‘randomised controlled trials’ identified the major reviews on the subject that 
were used to develop the list of factors  
The reviews used to design the survey questionnaire are briefly described below. 
The process of selecting and classifying the factors for inclusion in the survey 
questionnaire is illustrated in Table 13.  
1. Prescott et al 
The HTA report, ‘Factors that limit the quality, number and progress of 
randomised controlled trials’ by Prescott et al (Prescott et al. 1999) reported 
patient and clinician barriers to participation in randomised controlled trials. They 
conducted a systematic review of studies that reported problems related to 
recruitment of clinicians and patients to clinical trials and identified the important 
barriers.  
2. Campbell et al  
‘Recruitment to randomised trials: strategies for trial enrolment and participation 
study: The STEPS study’ aimed to identify the factors associated with good and 
poor recruitment to multicentre trials (Campbell et al. 2007). They conducted an 
epidemiological review (The STEPS study Part A) of a cohort of trials funded by 
the MRC (Medical Research Council) and the NHS HTA (National Health 
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Service Health Technology Assessment) programme between January 1994 and 
December 2002. They tested hypotheses of factors for association with 
recruitment success in the cohort of multicentre randomised controlled trials 
included in the review, described patterns of recruitment and reported trialists’ 
perceptions of factors associated with good or poor recruitment. The study also 
reported the reasons for delay in recruitment and early and late participant 
recruitment problems in the included cohort of trials based on the trialists’ reports 
submitted to the funding bodies. The STEPS study (Part B) reported case studies 
of trials that recruited successfully and had particularly interesting lessons for 
recruitment. This part of the study was aimed to gain role specific and location 
specific insights to the four included trials by interviewing 45 individuals in total 
across the four trials with different internal perspectives. They identified four key 
stages of a trial that may affect recruitment: foundation work involving 
engagement of collaborators, establishing scientific rigour, funding and financial 
considerations, recruitment processes, delivery of care and delivery of research 
and reported common factors in the success of these trials based on analysis of 
themes identified in these key stages and from the responses of the interviewees. 
3. Toerien et al 
Toerien et al reviewed the recruitment and retention rates in randomised 
controlled trials published in six major journals between July and December 2004 
and investigated their association with trial characteristics such as study size, 
number of arms, single/multicentre, treatment focus (drug/surgery/allied/others), 
active/placebo control, time to assessment and type of funding (Toerien et al. 
2009). 
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4. Caldwell et al  
The systematic review of strategies for increasing recruitment to randomised 
controlled trials by Caldwell et al (2010) looked at the effect of recruitment 
interventions such as novel trial designs, recruiter differences, incentives and 
different methods of providing trial information on recruitment success in 
randomised clinical trials.  
5. Treweek et al  
The Cochrane systematic review on strategies to improve recruitment to 
randomised controlled trials (Treweek et al. 2010) identified 45 randomised and 
quasi-randomised controlled trials of interventions directed at potential 
participants or clinicians, which aimed to improve recruitment of participants to 
clinical trials. These interventions were divided in six categories: design change, 
modification to the consent form or process, modification to the approach made to 
potential participants, financial incentives for participants, modification of 
training given to recruiters and greater contact between trial co-ordinator and trial 
sites. 
From the facilitators and barriers reported in the above studies (Prescott et al. 
1999, Campbell et al. 2007) and the potential factors and interventions tested for 
association with recruitment success (Campbell et al. 2007, Toerien et al. 2009, 
Treweek et al. 2010, Caldwell et al. 2010), a list of potential factors affecting 
recruitment was generated by classifying the facilitators and barriers into various 
categories. This process is illustrated in Table 13. The factors that were generic 
and expected to operate commonly at all sites were classified as trial level factors. 
These included factors such as funding for the trial, trial design, choice of patient 
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inclusion criteria, type of intervention, previous pilot/feasibility assessment, 
perception of clinical equipoise, publicity about the trial, trial management etc. 
The factors which could operate differentially between sites were classified as site 
level factors and included factors such as time to open up site, recruitment target, 
local clinical arrangements, number and availability of trained staff, competing 
research projects and local research culture to list a few. We excluded factors for 
which objective information is available such as delays in ethical clearance, R&D 
delays, and problems with supply of investigational drug/placebo etc.  The various 
facilitators and barriers relating to patients’ and clinicians’ participation in clinical 
trials, as described in the above studies were listed under patient related and 
clinical team related factors. The factors related to providing information to 
patients and seeking consent such as amount and complexity of trial information, 
clarity in presentation of trial information, time and setting of consent seeking and 
role and seniority of person seeking consent were categorised separately as 
information and consent related factors. Lastly, the study team factors such as 
motivation and research experience of study team, communication and 
coordination between research teams were presented.  Each category formed a 
separate question in the survey questionnaire to help the participants think through 
the issues arising during recruitment to the trial.  
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Table 12: Deriving the factors affecting recruitment from facilitators and 
barriers described in literature  
1. Prescott et al
 
Barriers to participation in clinical trials: patient and clinician barriers  
Barriers Classification Factor derived 
Patient barriers 
Additional demands of the RCT on the 
patient 
additional procedures, additional 
appointments, time pressures, 
venepuncture, inpatient hospital stays, 
discomfort from medical procedures, 
length of study, worry about 
experimentation, uncomfortable 
procedures, travel and travel costs, extra 
costs 
Patient level 
factors 
Additional trial 
investigations 
 
Additional travel and extra 
costs 
 
Duration of trial and follow 
up 
Patient preference for a particular 
treatment 
wish not to change medication, not to 
take placebo, not to take experimental 
medication, not to take any medication, 
patient request for a specific intervention, 
strong patient preference for one 
treatment option 
Aversion to treatment choice by random 
allocation 
Patient level 
factors 
Patients’/parents’ preference 
for a particular treatment 
 
Patients’/parents’ attitude 
towards their taking 
experimental medicine or 
placebo 
 
Treatment choice by 
random allocation 
Worry about uncertainty 
 efficacy of treatment on offer is 
unproven, distrust of hospital or 
medicine, fear of unknown 
Patient level 
factors 
Patients’/parents’ concerns 
about side effects of new 
drug 
 
Concerns about information and consent 
amount of information provided to 
research participants, wording of 
information, complexity of information 
provided, different forms of information 
presentation: written /verbal/video, 
Information 
and consent 
related factors 
 
 
 
Amount and complexity of 
trial information provided 
 
Clarity in presentation of 
trial information 
 
122 
 
limited reading skills and English not 
being the primary language, clinicians 
experience, difficulty in giving 
information, worry about level of 
information required and that information 
may be frightening, consent procedure 
barrier to recruitment 
 
 
 
 
Patient level 
factors 
 
 
 
 
 
Clinical team 
factors 
Experience and training of 
clinical team seeking 
consent 
 
Social and emotional 
dynamics of trial discussion 
 
Consent rate 
 
Language or cultural barrier 
 
Difficulty in approaching 
patents for consent  
Clinician barriers 
Time constraints 
time pressures from usual clinical 
practice, time demands of recruitment 
and follow up 
Clinical team 
factors 
Clinical workload 
 
Staffing and training 
lack of trained staff, no additional 
support, lack of research experience in 
clinicians, lack of available support staff 
Clinical team 
factors 
Research experience of 
clinical team 
 
Availability of designated 
research team 
 
Availability of research staff 
out of hours 
 
Presence of designated 
research nurse/practitioner 
Rewards and recognition 
economic incentives 
Excluded Information available from 
the Chief Investigator 
Impact on doctor patient relationship 
fear of adverse effect on doctor-patient 
relationship, perceived conflict in their 
role as clinicians and researchers 
Concern for patients   
Clinical team 
factors 
Clinician attitude to 
involving patients in 
research 
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concern about treatment toxicity, side 
effects, burden of trial for patients 
including travel distance and costs, 
reluctance to recruit severely ill patients 
Problems in complying with the protocol Clinical team 
factor 
 
Trial level 
factor 
Clinician preference for a 
particular treatment 
 
Study protocol compared to 
clinical practice 
2. Campbell et al 
Hypothesis of factors tested for association with recruitment success 
Trials with complex trial design do not 
recruit as well as simple trials 
Trial level 
factor 
Trial design 
Less well funded trials do not recruit well Trial level 
factor 
Funding 
Trials without dedicated trial 
management expertise do not recruit as 
well as those with trial management 
expertise 
Trial level 
factor 
Trial management 
Trial with multidisciplinary input recruit 
better than those that do not have this 
input 
Excluded Information available from 
the Chief Investigator 
Trials with consumer involvement recruit 
better than those that do not 
Excluded Information available from 
the Chief Investigator 
Trials that have a successful pilot phase 
recruit better than those that do not have 
a pilot phase 
Trial level 
factor 
Previous feasibility 
assessment 
 
Previous pilot trial 
Trials that have dedicated paid local 
coordinators recruit better than those that 
do not 
Trial level 
factor 
Trial management 
Cancer trials recruit better than non-
cancer trials 
Trial level 
factor 
Being a drug/cancer trial 
Drug trials recruit better than non-drug 
trials 
Trial level 
factor 
Being a drug/cancer trial 
Trials funded through a response mode Trial level Funding 
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funding have different recruitment rates 
to those funded through a commissioned 
process 
factor 
Reasons for delays in recruitment to the included cohort of trials 
problems with central staff, local 
research staff, internal problems e.g. staff 
Site level 
factor 
 
Clinical team 
factor 
Number of trained staff 
 
 
Motivation of clinical team 
local clinical arrangements, merging / 
reorganisation of trusts, major relocation 
of services, department policies 
Site level 
factor 
Local clinical arrangements 
funding issues Trial level 
factor 
Funding 
delays in ethical clearance, MREC, 
LREC 
R&D delays, time delay since grant 
application 
Excluded  Information available from 
the Chief Investigator 
delays in supply of drug/placebo Excluded Information available from 
the Chief Investigator 
adverse publicity about medical research, 
external problem e.g. publicity 
Trial level 
factor 
Publicity by the trial team 
 
External publicity 
setting up GP practices took longer than 
anticipated 
Site level 
factor 
Time to open up site 
simultaneous other local research 
projects, competing research, conflict 
with other trials 
Site level 
factor 
Competing local research 
projects 
delays due to changes in data legislation, 
changes in technology 
Excluded Information available from 
the Chief Investigator 
fewer eligible than expected, smaller 
percentage agreeing to participate, 
recruitment targets too ambitious 
Trial level 
factor 
 
Site level 
factor 
Lack of pilot/feasibility 
assessment 
 
Recruitment target 
absence of perceived clinical equipoise Trial level Clinical equipoise 
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factor 
issues with procedures/interventions trial 
process too demanding 
Patient level 
factor 
Additional trial 
investigations 
complexity of trial design, trial 
methodology considered too complex 
Trial level 
factor 
Trial design 
conflicting workload pressures, long 
waiting lists, additional theatre time 
required 
Clinical team 
factor 
Clinical workload 
language/written English difficulties Patient level 
factor 
Language or cultural barrier 
treatment preferences Patient level 
factor 
 
Clinical team 
factor 
Patients’/parents’ preference 
for a particular treatment 
 
Clinician preference for 
particular treatment 
research not considered as priority Clinical team 
factor 
Perceived importance of 
research generally in 
clinical practice 
 
Perceived importance of the 
particular research question 
no local access to intervention Patient level 
factor 
Intervention available only 
in the trial 
Case studies of trials: common factors in the successes of part B trials 
Facilitator  Classification Factor derived 
Important/interesting research question, 
topic important, urgent need for research, 
important question, timely and managed 
to roll several questions into one study 
Clinical team 
factor 
Perceived importance of the 
particular research question 
Good design/good protocol, pragmatic 
study 
Trial level 
factor 
Trial design 
 
Study protocol compared to 
clinical practice 
Clinicians keen to recruit to trial Clinical team 
factor 
Motivation of clinical team 
 
Clinician attitude to 
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involving patients in 
research 
Drugs already tested, so easy to explain 
to patients 
Patient level 
factor 
Familiarity with 
experimental treatment 
Didn’t demand extra effort from patients, 
Impact on practice running and costs 
minimised, minimising work for health 
professionals 
Patient level 
factor 
Additional trial demands 
No competing trials for those 
centres/patients 
Site level 
factor 
Competing local research 
projects 
Drugs not available outside the trial Patient level 
factor 
Intervention available only 
in the trial 
Excellent trial management, trial units 
helpful, caring, annual meetings for all 
concerned, role of trial steering group 
 
Good planning and organisation by 
CTSU,  CTSU responsive, efficient, 
central organisation of many aspects of 
research 
Trial level 
factor 
Trial management 
Good communication between trial team 
and clinicians, flexibility of trial teams 
Study team 
factor 
Communication and 
coordination between study 
team members at site 
Good public relations/feedback/updates Trial level 
factor 
Trial publicity 
Good funding, NHS funding Trial level 
factor 
Funding 
Trial run by good team/infrastructure, PI 
well respected, PIs worked hard to keep 
collaborators on board, trial team 
communicative, responsive and alert to 
problems. Communication within team, 
between team and collaborating 
clinicians 
 
Good trial team, good research assistants 
Study team 
factors 
 
 
 
 
 
 
 
Motivation of the study 
team at site 
Research experience of PI 
and study team members at 
site 
 
Communication and 
coordination between study 
team members at site 
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Team worked hard at how to explain the 
study to patients 
 
 
 
 
 
Clinical team 
factor 
 
Communication and 
coordination between study 
team at site and CTU 
 
Research experience of 
clinical team 
 
Communication skills of 
clinical team 
Role of research nurse Clinical team 
factor 
Presence of designated 
research nurse/practitioner 
Study included everybody Trial level 
factor 
Patient inclusion criteria 
3. Toerien et al 
Study design, number of arms, control: 
active/placebo 
Trial level 
factor 
Trial design 
Single/multi-centre Excluded Information will be present 
Intervention: drug/surgery/allied/others Trial level 
factor 
Being a 
drug/cancer/surgical/-----
trial 
Funding source Trial level 
factor 
Funding 
4. Caldwell et al   
Recruitment strategies 
Novel trial designs 
 
Trial level 
factor 
Trial design 
Recruiter differences 
 
Information 
and consent 
related factors 
Experience and training of 
doctors clinical team 
seeking consent 
 
Senior doctors and nurses 
seeking consent 
Financial incentives for 
patients/participants 
Excluded Monetary incentives not 
acceptable for clinical 
research in UK 
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Methods of providing information Information 
and consent 
related factors 
 
 
Patient level 
factor 
Amount and complexity of 
information provided  
 
Clarity in presentation of 
trial information 
 
Consent rate 
5. Treweek et al   
Recruitment strategies   
Design changes Trial level 
factor 
Trial design 
Modification to the consent form or 
process 
Patient level 
factor 
Consent rate 
 
Modification to the approach made to 
potential participants 
Information 
and consent 
related factors 
Amount and complexity of 
information provided  
 
Clarity in presentation of 
trial information 
 
Senior doctors and nurses 
seeking consent 
Financial incentives for 
patients/participants 
Excluded Monetary incentives not 
acceptable for clinical 
research in UK 
Modification to the training given to 
recruiters 
Information 
and consent 
related factors 
Experience and training of 
clinical team seeking 
consent 
Greater contact between trial co-
ordinator and trial sites 
Trial level 
factor 
Trial management 
 
  
129 
 
This section of the survey could be designed to elicit only barriers, only 
facilitators or both barriers and facilitators to recruitment. In order to decrease the 
length of the survey and capture information on both facilitators and barriers in a 
common question, the factors were reworded such that they could apply both as a 
facilitator or barrier depending on whether they boosted or hindered recruitment 
respectively.  The questions in this section were designed to obtain graded 
responses from -3 to +3, as described earlier. Open type questions were provided 
to obtain information on the various strategies applied to overcome the problems 
and for participants to express their reflective experiences and views on how trials 
could be organised differently in the future to improve recruitment.     
4.2.3 Pretesting/Piloting the questionnaire 
The paper version of the questionnaire was sent for piloting to a small sample of 5 
people. 3/5 people (60%) responded.  The initial version had separate lists of 
facilitators and barriers and participants were asked to identify the top 5 in each 
list. Two out of the three respondents found the questionnaire lengthy, difficult to 
complete and it took them 35-40 minutes to do so. Some questions were thought 
to be ambiguous and there was a suggestion for use of computers to enhance the 
presentation and make it easier to complete.  
After the pilot, the questionnaire was modified. The length of the questionnaire 
was reduced by combining the facilitators and barriers into a single list of factors 
that could be graded as either in the same question. Efforts were made to provide 
an evidence-based list of factors affecting recruitment while taking measures to 
keep the length of the survey and time of completion within reasonable limits. 
Factors, for which objective information was thought to be available from other 
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sources, such as delays in ethical or R&D approval or problems with supply of 
investigational drug/placebo were excluded from the questionnaire. However, free 
text space for additional comments was provided at the end for responders to note 
any issues not covered in the survey.  
The factors were reworded so that they were simpler and clearer. An online 
version was created by using a survey software (www.surveygizmo.com). The 
questions were arranged such that they had a logical flow. Each category of 
factors was arranged as small separate sections on a webpage for better 
presentation and ease of completion. The participants could easily navigate 
forwards and backwards to re-visit a section if they needed to and the completion 
time was restricted to 10-15 minutes. 
The survey instrument was used to investigate the recruitment experience of 
clinical teams in a large multicentre randomised controlled trial with children in 
the UK (the MAGNETIC trial), as described in Chapter 5.  
5.3 DISCUSSION 
A survey is a systematic method of collecting data from a population of interest, 
usually through the use of a structured and standardized questionnaire 
(Conducting Survey Research 1999). The methods of conducting survey research 
can be interviews, either face to face or telephonic, or using postal or electronic 
questionnaires. The advantages of a participant completed questionnaire over an 
interview are that it is quicker and cheaper, avoids interviewer bias and allows 
respondents to record their responses privately even to sensitive issues. The 
disadvantages are that questions may be misunderstood or not fully answered by 
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the respondent and the need to rely more on closed questions to ensure 
consistency in the range of answers for a question and for ease of analysis (Bruce, 
Pope & Stanistreet 2008). E-surveys offer a number of advantages over paper or 
telephone survey techniques in terms of lesser time and cost requirements, better 
accuracy in terms of lesser data transcription errors, faster creation and delivery, 
enhanced presentation and higher response rates. The potential disadvantages 
include response bias resulting from unequal access to internet, issues of 
authenticity, data security and confidentiality, and respondent non-response or 
procrastination (Anderson, Kanuka 2003).   
For these reasons, the recruitment survey questionnaire was developed as an 
online tool.  Care was taken to avoid errors due to respondent misinterpretation of 
questions by phrasing the questions in a simple and clear manner. A mix of open 
and closed questions was provided to obtain accurate responses but also provide 
respondents the freedom to express their views. Efforts were made to make the 
survey user friendly by arranging the questions in a logical order and restricting 
the length of the survey. However, as for any other survey instrument the 
generation of useful results depends on a good response rate from a representative 
sample of the population of interest and obtaining true and accurate responses 
from participants.  
Recruitment to a clinical trial and its conduct is shaped by various internal and 
external forces including the shifting dynamics at sites because of changes in 
jobs/roles of staff including periodic turnover of trainee doctors every few months 
and change in policies at the hospital or trust level. Understanding the working of 
individual trials and of trial teams at various sites in a multicentre trial, with their 
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unique challenges, as well as the responses of the research teams to these 
challenges can provide important information that can be used to inform the 
design and conduct of future trials (Campbell et al. 2007). 
This survey questionnaire could be a very useful tool to investigate the 
recruitment experience of clinical teams and identify facilitators and barriers to 
recruitment to a single or multi-centre clinical trial in any clinical setting or 
speciality involving adults or children. It provides a common list of questions to 
participants at multiple sites and can be used to elicit the facilitators and barriers 
to trial participation in general but can be adapted and modified by adding trial 
specific questions and highlighting trial/speciality specific recruitment issues. It is 
designed to gather data from people with a range of responsibilities related to 
recruitment to the trial. It can be aimed at staff directly involved with recruitment 
but can also be extended to other staff that facilitate recruitment or are involved 
indirectly to gain an insight into their perspective on issues around recruitment to 
the trial. The survey can be easily sent to a large number of participants at the 
same time. It can be used to gauge role and site specific perceptions of the 
research team and can provide a detailed understanding of the various factors 
affecting recruitment in addition to information provided by other monitoring 
tools such as screening logs.  
This survey tool was designed to be used at the end of the recruitment phase of a 
study to identify useful lessons for future research and other trialists. It could be 
used however, with some modification, in the pre-trial phase to identify potential 
problems or in the early and middle recruitment phases when observed 
participation rate is lower than expected. During a trial, the study team will often 
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contact under-recruiting sites to obtain information about problems encountered 
or higher than average recruiting sites to identify facilitators. This tool would 
provide a more systematic approach to the collection and consideration of such 
information, ensuring that all evidence-based barriers and facilitators are reviewed 
by the site in their response, so that appropriate strategies can be implemented to 
overcome the problems identified. If the survey is to be undertaken during the 
recruitment phase to identify modifiable aspects of the process, factors such as the 
time taken to open the site and whether there was a previous feasibility or pilot 
study would not be relevant. 
Since recruitment performance is usually variable at different sites, it can be used 
to investigate the various site specific issues. This will not only provide a detailed 
understanding of the internal milieu of the trial but also provides the opportunity 
for comparison of responses between successful and non-successful sites. 
Identification of facilitators or barriers and strategies applied at sites with 
successful recruitment in comparison to less successful sites may highlight some 
modifiable differences, which can form the basis of interventions and strategies to 
boost recruitment to an ongoing clinical trial or provide useful lessons for 
designing and conducting future trials.  
The survey questionnaire has some potential limitations. Being a subjective tool, 
it is prone to responder misinterpretation and the authors encourage trialists to 
pilot the questionnaire with a sample of their trial team prior to use to ensure 
consistent understanding of the listed factors. Exclusion of factors such as 
monetary incentives may potentially limit the applicability of the survey in 
settings where financial incentives are accepted practice.  
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Although it has been designed to provide an evidence based list of generic factors 
that affect recruitment to clinical trials, the authors would again encourage trialists 
to think about other anticipated or observed trial specific issues and modify and 
adapt the questionnaire before use taking into consideration the type of trial and 
the stage of recruitment. The length of the survey can be reduced further by 
excluding factors that are thought to be irrelevant to a particular trial.  
This recruitment survey tool was used to elicit barriers and facilitators to 
recruitment of children to the MAGNETIC trial, as described in the next Chapter.  
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Chapter 5 
A SURVEY OF FACILITATORS AND BARRIERS TO 
RECRUITMENT TO THE MAGNETIC TRIAL 
5.1 BACKGROUND 
Conducting clinical trials with children presents a unique set of challenges due to 
the vulnerability of the population. There are ethical considerations including the 
need to protect them from harm, and issues around obtaining informed consent, 
which is usually given by parents. There are other methodological issues which 
can make recruitment to paediatric trials challenging. The burden of disease in 
children due to chronic illness is relatively small; certain conditions may be 
uncommon reducing the pool of eligible population for a trial and the diagnostic 
criteria may be less precise and difficult to apply (Smyth, Weindling 1999, Smyth 
2001).  
Recruitment to a randomised controlled trial can be affected by an array of 
internal and external factors, which are important determinants of trial success or 
failure. Understanding the various factors that operate in a trial setting and at 
various sites in a multicentre clinical trial, along with the response of the clinical 
teams to overcome the challenges, can provide important information that can be 
used in the planning, design and conduct of future clinical trials (Campbell et al. 
2007).  
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Several studies have investigated clinical teams’ perspectives on barriers to 
patient recruitment (Spaar et al. 2009b, Fernandez et al. 2011) and their 
experiences, beliefs and attitudes (Caldwell, Butow & Craig 2002, Cook et al. 
2008) to patient participation in trials, as discussed in Chapter 4. Systematic 
reviews (Ellis 2000, Cox, McGarry 2003, Mills et al. 2006, Tournoux et al. 2006) 
of studies reporting barriers to participation in cancer trials reported various 
physician and patient related factors along with system or organisational barriers 
and other factors relating to protocol, stage of disease, associated co-morbidities, 
age, gender, ethnicity, and sociocultural factors etc.  However, none of the 
included surveys in these reviews provided a comprehensive list of barriers and 
facilitators. An assessment of study quality by Fayter et al (2007) showed the 
studies to be methodologically poor and highlighted several threats to internal and 
external validity of the included studies in terms of vulnerability to selection bias; 
lack of a reliable and validated survey instrument, and poor reporting of methods 
of recruitment, data collection and data analysis.  We conducted a survey of 
facilitators and barriers to recruitment with the clinical teams of a multicentre 
randomised controlled trial with children: the MAGNETIC trial (Powell et al. 
2013) using the recruitment survey tool, described previously.  
MAGNETIC trial 
The MAGNETIC trial was a randomised, multicentre, double blind, placebo 
controlled study evaluating the role of nebulised magnesium in severe acute 
asthma in children, unresponsive to standard inhaled treatment. Two to sixteen 
year old children presenting to the emergency department or children’s 
assessment unit with acute severe asthma were given conventional treatment on 
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presentation. They were reassessed after 20 minutes of conventional treatment and 
children who met the criteria for severe asthma after 20 minutes of standard 
inhaled therapy were enrolled into the study. Written informed consent was 
obtained from the parents or guardians in the 20 minute period when the child was 
receiving initial treatment. The MAGNETIC trial recruited from 30 sites across 
the UK. There were three other sites which had opened, but could not recruit any 
patients and a further four, where efforts were made to set up the trial but they did 
not open to recruitment (Powell et al. 2013). The list of sites is presented in 
Appendix 18.  
The MAGNETIC trial was chosen for surveying the clinical teams and 
investigating the facilitators and barriers to recruitment for a number of reasons. It 
was a large multicentre RCT that successfully recruited over 500 children from 30 
sites across the UK. The recruitment performance at sites was variable and 
therefore it was anticipated that surveying the clinical teams at all sites would 
provide a rich source of data on a wide range of facilitators and barriers to 
recruitment. Responses from the more successful sites could provide useful 
learning lessons in terms of facilitators and strategies adopted by clinical teams to 
overcome the identified barriers. On the other hand, responses from less 
successful sites could provide useful insight into barriers to recruitment and 
hurdles that were difficult or impossible to overcome. Additional logistical 
considerations that favoured the choice of MAGNETIC was that the trial had 
recently closed to recruitment and the timing of the survey was ideal to explore 
the recruitment experience of clinical teams.   
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5.2 AIMS 
The aims of this survey were:   
1. To establish the perception of clinical teams with regards to facilitators 
and barriers to recruitment to the trial.  
2. To elicit information on recruitment strategies or interventions, that were 
applied at various sites to improve recruitment 
3. To seek reflective comments from the study teams on how the trial could 
have been organised differently  
5.3 METHODS 
5.3.1 Survey tool 
The survey was conducted using an online questionnaire adapted from the web 
based recruitment survey tool described in Chapter 4 (Kaur, Smyth & Williamson 
2012). The questions were worded to apply specifically to the MAGNETIC trial. 
A copy of the survey questionnaire is presented in Appendix 19.  
5.3.1.1 Writing the questionnaire 
The first section was designed to collect information on responder characteristics 
such as the ID of the responder, study role, name of the hospital or site they were 
recruiting from and duration and period of involvement in the trial. Personal 
information such as name of individuals were not collected, but each potential 
responder was issued a unique identification number for data management 
purposes, which was sent to them in the email inviting them to participate. The 
second section was designed to elicit information on their perception with regards 
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to facilitators and barriers to recruitment to the trial. The responders were asked to 
score a preformed, evidence based list of potential factors (Table 14) affecting 
recruitment to a clinical trial. These factors were categorised in terms of operating 
at the level of trial, site, patient, clinical team, information and consent process 
and central study team. The responders were asked to grade each factor from -3 to 
+3 depending on whether the factor was perceived as a strong (-3), intermediate (-
2), or weak (-1) barrier, or weak (+1), intermediate (+2) or strong (+3) facilitator 
and (0) if thought to be not applicable.  
The final section was designed to collect information on interventions or 
strategies that were applied at sites, to overcome the barriers that were identified 
and the effectiveness of these interventions.  The responders were then asked for 
their views on how the trial could have been organised differently to improve 
recruitment. The responders were invited to give additional comments, if any.  
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Table 13: Factors listed in the recruitment survey questionnaire  
Trial level factors 
Funding 
Trial design 
Patient Inclusion Criteria 
MAGNETIC being a drug trial 
Study protocol compared to clinical practice Clinical equipoise 
Previous feasibility assessment 
Previous pilot trial 
Publicity by the trial team 
External publicity 
Trial management 
Protocol amendments 
Seasonal variation 
Site level factors 
Time to open up site 
Recruitment target 
Time to complete administrative work related to the trial 
Number of trained staff 
Local clinical arrangements 
Choice of recruitment setting 
GCP training 
Data collection process 
Competing local research projects 
Local research culture 
Patient related factors 
Consent rate 
Familiarity with experimental treatment 
Parent's attitude towards their taking experimental medicine or placebo 
Parent's preference for a particular treatment 
Parent's concerns about side effects of new drug 
Duration of trial and follow up 
Treatment choice by random allocation 
Additional trial investigations 
Additional travel and extra costs 
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Intervention available only in the trial 
Communication between research team and parents 
Clinician influence 
Language or cultural barriers 
Clinical team related factors 
Research experience of clinical team 
Presence of designated research nurse or practitioner 
Availability of designated research team 
Availability of research staff out of hours 
Shift patterns of work 
Motivation of clinical team 
Clinical workload 
Perceived importance of research generally in clinical practice 
Perceived importance of the particular research question 
Communication skills of clinical team 
Clinician preference for particular treatment 
Clinician attitude to involving patients in research 
Difficulty in approaching patients for consent 
Information and consent related factors 
Amount and complexity of trial information provided 
Clarity in presentation of trial information 
Social and emotional dynamics of trial discussion 
Time and setting of consent seeking 
Senior doctors and nurses seeking consent 
Experience and training of clinical team seeking consent 
Study team factors 
Motivation of MAGNETIC study team at site 
Communication and coordination between study team members at site 
Communication and coordination between study team at site and CTU 
Research experience of PI and study team members at site 
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5.3.1.2 Developing the online survey 
The survey questionnaire was developed using the survey gizmo software 
(www.surveygizmo.com). Each question was designed using the appropriate 
question type. Textbox design was used for questions asking about the ID of 
responders and name of site they were recruiting from. Checkbox style was used 
for responders to select options such as period of involvement in the trial. The 
question on factors affecting recruitment was presented as a radio-button grid, so 
that responders could select a single option only and give each factor only one 
score. The open questions on recruitment interventions and reflective comments 
were designed using essay type questions to provide appropriate space and word 
limit for responders to express themselves freely. Anonymity was maintained and 
no personal information was collected.  
The questions were arranged in a logical sequence. The section on responder 
characteristics was followed by section on choice of factors affecting recruitment 
to be followed by open questions on recruitment strategies and comments on 
organisation of the trial. A small number of questions were presented on a 
webpage. Each category of factors was presented on a separate webpage for better 
presentation and ease of completion. Skip logic was applied to direct questions to 
responders based on their response to the previous question, so that they may skip 
questions that were not relevant to them. The users could navigate forwards and 
backwards to revisit questions, if needed and the option to save progress and 
continue at a later time was available, using the web link that was sent to them.  
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5.3.1.3 Testing the survey 
The survey questionnaire was tested with the senior members of the research team 
(PW, CP) prior to launch. They were requested to complete the test versions of the 
survey using a test web link. The display of questions and webpages was checked. 
It was ensured that the survey software was functioning adequately to ensure that 
the questions could be answered accurately and the respondents could ‘save and 
return’ and navigate through the survey as planned. The survey software was able 
to calculate the approximate time taken to complete the survey and this was 
crosschecked with the actual time taken at the testing stage. Data validation 
checks were conducted. Test surveys were completed by GK and the responses 
collected and reported in the survey exports were crosschecked with the actual 
responses entered to ensure data was collected and reported accurately by the 
survey software. The test links to the survey were emailed via the automated 
email system to ensure that the emails were delivered appropriately, in the correct 
format and that the respondents could be tracked by the survey software.  
5.3.2 Ethical considerations 
The University of Liverpool and National Research Ethics Service (NRES) was 
contacted to check if ethical clearance was required prior to conducting the 
survey. The University of Liverpool directed the query to NRES, as National 
Health Service (NHS) staff was involved in the survey. The project details were 
sent to the queries line at National Research Ethics Service (NRES), and they 
confirmed that that ethical approval was not needed for this project, as per the 
‘Defining Research’ guidance issued by the NHS National Patient Safety Agency 
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(National Research Ethics Service). The correspondence with University of 
Liverpool and NRES is presented in Appendix 20. 
5.3.3 Administration of the survey 
5.3.3.1 Sites 
The survey was intended to be conducted at all 37 sites as recruitment experience 
was envisaged to be different at the various sites. The Chief Investigator of the 
MAGNETIC trial wrote to Principal Investigators at all sites requesting their 
participation in the study.  GK emailed the Principal Investigators subsequently, 
to seek permission to contact clinical staff at that site. The survey was emailed to 
clinical staff at sites, once permission was obtained from the PI, following which 
their contact details were requested from the NIHR Medicines for Children 
Research Network Clinical Trials Unit, who were responsible for managing the 
trial.  
5.3.3.2 Contact Details  
The names and email addresses of clinical staff involved with recruitment to the 
trial were requested from the NIHR Medicines for Children Research Network 
Clinical Trials Unit. Staff allocated to one or more of the following roles on the 
delegation log were identified to be contacted:  
 A- screening of patients 
 C- obtaining informed consent 
 D- prescription of trial treatment 
 E- Asthma severity score training 
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Roles A and C included staff directly involved in recruiting to the trial. Additional 
roles such as prescription of trial treatment and conducting asthma severity 
scoring training were selected to include clinical staff, who could provide valuable 
insight into the various patient and clinical team related factors and comment on 
training related issues if any. It was taken into consideration that the roles will 
overlap and individuals will have multiple roles; for example person delegated to 
perform ‘D’ will also be delegated to perform ‘A’ and/or ‘B’ but this approach 
was taken to minimise the chances of missing the relevant people involved in 
recruitment to the trial.  
5.3.3.3 Invitation to participate in the study 
An initial invitation describing the aims of the survey provided the link to the 
questionnaire.  Voluntary participation was requested and potential responders 
were reassured that no personal information will be collected, no sites will be 
identified in any publication and confidentiality of data will be maintained. Each 
responder was issued a unique identification number for data management 
purposes. A copy of the invitation letter is presented in Appendix 21.  
5.3.3.4 Reminders to non-responders 
The non-responders were sent two subsequent reminders spaced four weeks apart. 
The initial invitation and the reminders were sent using the automated email 
system of the survey software. Additional email and telephonic reminders were 
sent to principal investigators and research nurses, who did not respond to the 
questionnaire despite the two reminders.  
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5.3.4 Data collection 
5.3.4.1 Collecting survey responses 
The responses to the questionnaire were collected online. The responders had the 
option to save their progress and continue at a later time. These responses were 
logged as ‘partial’ responses. A response was categorised as ‘complete’, once it 
was submitted.  
5.3.4.2 Eligible population at site 
The Health and Social Care Information Centre (HSCIC) was requested for 
information on the number of two to sixteen year old children with asthma or 
wheeze, presenting to the Accident and Emergency departments of the hospitals 
which were the recruiting sites for the MAGNETIC trial. This data was requested 
to ascertain an estimate of the size of the eligible population at sites. However, 
data on diagnosis and the number of A&E admissions at each hospital site were 
not available; this data could only be obtained at the corresponding NHS trust 
level. The total number of annual A&E admissions in the given age group was 
taken as a proxy indicator of the eligible population at each site, making the 
assumption that the relationship between overall population size and the number 
of eligible children presenting to A&E is the same across all sites. This data could 
be obtained only for the 25 English sites.  
5.3.4.3 Calibrated site recruitment  
Site recruitment was calibrated to account for the hospital population base, by 
dividing the number recruited at site by the number of 2-16 year old children 
presenting to Accident & Emergency department at the corresponding NHS trust, 
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during the period the site was open for recruitment. The MRC Clinical Trials Unit 
was requested for information on the duration of recruitment and number of 
patients randomised at each site. Proportionate eligible population for the duration 
of recruitment at each site was then calculated. The calculations are shown below: 
1.Eligible population for the duration of recruitment at site (EP) 
 = 
                              
                                           
   
 
                                     
 
  
Number of days the site recruited for  
 =                                     –                          
2.Calibrated site recruitment (CR) = 
                          
  
 
5.3.5 Data Analysis 
5.3.5.1 Facilitators and barriers to recruitment  
Commonly identified facilitators and barriers were defined a priori as those that 
were identified as a facilitator or barrier by 50% of the responders or more. In 
addition to the overall responses, the PI and research nurse responses were 
analysed separately. One PI and one research nurse response per site was included 
in the analysis to ensure equal representation of sites.  
5.3.5.2 Recruitment strategies  
The free text responses were grouped into themes to identify the recruitment 
strategies that were applied to overcome the hurdles that were identified at various 
sites.  
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5.3.5.3 Comments on how the trial could have been organised differently to 
improve recruitment 
The free text responses were grouped to identify the recurring themes on the 
subject.  
5.3.5.4 Statistical analysis 
The survey data was exported to an excel spread sheet and analysed using 
Microsoft Excel 2010. NVivo, qualitative data analysis software package (QSR 
international Pty Ltd. Version 10) was used to assist analysis of free text 
responses for identification of recruitment strategies and recurring themes on 
organisation of the trial to improve recruitment. The association between PI 
response and calibrated site recruitment was examined using Spearman’s rank 
correlation and linear regression using SPSS 20 (IBM SPSS Statistics for 
Windows, Version 20, Armonk, NY). 
5.4 RESULTS 
5.4.1 Administration of the survey 
A list of 656 potential contacts was obtained from the study delegation log of 
which contact details could be obtained for 491. This included Principal 
Investigators and research nurses, where available, at all 37 sites and other clinical 
staff at 30 of the 33 open sites; permission to contact other staff could not be 
obtained from the Principal Investigators at the remaining 3 sites. 
The survey was conducted from August 2011 to February 2012. The link to the 
online survey was e-mailed to available contacts comprising of principal 
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investigators, research nurses and clinical staff involved with recruitment, such as 
medical practitioners, nurse practitioners and nursing staff. 
5.4.2 Survey responses 
5.4.2.1 Overall responses 
A total of 206 responses were received- 169 complete and 37 partial responses. Of 
the 37 partial responses, 14 were duplicate responses, no data were recorded in 20 
and less than 25% of the questions were answered in 3. These were excluded from 
analysis.  The number and percentage of overall responses by role, duration and 
period of involvement is shown in Table 15.    
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Table 14: Number (%) of responses by role, duration and period of 
involvement 
 n % 
Role (n=169) 
PIs 33 19.5 
Medical Practitioners 71 42 
Research Nurses 42 24.9 
Others 23 13.6 
Duration of involvement (n=169) 
Whole trial period 92 54.4 
Part of trial period* 75 44.4 
No response 2 1.2 
*Period of involvement (n=75) 
Set up/early recruitment period 14 18.7 
Once trial established at site 54 72 
Both 3 4 
No response 4 5.3 
*period of involvement for responders who were not involved for the whole trial period  
 
5.4.2.2 PI responses 
The survey questionnaire was completed by PIs at 32 sites. Of the 30 sites that 
opened and recruited, a PI response was obtained from 27 sites. The PI at one site 
was on maternity leave when the survey was conducted and the survey 
questionnaire could not be sent to her. One site had two PIs and both had 
responded to the questionnaire, one response was selected at random to be 
included in the analysis of PI responses. Of the three sites that opened but did not 
recruit, a PI response was obtained from all three sites. Of the four sites that did 
not open to recruitment, PIs from two sites completed the questionnaire.   
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5.4.2.3 Research nurse responses 
The survey questionnaire was completed by research nurses at 30 sites. Of the 30 
sites that opened and recruited, a research nurse response was obtained from 28 
sites. The survey could not be sent to research nurses at two sites as they had left 
post during the course of the trial. Of the three sites that opened but did not 
recruit, a research nurse was available at only one site and she responded to the 
questionnaire. There was no designated research nurse at one site and the research 
nurse at the other site had left post prior to the survey. Of the four sites that did 
not open to recruitment, only one site had a designated research nurse, who 
completed the questionnaire. 
 5.4.3 Response rates 
The overall response rate to the survey was 39%. The response rates of principal 
investigators and at least one research nurse per site are presented in Table 16.  
Table 15: Response rates for PIs and at least one research nurse per site  
Sites Number 
of PIs 
PI responses  Number of 
Research 
Nurses 
RN responses 
(one per site) 
Sites that recruited 
(n=30) 
29* 27 (93%) 28 
2α
 28 (100%) 
Sites that opened 
but didn’t recruit 
(n=3) 
3 3 (100%) 1 
α,β
 1 (100%) 
Sites that never 
opened (n=4) 
4 2 (50%) 1 
3 β
 1 (100%)  
*PI at one site on maternity leave 
α RN had left post before the survey was conducted, µ No designated research nurse at site 
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5.4.4 Facilitators and barriers to recruitment 
5.4.4.1 Overall responses 
The facilitators and barriers to recruitment identified in overall responses are 
ranked in order of frequency and presented in Table 17.  
Motivation and commitment of the study team was the most commonly identified 
facilitator to trial recruitment potentially offsetting the effects of practical 
constraints such as heavy clinical workload, shift patterns of work, lack of 
adequate number of trained staff and local clinical arrangements. Presence of a 
research nurse and a designated research team were thought to be very helpful in 
assisting busy clinical teams with trial recruitment and data collection.  
Effective communication and coordination between study team members at site 
was recognised to be an important factor that helped recruitment. An experienced 
Principal investigator and enthusiastic clinical team with good communication 
skills were thought to be instrumental in resolving local problems and ensuring 
successful trial recruitment at sites. Clinical teams’ perception of the importance 
of the research question and a positive attitude to involving patients in research 
was felt to be very important. Encouragement and support provided by PIs, senior 
clinicians and research nurses was important to keep up the motivation levels of 
staff and develop a positive research culture. 
Trial management support and good communication between the Clinical Trials 
Unit and study team at site were recognised as facilitators. Internal trial publicity 
by the study teams helped to maintain the presence of MAGNETIC trial among 
teams and increase parents’ and families’ awareness about the trial.  
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Simple patient inclusion criteria and clear presentation of trial information 
boosted recruitment. Good communication between research teams and parents 
and consent seeking by experienced and trained clinicians was thought to be very 
helpful in overcoming barriers such as parental anxiety about the potential adverse 
effects of the trial drug and their child taking an experimental medication or 
placebo. However, some responders expressed discomfort in approaching patients 
for taking consent. Excessive amount and complexity of trial information and time 
taken to complete trial related administrative work were criticised. Additionally, 
language and cultural barriers were thought to hinder recruitment. 
Another important hurdle was the time and setting of consent seeking. There was 
a 20 minute window period for taking informed consent while the patient was 
receiving initial treatment in the emergency department or children’s assessment 
unit. Seeking consent from the parents of an ill child in an acute or emergency 
setting in 20 minutes was found to be very challenging by the clinical teams.  
Lack of availability of research staff out of hours was recognised as an important 
barrier as these were noted to be times with excess patient flow but reduced staff, 
resulting in missing eligible participants for recruitment. An important regulatory 
hurdle identified by a high proportion of responders was Good Clinical Practice 
(GCP) training for clinical staff. Arranging GCP training and encouraging clinical 
staff to attend was found to be very difficult. Recruitment difficulties arising due 
to seasonal variation were also recognised.  
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Table 16: Facilitators and barriers to recruitment in order of frequency of 
responses 
Facilitators  (%) Barriers  (%) 
Motivation of MAGNETIC study 
team at site 
78.9 Clinical workload 87.3 
Communication and coordination 
between study team members at 
site 
74.5 Shift patterns of work 77.7 
Communication skills of clinical 
team 
70.3 Number of trained staff 77.3 
Presence of designated research 
nurse/practitioner 
68.1 Time and setting of consent 
seeking 
76 
Research experience of PI and 
study team members at site 
63.3 GCP training 69.6 
Publicity by the trial team 62.9 Time to complete 
administrative work related 
to the trial 
66.6 
Communication and coordination 
between study team at site and 
CTU 
62.1 Parent's concerns about side 
effects of new drug 
65.3 
Trial management 62 Parent's attitude towards their 
taking experimental medicine 
or placebo 
57.2 
Clinician attitude to involving 
patients in research 
60.9 Availability of research staff 
out of hours 
57 
Perceived importance of the 
particular research question 
60.1 Difficulty in approaching 
patients for consent 
53.9 
Availability of designated research 
team 
58.5 Local clinical arrangements 52.1 
Clarity in presentation of trial 
information 
58.4 Seasonal variation 51.8 
Patient inclusion criteria 57.5 Language or cultural barriers 50.3 
Motivation of clinical team 53.6 Amount and complexity of 
trial information provided 
50 
Experience and training of clinical 
team seeking consent 
50.4   
Communication between research 
team and parents 
50.4   
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5.4.4.2 Principal investigator responses 
The responses from the Principal investigators were also analysed separately. The 
facilitators and barriers to recruitment identified in responses from Principal 
investigators are ranked in order of frequency and presented in Table 18. The 
perception of Principal investigators was different from research nurses and 
overall responses in some respects. Motivation of the clinical team, their 
experience and training in providing information and seeking consent and 
communication between research team and parents were not recognised as 
facilitators. However, research experience of clinical team was thought to boost 
recruitment.   
The principal investigators did not see parents’ concerns about side effects of the 
drug or their anxiety related to their child taking experimental medicine, as 
barriers, which may be explained by their experience and skills in communicating 
with parents. This group did not find it difficult to approach patients for consent 
and language and cultural barriers were not perceived to be important. 
Information provided to parents or families was not felt to be excessive or too 
complex. However, a delay in opening of site was identified as a barrier by 
Principal investigators at more than 50% of the sites. This group regarded consent 
seeking by senior doctors and nurses as a hindrance to recruitment.  
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Table 17: Facilitators and barriers to recruitment in PI responses 
Facilitators % Barriers % 
Motivation of MAGNETIC study 
team at site 
80.7 Clinical workload 87.5 
Communication and coordination 
between study team members at 
site 
77.4 Shift patterns of work 84.4 
Communication skills of clinical 
team 
75 GCP training 84.4 
Presence of designated research 
nurse/practitioner 
68.8 Time and setting of consent 
seeking 
81.3 
Availability of designated 
research team 
65.7 Number of trained staff 81.3 
Patient inclusion criteria 64.5 Time to complete 
administrative work related 
to the trial 
62.5 
Perceived importance of the 
particular research question 
62.5 Seasonal variation  62.5 
Communication and coordination 
between study team at site and 
CTU 
61.3 Availability of research 
staff out of hours 
59.4 
Research experience of PI and 
study team members at site 
61.3 Senior doctors and nurses 
seeking consent 
58.1 
Publicity by trial team 59.4 Time to open up site 56.3 
Trial management 59.4 Local clinical arrangements 54.8 
Clarity in presentation of trial 
information 
59.4   
Clinician attitude to involving 
patients in research 
56.3   
Research experience of clinical 
team 
53.1   
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5.4.4.3 Research nurse responses 
The perception of research nurses was also different in some respects, compared 
to overall responses and Principal investigator responses. They recognised some 
additional factors as facilitators such as presence of clinical equipoise, which was 
not identified in overall responses or by the PIs. This group perceived that 
recruitment was better if senior doctors and nurses sought consent.  
They also identified some additional barriers. The clinical team was thought to be 
lacking in research experience and motivation, which hindered recruitment. 
Research was not perceived to be important in routine clinical practice and the 
local research culture was felt to be unhelpful. They identified additional practical 
constraints such as data collection and trial demands resulting from study protocol 
being different from routine clinical practice. It was felt that recruitment was 
hindered by the fact that MAGNETIC was a drug trial and parents were not 
familiar with the experimental medicine resulting in a low consent rate.  
The research nurse responses ranked in order of frequency are presented in Table 
19.  
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Table 18: Facilitators and barriers to recruitment in research nurse 
responses 
Facilitators % Barriers % 
Communication and coordination 
between study team at site and CTU 
90 Clinical workload 93.3 
Trial management 82.8 GCP training 86.7 
Publicity by trial team 75.9 Number of trained staff 83.3 
Motivation of MAGNETIC study 
team at site 
73.3 Shift patterns of work 83.3 
Communication and coordination 
between study team members at site 
73.3 Time and setting of consent seeking 76.7 
Research experience of PI and study 
team members at site 
70 Research experience of clinical team 76.7 
Communication between research 
team and parents 
70 Parent's concerns about side effects of 
new drug 
76.7 
Patient inclusion criteria 66.7 Local research culture 73.3 
Clarity in presentation of trial 
information 
66.7 Local clinical arrangements 70 
Presence of designated research 
nurse/practitioner 
65.5 Data collection process 66.7 
Communication skills of clinical 
team 
63.3 Availability of research staff out of 
hours 
63.3 
Availability of designated research 
team 
60 Perceived importance of research 
generally in clinical practice 
63.3 
Clinician attitude to involving 
patients in research 
60 Parent's attitude towards their taking 
experimental medicine or placebo 
62.1 
Perceived importance of the 
particular research question 
53.3 MAGNETIC being a drug trial 62.1 
Senior doctors and nurses seeking 
consent 
53.3 Time to complete administrative work 
related to the trial 
60 
Experience and training of clinical 
team seeking consent 
53.3 Seasonal variation  60 
  Familiarity with experimental 
treatment 
60 
  Motivation of clinical team 56.7 
  Consent rate 56.7 
  Study protocol compared to clinical 
practice 
56.7 
  Language or cultural barriers 53.3 
  Difficulty in approaching patients for 
consent 
50 
  Choice of recruitment setting 50 
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5.4.4.4 Differences in perception of PIs and research nurses 
Some additional facilitators and barriers identified only by the principal 
investigators or the research nurses have been mentioned previously.  There were 
also differences in opinion between PIs and research nurses in some of the 
domains as to whether they were facilitators or barriers. In 15 (55%) sites there 
was a difference of perception as to the impact of the experience of the research 
team on study success. 53% of PIs perceived this as a facilitator, whereas 77% of 
the research nurses regarded this as a barrier. In 12 (46%) sites, there was a 
difference in perception of the impact of senior clinicians and nurses seeking 
consent on ease of recruitment. 58% of PIs regarded this a barrier, whereas 77% 
of the research nurses regarded this as a facilitator.  
5.4.5 Correlation of PI responses with calibrated site recruitment 
Scatter charts were initially plotted for each factor against calibrated site 
recruitment to examine a possible relationship between the two variables. These 
are presented in Appendix 22.  Spearman’s rank-order correlation was calculated 
to measure the strength and direction of association between each factor and 
calibrated site recruitment. A positive correlation, indicating an increase in 
calibrated site recruitment with increase in PIs score for the factor and vice-versa, 
was noted with trial design (rs 0.462, p 0.031), MAGNETIC being a drug trial (rs 
0.488, p 0.021), trial management (rs 0.46, p 0.031), choice of recruitment setting 
(rs 0.504, p 0.017), consent rate (rs 0.553, p 0.008), parent's attitude towards their 
child taking experimental medicine or placebo (rs 0.639, p 0.001), language or 
cultural barriers (rs 0.426, p 0.048), research experience of clinical team (rs 0.428, 
p 0.047), presence of designated research nurse/practitioner (rs 0.442, p 0.04), 
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difficulty in approaching patients for consent (rs 0.582, p 0.004), communication 
and coordination between study team at site and CTU (rs 0.507, p 0.019). A 
negative correlation, indicating an increase in calibrated site recruitment with 
decrease in the PIs score for the factor and vice-versa, was noted with competing 
local research projects, which was statistically significant (rs -0.473, p 0.026).  
Univariate regression analysis was conducted and factors listed below were found 
to be significant predictors of calibrated site recruitment. The sample size was 
inadequate for the number of independent variables, to be able to conduct a 
multivariate analysis, since the data on PI responses and calibrated site 
recruitment was available only for 22 sites (Wilson VanVoorhis 2007).  The 
assumption of a normal distribution for calibrated site recruitment was felt to be 
reasonable, although a slight skew was noted (Appendix 23).  
 MAGNETIC being a drug trial (R2 0.2, p-value 0.037) 
 Choice of recruitment setting (R2 0.23, p-value 0.026) 
 Competing local research projects (R2 0.19, p-value 0.042) 
 Consent rate (R2 0.29, p-value 0.01) 
 Parent's attitude towards their child taking experimental medicine or 
placebo (R
2
 0.41, p-value 0.001) 
 Language or cultural barriers (R2 0.21, p-value 0.031) 
 Difficulty in approaching patients for consent (R2 0.27, p-value 0.013) 
 Amount and complexity of trial information provided (R2 0.18, p-value 
0.049) 
 Communication and coordination between study team at site and CTU (R2 
0.25, p-value 0.021) 
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These results are presented in Appendix 24.  
5.4.6 Recruitment strategies 
Free text responses were received from 108 participants on interventions or 
strategies that were applied to overcome the barriers to recruitment. Having a 
designated research nurse was the most commonly reported intervention (25%). 
Research nurses were found to be very helpful at all stages of recruitment; from 
identification of potential patients to notifying staff, helping with trial procedures 
and data collection and providing hands on support to the busy clinical teams. 
They were involved in providing training to staff and were thought to be 
instrumental in bringing about a change in culture at sites; motivating staff to be 
more involved and to recruit to the trial. Presence of Medicines for Children’s 
Research Network (MCRN) clinical research facilitators was thought to be helpful 
in reminding staff about the trial. 10 responders commented on the effectiveness. 
Responders described presence of a research nurse as ‘critical’, ‘essential to the 
success of the trial’ and ‘very effective’.  One site attributed its success to 
appointment of a paediatric research nurse who was described to have ‘generated 
enthusiasm in the clinical team’, ‘made protocol violations extremely unlikely 
through education and reminders’, leading to a ‘dramatic improvement in 
recruitment’. 
GCP training was the second most commonly reported strategy (20.4%). Training 
sessions were arranged and doctors were encouraged to undertake GCP training. 
Four responders commented on the practical aspects of conducting the training 
and found it to be challenging, ‘hard to maintain’ and difficult to train all doctors 
due to practical constraints such as heavy workload, short term sickness and high 
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rate of turnover of doctors. One responder commented on the effectiveness and 
found it to be very effective. One responder suggested that GCP training should 
be incorporated as a part of the core training for paediatric registrars. Additional 
funding to encourage GCP training was suggested by another.  
Teaching and training of staff was the next most commonly mentioned 
intervention (19.4%). Responders reported ‘multiple teaching and training 
activities’ and ‘roll out programmes’ to ensure that the staff were up to date with 
the study and could answer parents’ or patients’ questions with ease, follow the 
protocol and perform the asthma severity scoring accurately. Refresher sessions 
were provided to keep the staff trained during periods of no recruitment due to 
seasonal variation. Efforts were made to train most staff, so that a trained member 
of staff was available on most shifts. Training sessions were arranged for both 
doctors and nursing staff. One responder suggested training more nursing staff 
than doctors, due to rotational posts and frequent changeover of doctors. Only two 
responders commented on the effectiveness, who found this intervention to be 
very helpful and effective.  
Trial publicity was mentioned next (10.2%). Posters were put up in the ward and 
clinical areas to remind the parents, patients and clinical teams about the trial. 
Responders mentioned putting up posters across the hospital and ‘frequent change 
of posters to remind staff and attract attention’.  Recruitment graphs were 
displayed and emailed to staff with praise for recruiting to the trial. One responder 
mentioned that a variety of ‘aide memoires’ were placed throughout the 
department such as ‘MAGNETIC was go’; ‘Got a wheeze? Think MAGNETIC’. 
The trial was reported to be promoted via notice boards, memo books and 
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publicised during teaching sessions. Two responders commented on the 
effectiveness and found it to be effective.  
Motivation and support provided by principal investigator and senior medical 
team (10.2%) was thought to play a very important role.  Senior medical staff 
made themselves available and accessible to offer advice and practical help with 
recruitment. Regular communication with staff was felt to be important (8.3%).  
‘Regular updates and presentations at staff meetings to raise and maintain the 
profile of the study in the department’ were reported. Regular meetings and 
discussions with the team were thought to be very effective in increasing 
awareness about the trial and improve recruitment, ‘despite initial hindrances 
from the nurses and clinicians’. Repeated reminders to clinical staff (4%) 
emphasizing the importance of identification and recruitment of patients was 
mentioned.  
Measures to improve availability of doctors and research nurses (4.6%) to screen 
and consent were taken. Up to date list of people who could recruit and their 
contact details were made available to ward staff. Making a rota of prescribing 
doctors, giving bleeps to doctors and having an onsite doctor for screening and 
consent were mentioned. Research nurses were mobilised to be more available 
and to help with trial recruitment. Additional support measures during out of 
hours (4.6%), such as extra staff and twilight nurses and the funding to support 
this, was arranged. One responder mentioned limiting trial recruitment to office 
hours when more staff was available.  
Efforts were made to encourage clinical staff to recruit and to be more involved in 
the trial adding a competitive edge but staff attitudes were found to be very 
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difficult to change (4.6%). Motivated nursing staff in A&E who could identify 
patients and inform the research team was found to be effective in improving 
recruitment. Incentives were offered to staff for identifying and recruiting patients 
(3.7%), which was found to be effective. Good communication and improved 
relations between teams was found to be helpful. Recruitment and consent by 
senior and more experienced members of the team was felt to be very important as 
‘seeking consent in the acute setting where treatment needs to be initiated ASAP’, 
was thought to ‘put parents and clinical teams under pressure’. CTU support and 
having a dedicated trial manager was found to be very effective.   
Other measures that were taken were to ensure GCP trained staff at every shift 
which was reported to be not always possible. Nurse practitioners were 
encouraged to prescribe the drug and recruit patients. Shorter and simpler trial 
instructions and simpler paperwork were tried. Data collection was made simpler 
by giving the nursing staff fewer pages of the CRF. Clinical staff was encouraged 
to collect data that was needed at the time and research nurses collected 
demographic and other data retrospectively. Weekly screening was found to be 
useful to track if any patients were being missed.  Medical staff was chased for 
reasons for missing eligible patients.  
5.4.7 Free text responses on organisation of MAGNETIC  
The importance of having a designated research nurse at every centre was 
emphasized. It was felt that research nurses should be available to help with 
recruitment particularly at busy times and out of hours when more eligible 
patients came in and were missed due to heavy clinical workload. Availability of a 
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designated research nurse was described as ‘single most significant facilitator to 
recruitment and completion of the protocol in a timely manner’. 
Difficulties in seeking consent from parents of an acutely unwell child in 20 
minutes was reported to be very difficult and there were suggestions about 
increasing the recruitment window period and taking out the 20 minute time limit 
to consent. Responders recognised that there was no easy solution to seeking 
consent from parents in the acute situation but also felt that they got better as 
more patients were recruited to the trial. One responder suggested the option of 
introducing ‘emergency department criteria for consent’, whereby consent could 
be taken quickly using the patient summary sheet only and going through the 
whole information document once the trial had started. He/she felt that the 
experimental drug was a ‘known’ drug and that parents were always told about 
the option to discontinue from the study at any time, if they wished to. Another 
responder mentioned deferred consent.  
Training of medical and nursing staff to participate in the study was felt to be 
important. It was thought that junior doctors at the SHO level should be trained to 
seek consent and recruit patients, so that the middle grade doctors and registrars 
were less restricted. It was thought to be important to train staff in both A&E and 
paediatric wards and that research nurses in A&E be trained to recruit 
independently. Providing training sessions at new doctors’ induction and regional 
training was suggested.  
Having GCP trained staff available to recruit was thought to be very important. 
There were suggestions about making study leave available for GCP training, 
making it mandatory during registrar training and to have nationwide GCP 
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training sessions provided by CTU, for A&E doctors. However, encouraging 
doctors to attend GCP was felt to be a big hurdle as it was seen as ‘boring’, ‘time 
consuming’ and ‘not a priority for busy clinicians’.  
The need to encourage and motivate doctors and nursing staff to recruit and be 
more involved in the trial was recognised. Trainee doctors were reported to lack 
interest in research. The need to ‘change the research culture’ and ‘move towards 
a general ethos of research being an integral part of clinical practice’ was 
emphasized. Suggestions were made to simplify the trial protocol and wording of 
the parent information leaflets.  Data collection was thought to be too complex 
and time consuming and the need to minimise data collection was recognised, 
making it simpler and easier to collect.  
There were suggestions to improve the staffing levels particularly during out of 
hours with more doctors and nursing staff available to consent. There was a 
suggestion for research nurses to be available out of hours, as these were noted to 
be the busiest periods, when eligible patients presented and were missed as the 
ability to recruit them was determined by the clinical workload. Greater 
involvement of senior medical staff such as consultants was also recommended 
during these times.  
Recruitment over a long period of time was felt to be unhelpful in the A&E 
setting and preference was expressed for shorter, heavily resourced periods of 
recruitment in the asthma season. A selection of ‘fewer centres’, with track record 
for recruitment was recommended to ‘prevent dissipation of resource and effort 
across too many sites’. In-depth feasibility assessment to assess the suitability of 
site, setting and clinical teams was thought to be essential.  
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The choice of recruitment setting was highlighted by a few responders who felt 
that recruitment should have been done in A&E rather than the paediatric ward as 
patients were no longer eligible for the study by the time they reached the ward 
because of geographical distance or due to the treatment they had received in 
A&E. A preference for having an A&E consultant as the PI was expressed by a 
few responders. Adequate funding for the trial to be able to fund a research nurse 
at every site and twilight nurses, was thought to be important. Per patient funding 
was reported to be useful drivers and motivators for the team.  
Trial publicity by putting up posters in A&E and clinical areas, waiting rooms, 
and distributing leaflets to parents was thought to be helpful in increasing the 
consent rate and to ‘dampen fear of parents’.  Development of the role of nurse 
practitioners and non-medical prescribers in research was encouraged. Lack of 
communication of challenges and counter strategies between sites and the need 
for better communication was acknowledged. Other suggestions included a faster 
set up process, better availability of study drug and greater number of study co-
applicants.  
The study was thought to be very well organised by some responders. The success 
of the trial at sites was attributed to factors such as motivation and hard work of 
clinical staff, motivation of PI and nursing staff and presence of a designated 
research nurse. The trial manager was reported to be ‘excellent’ and ‘fantastically 
supportive’.  
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5.5 DISCUSSION 
This study explored the recruitment experience of the clinical teams involved in 
recruitment to the MAGNETIC trial at various sites. The responders endorsed the 
various facilitators and barriers to recruitment to clinical trials that have been 
identified in existing literature. Motivation of the clinical team, good 
communication skills, research experience of PI and clinical team, good trial 
management, research nurse support, positive research culture and effective 
communication between teams and with patients have been recognised as 
important factors that boost recruitment (Campbell et al. 2007). Time constraints 
of clinicians, heavy clinical workload, shift patterns and training and staffing 
issues have been recognised as important hindrances to recruitment (Ross et al. 
1999).  
The clinical teams recognised parents’ apprehension about their child taking an 
experimental medicine and their concerns about the potential adverse effects as 
barriers, which have been previously described as important considerations for 
parents when deciding for their child to participate in clinical trials (Caldwell, 
Butow & Craig 2002). Paediatricians have been found to consider trial 
participation as an additional burden for parents and practitioners express 
discomfort in approaching patients for research (Shilling et al. 2011).  Our study 
reiterates the need for mentoring and providing training and support to clinicians. 
Excess amount and complexity of trial information provided in the patient 
information leaflets, has been previously criticized similar to the findings in this 
survey.  
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This study highlights research nurse support and presence of designated research 
teams particularly out of hours, as very important. Having a designated research 
nurse was the most commonly reported intervention for improving recruitment. 
Another factor to note is GCP training, which has been described as a ‘massive 
hurdle’. Engaging doctors to undertake GCP training was found to be very 
difficult and described as ‘time consuming, boring and not a priority for busy 
clinicians’. The study highlights some differences in perception of principal 
investigators and research nurses with regards to certain facilitators and barriers to 
recruitment, which may be useful to keep in mind when planning future trials.  
An important trial specific barrier was seeking consent from the parents of an ill 
child in 20 minutes, which raises the issue of an option of deferred consent being 
available for paediatric trials in acute or emergency settings. The UK law 
incorporates a deferred consent process in emergency situations for minors 
(Legislation.gov.uk 2008) when treatment is required urgently, urgent action is 
required for the purposes of the trial, consent cannot be obtained prospectively 
and the procedure has been approved by the ethics committee. A postal survey 
(Gamble et al. 2012) investigating parents’ views about deferred consent in a 
paediatric emergency setting showed that majority of parents found it acceptable. 
However, death of a child during a trial in which deferred consent has been used 
presents a complex situation and the authors highlight the need for further 
evidence to guide appropriate management in these cases.  
This study highlights several important factors that affect recruitment to clinical 
trials.  The strengths of our study include an electronic survey design using an 
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evidence based recruitment survey tool, wide range of responders with different 
roles from sites with variable recruitment performance and high response rates 
from PIs and research nurses. E-surveys are quicker, less expensive, can be sent to 
multiple responders at the same time, avoid interviewer bias and the responders 
have the opportunity to express their views freely and anonymously, even to 
sensitive issues (Wiley 2008).  
Responses from a range of responders with different roles and sites with different 
recruitment performance increased the breadth of data gathered in terms of 
recruitment experience and perspectives, increasing the generalizability of the 
results. A high response rate from the PIs and at least one research nurse from 
each site ensured equal representation of sites in overall responses, thereby 
ensuring generalizability and avoiding selection and non-respondent bias.   
Our study was designed to be free of the threats to validity and quality issues 
identified in a review of previous studies (Fayter, McDaid & Eastwood 2007). 
The survey questionnaire was sent to all staff involved with trial recruitment at all 
sites irrespective of recruitment performance, to avoid selection bias. The survey 
instrument used in the study provided an evidence-based comprehensive list of 
potential factors affecting recruitment for responders to rate as facilitators or 
barriers. Additional free text comments were invited to capture their experiences 
and views on ways of improving recruitment to the trial. The method of 
developing and administration of the survey, data collection and analysis and the 
study results have been reported clearly.  
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The study has some potential limitations. The survey questionnaire has the 
disadvantage of respondent non-response, misinterpretation of questions, or 
selective responder bias. We tried to overcome these limitations by wording the 
questionnaire in simple and clear language and piloting the questionnaire prior to 
use. Frequent e-mail reminders were sent out and extra efforts were made to seek 
responses from PIs and research nurses at each site.  
The overall response rate to the survey was 39% but this was not a true 
representation of the actual response rate. The denominator included all contacts 
whose email addresses were available from the delegation logs and it is likely that 
not all contacts would have received the survey, if their email address had 
changed and were different at the time the survey was conducted. There was a 
high likelihood of people changing jobs or rotating between different NHS trusts 
during the two year duration of the trial, particularly doctors in training, nursing 
staff and other junior doctors, resulting in a change in their email address and 
contact details. This was pre-empted during the planning stage of this study and 
extra efforts were made to receive a response from the principal investigator and 
at least one research nurse per site. 
The results of the survey are based on subjective experiences of clinical staff who 
responded to the survey questionnaire. We tried to overcome this limitation by 
achieving a good representation of sites in overall responses and analysing PI and 
at least one research nurse response at each site separately. We looked for co-
relation between PI responses and calibrated recruitment at sites but this analysis 
was limited by non- availability of data. Data on the number of 2-16 year old 
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patients at each site was not available. The number of 2-16 year olds presenting to 
AE at the trust level was used a proxy indicator of the eligible population and this 
information was available only for the English sites.  
This study presents the recruitment experience of the clinical teams recruiting to 
the trial; understanding the perspective of other stakeholders such as parents, 
young people and families is also very important.  
5.6 SUMMARY & CONCLUSIONS  
This study explored the recruitment experience of various clinical teams recruiting 
to the MAGNETIC trial and identified important perceived facilitators and 
barriers and information on strategies adopted by clinical teams to boost 
recruitment. The findings of the study can be generalised to other trials 
particularly in the acute/emergency setting as it helped to identify generic 
facilitators and barriers that operate in these settings along with trial specific 
factors. The responders emphasized the importance of having motivated and 
enthusiastic clinical teams, good communication skills and a positive research 
culture. Good trial management, trial publicity, encouraging clinical staff to 
participate and constant efforts to keep up the momentum of the trial are 
important. The study recognises practical problems encountered by the clinical 
staff in acute and emergency settings and stresses on the presence of designated 
research teams and research nurse support particularly out of hours, to boost 
recruitment. Reducing data collection and administrative work related to the trial 
are recommended. GCP training is seen as a major hurdle and there is an 
emphasis on increasing the provision of training sessions and encouraging doctors 
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to attend training. Difficulties in seeking consent in a short time period in the 
emergency setting highlights the need to consider the option of deferred consent 
in future clinical trials with sick children in the emergency setting. The study 
acknowledges parents’ concerns and apprehensions about trial medication and 
their child’s participation in a trial; therefore provision of simple and clear 
information by trained staff is recommended.  
This study has generated valuable information on facilitators and barriers to 
recruitment to clinical trials and highlighted some recruitment strategies applied 
by the clinical teams to overcome the hurdles. The findings of this study can be 
used to inform the design and conduct of future clinical trials. It is recommended 
that trialists should consider using study designs with simpler protocols which are 
comparable to routine clinical practice, the inclusion criteria being less restrictive 
and data collection being not too excessive. Designated research nurses should be 
made available at sites to assist clinical staff with recruitment particularly during 
out of hours. This is particularly applicable to trials in the acute or emergency 
setting with heavy clinical workload. The option of deferred consent should be 
considered for trials in the emergency setting. Clinical staff should be encouraged 
to undertake GCP training and efforts should be made to motivate doctors and 
nursing staff to participate in research. Adequate training should be provided to 
doctors to enhance their confidence and skills in communicating with parents and 
families, seeking informed consent and allaying their concerns about the trial or 
experimental medicine. Patient information leaflets should be kept short and 
information should be provided in a simple and clear manner. Trial publicity 
measures such as posters and banners should be put up to maintain awareness of 
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trial among staff and patients. Central trial management support should be 
provided and efforts should be made to ensure effective communication between 
clinical teams at various sites.  
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Chapter 6 
DISCUSSION 
6.1 KEY FINDINGS WITH REFERENCE TO OBJECTIVES 
The work contained within this thesis presents some important findings in relation 
to the research objectives. These findings are discussed below, in the context of 
existing knowledge.    
Objective 1: To determine the recruitment performance of randomised 
controlled trials with children 
The review of recruitment to randomised controlled trials with children in the 
NIHR portfolio, described in chapter 3, confirmed that under-recruitment and 
recruitment delays are significant problems in paediatric trials. Overall, 69% of 
included trials recruited to target but only a third of the UK based paediatric 
randomised controlled trials recruited to target within the stipulated time frame or 
in a period not exceeding ten percent of the planned recruitment period. Nearly 
half of UK studies had to apply for a trial extension and the recruitment target 
needed to be revised in just under a quarter. Recruitment was discontinued earlier 
than planned in seven percent of trials because of problematic recruitment.  These 
findings are congruent with reviews of recruitment to multicentre RCTs with 
adults (Campbell et al. 2007, Sully, Julious & Nicholl 2013). Sully et al report 
failure to meet recruitment targets in 45% of studies with revision of target needed 
in 19% and trial extension in 47%, which shows an improving trend over time, 
compared to findings of Campbell et al. However, these reviews pertain mainly to 
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adult RCTs whereas our study reviewed recruitment to exclusively paediatric 
trials.  
The pilot systematic review, described in chapter 2, aimed to determine the 
recruitment performance of paediatric trials in published literature.  The study 
showed that reporting of recruitment and consent in paediatric RCTs was poor and 
it was not possible to obtain unbiased estimates of percentage of total recruitment 
achieved and consent rate from published literature.  
Objective 2: To test the association of potential factors that influence 
recruitment to paediatric randomised controlled trials with recruitment 
success   
The review of paediatric RCTs in the NIHR portfolio showed that presence of a 
dedicated trial manager was significantly associated with recruitment success. 
76.7% of trials with a dedicated trial manager recruited successfully compared to 
40% trials without a dedicated trial manager (p-value 0.015). The importance of 
good trial management is well recognised. Efficient trial management is 
considered to be one of the key components required to deliver high quality trials 
and it is thought that many trials fail because of the ‘lack of a structured, business-
like approach’ to trial management (Farrell, Kenyon & Shakur 2010).  The MRC 
recognises that some trials fail due to problems with trial management rather than 
scientific reasons or problems with trial design (Clinical Trials for Tomorrow, 
2003). The STEPS study (Campbell et al. 2007) found that trials with a dedicated 
trial manager were more likely to recruit successfully but the confidence interval 
was wide and this was not statistically significant (OR 3.8, 95% CI 0.79-36.14, p-
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value 0.087). However, the authors discuss that the analyses testing the 
association of factors and recruitment success were of limited value because of 
imprecision around the estimates and lack of sufficient power to undertake a 
multivariable analysis.  
Other factors such as being an IMP vs. non-IMP trial, trial of acute vs. chronic 
illness, having CTU involvement, pilot/feasibility study and additional trial 
demands were not found to have a significant association with recruitment 
success.  Studies with a pilot/feasibility assessment and CTU involvement were 
more likely to recruit successfully but the results were not statistically significant. 
This could be explained by confounding factors such as trial complexity in that 
simple and easy to recruit studies may not have had a pilot/feasibility study or 
CTU involvement compared to more complex trials. Sully et al reported that trials 
with CTU involvement recruited better than trials without CTU involvement but 
the results were not statistically significant (Sully, Julious & Nicholl 2013).   
There is paucity of data on factors that are associated with recruitment success in 
paediatric trials. Studies show that parents assess the risks and benefits of trial 
participation and take the practical aspects and inconvenience resulting due to trial 
participation into consideration, when taking a decision about their child’s 
participation in clinical research (Harth, Thong 1995, Langley et al. 1998, 
Hayman et al. 2001, Shilling et al. 2011). Our study did not find a significant 
association with additional trial demands and recruitment success though certain 
trends were noted. Trials recruited better if routine data collection was carried out 
and an additional test or procedure was offered but less well if an extra hospital 
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visit or extended hospital stay was involved. A bigger study with greater power 
may be needed to detect a significant association between the two.  
Objective 3: To identify facilitators and barriers to recruitment of children to 
a multi-centre RCT and strategies adopted by clinical teams to overcome 
barriers  
The survey of clinical teams recruiting to the MAGNETIC trial, described in 
chapter 5, identified the important facilitators and barriers to recruitment. A 
motivated clinical team with effective communication between team members and 
with parents, effective coordination between study team members at site and 
between sites and CTU, trial management support, presence of a research nurse 
and availability of a designated research team to help with recruitment were 
considered imperative for trial recruitment success. Research experience of PI, 
clinical teams’ perception of the importance of the research question, their attitude 
to enrolment of children in clinical trials and internal trial publicity were thought 
to be important facilitators. Simple inclusion criteria and clarity in presentation of 
trial information to parents were thought to help recruitment. These findings are 
consistent with the existing literature on facilitators identified in adult studies 
(Campbell et al. 2007). 
Heavy clinical workload, shift patterns of work, lack of trained staff particularly 
out of hours and local clinical arrangements were recognised as barriers to 
recruitment. Arranging GCP training and encouraging doctors to attend was 
identified as a problem. Parents were anxious about the side effects and safety of 
experimental treatment. Language and cultural barriers were recognised and the 
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amount and complexity of trial information was criticised. Seasonal variation was 
noted to hinder recruitment. These barriers to recruitment have been identified in 
existing literature on adult studies (Fayter, McDaid & Eastwood 2007).  
However, as discussed, the evidence on facilitators and barriers to recruitment to 
paediatric trials is limited and the existing literature is mostly confined to studies 
of adult recruitment (Prescott et al. 1999, Ellis 2000, Cox, McGarry 2003, 
Tournoux et al. 2006, Mills et al. 2006, Fayter, McDaid & Eastwood 2007). A 
study examining paediatricians’ attitudes towards RCTs with children found poor 
parental awareness of concepts such as random allocation, placebo usage and 
equipoise and thought that parents’ willingness to participate was influenced by 
their opinions. Parents were thought to be apprehensive regarding experimentation 
on their children (Caldwell, Butow & Craig 2002). Random allocation, clinical 
equipoise and clinician influence were not identified either as facilitators or 
barriers in our study.  However parents’ concerns about adverse effects of new 
treatments and their anxiety around their child having an experimental treatment 
or placebo were recognised. Language and cultural barriers were also identified, 
which is consistent with findings of Caldwell et al. Paediatricians are known to 
believe that parents would be less likely to participate in trials if their child’s 
condition is severe (Walterspiel 1990, Caldwell, Butow & Craig 2002). Clinical 
teams in our study expressed difficulty in seeking consent from parents of an 
acutely unwell child particularly in a limited time frame and suggestions were 
made for consideration of deferred consent in recruiting children from an 
emergency setting. Making trial participation more convenient for parents has 
been noted to increase trial participation (Caldwell, Butow & Craig 2002). 
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However, additional trial demands were not identified as a barrier in our study 
since this trial did not entail any extra blood tests, clinic visits or extra travel. The 
amount and complexity of trial information provided were criticised in line with 
existing research (Shilling et al. 2011).  
The commonly reported strategies adopted by clinical teams to boost recruitment 
were to have a designated research nurse, GCP training, trial related training of 
staff and regular communication, motivation provided by senior staff, trial 
publicity, measures to improve availability of clinical staff particularly out of 
hours and giving incentives to staff. A systematic review of studies that evaluated 
the recruitment activity of clinicians identified strategies such as use of qualitative 
research to identify and overcome barriers to recruitment, reduction in clinical 
workload, provision of extra training and protected research time to be effective 
strategies.  
6.2 CONTRIBUTION TO EXISTING LITERATURE   
This section summarises the contribution of this thesis in advancing knowledge 
about recruitment of children to randomised clinical trials.  
6.2.1 Recruitment of children to randomised clinical trials 
While there is available knowledge about recruitment of adults (Campbell et al. 
2007, Sully, Julious & Nicholl 2013), there is very little existing knowledge about 
recruitment of children to clinical trials and the scale and magnitude of the 
problem is not known. To the best of our knowledge, this thesis is the first to 
provide quantitative estimates of recruitment performance of a cohort of 
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exclusively paediatric randomised controlled trials and test the association of 
potential factors affecting recruitment with recruitment success.  
6.2.2 Facilitators and barriers to recruitment to randomised clinical trials 
with children 
An evidence-based online survey tool has been developed, as described in chapter 
4, to establish the recruitment experience of clinical teams with regard to the 
perceived facilitators and barriers to recruitment, to identify strategies applied to 
overcome the barriers and to obtain suggestions for change in organisation of 
future trials. There is no such existing recruitment survey tool to the best of our 
knowledge. It can be a useful instrument for the systematic recognition and 
management of recruitment problems in clinical trials and generate knowledge to 
inform the design and conduct of future trials.  
The survey of clinical teams recruiting to the MAGNETIC trial has provided 
important generic and trial specific information about the facilitators and barriers 
to recruitment that can be generalised to other paediatric trials and to trials 
recruiting acutely unwell children in the emergency setting.  
6.3 IMPLICATIONS FOR PRACTICE  
Several conclusions can be drawn from this thesis which has implications for 
clinical trialists undertaking research with children and provide guidance on how 
clinical trials should be designed, planned and conducted in the future.  
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6.3.1 Planning and designing clinical studies with children 
With increased recognition and acceptance of the importance of conducting 
clinical trials with children, it is imperative that clinical trials be planned, 
designed and conducted in a manner that maximises the potential for successful 
completion of the trial in the given budget and time frame. A clinically important 
and interesting research question that is relevant to clinical practice is more likely 
to engage the clinical teams to participate. Keeping the study protocol simple and 
more aligned to existing clinical practice is important to ensure adherence to 
protocol. Studies with less restrictive patient inclusion criteria and minimal 
additional demands on children, young people and their families are more likely 
to be easier to recruit.  
A dedicated trial manager is very important for successful trial recruitment. 
Previous pilot/feasibility study with careful assessment of sites and settings for 
recruitment may help to pre-empt potential issues and problems with recruitment 
that can be addressed early on. CTU involvement can be very helpful at all stages 
and help with study design, trial management, identification and liaison with sites, 
planning staffing, randomisation, trial monitoring, data management and 
conducting the analysis.  
6.3.2 Trial conduct 
It can be concluded with confidence that efficient trial management and presence 
of a dedicated trial manager is crucial for successful recruitment. Communication 
and coordination between study team members at site and between site and CTU 
are important for identification and resolution of any problems that may be 
183 
 
encountered. Local clinical arrangements need to be conducive to conducting the 
trial successfully and appropriate number of trained staff should be available. 
Heavy clinical workload and shift patterns of work are recognised barriers but 
efforts must be made to ensure adequate staffing levels and presence of support 
staff to help with recruitment. Presence of a research nurse and a designated 
research team are thought to be extremely helpful in assisting the busy clinicians 
with recruitment especially during out of hours. Arranging trial specific training 
sessions for staff including GCP training have been shown to be useful. Measures 
such as regular meetings with staff and internal trial publicity using posters are 
important to keep the clinical teams motivated and maintain the presence of a 
clinical study. Trial slogans and posters in waiting areas and clinics also help raise 
parents’ awareness about the trial. Efforts must be made to minimise the 
administrative work related to the trial and excessive data collection should be 
avoided.   
6.3.3 Information and consent  
Parents’ anxiety about trial participation and use of experimental medicine or 
placebo needs to be acknowledged and efforts should be made to allay their 
apprehension. Good communication between research teams and parents is 
imperative to help parents understand the purpose of the research and enable them 
to make an informed decision about their child’s participation in the study. Trial 
information should be provided in a simple and clear manner and efforts should 
be made to keep the patient information leaflets short and user-friendly. Given the 
importance of clear communication with parents and expressed discomfort of 
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clinicians in seeking consent, training and support should be offered to clinical 
teams. The option of deferred consent should be made available to trials in the 
emergency setting.  
6.3.4 Trial monitoring and sharing good practice  
The recruitment survey tool can be used as a trial monitoring tool to 
systematically record the facilitators, barriers and strategies applied at individual 
sites. Sharing this information between sites in a multicentre RCT can provide 
useful learning lessons and strategies to overcome barriers. The tool can be 
adapted for use after trial completion to generate knowledge that can influence 
future research with children.  
6.4 CONCLUSION AND FUTURE RESEARCH DIRECTION  
The thesis highlights a number of potential avenues that can be explored in future 
research studies. The results of the review of paediatric RCTs in the NIHR 
portfolio suggest possible association of pilot/feasibility study, CTU involvement 
and additional trial demands with recruitment success but the results were not 
statistically significant. A larger study with greater power is needed to detect the 
effect of these variables with certainty.  While this study reviews the recruitment 
to exclusively paediatric trials, there is a need to examine recruitment to trials 
with both adults and children.   
Survey of clinical teams recruiting to the MAGNETIC trial generated useful 
knowledge on facilitators and barriers to recruitment and strategies applied. The 
effect of these interventions such as having a designated research team, additional 
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trial specific training and GCP training for clinical teams, trial publicity measures 
like posters and incentives to staff can be tested further and validated by 
conducting nested trials of these interventions within an RCT setting. The effect 
of deferred consent on recruitment to trials with acutely ill children in the 
emergency setting needs to be evaluated.  
Use of the recruitment survey tool by clinical teams can lead to systematic 
recording of data on facilitators and barriers to recruitment, resulting in a build-up 
of literature on the same in paediatric trials and help identify useful strategies. The 
recruitment survey questionnaire, published in Trials (Kaur, Smyth & Williamson 
2012), has been adapted for use in trials to elicit barriers and facilitators to 
recruitment (Kaur et al. 2013, Kaur et al. 2013, Keightley et al. 2014). To date, the 
article has been accessed 5141 times on Bio Med Central site, cited by 17 papers 
(Appendix 25) and we have been contacted by six researchers (Appendix 26) to 
seek permission to use the questionnaire. The identified strategies can be further 
evaluated for effectiveness by conducting nested trials of interventions within 
RCTs.  
The review of published literature revealed poor reporting of recruitment and 
consent and the limitations of using this approach to determine the recruitment 
performance of paediatric RCTs have been discussed previously. We recommend 
that the highlighted issues be taken into consideration by other researchers prior to 
using this method. Further work is needed to ensure adequate reporting of 
paediatric RCTs. The CONSORT statement provides an evidence-based minimum 
set of recommendations to facilitate clear and transparent reporting of RCTs. It 
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includes recommendations on reporting of flow diagram, sample size and 
recruitment (CONSORT 2010). The CONSORT-C guidance is being developed 
as an extension of the CONSORT to develop an evidence-based checklist of items 
to be included when reporting paediatric randomised controlled trials (Equator 
network- CONSORT C). Studies to assess the impact of the CONSORT statement 
on paediatric randomised controlled trials and their adherence to it will be 
important in bringing about an improvement in reporting of paediatric trials. 
6.5 KEY MESSAGES 
 Recruitment to randomised controlled trials with children is challenging. 
Poor recruitment and recruitment delays are a common problem.  
 Trial management is significantly associated with recruitment success in 
paediatric RCTs. Trials with CTU support and pilot/feasibility assessment 
are more likely to recruit but further work is needed.  
 Reporting of recruitment and consent in paediatric trials is poor and needs 
improvement.  
 An online recruitment survey tool has been developed which can be used 
to investigate the recruitment experience of clinical teams. This can be 
used by trialists to systematically monitor recruitment to an on-going trial 
or gather information that can be used for conducting future trials. 
 A survey of facilitators and barriers to recruitment to a large, multicentre 
randomised controlled trial with children in the emergency setting found 
some important generic and trial specific facilitators and barriers to 
recruitment and strategies that were applied to overcome the barriers. This 
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information can be used by trialists in planning and conducting future 
trials with children.    
6.6 DISSEMINATION OF RESEARCH FINDINGS 
The findings of this thesis will be disseminated through publication in peer-
reviewed journals. The recruitment survey tool has been published in Trials (Kaur 
et al 2012). The review of recruitment to paediatric trials on the NIHR portfolio, 
described in Chapter 3, was presented as a poster presentation at the 2
nd
 clinical 
Trials Methodology Conference, UK and will be sent for publication. The survey 
of facilitators and barriers to recruitment to the MAGNETIC trial, described in 
Chapter 5, was presented at the 2nd Clinical Trials Methodology conference, UK 
and is being drafted for publication. Other potential dissemination strategies 
include podcasts on the NIHR website highlighting the key findings. 
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Appendix 1: Search strategy used in the pilot systematic review of 
recruitment and retention of children in randomised controlled trials, as 
described in Chapter 2 
CENTRAL was searched in January 2011 for clinical trials using the following search strategy: 
#1 Infant [MeSH]  
#2 Infant*  
#3 Infancy 
#4 Newborn* 
#5 Baby* 
#6 Babies 
#7 Neonat*  
#8 Preterm*  
#9 Prematur* 
#10 Postmatur*  
#11 Child[MeSH] 
#12 Child*  
#13 Schoolchild*  
# 14 Schoolage 
#15 Preschool* 
#16 Kid* 
#17 kids 
#18 Toddler* 
#19 Adolescent [MeSH]  
#20 Adoles* 
#21Teen* 
#22 Boy* 
#23 Girl* 
#24 Minors [MeSH] 
#25 Minors* 
#26 Puberty[MeSH]  
#27 Pubert* 
#28 Pubescen* 
#29 Prepubescen* 
#30 Pediatrics[MeSH] 
#31 Pediatric* 
#32 Paediatric* 
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#33 Peadiatric* 
#34 Schools[MeSH] 
#35 Nursery school* 
#36 Kindergar* 
#37 Primary school* 
#38 Secondary school* 
#39 Elementary school* 
#40 High school* 
#41 Highschool* 
#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR 
#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 
OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR 
#37 OR #38 OR #39 OR #40 OR #41  
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Appendix 2: Data extraction form used in pilot systematic review described 
in Chapter 2 
Name of trial: 
Source (Journal):  
Author: 
Year: 
Flow Diagram: Y/N 
Sample size calculation: Y/N 
Sample size estimate: 
Number of participants randomised: 
Number of participants who refused consent: 
Numbers analysed for primary outcome variable: 
Additional notes/comments: 
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Appendix 3: Studies excluded from the pilot systematic review described in 
Chapter 2 
Study [ref list at end of appendix] Reason for exclusion 
Bellinger 2007 [1] This study was a secondary analysis of a 
previously published randomised controlled trial  
Berrak 2007 [2] This trial included participants more than 18 
years of age 
Boivin 2008 [3] This trial was pseudo-randomised 
Chen 2008 [4] This trial was non-randomised 
Jurg 2006 [5] This trial was non-randomised 
Knott 2007 [6] This trial was non-randomised 
Ladas 2010 [7] This trial included participants more than 18 
years of age 
Mamtani 2009 [8] This was a secondary publication- report of 
functional outcomes of a previously published 
randomised controlled trial 
Manger 2008 [9] This was a secondary publication- report of a 
previously published trial 
  
O’Kearney 2009 [10] This trial was non-randomised 
Powell 2008 [11] This trial was non-randomised 
 
Reference list of excluded studies 
1. Bellinger, D. C., Trachtenberg, F., Daniel, D., Zhang, A., Tavares, M. A., & 
McKinlay, S.A dose-effect analysis of children's exposure to dental amalgam and 
neuropsychological function. The Journal of the American Dental Association, 
138(9), 1210-1216. doi:10.14219/jada.archive.2007.0345  
2. Berrak, S. G., Ozdemir, N., Bakirci, N., Turkkan, E., Canpolat, C., Beker, B., & 
Yoruk, A. (2007). A double-blind, crossover, randomized dose-comparison trial 
of granisetron for the prevention of acute and delayed nausea and emesis in 
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children receiving moderately emetogenic carboplatin-based chemotherapy. 
Supportive Care in Cancer : Official Journal of the Multinational Association of 
Supportive Care in Cancer, 15(10), 1163-1168. doi:10.1007/s00520-007-0242-y  
3. Boivin, J. M., Poupon-Lemarquis, L., Iraqi, W., Fay, R., Schmitt, C., & 
Rossignol, P. (2008). A multifactorial strategy of pain management is associated 
with less pain in scheduled vaccination of children. A study realized by family 
practitioners in 239 children aged 4-12 years old. Family Practice, 25(6), 423-
429. doi:10.1093/fampra/cmn069 [doi]  
4. Chen, P. L., Chen, J. T., Fu, J. J., Chien, K. H., & Lu, D. W. (2008). A pilot study 
of anisometropic amblyopia improved in adults and children by perceptual 
learning: An alternative treatment to patching. Ophthalmic & Physiological 
Optics : The Journal of the British College of Ophthalmic Opticians 
(Optometrists), 28(5), 422-428. doi:10.1111/j.1475-1313.2008.00588.x [doi]  
5. Jurg, M. E., Kremers, S. P. J., Candel, M. J. J. M., Van, d. W., & Meij, J. S. B. D. 
(2006). A controlled trial of a school-based environmental intervention to 
improve physical activity in dutch children: JUMP-in, kids in motion. Health 
Promotion International, 21(4), 320-330.  
6. Knott, P. D., Zins, J. E., Banbury, J., Djohan, R., Yetman, R. J., & Papay, F. 
(2007). A comparison of dermabond tissue adhesive and sutures in the primary 
repair of the congenital cleft lip. Annals of Plastic Surgery, 58(2), 121-125. 
doi:10.1097/01.sap.0000232984.68797.62 [doi]  
7. Ladas, E. J., Kroll, D. J., Oberlies, N. H., Cheng, B., Ndao, D. H., Rheingold, S. 
R., & Kelly, K. M. (2010). A randomized, controlled, double-blind, pilot study of 
milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic 
leukemia (ALL). Cancer, 116(2), 506-513. doi:10.1002/cncr.24723 [doi]  
8. Mamtani, M., Patel, A., Hibberd, P. L., Tuan, T. A., Jeena, P., Chisaka, N., . . . 
Kulkarni, H. (2009). A clinical tool to predict failed response to therapy in 
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children with severe pneumonia. Pediatric Pulmonology, 44(4), 379-386. 
doi:10.1002/ppul.21014 [doi]  
9. Manger, M. S., McKenzie, J. E., Winichagoon, P., Gray, A., Chavasit, V., 
Pongcharoen, T., . . . Gibson, R. S. (2008). A micronutrient-fortified seasoning 
powder reduces morbidity and improves short-term cognitive function, but has no 
effect on anthropometric measures in primary school children in northeast 
thailand: A randomized controlled trial. The American Journal of Clinical 
Nutrition, 87(6), 1715-1722. doi:87/6/1715 [pii]  
10. O'Kearney, R., Kang, K., Christensen, H., & Griffiths, K. (2009). A controlled 
trial of a school-based internet program for reducing depressive symptoms in 
adolescent girls. Depression and Anxiety, 26(1), 65-72. doi:10.1002/da.20507 
[doi]  
11. Powell, ,Lesley, Gilchrist, ,Mollie, & Stapley, ,Jacqueline.  
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Appendix 4: Description of studies included in the pilot systematic review 
(Chapter 2) 
Author (Year) Study details 
Akbay et al 2010 This study was a randomised controlled trial evaluating the 
efficacy of topical tramadol in the control of postoperative 
pain in children after tonsillectomy 
Bojang et al 
2010 
This study was an open-label randomised trial comparing the 
safety, tolerability and efficacy of three drug combinations for 
intermittent preventive treatment of malaria in children 
Boots 2010 This study was a randomised controlled trial comparing single 
to multiple application of lidocaine analgesia in paediatric 
patients undergoing urethral catheterisation procedures 
Diez-
Domingo2010 
This study was a randomised clinical trial to assess the 
immunogenicity of a Meningococcal C vaccine booster dose 
administered to children between the ages of 14-18 months 
Okan 2010 This study evaluated the analgesic effects of skin- to- skin 
contact and breastfeeding in procedural pain in healthy term 
neonates 
Schuttelar 2010 This study was a randomised controlled trial comparing the 
level of care provided by nurse practitioners as compared to 
dermatologists to children with eczema 
Swadi 2010 This study evaluated the efficacy and tolerability of quetiapine 
compared with risperidone in the treatment of first onset 
psychosis among 15 and 18-year old adolescents. 
Waling 2010 This study was a randomised open trial to evaluate the effect 
of group sessions with themes regarding food and physical 
activity on the energy and micronutrient intake of overweight 
and obese Swedish children 
Zampieri 2010 This study was a prospective, randomised controlled study to 
evaluate the pre and post- surgery use of Vitamin E in surgical 
incisions in children 
Bassiouny 2009 This study was a randomised controlled trial on parenteral 
nutrition, oxidative stress and chronic lung disease in preterm 
infants. 
Berrard 2009 This study was a randomised controlled trial evaluating the 
role of a positioning pillow to improve the lumbar puncture 
success rate in paediatric haematology-oncology patients 
Gelotte 2009 This study was a randomised placebo controlled trial of 
ibuprofen and pseudoephedrine in the treatment of primary 
nocturnal enuresis in children 
Kadan Lottick 
2009 
This study was a comparison of neurocognitive functioning in 
children randomised to dexamethasone or prednisone in the 
treatment of childhood acute lymphoblastic leukaemia 
Morita 2009 This study was a randomised prospective study assessing a 
novel skin traction method for ultrasound guided internal 
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jugular vein catheterisation in infants and neonates weighing 
less than 5 kg 
Haas 2009 This study was a randomised, double blind, placebo controlled 
study to evaluate the safety and efficacy of risperidone in 
adolescents with schizophrenia 
Parker 2009 This study was a randomised controlled trial to compare 
postoperative pain in children undergoing tonsillectomy using 
two different techniques, cold steel dissection and coblator 
dissection 
Turk 2009 This study was a clinical trial evaluating the role of silicone 
earplugs for very low birth weight newborns in intensive care 
Beaumont 2008 This study investigated the effectiveness of a new 
multicomponent social skills intervention with Asperger 
Syndrome 
Greenberg 2009 This study was a randomised controlled trial comparing oral 
dexamethasone with oral prednisolone in paediatric asthma 
exacerbations treated in the Emergency department 
Lee 2008 This study was a randomised comparison of end tidal 
sevoflurane concentration for removal of laryngeal mask 
airway and laryngeal tube in anaesthetised children 
Lynch 2008 This study was a randomised double blind study comparing 
albumin bolus versus normal saline bolus for treating 
hypotension in neonates 
Patrizi 2008 This study was a double blind, randomised clinical study to 
evaluate the efficacy and safety of MAS063DP in the 
management of atopic dermatitis in paediatric patients 
Szmuk 2008 This study was a prospective randomised comparison of 
perilaryngeal airway and laryngeal mask airway in paediatric 
patients 
Channon 2007 This study was a multicentre randomised controlled trial of 
motivational interviewing in teenagers with diabetes 
Dewan 2007 This study was a pilot study to assess the impact of 
supplementation of curd and leaf protein concentrate on 
nutritional status and immunity in children with protein energy 
malnutrition 
Gazal 2007 This study was a randomised trial comparing the effectiveness 
of different oral analgesics for relieving pain and distress in 
children undergoing dental extraction under general 
anaesthesia 
Lewis 2007 This study was a double blind, dose comparison study of 
topiramate for prophylaxis of basilar type migraine in children 
Lottman 2007 This study was a randomised comparison of oral desmopressin 
lyophilisate (MELT) and tablet formulations in children and 
adolescents with primary nocturnal enuresis 
Manzoni 2007 This study was a randomised trial of prophylactic fluconazole 
in preterm neonates 
Millar 2007 This study was a randomised placebo controlled trial of the 
effects of midazolam premedication on children’s 
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postoperative cognition 
Ahonen et al 
2006 
This study was a randomised placebo controlled trial 
evaluating the role of rizatriptan in migraine attacks in 
children 
Berens et al 
2006 
This study was a prospective, randomised, double blind 
comparison of 5 day versus 10 day enteral methadone wean in 
opioid dependent patients 
Boo 2006 This study was a randomised controlled trial of cling film for 
the prevention of hypothermia in term infants during 
phototherapy 
Hayden 2007 This study was an open, randomised controlled, prospective 
study assessing the impact of cranial osteopathy for the relief 
of infantile colic 
Ng 2006 This study was a double blind, randomised, controlled study to 
assess the effectiveness of a stress dose of hydrocortisone for 
the treatment of refractory hypertension in preterm infants 
Luhmann 2006 This study was a randomised comparison of nitrous oxide plus 
hematoma block versus ketamine plus midazolam for 
emergency department forearm fracture reduction in children 
Mathai 2006 This study was a comparative study of non-pharmacological 
methods such as non-nutritive sucking (NNS), rocking, 
massaging, sucrose, distilled water and expressed breast milk 
(EBM) to reduce the pain of heelpricks in stable term 
neonates.  
Mulenga 2006 This study was a randomised, double blind, placebo controlled 
trial to compare the efficacy of atovaquone-proguanil and 
sulphadoxine- pyrimethamine in the treatment of malarial 
anaemia in Zambian children 
Galli 2006 This study was a double blind, randomised placebo controlled 
trial to perform the safety and effectiveness of double-dose 
intradermal β-Glucuronidase therapy in preventing chronic 
rhinoconjunctivitis and/or asthma in children 
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Appendix 5: Summary of missing and unclear information in trial reports 
and contact with authors 
Trial 
report 
Missing 
information 
Unclear 
information 
Authors’ responses 
2010    
Akbay numbers refusing 
consent, numbers 
included in analysis 
of primary outcome 
 no response 
Bojang numbers refusing 
consent 
numbers randomised, 
numbers included in 
analysis of primary 
outcome 
Author wanted the query 
to be sent formally to 
their ethics committee 
for review and decision.  
Boots numbers refusing 
consent 
 did not record 
Diez-
Domingo 
numbers refusing 
consent  
 did not record 
Zampieri numbers refusing 
consent, sample size 
estimate 
 no response 
Swadi sample size estimate  no response 
2009    
Bassiouny sample size estimate  sample of convenience 
Gelotte numbers refusing 
consent 
 did not record data on 
consent refusal, no 
response about sample 
size estimate 
Kadan- 
Lottick 
sample size estimate  no response 
Morita numbers refusing 
consent 
 no consent refusal 
Turk numbers refusing 
consent, sample size 
estimate 
 did not record consent 
refusals 
sample size of 
convenience 
2008    
Beaumont numbers refusing 
consent, sample size 
estimate, numbers 
included in analysis 
of primary outcome 
 no response 
Greenberg numbers refusing 
consent  
numbers included in 
analysis of primary 
outcome 
no response 
Lee numbers refusing 
consent, sample size 
estimate 
 no response 
Lynch numbers refusing 
consent 
numbers randomised, 
numbers included in 
analysis of primary 
outcome 
no response 
Patrizi numbers refusing 
consent, sample size 
 3 refused consent, 
no sample size 
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estimate calculation 
Szmuk numbers refusing 
consent 
 did not record 
information, estimate 10-
15% 
2007    
Dewan numbers refusing 
consent, sample size 
calculation 
 consent rate not 
recorded, estimate 15%; 
no sample size 
calculation-pilot study 
Ghazal numbers refusing 
consent 
 6 refused consent 
Lewis numbers refusing 
consent, sample size 
estimate 
 no response 
Lottman numbers refusing 
consent 
 don’t have information 
Manzoni sample size estimate  no response 
Millar numbers refusing 
consent 
 no response 
2006    
Ahonen numbers refusing 
consent 
 no response 
Berens numbers refusing 
consent, sample size 
estimate 
 no response 
Hayden numbers refusing 
consent, sample size 
estimate 
 no response 
Luhman numbers refusing 
consent 
 no response 
Mathai numbers refusing 
consent, sample size 
estimate, numbers 
included in analysis 
of primary outcome 
 no response 
Mulenga numbers refusing 
consent 
 no response 
Galli numbers refusing 
consent, sample size 
estimate 
 no response 
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Appendix 6: Correspondence with NIHR CRN coordinating centre, 15/11/2010 
From: Kaur, Geetinder [mailto:Geetinder.Kaur@liverpool.ac.uk]  
Sent: 15 November 2010 23:51 
To: Joanna Olliver 
Cc: Smyth, Rosalind; Williamson, Paula 
Subject: Request for information 
 
Dear Dr Olliver, 
  
My name is Dr Geetinder Kaur and I'm a clinical PhD student (MRC funded) in the MRC North 
West Hub for Trials Methodology Research and Department of Women's and Children's Health at 
the University of Liverpool under the supervision of Professor Rosalind Smyth (Director of NIHR 
Medicines for Children Research Network and Director of Clinical Research at University of 
Liverpool) and Professor Paula Williamson (Associate Director, NIHR MCRN and Director of the 
MCRN Clinical Trials Unit). 
 
The aim of our research is to review the recruitment and retention of children in clinical trials to 
assess the magnitude of the problem and identify the factors which influence the same. We are 
interested in this area because under-recruitment and attrition are known to be common problems 
and have an adverse effect on the success of a clinical trial; however there is limited research on 
the subject in children. There is a need to study the subject further in children in a holistic manner 
so that effective strategies can be developed to counter these problems. 
 
We would like to review the trials in children in the NIHR portfolio, and compare them to trials in 
adults in the NIHR portfolio. I would like to enquire if it is possible to gain access to the NIHR 
portfolio database (with appropriate confidentiality safeguards) for trials in the MCRN portfolio 
and other networks. If so, I would be grateful if you could outline the procedure to seek permission 
to do this. We can supply a protocol for our planned research. 
  
Many Thanks 
  
Kind Regards 
Dr Geetinder Kaur 
Clinical Research Fellow 
Institute of Child Health 
Alder Hey Hospital 
Liverpool 
 
From: Joanna Olliver [joanna.r.olliver@nihr.ac.uk] 
Sent: 23 November 2010 21:58 
To: Kaur, Geetinder 
Subject: RE: Request for information 
Dear Geetinder,  
I am looking into this for you and will be in touch ASAP with further information regarding 
whether access could be granted and if so what the permissions process would be. 
Kind regards 
Joanna  
Dr Joanna Olliver 
Acting Portfolio Lead 
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NIHR CRN CC 
T: 0113 343 0374 
E: joanna.r.olliver@nihr.ac.uk  
 
 
Response received 10/12/2010 
 
RE: Request for information 
From: Joanna Olliver joanna.r.olliver@nihr.ac.uk 
Sent: 10 December 2010 10:40 
To: Kaur, Geetinder <gkaur@liverpool.ac.uk> 
Cc: Williamson, Paula <prw@liverpool.ac.uk> 
 
 
Dear Geetinder,  
 
I have discussed this with colleagues in the NIHR Clinical Research Network Coordinating Centre 
and unfortunately we are unable to give you the access to the Portfolio Database that you have 
requested. Current access for NHS Trusts or Universities is via the public search tool or reporting. 
It may be that the data you require could be made available via a reporting request and would 
advise you initially to make this request to the MCRN Coordinating Centre. If the Portfolio 
Managers in the MCRN Coordinating Centre do not have the appropriate permissions to be able to 
provide you with the report you require, please do get back in touch as this may be something that 
the NIHR CRN Coordinating Centre Information Management Team could provide you with.  
 
Best of luck with your research project 
 
Kind regards 
Joanna  
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Appendix 7: Format of existing data and modifications for use in NIHR 
portfolio review (Chapter 3) 
The study lists and recruitment data requested from the NIHR CRN coordinating centre was 
provided in excel spread-sheets. ‘Meds Children’ (MCRN studies) were selected from the ‘Topic 
Study Summary’ report May 2013.  The data was present under the following headings: 
 Main Topic / Portfolio study ID / IRAS project ID / Study acronym/short title / Study title  
 Active status: Open/closed-in follow up, closed-follow up complete, suspended  
 Portfolio eligibility: adopted commercial study, adopted non-commercial study, 
automatically eligible 
 Commercial study?: commercial/non-commercial 
 Main Network (supporting network) / NIHR owning organisation 
 Lead country: England/Wales/Northern Ireland/Scotland/ unknown/non-UK country/null 
 All Topics: Main Topic (Supporting Topics) 
 Primary CSG/ All CSG/Main topic disease 
 Randomisation 
 Study design/ intervention type/observational type 
 Phase/study setting/geographical scope 
 Actual/planned original opening and closing dates 
 Global sample size/UK sample size 
 CI name and details 
 Funder/sponsor 
 ISRCTN/MREC number 
 Study notes 
The excel spread-sheet was filtered to identify studies with: 
 Main or supporting network being ‘Medicines for Children’  
 Randomisation status: randomised and both. The randomisation status of studies labelled 
‘both’ was confirmed by checking the study protocols.  
 Active status: closed –in follow up and follow up complete 
 Study duration-April 2006 and beyond up to March 2013. 
For the Paediatric non-medicinal studies, the report were filtered to identify studies under ‘Generic 
Relevance and Cross cutting themes’. Filters for randomisation status, active status (closed in 
follow up and follow up complete) and study duration were applied similar to MCRN studies 
described previously. The required data was transferred to an excel spread-sheet for purposes of 
the current study. The identified studies were listed with Study ID, randomisation status that was 
confirmed with study teams/protocol, active status, geographical scope (international, UK single or 
multicentre), commercial/publicly funded, information on original and actual opening and closing 
dates, original sample sizes and actual recruitment. 
Information on factors affecting recruitment was obtained from NIHR CRN and studies were 
classified as IMP/non-IMP based on type of intervention, and acute/chronic/healthy based on type 
of disease. The CIs and study teams were sent an online questionnaire to gather information about 
pilot/feasibility assessment, CTU involvement, trial management and additional trial demands.   
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Appendix 8: Recruitment discrepancies and recruitment information from 
various sources for UK based studies in NIHR portfolio review (Chapter 3) 
MCRN trials 
Sources of data 
Name of Trial  NIHR report 
Target sample size  NIHR reports: original and planned sample size, CI 
questionnaire, protocol 
UK recruitment  NIHR reports: UK recruitment, CI questionnaire, 
ClinicalTrials.gov (International studies) 
Target recruitment period 
(months) 
 NIHR reports: original closure date - original opening 
date (days); divided by 30 for number of months, CI 
questionnaire, SAC form 
Actual recruitment period 
(months) 
 NIHR report: actual closure date - actual opening 
date (days); divided by 30 for number of months 
Recruitment success (P)  S if recruited to 100% or more of original recruitment 
target 
Recruitment success (S)  S if recruited to 100% target or more in a period not 
exceeding 10% of originally planned recruitment 
period 
Target revised  Questionnaire sent to CI 
Recruitment discontinued 
earlier than planned 
 Questionnaire sent to CI 
Extension requested  Questionnaire sent to CI 
Extension granted  Questionnaire sent to CI 
Notes  Additional information from MCRN files and 
correspondence with CIs/study teams ( if applicable) 
Discrepancy   
Action rule   
 
ADEPT  
Target sample size 400 Original sample size 400 as per CI and NIHR report, 
planned sample size 400 
UK recruitment 404 as per CI and NIHR data 
Target recruitment period 
(months) 
24  28 as per original opening and closing dates in 
NIHR report but 24 months in protocol, 24 as per CI 
Actual recruitment period 
(months) 
39 39 months 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) U Recruited to 100% target in a period exceeding 10% 
beyond the planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y Both ( cost and time extension); recruitment slower 
than anticipated 
Extension granted Y  
Discrepancy  Target recruitment period 
Action rule 1 Figure provided by CI matches the figure in protocol 
 
Amitriptyline in EB Pain 
Target sample size 40 Original sample size 40 as per NIHR report but 30 as 
per CI, planned sample size 40, 40 in protocol 
UK recruitment 31 31 as per NIHR data but 22 as per CI 
246 
 
Target recruitment period 
(months) 
 24 as per original opening and closing dates in NIHR 
report but 12 months as per CI 
Actual recruitment period 
(months) 
41  
Recruitment success (P) U failed to recruit to 100%  
Recruitment success (S) U failed to recruit to 100% target  
Target revised N  
Recruitment discontinued 
earlier than planned 
N No 
Extension requested Y No cost extension ( time only); Delay in receiving 
placebo IMP, slow recruitment 
Extension granted Y had a no cost extension 
Discrepancy  Target recruitment period and numbers recruited 
Action rule 1 NIHR figure for target recruitment period accepted 
as matches with protocol, corresponding NIHR 
figure for recruitment numbers accepted. 
Outcome same with either NIHR or CI data 
 
 
An alternative booster vaccine against meningitis and ear infections 
 
Target sample size 168 Original sample size 168 as per NIHR report but 178 
as per CI, planned sample size 168, 168 in protocol 
UK recruitment 178 178 as per NIHR data and CI 
Target recruitment period 
(months) 
7 7 as per original opening and closing dates in NIHR 
report and CI 
Actual recruitment period 
(months) 
5  
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) S Recruited to 100% target in a period not exceeding 
10% beyond the planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Target sample size 
Action rule 1 NIHR figure for target sample size accepted as 
matches with protocol 
 
BOOST II UK 
 
Target sample size 1200 Original sample size 1200 as per NIHR report and 
CI, planned sample size 1200, 1200 in protocol 
UK recruitment 973 973 as per NIHR data and CI 
Target recruitment period 
(months) 
48 91 as per original opening and closing dates in 
NIHR report but 49 months as per intended opening 
and closing dates in SAC form, 48 months as per CI 
Actual recruitment period 
(months) 
39  
Recruitment success (P) S  
Recruitment success (S) S  
Target revised N  
Recruitment discontinued 
earlier than planned 
Y As per CI- Data monitoring committee (DMC) 
recommended to the Trial steering committee that 
recruitment should cease because a meta-analysis of 
the on-going trials showed a highly significant and 
247 
 
unexpected difference in mortality 
Extension requested N  
Discrepancy  Target recruitment period 
Action rule 1 CI figure for target recruitment period accepted as 
close to figure as per SAC form 
Query and rationale  Numbers recruited to the trial less than the planned 
target but trial recruitment discontinued early due to 
difference in mortality. The numbers recruited just 
exceed the recruitment target for the duration of 
recruitment to the trial.   
 
Bronchiolitis of Infancy Discharge Study (BIDS) 
 
Target sample size 600 Original sample size 720 as per NIHR report but 600 
as per CI, planned sample size 600, 600 in protocol 
UK recruitment 615 615 as per NIHR data and CI 
Target recruitment period 
(months) 
12 24 months as per original opening and closing dates 
in NIHR report, 24 months as per SAC form, 12 
months as per CI 
Actual recruitment period 
(months) 
12 18 months as per NIHR data but 12 months as per CI 
Recruitment success (P) S recruited to 100% target 
Recruitment success (S) S Recruited to 100% target in a period not exceeding 
10% beyond the planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancies  Target sample size- planned sample size accepted as 
target as matches with figure in protocol and that 
provided by CI.  
Target and actual recruitment period- Discrepancies 
clarified by CI 
Notes  As per CI questionnaire: Recruitment was planned as 
2 x 6 month winter bronchiolitis seasons. CI has 
confirmed that the trial recruited precisely to 
schedule a per protocol and agreement signed with 
NIHR 
Action rule 1 
 
2 
Target sample size 
Target recruitment period 
 
CATCH 
 
Target sample size 1200 Original sample size 1200 as per NIHR report and 
CI 
UK recruitment 1484 1484 as per NIHR data and 1450 as per CI, 1484 as 
per trial coordinator at CTU 
Target recruitment period 
(months) 
20 37 months as per original opening and closing dates 
in NIHR report, 24 months as per CI, 36 months as 
per SAC form. 20 months as per dates provided by 
trial coordinator. 
Actual recruitment period 
(months) 
23 25 months as per NIHR report, 23 months as per 
dates provided by trial coordinator  
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) U Recruited to 100% target in a period exceeding 10% 
beyond the planned recruitment period 
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Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y No cost extension requested to ensure data capture 
and because centres started late.  
Extension granted Y  
Notes  Recruitment dates provided by the trial coordinator 
Planned recruitment period:  June 2010 – 31 Jan 
2012 (dates given to the HTA in the milestones). 
Actual recruitment period: 1 Oct 2010 – 31 August 
2012 (dates given by Stats team recruitment graph), 
no cost extension recruitment extended to 28 Feb 
2013 
Discrepancy  Numbers recruited and target recruitment period 
Action rule 2 Information obtained from the trial coordinator 
 
CHIP trial 
 
Target sample size 1500 Original sample size 1500 as per NIHR report and 
CI 
UK recruitment 1384 1384 as per NIHR data and 1372 as per CI, 1384 on 
website 
Target recruitment period 
(months) 
24 24 months as per original opening and closing dates 
in NIHR report, CI has not provided the data, 24 
months in protocol  
Actual recruitment period 
(months) 
41  
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U  
Revision of target N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y  
Extension granted Y Limited extension granted with modified follow-up 
(no follow-up at 1 year for final 12 months of 
recruitment) 
Discrepancy  Numbers recruited and target recruitment period 
Action rule 1 
 
 
Numbers recruited- NIHR figure matches with the 
figure on study website 
Target recruitment period- NIHR data matches 
protocol 
 
Cognative GA Study - TIVA versus volatile anaesthesia in children: cognitive effects 
 
Target sample size 150 Original sample size 150 as per NIHR report and 80 
as per CI 
UK recruitment 58 0 as per NIHR data and 32 as per CI 
Target recruitment period 
(months) 
36 4 months as per original opening and closing dates 
in NIHR report, 36 months as per CI 
Actual recruitment period 
(months) 
41 41 months as per NIHR report  
Recruitment success (P) U  
Recruitment success (S) U  
Target revised Y One revision. recruitment to the trial was very 
effective but repeated staff shortages and 
cancellation of clinics meant that many patients who 
had consented to participate were lost to the study 
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Recruitment discontinued 
earlier than planned 
N  
Extension requested Y No cost extension - To increase the sample size to a 
satisfactory number for statistical purposes 
Extension granted Y  
Discrepancy  Target sample size, numbers recruited and target 
recruitment period 
Action rule 2 The CI confirmed that the original intention was to 
recruit 150 patients and the target was revised down 
to 80. The study was originally planned to run over 
36 months and 58 patients were randomised in the 
study. The original recruitment target was accepted 
as it was brought down due to problems with 
recruitment and there was insufficient information to 
justify reduction in sample size. 
 
DECIDE 
 
Target sample size 200 Original sample size 240 as per NIHR report and CI, 
planned sample size 200 
UK recruitment 203 203 as per NIHR data and CI 
Target recruitment period 
(months) 
18 18 months as per original opening and closing dates 
in NIHR report and CI 
Actual recruitment period 
(months) 
40 40 months as per NIHR report  
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) U Recruited to 100% target in a period exceeding 10% 
beyond the planned recruitment period 
Target revised Y Revised once downwards to 200 in the context of 
trial progress and experience of drop-outs. 
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y No cost extension- Slower than anticipated 
recruitment rates. 
Notes (MCRN files)  The original sample size was calculated at 200 but 
set at 240 to allow for a 17% withdrawal rate, 
however the withdrawal rate has been minimal (only 
1 patient). Recruitment was slower than anticipated 
throughout the trial and so the decision was made by 
the TSC (acting as IDMC) in conjunction with the 
TMG, to cease recruiting on 31st October 2011 
when it was calculated that 200 patients would have 
been recruited. In fact by this date 203 patients were 
recruited. 
Action rule 1 The planned sample size of 200 was accepted as 
target sample size since the original target was 
revised due to a reduced drop-out rate. This 
information was obtained from MCRN study 
records. 
 
 
DRN067 (FACTS) 
 
Target sample size 300 Original sample size 300 as per NIHR report and CI 
UK recruitment 305 305 as per NIHR data and CI 
Target recruitment period 12 or 18 12 months as per original opening and closing dates 
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(months) in NIHR report, 18 months as per CI 
Actual recruitment period 
(months) 
24 24 months as per NIHR report  
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) U Recruited to 100% target in a period exceeding 10% 
beyond the planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y No cost extension 
Extension granted Y  
Reason for requesting 
extension 
 It was expected that all sites would recruit 
simultaneously but delays in local R&D approvals as 
well as staff health issues (20 paediatric 
nurses/dietetians having babies, maternity leave, sick 
leave etc)and NHS structural changes (some sites 
were completely relocated from NHS site into 
community during the trial)all contributed to 
staggered recruitment. 
Discrepancy  Target recruitment period 
Action rule 1 Outcome same with NIHR data and information 
provided by CI 
 
H1N1 
 
Target sample size 1000 Original sample size 1000 as per NIHR report, and 
CI 
UK recruitment 943 943 as per NIHR data and CI 
Target recruitment period 
(months) 
2 3 months as per NIHR report, 2 months as per CI 
Actual recruitment period 
(months) 
1 1 month 
Recruitment success (P) S  
Recruitment success (S) S  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Notes  Numbers recruited to the trial less than the planned 
target but recruitment to the study took place over 5 
weekends and study stopped at 943 because data 
was needed ASAP due to the nature of the study. 
The numbers recruited exceed the recruitment target 
for the actual duration of recruitment to the study.   
 
I2S2 
 
Target sample size 1100-
1700 
Original sample size 650 as per NIHR report, 1300 
as per CI, 110-1700 in protocol, planned sample size 
1400 
UK recruitment 1275 1275 as per NIHR data and CI 
Target recruitment period 
(months) 
27 41 months as per NIHR report, 36 months as per CI 
Actual recruitment period 
(months) 
33 34 month 
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Recruitment success (P) S recruited to 100% target 
Recruitment success (S) U recruited to 100% target 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y Both cost and time extension because of slower than 
anticipated recruitment 
Extension granted Y  
Discrepancy  Target sample size and target recruitment period 
 
Action rule 2 CI confirmed that target recruitment period was 27 
months and actual recruitment period was 33 
months; the target recruitment was a range from 
1100 to 1700; 1400 was arbitrarily selected as a 
range could not be entered. 
 
 
INDIGO - Pump versus MDI insulin and hypoglycaemia in children. 
 
Target sample size 10 Original sample size 10 as per NIHR report 
UK recruitment 10 10 as per NIHR data , 10 as per study report sent by 
CI 
Target recruitment period 
(months) 
24 24 months as per NIHR report 
Actual recruitment period 
(months) 
32 32 months 
Recruitment success (P) S recruited to 100% target 
Recruitment success (S) U recruited to 100% target in a period exceeding 10% 
of planned recruitment period 
Target revised  Information not available 
Recruitment discontinued 
earlier than planned 
 Information not available 
Extension requested  Information not available 
Notes  CI did not respond to the questionnaire 
 
 
MAGNETIC 
 
Target sample size 500 Original sample size 500 as per NIHR report and CI, 
planned sample size 20 
UK recruitment 508 508 as per NIHR data and CI 
Target recruitment period 
(months) 
24 24 months as per NIHR report, 24 months as per 
trial coordinator 
Actual recruitment period 
(months) 
28 28 months 
Recruitment success (P) S recruited to 100% target 
Recruitment success (S) U Recruited to 100% target in a period exceeding 10% 
of planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Notes   
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MASCOT 
 
Target sample size 450 Original sample size 450 as per NIHR report and 
900 as per CI, planned sample size 450. Checked 
MCRN files- target for registration 900 and 
randomisation 450 
UK recruitment 160 170 as per NIHR data and 160 as per CI 
Target recruitment period 
(months) 
 12 months as per NIHR report, 24 months as per CI 
Actual recruitment period 
(months) 
 18 months 
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target 
Target revised N  
Recruitment discontinued 
earlier than planned 
Y Funders unwilling to continue 
Extension requested Y Both cost and time- not granted 
Extension granted N  
Discrepancy  Target sample size 
Action rule 1  
 
MCRN 002 
 
Target sample size 600 Original sample size 250 as per NIHR report, 600 as 
per CI, planned sample size 250. 600 in protocol 
UK recruitment 278 146 as per NIHR data and 286 as per CI 
Target recruitment period 
(months) 
3 19 months as per NIHR report and 3 months as per 
CI 
Actual recruitment period 
(months) 
8 8 months 
Recruitment success (P) U  
Recruitment success (S) U  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Target sample size, numbers recruited and target 
recruitment period 
Action rule 1 
 
2 
Target sample size- figure provided by CI matches 
the figure in protocol 
Numbers recruited and target recruitment period 
clarified with the study team  
 
 
MCRN 033 
 
Target sample size 280 Original sample size 280 as per NIHR report and CI, 
planned sample size 280, 280 in protocol 
UK recruitment 280 284 as per NIHR data, 280 as per CI 
Target recruitment period 
(months) 
5 14 months as per NIHR report and 5 months as per 
CI 
Actual recruitment period 
(months) 
6 6 months (165 days) 
Recruitment success (P) S recruited to 100% target 
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Recruitment success (S) S Recruited to 100% target in a period not exceeding 
10% of planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Target recruitment period 
Action rule 1  
 
MCRN 089 
Target sample size 384 Original sample size 300 as per NIHR report, 384 as 
per CI, planned sample size 384, 384 in protocol 
UK recruitment 385 385 as per NIHR data, 384 as per CI  
Target recruitment period 
(months) 
15 15 months as per NIHR report, 12 months as per CI 
Actual recruitment period 
(months) 
11 11 month 
Recruitment success (P) S recruited to 100% 
Recruitment success (S) S Recruited to 100% target in period not exceeding 
10% of planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
Y Recruitment target reached early 
Extension requested N  
Notes  Target sample size 384 and numbers recruited 385 as 
per MCRN study files 
Discrepancy  Target sample size and numbers recruited 
Action rule 1  
 
MCRN 164 
Target sample size 284 Original sample size 284 as per NIHR report, 284 as 
per CI, planned sample size 284, 284 in protocol 
UK recruitment 284 284 as per NIHR data, 284 as per CI 
Target recruitment period 
(months) 
6 5 months as per NIHR report, 6 months as per CI, 6 
months as per SAC form 
Actual recruitment period 
(months) 
7 7 months (219 days) 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) U Recruited to 100% target in a period exceeding 10% 
of planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Notes   
 
MENDS 
Target sample size 172 Original sample size 172 as per NIHR report, 180 as 
per CI, planned sample size 172, 172 in protocol 
UK recruitment 146 146 as per NIHR data, 180 as per CI, 146 as per 
CTU 
Target recruitment period 
(months) 
9 9 months as per NIHR report, CI not stated 
Actual recruitment period 32 32 months 
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(months) 
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target  
Target revised Y  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y Both time and cost extension requested. Slow early 
recruitment rate (many reasons for this): time 
extension. Add-on genetic study which required 
funding: cost (money) extension 
Extension granted Y  
Discrepancy  Target sample size and numbers recruited 
Action rule 1 Information requested from the Clinical Trials Unit 
 
MIGS 
Target sample size 60 Original sample size 60 as per NIHR report, 60 as 
per CI, planned sample size 60, 60 in protocol 
UK recruitment 62 62 as per NIHR data, 62 as per CI 
Target recruitment period 
(months) 
33 16 months as per NIHR report, 33 months as per CI  
Actual recruitment period 
(months) 
32 32 months 
Recruitment success (P) S recruited to 100% target 
Recruitment success (S) S Recruited to 100% target in a period not exceeding 
10% of planned recruitment period 
Target revised Y CI questionnaire- 2 patients replaced due to not 
meeting timing of primary endpoint, discussed at 
DMEC and ratified by TSC 
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Target recruitment period 
Action rule 1  
 
Nephrotic Syndrome 
Target sample size 50 Original sample size 50 as per NIHR report, 50 as 
per CI, planned sample size 50, 50 in protocol 
UK recruitment 53 53 as per NIHR data, 53 as per CI 
Target recruitment period 
(months) 
24 35 months as per NIHR data, 24 months as per CI 
Actual recruitment period 
(months) 
20 20 months 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) S Recruited to 100% target in planned recruitment 
period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Target recruitment period 
Action rule 1  
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NEST 
Target sample size 118 Original sample size 118 as per NIHR report, 94 as 
per CI, planned sample size 118, 118 in protocol 
UK recruitment 111 111 as per NIHR data, 96 as per CI 
Target recruitment period 
(months) 
35 35 months as per NIHR data, 36 months as per CI 
Actual recruitment period 
(months) 
46 46 months 
Recruitment success (P) U  
Recruitment success (S) U  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y Both time and cost extension.  
Extension granted Y H1N1 epidemic prevented availability of ECMO 
beds in UK 
Discrepancy  Target sample size and numbers recruited 
Action rule 1 Information checked on study website: target 118, 
numbers recruited 111 
 
P3MC 
Target sample size 600 Original sample size 600 as per NIHR report, 600 as 
per CI, planned sample size 600 
UK recruitment 47 47 as per NIHR data, 47 as per CI 
Target recruitment period 
(months) 
24 43 months as per NIHR data, 24 months as per CI 
Actual recruitment period 
(months) 
12 12 months 
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target 
Target revised N  
Recruitment discontinued 
earlier than planned 
Y  
Extension requested N  
Notes  The funding was pulled due to poor recruitment 
rates. This was recommended by the Trial Steering 
Committee and agreed by the funders. 
 
POP study 
Target sample size 216 Original sample size 270 as per NIHR report, 270 as 
per CI, planned sample size 216 
UK recruitment 217 210 as per NIHR data, 217 as per CI 
Target recruitment period 
(months) 
18 31 months as per NIHR data, 18 months as per CI 
Actual recruitment period 
(months) 
52 52 months 
Recruitment success (P) S  
Recruitment success (S) U  
Target revised Y  
Recruitment discontinued 
earlier than planned 
N  
Extension Y  
Notes (CI questionnaire)  One revision. The sample size was calculated 
initially at 270. Using an increase of 0.5 SDS in 
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BMD in the treated group compared to the control 
for a test with 80% confidence and a significance 
level of 5%, we will require 75 children in each of 
the three study arms, (225) allowing for a 15% 
dropout rate. It was further expected that 
approximately 20% of this population will not 
receive steroids for 3 months. Thus to ensure that an 
adequate number of children do complete the study 
on steroids we had planned to recruit 90 children to 
each arm; a total of 270. However at the interim 
analysis the dropout rate was much lower than 
anticipated and the majority of children received 
steroids for more than 3 months. The trial statistician 
reanalysed the power calculation 
Sample size required: 216 
Discrepancy  Target sample size, numbers recruited 
Action  216 accepted as target sample size as reduction in 
sample size due to reduced drop-out rate 
 
Salford Bright Smiles Baby Study 
 
Target sample size 660 Original sample size 732 as per NIHR report, 660 as 
per CI, planned sample size 330, 732 in protocol 
UK recruitment 409 330 as per NIHR data, 409 as per CI 
Target recruitment period 
(months) 
6 6 months as per NIHR data and CI 
Actual recruitment period 
(months) 
14 14 months 
Recruitment success (P) U  
Recruitment success (S) U Did not recruit to 100% target 
Target revised Y  
Recruitment discontinued 
earlier than planned 
N  
Extension Y No cost, underestimation of recruitment period 
Notes (CI questionnaire)  Target reduced from 660 to 330 as new evidence 
available to support reduced sample size (would still 
be able to determine effect). 
Re-opened recruitment due to underestimation of 
drop out, to increase sample size to current 409. 
Notes (MCRN files)  A comprehensive review of the study has been 
undertaken due to concerns that the original sample 
size (n =630) would not be achieved within a 
reasonable time frame. Part of the review re-
examined the setting of the minimum clinically 
significant difference. At the time of writing the 
original bid, the Cochrane Review of the efficacy of 
fluoride varnishes informed this decision (1).   A re-
examination of this Cochrane Review identified that 
it had been published in 2002 and not updated. 
Further, that no studies involved the very young age 
group of our trial were included.  A more recent 
study (Weintraub et al, 2006) (2) has been conducted 
to GCP in early childhood caries. This trial of 
fluoride varnish in children of a similar age group 
showed an odds ratio of 3.5 in caries incidence for 
children randomised to receive 2 fluoride varnish 
applications per year. This new information 
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informed a fresh discussion of the minimum 
clinically significant difference and led to the 
decision that this be reduced from 20% with caries in 
the test groups to 17.5% with caries.  Therefore the 
revised sample size will be 330 participants and we 
have so far accrued 60 % of this new final target 
Discrepancy  Target sample size and numbers recruited 
Action rule 1 target sample size accepted as 660 because target 
revised down due to recruitment difficulties 
 
SCAMP 
Target sample size 150 Original sample size 150 as per NIHR report, 
planned sample size 150, 150 in protocol 
UK recruitment 115 115 as per NIHR data 
Target recruitment period 
(months) 
24 24 months as per NIHR data  
Actual recruitment period 
(months) 
34 34 months 
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target 
Target revised  Information not available 
Recruitment discontinued 
earlier than planned 
 Information not available 
Extension  Information not available 
 
StePS 
Target sample size 90 Original sample size 90 as per NIHR report, 90 as 
per CI, planned sample size 90 
UK recruitment 29 29 as per NIHR data and CI 
Target recruitment period 
(months) 
24 18 months as per NIHR data, 24 months as per CI 
Actual recruitment period 
(months) 
51 51 months 
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y No cost extension 
Extension granted Y Requested for low recruitment 
Discrepancy  Target recruitment period 
Action rule 1  
 
SWET 
Target sample size 310 Original sample size 310 as per NIHR report, 310 as 
per CI, planned sample size 336, 310 in protocol 
UK recruitment 336 440 as per NIHR data and 336 as per CI 
Target recruitment period 
(months) 
18 18 months as per NIHR data, not mentioned by CI, 
18-20 months in protocol 
Actual recruitment period 
(months) 
26 26 months  
Recruitment success (P) S recruited to 100% target 
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Recruitment success (S) U recruited to 100% target in a period exceeding 10% 
of the planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Numbers recruited  
Notes  Numbers recruited, target and actual recruitment 
period checked on study website and publication 
 
The first BCVC nasal flu vaccine study 
 
Target sample size 151 Original sample size 200 as per NIHR report, 200 as 
per CI, planned sample size 151, 200 in protocol 
UK recruitment 152 151 as per NIHR data and 152 as per CI 
Target recruitment period 
(months) 
2 4 months as per NIHR data, 2 months as per CI 
Actual recruitment period 
(months) 
2 2 months 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) S Recruited to 100% target in a period not exceeding 
10% of planned recruitment period 
Target revised Y one revision original sample size arbitrary as no data 
available to estimate likely size of effect the 
relevance of which is biological rather than clinical 
Recruitment discontinued 
earlier than planned 
N  
Extension   
Notes (MCRN files)  The 200 target was pretty arbitrary - roughly what 
we thought we would be able to get in the time 
available. The aim of the study is to see if there is 
any biological effect of vaccination on bacterial 
carriage. 152 will permit us to do that. 
Discrepancy  Target sample size 
Action  151 accepted as target sample size 
 
TIPIT 
Target sample size 150 Original sample size 150 as per NIHR report, 150 as 
per CI, planned sample size 150, 150 in protocol 
UK recruitment 153 153 as per NIHR data and 153 as per CI 
Target recruitment period 
(months) 
24 27 months as per NIHR data, 24 as per CI 
Actual recruitment period 
(months) 
19 19 months 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) S Recruited to 100% target in a period not exceeding 
10% of planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Target recruitment period 
Action rule 1  
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Treatments for Childhood Crohn's Disease 
 
Target sample size 80 Original sample size 80 as per NIHR report, 80 as 
per CI, planned sample size 80, 80 in protocol 
UK recruitment 83 84 as per NIHR data and 83 as per CI 
Target recruitment period 
(months) 
24 16 months as per NIHR data, 24 as per CI 
Actual recruitment period 
(months) 
16 16 months 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) S Recruited to 100% target in a period not exceeding 
10% of planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Target recruitment period 
Action rule 1  
 
Wheeze and Intermittent Treatment: WAIT 
Target sample size 1300 Original sample size 1300 as per NIHR report, 1300 
as per CI, planned sample size 1300 
UK recruitment 1368 1368 as per NIHR data and 1367 as per CI 
Target recruitment period 
(months) 
24 24 months as per NIHR data, 24 as per CI 
Actual recruitment period 
(months) 
26 26 months 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) S Recruited to 100% target in a period not exceeding 
10% of planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y  
Extension granted Y  
Notes  A 6 month funding and 18 month time extension 
was requested. This represented 6 months additional 
active recruiting time and 12 months to account for a 
delay in starting recruitment. In effect only one extra 
month of recruitment was required but the additional 
data analysis time and closing out time was 
invaluable. 
 
 
Paediatric Non-medicines studies 
 
A Pilot Study to Explore the Feasibility of Computerised CBT for Children 
Target sample size 45 Original sample size 45 as per CI and NIHR report 
UK recruitment 20 19 as per NIHR data and 20 as per CI 
Target recruitment period 
(months) 
12 12 as per original opening and closing dates in 
NIHR report and CI 
Actual recruitment period 
(months) 
13 13 months 
Recruitment success (P) U Did not recruit to 100% target 
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Recruitment success (S) U Did not recruit to 100% target 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
 
AIRS 
Target sample size 295 Original sample size 294 as per NIHR report and 295 
as per CI 
UK recruitment 320 341 randomisation events as per NIHR data and 320 
as per CI 
Target recruitment period 
(months) 
24 8 months as per original opening and closing dates in 
NIHR report and 24 months as per CI 
Actual recruitment period 
(months) 
36 36 months 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) U Recruited to 100% target in a period exceeding 10% 
of the planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension N  
Discrepancy  Numbers recruited 
Action rule 1  
 
Atomoxetine HSEN 
Target sample size 40 Original sample size 40 as per NIHR report and CI 
UK recruitment 15 11 as per NIHR data and 15 as per CI 
Target recruitment period 
(months) 
36 17 months as per original opening and closing dates 
in NIHR report and 36 months as per CI 
Actual recruitment period 
(months) 
22 22 months 
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target  
Target revised N  
Recruitment discontinued 
earlier than planned 
Y insufficient recruitment 
Extension requested N  
Discrepancy  Numbers recruited and target recruitment period 
Action rule 1  
 
Baby wipes trial 
 
Target sample size 280 Original sample size 280 as per NIHR report and CI 
UK recruitment 280 280 as per NIHR data and CI 
Target recruitment period 
(months) 
9 12 months as per original opening and closing dates 
in NIHR report and 9 months as per CI 
Actual recruitment period 
(months) 
9 13 months as per NIHR data, 9 months as per study 
team and publication 
Recruitment success (P) S Did not recruit to 100% target 
Recruitment success (S) S  
Target revised Y Initial recruitment target based on available thigh 
data.  One planned revision, agreed by Data 
Monitoring Committee, based on data collected at 
buttocks on first 29 participants.  Sample size 
reduced to at least 266 (133 participants per group). 
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Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Discrepancy  Target recruitment period and actual recruitment 
period 
Action rule 1 Information checked with study statistician and in 
published report  
 
CHAFFINCH Trial Pilot 
 
Target sample size 32 Original sample size 40 as per NIHR report and CI 
UK recruitment 32 29 as per NIHR data and 32 as per CI 
Target recruitment period 
(months) 
3 2 months as per original opening and closing dates in 
NIHR report and 3 months as per CI 
Actual recruitment period 
(months) 
5 5 months 
Recruitment success (P) S Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target 
Target revised Y For the pilot study, we initially planned to recruit 40 
children. In line with the CLRN guidelines, when we 
observed that there would be enough children for the 
pilot, we reduced the target to 80% i.e. 32 children 
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y No cost extension 
Extension granted Y Preparation of the material related to good clinical 
practice (GCP) and to homogenise forms between 
the College and the participant Trusts. 
Action  Revised target of 32 accepted  
 
CLICK-EAST: The Edinburgh Autism Social-attention Trial 
 
Target sample size 60 Original sample size 60 as per NIHR report and CI 
UK recruitment 61 61 as per NIHR data and 54 as per CI 
Target recruitment period 
(months) 
18 18 months as per original opening and closing dates 
in NIHR report and CI 
Actual recruitment period 
(months) 
9 9 months 
Recruitment success (P) S  
Recruitment success (S) S  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Notes (Information requested 
from CI) 
 61 children were assessed at baseline and their 
parents gave consent. 54 children began the trial. 
There were seven children who did not meet 
inclusion criteria so they were recruited but not 
enrolled.  
Recruitment was 9 months in terms of the period in 
which participants were signing consents. The 18 
month estimate covered from initial contact with 
potential recruiters and participants until final data 
collection.  
Discrepancy  Numbers recruited and recruitment period  
Action rule 2 Numbers recruited taken as 61- as 61 consented and 
recruited to the study though 7 were excluded later 
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as did not meet the inclusion criteria.  
 
Dolphin study 1 
Target sample size 60 Original sample size 60 as per NIHR report and CI 
UK recruitment 62 61 as per NIHR data and 62 as per CI 
Target recruitment period 
(months) 
24 27 months as per original opening and closing dates 
in NIHR report and 24 months as per CI 
Actual recruitment period 
(months) 
33 33 months 
Recruitment success (P) S Recruited to 100% target 
Recruitment success (S) U Recruited to 100% target in a period exceeding 10% 
of the planned recruitment period 
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y both 
Extension granted Y Recruitment into the Study was intended to run for 2 
years from 2009 but was slow to start. The first 
recruit did not enter until April 2010 and by the end 
of the year only 15 recruits had joined. An extension 
to recruitment was sought from and approved by the 
University's R&D Dept. in 2011 and additional funds 
were agreed by both the Study's Charitable Sponsors. 
Discrepancy   Target recruitment period 
Action rule 1  
 
Dolphin study 2 
Target sample size 60 Original sample size 60 as per NIHR report and CI 
UK recruitment 40 40 as per NIHR data and CI 
Target recruitment period 
(months) 
24 38 months as per original opening and closing dates 
in NIHR report and 24 months as per CI 
Actual recruitment period 
(months) 
50 50 months 
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y both 
Extension granted Y  
Notes (CI questionnaire)  Recruitment into this cohort of the study proved 
problematic from the outset. It was primarily 
dependent on the referral of potential recruits by 
Community Paediatric Consultants who had agreed 
to act as Study Collaborators. Some proved better 
than others and remembering the study and 
mentioning it to families attending their clinics. 
Additionally, it is also suspected that eventual 
success in recruiting into the Dolphin I cohort had 
the effect of reducing the potential recruits into this 
cohort. 
Discrepancy  Target recruitment period 
Action rule 1  
 
Evaluation of Telephone Administered CBT for Young People with OCD 
Target sample size 72 Original sample size 80 as per NIHR report and not 
mentioned in CI response 
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UK recruitment 72 72 as per NIHR data and CI 
Target recruitment period 
(months) 
24 27 months as per original opening and closing dates 
in NIHR report and 24 months as per CI 
Actual recruitment period 
(months) 
38 38 months 
Recruitment success (P) S  
Recruitment success (S) U Did not recruit to 100% target  
Target revised Y we had fewer dropouts than anticipated, so we were 
able to reduce the recruitment target because that 
allowed for drop outs within each condition 
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y both 
Extension granted Y extension was requested because of the slower than 
expected rate of recruitment 
Discrepancy  Target sample size and target recruitment period 
Action  Revised target of 72 accepted as target sample size 
as this was a result of a reduced dropout rate. 
   
 
i- BASIS 
Target sample size 50 Original sample size 50 as per NIHR report and CI  
UK recruitment 54 52 as per NIHR data and 54 as per CI 
Target recruitment period 
(months) 
10 17 months as per original opening and closing dates 
in NIHR report and 10 months as per CI 
Actual recruitment period 
(months) 
21 21 months 
Recruitment success (P) S  
Recruitment success (S) U  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y no cost extension 
Extension granted  Y Slow initial recruitment, interference from the 
Olympics 
Discrepancy  Numbers recruited and target recruitment period 
Action rule 1  
 
IMPACT 
Target sample size 540 Original sample size 540 as per NIHR report  
UK recruitment 472 472 as per NIHR data  
Target recruitment period 
(months) 
19 19 months as per original opening and closing dates 
in NIHR report  
Actual recruitment period 
(months) 
31 31 months 
Recruitment success (P) U  
Recruitment success (S) U  
Target revised  Information not available 
Recruitment discontinued 
earlier than planned 
 Information not available 
Extension requested  Information not available 
Notes  CI has not responded to the questionnaire 
 
 
Intervention for Parents with Young Asthmatic Children 
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Target sample size 180 Original sample size 180 as per NIHR report  
UK recruitment 136 136 as per NIHR data  
Target recruitment period 
(months) 
24 24 months as per original opening and closing dates 
in NIHR report 
Actual recruitment period 
(months) 
23 23 months 
Recruitment success (P) U  
Recruitment success (S) U  
Target revised  Information not available 
Recruitment discontinued 
earlier than planned 
 Information not available 
Extension requested  Information not available 
Notes  CI has not responded to the questionnaire 
 
 
Kneeblock Study 
Target sample size 110 Original sample size 100 as per NIHR report and 
110 as per CI  
UK recruitment 40 1 as per NIHR data and 40 as per CI 
Target recruitment period 
(months) 
24 70 months as per original opening and closing dates 
in NIHR report and 24 months as per CI 
Actual recruitment period 
(months) 
17 17 months 
Recruitment success (P) U  
Recruitment success (S) U  
Target revised N  
Recruitment discontinued 
earlier than planned 
Y Because of lack of recruitment 
Extension requested N  
Discrepancy  Target sample size and recruitment period, numbers 
recruited 
Action rule  1  
 
LEAP study 
Target sample size 640 Original sample size 640 as per NIHR report and 
480 as per CI  
UK recruitment 640 111 as per NIHR data and 640 as per CI 
Target recruitment period 
(months) 
30 23 months as per original opening and closing dates 
in NIHR report, 24 months for target of 480 and 30 
months for revised target of 640 
Actual recruitment period 
(months) 
30 30 months 
Recruitment success (P) S  
Recruitment success (S) S  
Target revised Y Initial powering of study was potentially 
compromised by high number of patients screened 
with pre-existing peanut allergy 
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y No cost extension 
Extension granted Y Time extension only, to complete final study visits 
Notes (Information from study 
team) 
 The originally approved LEAP Study protocol 
(September 2006) had a target sample size of 480. 
This was revised in 2008 and increased to 640. The 
target sample was amended accordingly in the NIHR 
database. We proceeded to recruit 640 participants 
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into the LEAP Study, with recruitment coming to an 
end in May 2009. Unfortunately we were only able 
to enter the last 111 of these 640 participants into the 
UKCRN/NIHR database, due to technical 
limitations of the online accrual system introduced at 
the time.  
Discrepancy  Target sample size and recruitment period 
Action rule 2  
 
NIRS 
Target sample size 30 Original sample size 30 as per NIHR report and 
checked with NIHR data manager, 32 as per CI 
UK recruitment 12 16 as per NIHR data, 12 running total in NIHR 
spreadsheet, 7 as per CI 
Target recruitment period 
(months) 
12 23 months as per original opening and closing dates 
in NIHR report and 12 months as per CI 
Actual recruitment period 
(months) 
30 30 months 
Recruitment success (P) U Did not recruit to 100% target 
Recruitment success (S) U Did not recruit to 100% target  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Notes (CI questionnaire)  a) Recruitment proved very difficult.  
b) The equipment used for respiratory 
measurements had unforeseen technical 
issues 
Discrepancy  Target sample size and recruitment period, numbers 
recruited 
Action rule 1  
 
 
Nitric Oxide levels 
Target sample size 150 Original sample size 150 as per NIHR report and CI  
UK recruitment 90 96 as per NIHR data and 90 as per CI 
Target recruitment period 
(months) 
12 25 months as per original opening and closing dates 
in NIHR report and 12 months as per CI 
Actual recruitment period 
(months) 
23 23 months 
Recruitment success (P) U  
Recruitment success (S) U  
Target revised Y ‘Recruitment was challenging. Alpha level was 
revised from 2.5 to 5% reducing the required number 
to 90’ 
Recruitment discontinued 
earlier than planned 
N  
Extension N  
Discrepancy   Target recruitment period and numbers recruited 
Action rule 2  
 
Optigrow Infant feeding study 
Target sample size 500 Original sample size 500 as per NIHR report and 90 
as per CI, 500 as checked with NIHR data manager 
UK recruitment 647 633 as per NIHR data and 647 as per CI 
Target recruitment period 24 32 months as per original opening and closing dates 
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(months) in NIHR report and 24 months as per CI 
Actual recruitment period 
(months) 
31 31 months 
Recruitment success (P) S recruited to 100% target 
Recruitment success (S) S  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y No cost extension 
Extension granted Y In order to continue to follow-up children 
Discrepancy  Target sample size and recruitment period, numbers 
recruited 
Notes (Information from CI)  The numbers recruited were 647 which is higher 
than target but since this is a long term study, 
permission was obtained to continue recruiting to 
ensure adequate numbers at FU many years down 
the line  
Action rule 1,2  
 
 
PACT  
Target sample size 144 Original sample size 144 as per NIHR report and 
147 as per CI  
UK recruitment 152 163 as per NIHR data and 152 as per CI 
Target recruitment period 
(months) 
19 15 months as per original opening and closing dates 
in NIHR report and  24 months as per CI 
Actual recruitment period 
(months) 
19  months 
Recruitment success (P) S recruited to 100% target 
Recruitment success (S) S recruited to 100% target  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y no cost extension for 6 months due to recruitment 
rate 
Extension granted Y  
Discrepancy  Target sample size and recruitment period, numbers 
recruited 
Notes ( Information from CI)  144 target, 152 recruited in 19 months, target 
recruitment period 19 months 
Action rule 2  
 
Pilot RCT comparing Surgery to Observation for Intermittent Exotropia 
Target sample size 144 Original sample size 240 as per NIHR report and 
144 as per CI  
UK recruitment 49 49 as per NIHR data and CI 
Target recruitment period 
(months) 
6 3 months as per original opening and closing dates 
in NIHR report and 6 months as per CI 
Actual recruitment period 
(months) 
8 8 months 
Recruitment success (P) U  
Recruitment success (S) U  
Target revised N Did not recruit to 100% target but did not close 
earlier than planned 
Recruitment discontinued 
earlier than planned 
N  
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Extension requested Y No cost extension for 3 months due to poor 
recruitment 
Extension granted Y  
Discrepancy  Target sample size and recruitment period, numbers 
recruited 
Action rule 1  
 
 
 
 
Preventing asthma exacerbations by avoiding mite allergen 
 
Target sample size 284 Original sample size 450 as per NIHR report and 
284 as per CI  
UK recruitment 284 434 as per NIHR data and 284 as per CI 
Target recruitment period 
(months) 
18 18 months as per original opening and closing dates 
in NIHR report and 12-18 months as per CI 
Actual recruitment period 
(months) 
16 16 months 
Recruitment success (P) S  
Recruitment success (S) S  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension N  
Notes (Information from CI)  Target sample size 284 (450 consented to be able to 
randomise 284) and 284 randomised. The NIHR  
 
STATbiTR 
 
Target sample size 30 Original sample size 36 as per NIHR report and 30 
as per CI  
UK recruitment 35 38 as per NIHR data and 35 as per CI 
Target recruitment period 
(months) 
24 24 months as per original opening and closing dates 
in NIHR report and CI has not reported 
Actual recruitment period 
(months) 
17 17 months 
Recruitment success (P) S  
Recruitment success (S) S  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension N  
Notes  Questionnaire completed by Research assisstant 
involved at the end of the study. CI on long term sick 
leave 
Discrepancy  Target sample size and numbers recruited 
Action rule 1  
 
Study of Tolerance to Oral Peanut 
 
Target sample size 104 Original sample size 104 as per NIHR report and CI  
UK recruitment 104 104 as per NIHR data and CI 
Target recruitment period 
(months) 
12 48 months as per original opening and closing dates 
in NIHR report and 12 months as per CI  
Actual recruitment period 35 35 months 
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(months) 
Recruitment success (P) S  
Recruitment success (S) U  
Target revised N  
Recruitment discontinued 
earlier than planned 
N  
Extension requested Y no cost extension 
Extension granted Y Limited capacity to undertake research procedures 
on research ward 
Discrepancy  Target recruitment period 
Action 1  
 
Telephone consultations for children with inflammatory bowel disease 
 
Target sample size 92 Original sample size 92 as per NIHR report  
UK recruitment 86 86 as per NIHR data  
Target recruitment period 
(months) 
37 37 months as per original opening and closing dates 
in NIHR report and CI has not reported 
Actual recruitment period 
(months) 
12 12 months 
Recruitment success (P) U  
Recruitment success (S) U  
Target revised  Information not available 
Recruitment discontinued 
earlier than planned 
 Information not available 
Extension  Information not available 
Notes  CI has not responded to questionnaire.  
 
Use of sensory blankets for children with autistic spectrum disorder 
  
Target sample size 70 Original sample size 100 as per NIHR report and CI, 
planned sample size 70 
UK recruitment 85 72 as per NIHR data and 85 as per CI 
Target recruitment period 
(months) 
18 18 months as per original opening and closing dates 
in NIHR report and CI  
Actual recruitment period 
(months) 
10 10 months 
Recruitment success (P) S  
Recruitment success (S) S  
Target revised Y One revision was made as dropout rate was less than 
anticipated 
Recruitment discontinued 
earlier than planned 
N  
Extension requested N  
Notes  Recruitment started later than anticipated, but all ran 
within the timeframe of the trial. 
Discrepancy  Target sample size and numbers recruited 
Action 1 Revised target accepted as revised due to a reduced 
dropout rate 
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Appendix 9: Covering letter for questionnaire sent to Chief Investigators 
(Chapter 3) 
We are conducting a study to investigate what factors affect recruitment to clinical trials 
with children.  This study is part of the work of the MRC North West Hub for Trials 
Methodology Research and is being undertaken by our clinical PhD student, Geetinder 
Kaur. We are conducting a review of recruitment to paediatric trials on the NIHR 
portfolio and would like to ask you for a small amount of information about the trial 
which you have led.  
All information provided will be strictly confidential. Please note that while we need to 
know the trial details for data management purposes, no individual or trial will be 
identified in any publication. 
The questionnaire is short and will only take about 10 minutes to complete via the 
following link http://edu.surveygizmo.com/s3/1263672/NIHR-portfolio-review-
questionnaire. Please answer all questions and submit the questionnaire by 15
th
 June 
2013. 
Please feel free to contact us, by e-mail to gkaur@liv.ac.uk, if you experience any 
technical difficulties or have any queries about completing the questionnaire.  
 
Many Thanks 
Kind Regard 
 
 
 
 
Professor Paula Williamson 
Director, MRC North West Hub for Trials  
Methodology Research 
University of Liverpool 
Brownlow Street 
Liverpool L69 3GS 
 
Liverpool L69 3 GS 
 
 
 
Professor Rosalind L Smyth  
Director, Institute of Child Health 
University College London (UCL) 
30 Guilford Street 
London WC1N 1EH 
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Appendix 10: Questionnaire sent to Chief Investigators in NIHR portfolio 
review (Chapter 3) 
1) Name of the trial* 
_____________________________________________________________  
 
2) Please enter your name and role in the trial* 
____________________________________________________________  
 
3) What was the design of the trial? 
( ) Parallel 
( ) Factorial 
( ) Crossover 
( ) Other 
 
Please specify________________________________________________ 
 
4) Was the trial 
( ) individually randomised 
( ) cluster randomised 
( ) other 
 
5) Please specify_______________________________________________ 
 
 
6) What was the clinical setting for recruitment? 
Please hold 'ctrl' key for Windows and 'cmd' key for Mac, when clicking on options to select 
multiple options 
( ) Outpatient clinic 
( ) Paediatric Ward 
( ) Children's Accident & Emergency 
( ) Accident & Emergency Department 
( ) Paediatric Intensive Care Unit 
( ) Neonatal Intensive Care Unit 
( ) Postnatal Ward 
( ) General practice 
( ) Community clinic 
( ) School 
( ) Other 
 
Other (please specify)_____________________________________ 
 
7) Was blinding implemented? 
( ) Yes 
( ) No 
 
Who was blinded? 
[ ] Patients 
[ ] Health care providers 
[ ] Data collectors 
[ ] Outcome adjudicators 
[ ] Data analysts 
[ ] Other 
271 
 
 
Please specify__________________________________________ 
 
8) Was the primary outcome measure available from routinely collected data such as patient 
notes or electronic records? 
( ) Yes 
( ) No 
 
What was the method of data collection for primary outcome variable? 
 
 
9) What was the total number of participants recruited to the trial? 
__________________________________________________________  
 
10) What was the sample size in original approved protocol? 
__________________________________________________________  
 
11) Was this revised during the course of the trial? 
( ) Yes 
( ) No 
 
Please give details, including the number of revisions, final recruitment target and the 
reasons for revision. 
__________________________________________________________ 
 
12) What was the planned duration for recruitment in the original approved protocol? 
___________________________________________________________  
 
13) Was trial recruitment discontinued earlier than planned? 
( ) Yes 
( ) No 
 
Please give reasons_______________________________________________ 
 
14) Was a trial extension requested? 
( ) Yes 
( ) No 
 
Was the request for a 
( ) cost extension (extension of trial grant) 
( ) no cost extension ( time only extension) 
( ) Both 
 
Was the extension granted? 
( ) Yes 
( ) No 
 
Please give details including reasons for requesting a trial extension? 
_________________________________________________________________ 
 
Additional comments, if any 
 
 
15) Based on trial protocol, did the participant or parent/carer have to undergo any of the 
following as a part of the trial, which was outside of routine clinical practice? 
Please hold the 'ctrl' key for Windows and 'cmd' key for Mac, when clicking on options to select 
multiple options. 
( ) Additional painful/invasive procedure for trial that would not happen otherwise 
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( ) Extra blood tests i.e. additional venepuncture event that would otherwise not be necessary 
( ) Extra blood taken with routine bloods 
( ) Any other extra tests/procedure 
( ) Additional hospital/clinic visit for protocol defined follow up 
( ) Additional/prolonged clinic visits 
( ) Extended hospital stay 
( ) Extra travel cost 
( ) Extra travel distance/ time 
( ) Extra days off work for family/young adult 
( ) Extra days off school 
( ) Change in lifestyle of child/young adult/family 
( ) Extra paperwork for child/young adult/family e.g. questionnaires, treatment diaries etc. 
( ) Other 
( ) None 
 
Please give relevant details___________________________________________ 
 
 
16) Did the trial have Clinical Trials Unit (CTU) support? 
( ) Yes 
( ) No 
 
Name of the CTU 
____________________________________________________________  
 
Is the CTU UKCRC registered? 
( ) Yes 
( ) No 
 
What was the nature and degree of support provided by the CTU? 
Please hold the 'ctrl' key for Windows and 'cmd' key for Mac, when clicking on options to select 
multiple options. 
( ) Advice on trial design 
( ) Costing of the trial and planning of staffing required to develop and manage the trial 
( ) Communication with the Clinical Research Networks regarding feasibility and levels of interest 
( ) Management of the trial 
( ) Liaising with potential centres, identifying and initiating participating centres, and maintaining 
good communication with each centre 
( ) Recruiting clinical sites in order to identify and recruit eligible trial patients and allocating a 
trial entry number and treatment to trial patients 
( ) Data management 
( ) Trial monitoring 
( ) Conducting interim and final analyses 
( ) Other 
 
Please specify___________________________________________________ 
 
17) Did the trial have a trial coordinator/manager? 
( ) Yes 
( ) No 
 
Was the trial coordinator/manager 
( ) Employed within the CTU 
( ) Research fellow 
( ) Chief Investigator 
( ) Other 
 
Please give relevant details________________________________________ 
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Was the trial coordinator 
( ) Full time equivalent throughout the trial 
( ) Less than full time 
( ) Other 
 
What % of full time equivalent? 
______________________________________________________________  
 
Please give details 
 
 
18) Was a pilot study or feasibility assessment conducted prior to starting the trial? 
( ) Yes 
( ) No 
( ) Not applicable as the trial itself is a pilot/feasibility study 
 
What was the nature of the study? 
( ) Pilot study 
( ) Feasibility assessment 
 
Please describe the 'design, aims and methods' of the pilot study 
_________________________________________________________ 
 
Please describe the 'design, aims and methods' of the feasibility assessment 
_________________________________________________________ 
 
19) Did it lead to any change in the recruitment target or recruitment strategy? 
( ) Yes 
( ) No 
 
Please specify______________________________________________ 
 
 
Thank You! 
Many thanks for providing this information. Your response is very important to us. 
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Appendix 11: Recruitment information from various sources for International studies in NIHR portfolio review (Chapter 3) 
SR Study  Global sample size Enrolment 
(Clinical 
Trials.gov) 
Sample 
size 
(CI) 
Recruitment 
(CI) 
Study start date 
(ClinicalTrials.gov) 
Primary completion date (final 
data collection date for POM) 
(ClinicalTrials.gov) 
 UKCRN 
portfolio 
NIHR 
study 
report 
1 Can we Reduce the 
Number of Vaccine 
Injections for 
Children? 
498 498 Estimated 
enrolment 498 
384  509 
(confirmed 
with study 
team) 
Jan 2010 June 2013 
Recruitment stopped 280113 
2 CASG 112 106 106 109 104 109 June 2008 Dec 2011 
3 MCRN 000 54 54 79 Not responded Sept 2006 Nov 2008 
4 MCRN 003 300 300 306 306 306 June 2007 Sept 2008 
5 MCRN 011 108 108 112 5 5 May 2008 Sep 2009 
6 MCRN 014 184 184 192 80 1 April 2007 May 2010 
7 MCRN 017 120 120 139 120 137 July 2008 Nov 2009 
8 MCRN 018 266 266 207 Not responded Dec 2008 March 2011 
9 MCRN 020 720 720 719 70 0 July 2008 Aug 2012 
10 MCRN 023 1885 1800 1467 1885 1800 Aug 2008 July 2010 
11 MCRN 024 333 333 336 336 336 Oct 2008 April 2011 
12 MCRN026 100 100 101 100 101 March 2009 Aug 2012 
13 MCRN 042 252 252 304 Not responded Dec 2007 Aug 2012 
14 MCRN 049 185 185 188 Not responded Nov 2009 Jan 2013 
15 MCRN 052 1550 1550 1579 1550 1582 March 2009 May 2011 
16 MCRN 057 620 620 1000 e 620 812 Jan 2010 Sep 2015  
Recruitment stopped Oct 2010 
17 MCRN067 214 214 177 5 4 July 2009 Sep 2011 
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18 MCRN 071 900 900 1382 Not responded Nov 2009 April 2011 
19 MCRN 076 32 32 31 1 1 Aug 2009 July 2010 
20 MCRN 084 60 60 52 (Target 30 
in CTR) 
30 52 Aug 2009 Nov 2010 
21 MCRN 105 180 180 228 6 10 July 2010 March 2013 
22 MCRN 112 510 510 528 510 528 May 2010 June 2013, Recruitment stopped 22 
March 2013 
23 MCRN 119 16 16 16 12 14 Nov 2009 Oct 2012 
24 MCRN 128 90 90 90  Not responded   
25 MCRN 129 210 210 215 3 3 Apr 2011 March 2013 
26 MCRN 142 150 150 110 3 3 May 2010 Jan 2013 
27 MCRN 144 8200 8200 12000 Not responded Oct 2011 Jan 2015 
28 MCRN 153 346 346 350 6 4 Jan 2012 July 2013 
29 MCRN 171 75 75 92  75 75 March 2012 Jan 2014 
Recruitment stopped Jan 2013 
30 NCRN 308 300 300 307 Not responded Sep 2011 March 2013 
31 PENTA 18 160 160 173 160 173 Aug 2010 July 2012 
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Appendix 12: Study details of identified MCRN studies in NIHR portfolio review (Chapter 3) 
SR. 
No. 
Portfolio 
Study ID 
Study Acronym / 
Short Title 
Study Title Active 
Status 
Randomisation
? 
Actual 
Opening 
Date 
Actual 
Closure 
Date 
1 2312 ADEPT Abnormal Doppler Enteral Prescription Trial Closed - 
follow-up 
complete 
Randomised 01/04/2006 31/05/2009 
2 3217 Amitriptyline in EB Pain Double blind, placebo controlled crossover 
study of the efficacy and side effects of low 
dose amitriptyline treatment for chronic 
pain, disordered sleep and reduced mobility 
in children with Epidermolysis Bullosa 
Closed - 
follow-up 
complete 
Randomised 26/09/2006 12/02/2010 
3 12221 An alternative booster 
vaccine against 
meningitis and ear 
infections 
A phase III randomised, open label clinical 
trial evaluating the immunogenicity of a 10-
valent pneumococcal conjugate vaccine 
booster compared to the standard 13-valent 
pneumococcal conjugate vaccine booster 
given at 12 months of age to healthy 
children who have received the 13-valent 
pneumococcal conjugate vaccine at 2 and 4 
months of age. 
Closed - in 
follow-up 
Randomised 05/04/2012 07/09/2012 
4 7544 BEEP Feasibility Study of Barrier Enhancement 
for Eczema Prevention 
Closed - in 
follow-up 
Randomised 22/03/2010 31/01/2011 
5 2231 BOOST II UK Which oxygen saturation level should we 
use for very premature infants? A 
randomised controlled trial 
Closed - in 
follow-up 
Randomised 29/09/2007 24/12/2010 
6 11354 Bronchiolitis of Infancy 
Discharge Study (BIDS). 
Bronchiolitis of Infancy Discharge Study 
(BIDS). 
Closed - in 
follow-up 
Randomised 03/10/2011 31/03/2013 
7 8976 Can we Reduce the 
Number of Vaccine 
An open label randomised controlled study 
to evaluate the induction of immune memory 
Closed - in 
follow-up 
Randomised 13/07/2010 29/07/2011 
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Injections for Children? following infant vaccination with a glyco-
conjugate Neisseria meningitidis serogroup 
C vaccine and to assess the immune 
response to the concurrent infant routine 
immunisations administered in consistent 
versus alternating limbs. 
8 4506 CASCADE Maximising engagement, motivation and 
long term change in a Structured Intensive 
Education Programme in Diabetes for 
children, young people and their families: 
Child and Adolescent Structured 
Competencies Approach to Diabetes 
Education 
Closed - 
follow-up 
complete 
Randomised 01/02/2009 18/09/2010 
9 5799 CASG112 A Phase III, Randomized, placebo-
controlled, blinded investigation of six 
weeks vs. six months of oral valganciclovir 
therapy in infants with symptomatic 
congenital cytomegalovirus infection 
(CASG 112) 
Closed - in 
follow-up 
Randomised 04/04/2011 16/06/2011 
10 7976 CATCH A randomised controlled trial comparing the 
effectiveness of heparin bonded or antibiotic 
impregnated central venous catheters with 
standard conetral venous catheters for the 
prevention of hospital acquired blood stream 
infection in children 
Closed - in 
follow-up 
Randomised 25/11/2010 30/11/2012 
11 9601 CCRN 415 (Haemophilia 
A) 
A-LONG: An Open-label, Multicenter 
Evaluation of the Safety,   Pharmacokinetics, 
and Efficacy of Recombinant Factor VIII Fc 
Fusion (rFVIIIFc) in the Prevention and 
Treatment of Bleeding in Previously Treated 
Subjects With Severe Haemophilia A 
Closed - in 
follow-up 
Randomised 10/10/2011 09/12/2011 
12 10035 CCRN 470 
(Haemophilia) 
A multi-centre, single-blind trial evaluating 
the safety and efficacy, including 
pharmacokinetics, of NNC-0156-0000-0009 
Closed - in 
follow-up 
Randomised 26/04/2011 20/02/2012 
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when used for treatment and prophylaxis of 
bleeding episodes in patients with 
haemophilia B 
13 10451 CCRN 515 (Acute pain) A randomised, double blind, multi-centre, 
placebo controlled study to evaluate the 
efficacy and safety of methoxyflurane 
(PenthroxT) for the treatment of acute pain 
in patients presenting to an Emergency 
Department with minor trauma 
Closed - in 
follow-up 
Randomised 14/07/2011 03/08/2012 
14 3218 CHIP Trial Control of Hyperglycaemia in Paediatric 
Intensive Care: The CHIP Trial 
Closed - in 
follow-up 
Randomised 07/04/2008 31/08/2011 
15 11447 Closing the loop in 
adolescents during non-
compliance behaviours 
An open-label, single-centre, randomised, 2-
period cross-over study to assess the efficacy 
and safety of 24-hour closed-loop glucose 
control in comparison with conventional 
subcutaneous insulin pump treatment 
simulating noncompliant behaviours in 
adolescents with type 1 diabetes 
Closed - in 
follow-up 
Randomised 01/12/2011 30/04/2012 
16 9111 Cognative GA Study - 
TIVA versus volatile 
anaesthesia in children: 
cognitive effects 
Randomised clinical trial of the effects of 
total intravenous anaesthesia 
(TIVA:propofol) versus volatile anaesthesia 
(sevoflurane:nitrous oxide) on children's 
post-operative cognition, behaviour and 
physical morbidity. 
Closed - 
follow-up 
complete 
Randomised 01/02/2007 31/05/2010 
17 9530 CRITIC-1 Circadian Rhythm in Tobramycin 
Elimination in Cystic Fibrosis CRITIC-1 
Closed - 
follow-up 
complete 
Randomised 10/05/2011 08/01/2013 
18 4171 DECIDE Delivering Early Care in Diabetes 
Evaluation: An RCT to assess hospital 
versus home management at diagnosis in 
childhood diabetes 
Closed - in 
follow-up 
Randomised 09/07/2008 31/10/2011 
19 3837 DEPICTED Development and Evaluation of a 
Psychosocial Intervention for Children and 
Teenagers Experiencing Diabetes 
Closed - in 
follow-up 
Randomised 14/01/2008 30/11/2008 
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20 3777 DRN067 (FACTS) A randomised controlled trial to examine 
whether enhanced family commmunication 
improves glycaemic control in adolescents 
with type 1 diabetes 
Closed - 
follow-up 
complete 
Randomised 24/10/2007 14/10/2009 
21 5015 DRN191 KICk-OFF A multi-centre, randomised controlled trial 
comparing intensive structured education 
with standard education in 11-16 year olds 
on intensive insulin therapy 
Closed - in 
follow-up 
Randomised 04/02/2009 23/06/2010 
22 6060 DRN229 (MCRN028) A Phase III, 3-Arm, Randomized, Double-
Blind, Placebo-Controlled, Multicenter 
Study, to Investigate the Impact of 
Diamyd® on the Progression of Diabetes in 
Patients Newly Diagnosed with Type 1 
Diabetes Mellitus. 
Closed - 
follow-up 
complete 
Randomised 29/11/2008 30/04/2009 
23 7390 DRN359 DRN 359- A 16-week, randomised, 
controlled, open label, multicentre, 
multinational, three-arm, parallel, treat-to 
target  trial comparing efficacy and safety of 
three different dosing regimens of either 
SIBA or insulin glargine (Lantus®) 
administered as once daily basal-bolus 
insulin all in combination with standard pre-
meal bolus insulin in subjects with type 1 
diabetes mellitus currently well controlled 
on basal bolus insulin regimens 
Closed - 
follow-up 
complete 
Randomised 03/03/2010 26/05/2010 
24 6092 EPIC Project Evidence into practice: evaluating a child-
centred intervention for diabetes medicine 
management. 
Closed - in 
follow-up 
Randomised 16/02/2010 11/08/2011 
25 2311 EVERT Cryotherapy versus salicylic acid for the 
treatment of verrucae: A randomised 
controlled trial 
Closed - 
follow-up 
complete 
Randomised 08/11/2006 08/01/2010 
26 3221 GAP Study A randomised controlled trial of garlic as a 
quorum sensing inhibitor in patients with 
cystic fibrosis and chronic Pseudomonas 
Closed - 
follow-up 
complete 
Randomised 24/04/2007 25/09/2007 
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aeruginosa 
27 6635 GAS A multi-site RCT comparing regional and 
general anaesthesia for effects on 
neurodevelopmental outcome and apnoea in 
infants 
Closed - in 
follow-up 
Randomised 01/10/2009 31/01/2013 
28 6377 Glutamine in CF Glutamine supplementation for cystic 
fibrosis: a parallel group randomized 
controlled trial 
Closed - 
follow-up 
complete 
Randomised 01/04/2009 31/03/2011 
29 7464 H1N1 Open Label Randomized Parallel-Group 
Multi-Centre Study to Evaluate the Safety, 
Tolerability and Immunogenicity of Baxter 
H1N1 vaccine and GlaxoSmithKline H1N1 
vaccine in children 6 months to 12 years of 
age. 
Closed - 
follow-up 
complete 
Randomised 24/09/2009 31/10/2009 
30 7552 I2S2 A randomised control trial of iodine 
supplementation in preterm infants. 
Closed - in 
follow-up 
Randomised 10/03/2010 31/12/2012 
31 8814 INDIGO - Pump versus 
MDI insulin and 
hypoglycaemia in 
children. 
"INDIGO - ""Tight glycaemic control"" and 
the risk of hypoglycaemia:  Is this different 
between multiple injections versus insulin 
pump therapy?    A UK multi-centre, open 
randomised control trial." 
Closed - 
follow-up 
complete 
Randomised 01/04/2008 04/11/2010 
32 7553 KONCERT (PENTA18) A study of the pharmacokinetics, safety and 
efficacy of twice-daily versus once-daily 
lopinavir/ritonavir tablets dosed by weight 
as part of combination antiretroviral therapy 
in HIV-1 infected children. 
Closed - in 
follow-up 
Randomised 07/08/2010 24/08/2012 
33 2276 MAGNETIC MAGnesium NEbuliser Trial In Children - 
A randomised controlled trial of nebulised 
magnesium in acute severe asthma in 
children 
Closed - 
follow-up 
complete 
Randomised 04/12/2008 21/03/2011 
34 9932 MAMA Measures to address maternal anxiety Closed - in 
follow-up 
Randomised 01/03/2011 19/12/2012 
35 3774 MASCOT Management of Asthma in School Age Closed - in Randomised 01/01/2009 30/06/2010 
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Children on Therapy follow-up 
36 2736 MCRN000 
(MEE103219) 
A Randomized, Double-Blind, Parallel 
Group Clinical Trial to Assess Safety, 
Tolerability, Pharmacokinetics, and 
Pharmacodynamics of Intravenous 
Mepolizumab (SB240563)(0.55mg/kg, 
2.5mg/kg or 10mg/kg) in Pediatric Subjects 
With Eosinophilic Esophagitis, Aged 2 to 17 
Years (Study MEE103219) 
Closed - 
follow-up 
complete 
Randomised 01/09/2006 07/03/2008 
37 2525 MCRN001  
(DPM-CF-301) 
Long Term Administration Of Inhaled Dry 
Powder Mannitol In Cystic Fibrosis - A 
Safety And Efficacy Study 
Closed - 
follow-up 
complete 
Randomised 01/07/2007 15/08/2008 
38 3297 MCRN002 (6096A1-
007) 
A Phase 3, Randomized, Active-Controlled, 
Double-Blind Trial Evaluating The Safety, 
Tolerability, And Immunogenicity Of A 13-
Valent Pneumococcal Conjugate Vaccine In 
Healthy Infants Given With Routine 
Pediatric Vaccinations In The United 
Kingdom 
Closed - 
follow-up 
complete 
Randomised 01/10/2006 12/06/2007 
39 3826 MCRN003 (MK0954-
326) 
A Randomized, Double-Blind, Parallel, 
Placebo- Or Amlodipine-Controlled Study 
Of The Effects Of Losartan On Proteinuria 
In Pediatric Patients With Or Without 
Hypertension 
Closed - 
follow-up 
complete 
Randomised 31/10/2007 28/05/2008 
40 4108 MCRN008 (A6281287) A Two-Year Multi-Centre, Randomized 
Two Arm Study Of Genotropin Treatment In 
Very Young Children Born Small For 
Gestational Age: Early Growth And 
Neurodevelopment (EGN) 
Closed - 
follow-up 
complete 
Randomised 19/08/2008 08/02/2010 
41 4497 MCRN011 (WA18221) A 12-week randomized, double blind, 
placebo-controlled, parallel group, 2-arm 
study to evaluate the efficacy and safety of 
tocilizumab in patients with active systemic 
Closed - 
follow-up 
complete 
Randomised 16/10/2008 02/06/2009 
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juvenile idiopathic arthritis (sJIA); with a 
92-week single arm open-label extension to 
examine the long term use of tocilizumab 
42 4614 MCRN012 (PTC124-
GD-007-DMD) 
A Phase 2b Efficacy and Safety Study of 
PTC124 in Subjects with Nonsense-
Mutation-Mediated Duchenne and Becker 
Muscular Dystrophy 
Closed - 
follow-up 
complete 
Randomised 28/07/2008 05/01/2009 
43 4615 MCRN014  
(M06-806) 
A Multi-center, Double-blind Study to 
Evaluate the Safety, efficacy and 
Pharmacokinetics of the Human Anti-TNF 
Monoclonal Antibody Adalimumab in 
Paediatric Subjects with Moderate to Severe 
Crohn's Disease. 
Closed - 
follow-up 
complete 
Randomised 24/10/2008 24/04/2009 
44 5641 MCRN016 (205.339) A randomized, double-blind, placebo-
controlled parallel group study to investigate 
the safety and efficacy of two doses of 
tiotropium bromide (2.5 µg and 5 µg) 
administered once daily via the Respimat® 
device for 12 weeks in patients with cystic 
fibrosis 
Closed - 
follow-up 
complete 
Randomised 10/10/2008 15/12/2009 
45 5716 MCRN017 (A6111137) A Phase 3 Prospective, Randomized, 
Double-Masked, 12-Week, Parallel Group 
Study Evaluating The Efficacy And Safety 
Of Latanoprost And Timolol In Paediatric 
Subjects With Glaucoma 
Closed - 
follow-up 
complete 
Randomised 28/11/2008 16/06/2009 
46 4739 MCRN018 
(E2090-E044-312) 
A double-blind, randomised, placebo-
controlled, multi-centre study to assess the 
efficacy and safety of adjunctive zonisamide 
in paediatric partial onset seizures 
Closed - 
follow-up 
complete 
Randomised 12/03/2009 30/09/2010 
47 5788 MCRN020  
(MI-CP178) 
A Phase 1/2a, Randomized, Double-Blind, 
Placebo-Controlled, Dose-Escalation Study 
to Evaluate the Safety, Tolerability, 
Immunogenicity and Vaccine-like Viral 
Shedding of MEDI-534, a Live, Attenuated 
Closed - 
follow-up 
complete 
Randomised 10/07/2009 18/08/2011 
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Intranasal Vaccine Against Respiratory 
Syncytial Virus (RSV) and Parainfluenza 
Virus Type 3 (PIV3), in Healthy 6 to < 24 
Month-Old Children and in 2 Month Old 
Infants 
48 5830 MCRN021  
(E2007-G000-305) 
A double-blind, placebo-controlled, dose-
escalation parallel group study to evaluate 
the efficacy and safety of E2007 
(perampanel) given as adjunctive therapy in 
subjects with refractory partial seizures 
Closed - 
follow-up 
complete 
Randomised 17/12/2008 10/06/2010 
49 5831 MCRN023 (V72P12) A Phase 2b, Open Label, Randomized, 
Parallel-Group, Multi-Center Study to 
Evaluate the Safety, Tolerability and 
Immunogenicity of Novartis Meningococcal 
B Recombinant Vaccine When 
Administered with or without Routine Infant 
Vaccinations to Healthy Infants 
Closed - 
follow-up 
complete 
Randomised 01/08/2008 07/08/2009 
50 5858 MCRN024 (SPD489-
325) 
A Phase III, Randomised, Double-Blind, 
Multicentre, Parallel-Group, Placebo- and 
Active-Controlled, Dose-Optimisation 
Safety and Efficacy Study of 
Lisdexamfetamine Dimesylate (LDX) in 
Children and Adolescents Aged 6-17 with 
Attention-Deficit/Hyperactivity Disorder 
(ADHD) 
Closed - 
follow-up 
complete 
Randomised 30/09/2008 06/01/2011 
51 5906 MCRN026 (0954_337-
01) 
A Phase III, Randomized, Open-Label, 
Parallel-Group, Dose-Ranging Clinical Trial 
to Study the Safety and Efficacy of MK-
0954/Losartan Potassium in Paediatric 
Patients with Hypertension 
Closed - in 
follow-up 
Randomised 17/07/2009 24/05/2012 
52 6308 MCRN033 (111709) A phase II, open-label, randomized, 
multicentre study to evaluate the feasibility 
of GSK Biologicals' DTPa-IPV/Hib-MenC-
TT vaccine co-administered with PrevenarT 
Closed - in 
follow-up 
Randomised 26/06/2009 08/12/2009 
284 
 
compared with PediacelT co-administered 
with MenjugateT and PrevenarT, when 
given in healthy infants as a three-dose 
primary vaccination course at 2, 3 and 4 
months of age and to evaluate MenitorixT 
given to these children as a booster dose at 
12 months of age. 
53 6309 MCRN036 (PTC124-
GD-009-CF) 
A Phase 3 Efficacy and Safety Study of 
PTC124 as an Oral Treatment for Nonsense-
Mutation-Mediated Cystic Fibrosis 
Closed - in 
follow-up 
Randomised 09/02/2010 24/11/2010 
54 6692 MCRN037  
(GS-US-205-0110) 
An Open-Label, Randomized, Phase 3 Trial 
to Evaluate the Efficacy and Safety of 
Aztreonam 75 mg Powder and Diluent for 
Nebulizer Solution (AZLI) versus 
Tobramycin Nebulizer Solution (TNS) in an 
Intermittent Aerosolized Antibiotic 
Regimen, in subjects with Cystic Fibrosis 
followed by an Open-Label, Single Arm 
Extension 
Closed - 
follow-up 
complete 
Randomised 22/08/2008 23/10/2009 
55 6310 MCRN042 (SCO/BIA-
2093-305) 
Efficacy and safety of eslicarbazepine 
acetate (BIA 2-093) as adjunctive therapy 
for refractory partial seizures in children  a 
doublie-blind, randomised, placebo-
controlled, parallel-group, multicentre 
clinical trial 
Closed - in 
follow-up 
Randomised 02/07/2009 23/12/2011 
56 8236 MCRN043 
(TRA108062) 
A three part, staggered cohort, open-label 
and double-blind, randomized, placebo 
controlled study to investigate the efficacy, 
safety, tolerability and pharmacokinetics of 
eltrombopag, a thrombopoietin receptor 
agonist, in previously treated paediatric 
patients with chronic idiopathic 
thrombocytopenic purpura (ITP). 
Closed - in 
follow-up 
Both 28/09/2009 21/12/2012 
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57 6953 MCRN048 (V72P12E1) A Phase 2b, Open Label, Multi-Center, 
Extension Study to Evaluate the Safety, 
Tolerability and  Immunogenicity of a 
Booster Dose of Novartis Meningococcal B 
Recombinant Vaccine Administered  at 12, 
18 or 24 Months of Age in Subjects Who 
Previously Received a Three-Dose Primary 
Series of  the Novartis Meningococcal B 
Recombinant Vaccine as Infants in Study 
V72P12 
Closed - 
follow-up 
complete 
Both 13/07/2009 15/07/2010 
58 7050 MCRN049 (WA19977A) A multi-center international study to 
evaluate the efficacy and safety of 
tocilizumab in subjects with active 
polyarticular-course juvenile idiopathic 
arthritis; followed by an open-label 
extension to examine the long term use of 
tocilizumab. 
Closed - in 
follow-up 
Randomised 23/09/2009 31/01/2011 
59 7122 MCRN052 (MAB-N007) A Phase 2b/3, Multi-Center, Randomized, 
Double-Blind, Placebo Controlled Trial to 
Evaluate the Safety and Efficacy of 
Pagibaximab Injection in Very Low Birth 
Weight (VLBW) Neonates for the 
Prevention of Staphylococcal Sepsis 
Closed - 
follow-up 
complete 
Randomised 22/12/2009 30/11/2010 
60 7357 MCRN057 (GT-21) A Randomised,parallel-group.double -
blind,placebo-controlled,multi-
mational,multi-centre,Phase III trial 
investigating the asthma preventing effect of 
Grazax® compared to placebo in children 
with grass pollen induced rhinoconjunctivitis 
Closed - in 
follow-up 
Randomised 04/01/2010 21/06/2010 
61 7299 MCRN059 
(CRAD001M2301) 
A randomised, double-blind, placebo-
controlled study of RAD001 in the treatment 
of patients with subependymal giant cell 
astrocytomas (SEGA) associated with 
Tuberous Sclerosis Complex (TSC) 
Closed - in 
follow-up 
Randomised 06/07/2010 06/08/2010 
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62 7768 MCRN067 
(CACZ885G2301) 
A randomized, double-blind, placebo 
controlled, withdrawal study of flare 
prevention of canakinumab (ACZ885) in 
patients with Systemic Juvenile Idiopathic 
Arthritis (SJIA) and active systemic 
manifestations 
Closed - 
follow-up 
complete 
Randomised 05/03/2010 15/11/2010 
63 7769 MCRN068 
(CACZ885G2305) 
A randomized, double-blind, placebo 
controlled, single-dose study to assess the 
initial efficacy of canakinumab (ACZ885) 
with respect to the adapted ACR Pediatric 
30 criteria in patients with Systemic Juvenile 
Idiopathic Arthritis (SJIA) and active 
systemic manifestations 
Closed - 
follow-up 
complete 
Randomised 05/03/2010 15/11/2010 
64 7816 MCRN071 (082-00) A Worldwide, Randomised, Double Blind, 
Placebo-Controlled, Parallel Group Clinical 
Trial to Evaluate the Safety and Efficacy of 
Rizatriptan for the Acute Treatment of 
Migraine in Children and Adolescents 
Closed - 
follow-up 
complete 
Randomised 05/05/2010 02/02/2011 
65 7985 MCRN076 (NN8630-
1824) 
A randomised, open-labelled, single dose, 
dose-escalation trial investigating safety, 
tolerability, pharmacokinetics and 
phamacodynamics of pegylated long-acting 
human growth hormone (NNC126-0083) 
compared to Norditropin NordiFlex in 
growth hormone deficient children 
Closed - 
follow-up 
complete 
Randomised 10/11/2009 20/06/2010 
66 8030 MCRN077 (CT0140) A prospective, double blind randomised 
controlled trial to evaluate the 
immunological benefits and clinical effects 
of an elimination diet using an amino acid 
formula (AAF) with added pre-probiotic 
blend ion infants with Cow Milk Allergy 
(CMA). 
Closed - 
follow-up 
complete 
Randomised 04/03/2011 16/05/2012 
67 8309 MCRN084  
(VX08-770-103) 
A Phase 3, 2 Part, Randomized, Double-
Blind, Placebo Controlled, Parallel Group 
Closed - in 
follow-up 
Both 31/03/2010 06/05/2010 
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Study To Evaluate The Pharmacokinetics, 
Efficacy And Safety Of VX 770 In Subjects 
Aged 6 To 11 Years With Cystic Fibrosis 
And The G551D Mutation 
68 8499 MCRN085 
(DMD114117) 
A phase II, double blind, exploratory, 
parallel-group, placebo controlled clinical 
study to assess two dosing regimens of 
GSK2402968 for efficacy, safety, 
tolerability and pharmacokinetics in  
ambulant subjects with Duchenne muscular 
dystrophy. 
Closed - in 
follow-up 
Randomised 28/07/2010 30/08/2011 
69 8526 MCRN089 (111763) A phase III, open-label, randomised 
multicentre study to evaluate the 
immunogenicity and safety of a booster  
dose of GlaxoSmithKline Biologicals' dTpa-
IPV vaccine (Boostrix Polio) compared with 
Sanofi Pasteur MSD's dTpa-IPV vaccine 
(Repevax), when coadministered with GSK 
Biologicals' MMR vaccine (Priorix) in 3 and 
4-year-old healthy children. 
Closed - in 
follow-up 
Randomised 04/04/2011 29/02/2012 
70 8943 MCRN094 (NN2211-
1800) 
A Randomized, Double-blind, Placebo 
Controlled Trial to Assess 
Safety/Tolerability, Pharmacokinetics & 
Pharmacodynamics of Liraglutide in 
Pediatric  (10 - 17 years old) and Adult 
Subjects with Type 2 Diabetes 
Closed - 
follow-up 
complete 
Randomised 09/02/2011 30/08/2011 
71 9017 MCRN096 (205.438) A randomised, double-blind, placebo-
controlled parallel-group trial to confirm the 
effeicacy after 12 weeks and the safety of 
tiotropium 5 µg administered once daily via 
the Respimat® device in patients with cystic 
fibrosis 
Closed - in 
follow-up 
Randomised 18/01/2011 01/06/2011 
72 9460 MCRN103 (VX10-770-
106) 
A Phase 2, Randomized, DoubleBlind, 
PlaceboControlled, Crossover Study to 
Closed - in 
follow-up 
Randomised 01/02/2011 22/08/2011 
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Evaluate the Effect of VX770 on Lung 
Clearance Index in Subjects with Cystic 
Fibrosis, the G551D Mutation, and FEV1 
>90% Predicted 
73 9513 MCRN105  
(AI463-189) 
A Comparative Study of the Antiviral 
Efficacy and Safety of Entecavir (ETV) 
versus Placebo in Pediatric Subjects with 
Chronic Hepatitis B Virus (HBV) Infection 
who are HBeAg-Positive 
Closed - in 
follow-up 
Randomised 09/05/2011 04/03/2013 
74 9607 MCRN106  
(MOR 004) 
A Phase 3, Randomized, Double-Blind, 
Placebo-Controlled, Multinational Clinical 
Study to Evaluate the Efficacy and Safety of 
2.0 mg/kg/week and 2.0 mg/kg/every other 
week BMN 110 in Patients with 
Mucopolysaccharidosis IVA (Morquio A 
Syndrome). 
Closed - in 
follow-up 
Randomised 24/01/2011 29/02/2012 
75 10290 MCRN112 (SPD503-
315) 
A phase 3 double blind placebo controlled 
multi centre randomised withdrawal long 
term maintenance of efficacy and safety 
study of extended release Guanfacine 
Hydrochloride in Children and Adolescents 
aged 6-17 with Attention Deficit/ 
Hyperactivity Disorder 
Closed - in 
follow-up 
Randomised 19/04/2011 09/07/2012 
76 9998 MCRN119  
(HGT-HIT-045) 
A Phase I/II, Randomized, Safety and 
Ascending Dose Ranging Study of 
Intrathecal Idursulfase-IT Administered in 
Conjunction with Intravenous Elaprase? in 
Pediatric Patients with Hunter Syndrome 
and Cognitive Impairment 
Closed - in 
follow-up 
Randomised 28/02/2011 31/01/2012 
77 10291 MCRN128  
(CL2-16257-090) 
Determination of the efficient and safe dose 
of ivabradine in paediatric patients with 
dilated cardiomyopathy and symptomatic 
chronic heart failure aged 6 months to 18 
years.  A placebo controlled phase II/III 
Closed - in 
follow-up 
Randomised 16/01/2012 15/02/2013 
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dose-finding study with a 1 year 
efficacy/safety evaluation. 
78 10292 MCRN129  
(M0001-C303) 
Trial consisting of an 8-week double-blind 
placebo-controlled part to evaluate efficacy, 
safety, tolerability and pharmacokinetics of 
prucalopride in paediatric subjects with 
functional constipation, aged =6 months to 
<18 years, followed by a 16-week open-
label comparator (PEG) controlled part, to 
document safety and tolerability up to 24 
weeks 
Closed - in 
follow-up 
Randomised 03/08/2011 06/09/2012 
79 10616 MCRN136  
(TR02-108) 
Randomised, Active-Controlled Multicenter 
Study to Assess the Efficacy, Safety and 
Tolerability of ArikaceT in Cystic Fibrosis 
Patients with Chronic Infection due to 
Pseudomonas Aeruginosa (Pa) 
Closed - in 
follow-up 
Randomised 13/03/2012 07/11/2012 
80 10907 MCRN142 
(CNTO1275PSO3006) 
A Phase 3 Multicenter, Randomized, 
Double-blind, Placebo-controlled Study 
Evaluating the Efficacy and Safety of 
Ustekinumab in the Treatment of Adolescent 
Subjects With Moderate to Severe Plaque-
type Psoriasis 
Closed - in 
follow-up 
Randomised 01/12/2011 04/09/2012 
81 10909 MCRN144 (115345) An efficacy study of GSK Biologicals' 
quadrivalent influenza vaccine 
GSK2321138A (FLU D-QIV) when 
administered in children 
Closed - in 
follow-up 
Randomised 01/10/2011 30/11/2012 
82 11222 MCRN153 (NN1250-
3561) 
A trial investigating efficacy and safety of 
insulin degludec in children and adolescents 
with type 1 diabetes mellitus 
Closed - in 
follow-up 
Randomised 12/03/2012 18/07/2012 
83 11587 MCRN164 (PRI01C) A phase III open-label randomised study, to 
evaluate the immunogenicity and safety of 
the concomitant administration of V419 
(PR5I) given at 2, 3 and 4 months of age 
with two types of meningococcal serogroup 
Closed - in 
follow-up 
Randomised 27/02/2012 03/10/2012 
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C conjugate (MCC) vaccines given at 3 and 
4 months of age, followed by the 
administration at 12 months of age of a 
combined Haemophilus influenzae type b-
MCC vaccine 
84 11860 MCRN171 
(TRA115450) 
A two part, double-blind, randomized, 
placebo-controlled and open-label study to 
investigate the efficacy, safety and 
tolerability of eltrombopag, a 
thrombopoietin receptor agonist, in 
paediatric patients with previously treated 
chronic immune (idiopathic) 
thrombocytopenic purpura (ITP) 
Closed - in 
follow-up 
Randomised 08/05/2012 03/09/2012 
85 12419 MCRN185  
(MOR-008) 
A Randomized, Double-Blind, Pilot Study 
of the Safety and Physiological Effects of 
Two Doses of BMN 110 in Patients with 
Mucopolysaccharidosis IVA (Morquio A 
Syndrome) 
Closed - in 
follow-up 
Randomised 08/06/2012 24/08/2012 
86 2258 MENDS The use of melatonin in children with 
neurodevelopmental disorders and impaired 
sleep: an RCT 
Closed - 
follow-up 
complete 
Randomised 01/11/2007 07/06/2010 
87 6739 MIGS Microbial invasion during parenteral 
nutrition in surgical infants receiving 
glutamine 
Closed - in 
follow-up 
Randomised 21/07/2009 29/12/2011 
88 8659 MINT Melatonin As A Novel Neuroprotectant In 
Preterm Infants-Trial Study 
Closed - in 
follow-up 
Randomised 01/11/2011 09/07/2012 
89 4509 MYCYC A randomised clinical trial of 
mycophenolate mofetil versus 
cyclophosphamide for remission induction 
in ANCA associated vasculitis 
Closed - in 
follow-up 
Randomised 12/03/2007 03/08/2011 
90 10727 NCRN308 - Aprepitant 
in paediatric CINV 
A Phase III, Randomized, Double-Blind, 
Active Comparator-Controlled Clinical 
Trial, Conducted Under In-House Blinding 
Conditions, to Examine the Efficacy and 
Closed - in 
follow-up 
Randomised 05/03/2012 12/02/2013 
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Safety of Aprepitant for the Prevention of 
Chemotherapy-Induced Nausea and 
Vomiting (CINV) in Pediatric Patients 
91 2522 NEPHROTIC 
SYNDROME 
Long-term tapering versus standard 
prednisolone therapy for the treatment of the 
initial episode of childhood nephritic 
syndrome: national multicentre randomised 
double blind pilot study 
Closed - 
follow-up 
complete 
Randomised 15/08/2006 01/04/2008 
92 3776 NEST Neonatal ECMO Study of Temperature Closed - in 
follow-up 
Randomised 19/06/2006 31/03/2010 
93 2502 P3MC A double blind, parallel group, randomised, 
placebo-controlled trial of Propranolol and 
Pizotifen in preventing migraine in children 
Closed - 
follow-up 
complete 
Randomised 02/02/2010 11/02/2011 
94 2313 POP Study Prevention and treatment of steriod-induced 
osteopaenia in children and adolescents with 
rheumatic diseases 
Closed - in 
follow-up 
Randomised 22/08/2007 30/11/2011 
95 7857 PREPAC Prevent pseudomonas Aeruginosa 
Colonisation - PREPAC 
Closed - in 
follow-up 
Randomised 01/12/2009 14/01/2011 
96 8483 Salford Bright Smiles 
Baby Study 
A comparison of community based 
preventive services to improve child dental 
health 
Closed - in 
follow-up 
Randomised 01/11/2010 31/12/2011 
97 6906 SCAMP Standardised, Concentrated, Additional 
Macronutrients, Parenteral (SCAMP) 
nutrition in preterm infants: a phase IV 
randomised controlled study of 
macronutrient intake, growth and other 
aspects of neonatal care 
Closed - in 
follow-up 
Randomised 01/10/2009 07/07/2012 
98 3358 SLEEPS Safety profile, efficacy and equivalence in 
paediatric intensive care sedation 
Closed - 
follow-up 
complete 
Randomised 18/11/2009 30/05/2012 
99 4168 StePS Evaluation of Corticosteroid therapy in 
Childhood Sepsis - a randomised pilot study 
Closed - in 
follow-up 
Randomised 27/03/2008 31/05/2012 
100 4050 SWET A multi-centre randomised controlled trial of Closed - Randomised 01/05/2007 04/06/2009 
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ion-exchange water softeners for the 
treatment of eczema in children 
follow-up 
complete 
101 4507 TAPS Transfusion Alternatives Preoperatively in 
Sickle Cell Disease 
Closed - 
follow-up 
complete 
Randomised 20/11/2007 17/03/2011 
102 13601 The first BCVC nasal flu 
vaccine study 
The effects of live attenuated trivalent 
intranasal influenza vaccine on the 
nasopharyngeal bacterial colonisation in 
healthy children aged 2-4 years attending 
day care centres. A single centre, 
randomised, placebo-controlled intervention 
study. 
Closed - in 
follow-up 
Randomised 01/10/2012 29/11/2012 
103 3838 TIPIT A Randomised Controlled Trial of 
Thyroxine in Preterm Infants Under 28 
weeks Gestation 
Closed - in 
follow-up 
Randomised 29/09/2007 29/04/2009 
104 2290 TRACS TRAining Caregivers after Stroke: A cluster 
randomised controlled trial of a structured 
training programme for caregivers of in-
patients after stroke 
Closed - in 
follow-up 
Randomised  27/02/2008 09/02/2010 
105 4417 Treatments for 
Childhood Crohn's 
Disease 
Adverse Effects of Glucocorticoid Therapy 
on Bone in Childhood Crohn's Disease 
Closed - 
follow-up 
complete 
Randomised 15/11/2007 11/03/2009 
106 10016 TROPHOS19622 Phase II, multicenter, randomized, adaptive, 
double-blind,placebo controlled study to 
assess safety and efficacy of olesoxime  
(TRO19622) in 3-25 year old Spinal 
Muscular Atrophy (SMA) patients 
Closed - in 
follow-up 
Randomised 09/03/2011 31/08/2011 
107 8869 Wheeze and Intermittent 
Treatment: WAIT 
Parent-Determined Oral Montelukast 
Therapy for Preschool Wheeze 
Closed - in 
follow-up 
Randomised 01/10/2010 19/11/2012 
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Appendix 13: Study details of identified Paediatric non-medicines studies in NIHR portfolio review (Chapter 3) 
SR 
No. 
Portfolio 
Study ID 
Study Acronym / Short 
Title 
Study Title Active Status Randomisatio
n? 
Actual 
Opening Date 
Actual 
Closure 
Date 
1 6487 07Sg35 Fat metabolism in infants and children: effects of 
liver dysfunction and severe infection 
Closed - follow-
up complete 
Randomised 01/01/2008 01/02/2009 
2 6625 A Pilot Study to Explore 
the Feasibility of 
Computerised CBT for 
Children 
A Pilot Study to Explore the Feasibility of 
Computerised Cognitive Behaviour Therapy 
(Think, Feel, Do) for Children with Emotional 
Disorders 
Closed - follow-
up complete 
Randomised 01/02/2009 28/02/2010 
3 5759 ADOLESCENT 
HAYFEVER AND 
QUALITY OF LIFE 
Cluster randomised controlled trial of an 
educational intervention for healthcare 
professionals into the management of school-age 
children with hayfever 
Closed - follow-
up complete 
Randomised 29/09/2008 30/04/2010 
4 6525 AIRS An open randomised study of autoinflation in 
school age children (4-11 years) with otitis media 
with effusion (OME) in primary care 
Closed - in 
follow-up 
Randomised 02/02/2010 31/01/2013 
5 5025 Assessment of Suspected 
Auditory Processing 
Disorder 
Assessment of auditory and cognitive function in 
children with suspected auditory processing 
difficulties 
Closed - follow-up complete 24/04/2006 24/04/2009 
6 6030 Atomoxetine HSEN Open label trial of Atomoxetine for Attention 
Deficit Hyperactivity Disorder (ADHD) in 
children with special educational needs 
Closed - follow-
up complete 
Randomised 10/09/2009 30/06/2011 
7 7861 Baby wipes trial Baby Skin Care Research Programme: assessor 
blinded randomised controlled trial comparing 
cleansing wipes and product with water in infants 
Closed - follow-
up complete 
Randomised 01/10/2009 22/10/2010 
8 6818 BEADI (qualitative) The BEADI qualitative study of clinicians views 
about the barriers and facilitators to using 
research findings to change neonatal practice (a 
follow on from the BLISS cluster randomised 
Closed - follow-
up complete 
Randomised 01/05/2008 01/10/2008 
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controlled trial of the effect of active 
dissemination and information on standards of 
care of premature babies in England REC 
05/Q0605/180 
9 11874 CHAFFINCH Trial Pilot The Chelsea Asthma and Fresh Fruit Intake in 
Children - Trial Pilot phase 
Closed - follow-
up complete 
Randomised 01/08/2012 17/12/2012 
10 10428 CLICK-EAST: The 
Edinburgh Autism Social-
attention Trial 
CLICK-EAST: Computer Learning in Children - 
the Edinburgh Autism Social-attention Trial 
Closed - in 
follow-up 
Randomised 23/04/2012 01/02/2013 
11 9348 Dolphin Study 1 Optimising nutrition to improve growth and 
reduce neurodisabilities in neonates at risk of 
neurological impairment 
Closed - follow-
up complete 
Randomised 15/04/2010 31/12/2012 
12 6797 Dolphin Study 2 Optimising nutrition to improve growth and 
reduce neurodisabilities in children with 
suspected or confirmed Cerebral Palsy 
Closed - follow-
up complete 
Randomised 01/12/2008 31/12/2012 
13 5279 DRN210 A randomised, 2 period cross over study to assess 
the performance of post-exercise overnight 
computer based glucose control based on 
continuous subcutaneous glucose monitoring in 
comparison with conventional pump therapy in 
children and adolescents with type 1 diabetes 
(T1D) 
Closed - follow-
up complete 
Randomised 01/12/2007 30/09/2008 
14 5286 Evaluation of Telephone 
Administered CBT for 
Young People with OCD 
An evaluation of the clinical effectiveness, cost-
effectiveness and acceptability of a telephone-
administered cognitive-behaviour therapy (CBT) 
program for children and young people with 
obsessive-compulsive disorder (OCD) 
Closed - in 
follow-up 
Randomised 01/07/2008 30/08/2011 
15 7038 Exercise as a Treatment for 
Postnatal Depression 
The Effectiveness of Exercise as a Treatment for 
Postnatal Depression 
Closed - in 
follow-up 
Randomised 01/02/2010 01/03/2012 
16 9598 Family centred nutrition 
intervention in children's 
centres (Version 1) 
Exploratory and developmental trial of a family 
centred nutrition intervention delivered in 
Children's Centres and the home environment 
Closed - in 
follow-up 
Randomised 01/11/2010 30/11/2011 
17 7738 Feasibility study for a 
Schools-based, Peer-led, 
Feasibility study for a schools-based, peer-led, 
drugs prevention programme, based on the 
Closed - follow-
up complete 
Randomised 01/06/2007 30/11/2008 
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Drugs Prevention 
Programme (ASSIST 
Programme) 
ASSIST programme 
18 9867 FiCTION Feasibility Study Filling Children's Teeth: Indicated or Not? Closed - follow-
up complete 
Both 21/03/2011 30/04/2011 
19 6042 FRAMEA (Framework for 
the Assessment of 
Emotional Abuse) 
Does Training in a Systematic Approach to 
Emotional Abuse Improve the Quality of 
Childrens Services 
Closed - follow-
up complete 
Randomised 01/10/2007 29/05/2009 
20 12027 HAPPY pilot randomised 
controlled trial 
Evaluation of an intervention to prevent 
childhood obesity in a bi ethnic population: the 
Born in Bradford NHS programme grant 
Closed - in 
follow-up 
Randomised 26/03/2012 30/11/2012 
21 10023 Helping our premature 
infants on to better motor 
skills (HOP-ON) 
Development and evaluation of a parenting 
intervention to promote development in infants 
born very premature 
Closed - in 
follow-up 
Randomised 01/03/2011 01/04/2012 
22 11188 Home NB-UVB for focal 
or early vitiligo 
Pilot randomised double blind controlled trial of 
hand held NB-UVB  phototherapy for the 
treatment of focal or early vitiligo at home 
Closed - in 
follow-up 
Randomised 29/02/2012 31/05/2012 
23 9666 i-BASIS Intervention within the British Autism Study of 
Infant Siblings 
Closed - in 
follow-up 
Randomised 01/04/2011 31/12/2012 
24 5863 IMPACT Randomised controlled trial of brief 
psychodynamic therapy (BPP), cogntive 
behaviour (CBT) and active clinical care (ACC) 
in adolescents with moderate to  severe 
depression attending routine child and adolescent 
mental health clinics 
Closed - follow-
up complete 
Randomised 02/07/2010 31/01/2013 
25 8624 Intervention for Parents 
with Young Asthmatic 
Children 
The effects of parenting intervention on quality 
of life and parental confidence in management of 
young asthmatic children 
Closed - follow-
up complete 
Randomised 01/06/2010 17/04/2012 
26 4227 Kneeblock Study Does the use of a knee block influence hip 
deformity, functional ability and pain in children 
with bilateral cerebral palsy 
Closed - in 
follow-up 
Randomised 01/01/2007 30/05/2008 
27 9469 Later effects of promoting 
catch-up growth in SGA 
Long-term effects of nutritional supplementation 
in term, small-for-gestational-age infants on bone 
Closed - follow-
up complete 
Randomised 01/12/2010 17/02/2012 
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infants health, body composition and cognitive outcome: 
16-year follow-up of a randomised, controlled 
trial 
28 5823 LEAP Study Induction of tolerance through early introduction 
of peanut in high risk children 
Closed - follow-
up complete 
Randomised 29/11/2006 29/05/2009 
29 6643 Leptin and growth in 
preterm infants 
Leptin, appetite, fat deposition and growth in 
preterm infants from birth to adolescence 
Closed - follow-
up complete 
Randomised 01/05/2007 30/09/2009 
30 5366 MUMS4MUMS Structured Telephone Peer Support for Women 
Experiencing Postnatal Depression. Pilot and 
Exploratory RCT of its Clinical and Cost 
Effectiveness 
Closed - in 
follow-up 
Randomised 20/03/2009 30/09/2011 
31 4395 NECOT NECOT (North-East Cot) trial: postnatal care and 
breastfeeding duration 
Closed - in 
follow-up 
Randomised 07/01/2008 30/06/2009 
32 6532 NIRS Which is the most effective method of providing 
non-invasive respiratory support (NIRS) to 
preterm neonates  with lung disease? 
Closed - follow-
up complete 
Randomised 01/11/2008 07/09/2011 
33 6251 Nitric Oxide Levels Can monitoring exhaled nitric oxide levels in 
outpatients improve the management of children 
with asthma? 
Closed - follow-
up complete 
Randomised 10/08/2006 01/07/2008 
34 8163 Optigrow Infant Feeding 
Study 
The Optigrow Infant Feeding Study. Effects of 
Early Nutrient Intake on Growth and Body 
Composition - A Multicentre Randomised 
Controlled Trial 
Closed - in 
follow-up 
Randomised 01/03/2010 04/09/2012 
35 2165 PACT The Pre-School Autism Communication Trial Closed - follow-
up complete 
Randomised 29/06/2006 31/01/2008 
36 6094 PATH Psychological Advocacy towards healing: pilot 
for an Individually, randomised parallel group 
controlled trial to determine if a psychological 
intervention delivered by domestic violence 
advocates is effective and cost - effective 
Closed - follow-
up complete 
Randomised 15/04/2009 13/11/2009 
37 9967 Pilot RCT comparing 
Surgery to Observation for 
Intermittent Exotropia 
An External Pilot Study to Test the Feasibility of 
a Randomised Controlled Trial comparing Eye 
Muscle Surgery against Active Monitoring for 
Closed - in 
follow-up 
Randomised 01/09/2011 01/05/2012 
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Childhood Intermittent Distance Exotropia 
[X(T)] 
38 11078 Preventing asthma 
exacerbations by avoiding 
mite allergen 
Preventing asthma exacerbations in children by 
avoiding mite allergen 
Closed - in 
follow-up 
Randomised 01/11/2011 22/02/2013 
39 4754 PROMISE PROmoting Mental health In Schools through 
Education - A Single Blind Randomised 
Controlled Trial to Determine the Effectiveness 
of CBT in the Prevention of Depression in High 
Risk Adolescents 
Closed - follow-
up complete 
Randomised 15/12/2008 01/01/2010 
40 5642 Proteomic Fingerprinting 
for RSV 
Proteomic fingerprinting for Respiratory 
Syncytial Virus Infection in Infants and children 
Closed - follow-
up complete 
Randomised 01/11/2007 30/09/2009 
41 12325 REFRESH Reducing children's exposure to second-hand 
smoke in the home (REFRESH) 
Closed - follow-
up complete 
Randomised 08/02/2010 30/04/2012 
42 5734 Regulation of mucosal 
immune response to 
systemic MenB vaccine 
A phase II open label randomised single centre 
study to evaluate the importance of naturally 
induced immune regulation on the mucosal 
immune response to meningococcal serogroup B 
outer membrane vesicle (OMV) vaccine when 
administered intramuscularly to adults and 
adolescents. 
Closed - follow-
up complete 
Randomised 01/02/2009 14/09/2012 
43 6933 SPARCLE2 Determinants of participation and quality of life 
of adolescents with cerebral palsy: A longitudinal 
study 
Closed - follow-
up complete 
Randomised 01/01/2009 30/06/2010 
44 6817 STATbiTR Effectiveness and feasibility of intensive short-
term graded exercise programmes, using either 
treadmill or static exercise bicycle for non-
ambulant children and young people with 
cerebral palsy in improving functional motor 
ability and quality of life 
Closed - follow-
up complete 
Randomised 01/10/2008 23/02/2010 
45 7993 Study of Tolerance to Oral 
Peanut 
Study of Tolerance to Oral Peanut Closed - in 
follow-up 
Randomised 01/09/2009 31/07/2012 
46 8133 Telephone consultations 
for children with 
Telephone consultation as a substitute for routine 
out-patient face-to-face consultation for children 
Closed - in 
follow-up 
Randomised 12/07/2010 30/06/2011 
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inflammatory bowel 
disease 
with inflammatory bowel disease: randomised 
controlled trial and economic evaluation 
47 8325 The Effects of Prenatal 
Vitamin D 
Supplementation on Child 
Health 
Effects of prenatal vitamin D supplementation on 
respiratory and allergic phenotypes and bone 
density in the first three years of life 
Closed - follow-
up complete 
Randomised 01/03/2010 31/03/2011 
48 3813 The EQUIP Study Enhancing the Quality of Information-sharing in 
Primary care for children with respiratory tract 
infections. 
Closed - follow-
up complete 
Randomised 01/09/2006 30/04/2008 
49 10663 The impact of providing 
post-abortion contraceptive 
support 
Randomised controlled study of the impact of 
provision of followup  contraceptive support to 
women who have had an abortion 
Closed - in 
follow-up 
Randomised 03/10/2011 28/02/2013 
50 7402 Towards a better 
understanding of 
hyperglycaemia in the 
critically ill 
Towards a better understanding of 
hyperglycaemia in critically ill children. A sub-
study of the Control of Hyperglycaemia in 
Paediatric intensive care (CHiP) trial. 
Closed - in 
follow-up 
Randomised 01/06/2009 31/08/2011 
51 10077 Trial of Advice on Starting 
Taste Exposure (TASTE) 
The impact of parental guidance on early 
exposure to a variety of fruit and vegetables on 
infants' liking and consumption 
Closed - in 
follow-up 
Randomised 28/02/2011 31/12/2011 
52 10090 Use of sensory blankets for 
children with autistic 
spectrum disorder 
Snuggledown - The use of sensory weighted 
blankets in children with autistic spectrum 
disorders and poor sleep: A randomised crossover 
study 
Closed - in 
follow-up 
Randomised 07/11/2011 17/09/2012 
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Appendix 14: Excluded MCRN and Paediatric non-medicines studies 
(Chapter 3) 
SR Study 
ID 
Title Reason for exclusion 
MCRN studies 
1 7544 BEEP no defined recruitment target 
2 4506 CASCADE cluster randomised trial 
3 9601 CCRN 415 (Haemophilia A) mixed trial; participants adults and children 
4 10035 CCRN 470 (Haemophilia) mixed trial; age range of participants 13-70 
years 
5 10451 CCRN 515 (Acute pain) mixed trial; participants 5 years and older 
6 11447 Closing the loop in 
adolescents during non-
compliance behaviours 
cluster randomised trial 
7 9530 CRITIC-1 mixed trial; participants 12 years and older 
8 3837 DEPICTED cluster randomised trial 
9 5015 DRN191 KICk-OFF cluster randomised trial 
10 7390 DRN359 participants > 18 years  
11 6092 EPIC Project mixed methods study 
12 2311 EVERT mixed trial; participants 12 years and older 
13 3221 GAP Study mixed trial; participants 8 years and older 
14 6377 Glutamine in CF mixed trial; participants 14-45 years old 
 
15 6635 GAS International study, recruitment period extends 
beyond the cut off period for inclusion in the 
review 
16 2525 MCRN001 (DPM-CF-301) 
 
mixed trial;  
participants 6 years and older 
 
 
17 4614 MCRN012 (PTC124-GD-
007-DMD) 
 
mixed trial;  
participants 5 yrs and older 
 
 
18 5641 MCRN016 (205.339) 
 
mixed trial;  
participants adults and children 
 
19 5830 MCRN021 (E2007-G000-
305) 
 
mixed trial;  
participants adults and children 
 
20 6309 MCRN036 (PTC124-GD-
009-CF) 
 
mixed trial;  
participants adults and children 
21 6692 MCRN037 (GS-US-205-
0110) 
 
mixed trial;  
participants adults and children 
22 6953 MCRN048 (V72P12E1) 
 
extension study 
 
23 7299 MCRN059 
(CRAD001M2301) 
 
mixed trial; participants all ages 
 
24 8499 MCRN085 (DMD114117) mixed trial; participants 5 years and older 
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25 8943 MCRN094 (NN2211-1800) mixed trial; participants adults and children 
26 9017 MCRN096 (205.438) mixed trial; participants adults and children 
27 9460 MCRN103 (VX10-770-106) mixed trial; participants adults and children 
28 9607 MCRN106 (MOR 004) mixed trial; participants adults and children 
29 10616 MCRN136 (TR02-108) mixed trial; participants 6 years and older 
30 12419 MCRN185 (MOR-008) mixed trial; participants adults and children 
31 9932 MAMA participants were mothers 
32 8659 MINT cluster randomised trial 
33 4509 MYCYC mixed trial; participants adults and children 
34 7857 PREPAC cluster randomised trial 
35 3358 SLEEPS cluster randomised trial 
36 4507 TAPS mixed trial; participants 1 years and older 
37 10016 TROPHOS19622 mixed trial; age range of participants 3-25 
years 
38 2290 TRACS cluster randomised trial, mixed trial 
39 4108 MCRN 008 International study, recruitment period 
extended beyond the cut off period for 
inclusion in the review 
40 8030 MCRN077 International study; up to date information on 
global recruitment not available 
41 7769 MCRN068 International study; terminated on advice of 
Data Monitoring Committee  
42 6060 DRN229 International study; terminated as primary end 
point was not met  
43 8236 MCRN043 International study; global recruitment data not 
available 
Paediatric non-medicinal studies 
1 5759 ADOLESCENT HAYFEVER 
AND QUALITY OF LIFE 
Cluster randomised trial 
2 5025 Assessment of Suspected  
Auditory Processing Disorder 
Observational study 
3 6818 BEADI (qualitative) Observational study 
4 7038 Exercise as a Treatment for 
Postnatal Depression 
Adult participants (>18 yrs) 
5 9598 Family centred nutrition 
intervention in children’s 
centres (Version 1) 
parents recruited 
6 7738 Feasibility study for a 
Schools-based, Peer-led, 
Drugs Prevention Programme 
(ASSIST Programme) 
Cluster randomised trial 
7 9867 FiCTION Feasibility Study observational study 
8 6042 FRAMEA (Framework for the 
Assessment of Emotional 
Abuse) 
Non randomised 
 
9 12027 HAPPY pilot randomised 
controlled trial 
 
participants were antenatal women and 
children in the first year 
10 10023 Helping our premature infants 
on to better motor skills 
(HOP-ON) 
Parenting intervention with participants 
parents of preterm infants 
11 11188 Home NB-UVB for focal or 
early vitiligo 
Participants adults and children 
12 9469 Later effects of promoting 
catch-up growth in SGA 
infants 
Follow up of an RCT 
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13 6643 Leptin and growth in preterm 
infants 
observational study 
14 5366 MUMS4MUMS 
 
participants  women with postnatal depression 
15 4395 NECOT 
 
pregnant women recruited and randomised 
16 6094 PATH 
 
mixed trial, participants women 18-40 years 
17 4754 PROMISE cluster randomised trial 
18 5642 Proteomic Fingerprinting for 
RSV 
observational study 
19 12325 REFRESH 
 
Eligible participants were mothers who 
smoked and had a child < 6 years old 
20 5734 Regulation of mucosal 
immune response to systemic 
MenB vaccine 
participants 16-40 yrs 
 
21 6933 SPARCLE2 observational study 
22 3813 The EQUIP Study cluster randomised trial 
23 7402 Towards a better 
understanding of 
hyperglycaemia in the 
critically ill 
observational cohort study 
 
24 6487 07Sg35 observational study 
25 8325 The Effects of Prenatal 
Vitamin D Supplementation 
on Child Health 
follow up of previously conducted RCT 
 
26 10077 Trial of Advice on Starting 
Taste Exposure (TASTE) 
mothers recruited during pregnancy or after 
birth 
27 10663 Impact of providing post-
abortion contraceptive support 
Participants are women who have had an 
abortion 
28 5279 DRN 210 Cluster randomised trial 
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Appendix 15: Characteristics of studies included in the NIHR portfolio review (Chapter 3) 
Study 
ID 
Study Title Design Setting Blindin
g 
Who was blinded? POM Source 
2312 ADEPT Parallel Neonatal Intensive 
Care Unit 
 
No 
 
 No 
 
Paper data collection form 
 
3217 Amitriptyline in EB 
Pain 
Crossover Outpatient clinic Yes 
 
Patients, Health care 
providers, Data collectors, 
Outcome adjudicators 
No 
 
CRF 
 
12221 An alternative 
booster vaccine 
against meningitis 
and ear infections 
Parallel Other- Healthy 
volunteers - via 
Open Exeter 
database 
Yes 
 
Patients, 
Data collectors 
 
 
No Immunogenicity analysis - non- 
routine blood samples 
2231 BOOST II UK Parallel Neonatal Intensive 
Care Unit 
Yes 
 
Patients, 
Health care providers, 
Data collectors 
 
No Face-to-face developmental 
assessments by paediatricians and age 
2 years (corrected for gestation) 
 
11354 Bronchiolitis of 
Infancy Discharge 
Study (BIDS) 
 
 
 
 
Parallel Paediatric Ward Yes 
 
Patients, 
Health care providers, Data 
collectors, 
Outcome adjudicators 
 
Yes  
8976 Can we Reduce the 
Number of Vaccine 
Injections for 
Children? 
Parallel 
 
Other- Child Health 
departments 
No  No immunogenicity analysis on non-
routine blood samples 
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5799 CASG112 Parallel Paediatric Ward Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
 
 
No 
 
hearing loss 
 
7976 CATCH Parallel Paediatric Intensive 
Care Unit 
 
No 
 
 Yes 
 
 
3218 CHIP Trial Parallel Paediatric Intensive 
Care Units 
No 
 
 Yes 
 
 
9111 Cognative GA 
Study - TIVA 
versus volatile 
anaesthesia in 
children: cognitive 
effects 
Other-
randomised 
trial 
Outpatient clinic 
 
Yes Patients, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
 
 
 
 
No 
 
Standardised cognitive assessments 
 
 
4171 DECIDE Parallel Paediatric Ward, 
Children's Accident 
& Emergency, 
Accident & 
Emergency 
Department 
No  No Centrally analysed HbA1c 
measurement. 
 
3777 DRN067 (FACTS) Parallel Outpatient clinic No  Yes  
7464 H1N1 Parallel Other- 
Healthy volunteers 
- child Health 
Departments, 
media, emails 
 
No  No immunogenicity analysis from non-
routine blood sampling 
 
7552 I2S2 Parallel Neonatal Intensive Yes Patients, No Specific face-to-face developmental 
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Care Unit Health care providers, 
Data collectors 
assessment at age 2 years 
8814 INDIGO - Pump 
versus MDI insulin 
and hypoglycaemia 
in children. 
Information on study characteristics not available, no response from CI 
7553 KONCERT 
(PENTA18) 
Parallel Outpatient clinic No  Yes  
2276 MAGNETIC Parallel Children's Accident 
& Emergency 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No Trained clinicians/nurses recording 
an Asthma Severity Score 
3774 MASCOT Parallel Outpatient clinic, 
Children's Accident 
& Emergency, 
General practice 
Yes Patients, 
Health care providers, 
Data collectors 
Yes  
2736 MCRN000 
(MEE103219) 
Information on study characteristics not available, no response from CI 
3297 MCRN002 
(6096A1-007) 
Parallel Other- Healthy 
children - child 
health departments 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No Immunogenicity analysis - non-
routine samples collected 
3826 MCRN003 
(MK0954-326) 
Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No Urine PCR from central lab 
4108 MCRN008 
(A6281287) 
Crossover Outpatient clinic No  Yes  
4497 MCRN011 
(WA18221) 
Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
No CRFs 
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Data analysts 
4615 MCRN014 (M06-
806) 
Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No e portfolio 
5716 MCRN017 
(A6111137) 
Other- 
Stratified by 
age, diagnosis, 
and 
intraocular 
pressure (IOP) 
level, subjects 
were 
randomized 
(1:1) to 
latanoprost 
vehicle at 8 
am and 
latanoprost 
0.005% at 8 
pm or timolol 
0.5% (0.25% 
for those aged 
<3 years) 
twice daily (8 
am, 8 pm). 
Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No Clinical examination. Additional data 
was collected for the purposes of the 
trial. 
4739 MCRN018 (E2090-
E044-312) 
Information on study characteristics not available, no response from CI 
5788 MCRN020 (MI-
CP178) 
Parallel Outpatient clinic, 
Paediatric ward 
Yes Patients, Health care 
providers, Data collectors 
No blood sample and eCRF 
5831 MCRN023 
(V72P12) 
Parallel Other- Healthy 
volunteers - Child 
Health Departments 
No  No Immunogenicity analysis - non-
routine blood samples collected 
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5858 MCRN024 
(SPD489-325) 
Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators 
No Interview with parents and child 
5906 MCRN026 
(0954_337-01) 
Parallel Outpatient clinic, No  Yes  
6308 MCRN033 
(111709) 
Parallel Other- Healthy 
children - Child 
Health Department 
No  No Immunogenicity analysis - non 
routine blood samples 
6310 MCRN042 
(SCO/BIA-2093-
305) 
Crossover Outpatient clinic, 
Paediatric ward 
Yes Patients, health care 
providers 
Yes  
7050 MCRN049 
(WA19977A) 
Information on study characteristics not available, no response from CI 
7122 MCRN052 (MAB-
N007) 
Parallel Neonatal Intensive 
Care Unit 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
Yes  
7357 MCRN057 (GT-21) Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators 
No CRF 
7768 MCRN067 
(CACZ885G2301) 
Parallel Outpatient clinic Yes Patients 
 
No CRF 
7816 MCRN071 (082-
00) 
Information on study characteristics not available, no response from CI 
7985 MCRN076 
(NN8630-1824) 
Other- 
randomised, 
open label, 
single-dose, 
clinical trial of 
drug agent 
 Yes Patients, 
Health care providers 
No specific laboratory data (PK and PD 
study) 
307 
 
8309 MCRN084 (VX08-
770-103) 
Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators 
No trial visit spirometry 
8526 MCRN089 
(111763) 
Parallel Other- participants' 
homes 
No  No laboratory sample 
9513 MCRN105 (AI463-
189) 
Parallel Paediatric Ward Yes Patients Yes  
10290 MCRN112 
(SPD503-315) 
Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Data analysts 
No doctor  collected prospectively in 
research appointments 
9998 MCRN119 (HGT-
HIT-045) 
Parallel Other- Clinical 
research facillity 
with overnight stay 
ability. 
No  No Yes- ultra rare disease and 
exploratory endpoint. 
10291 MCRN128 (CL2-
16257-090) 
Information on study characteristics not available, no response from CI 
10292 MCRN129 
(M0001-C303) 
Other- Run in 
period (1-2.5 
weeks) 
Double blind 
placebo 
controlled 
(8weeks) 
Open labeeled 
controlled 
period(16week
s) 
Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No electronic patient diary 
10907 MCRN142 
(CNTO1275PSO30
06) 
Crossover Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors 
Yes  
10909 MCRN144 
(115345) 
Parallel General practice, 
Patients homes 
Yes Patients, 
Health care providers, 
No complicated parental reporting and 
sample taking from children affected 
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Clinical Research 
Facilities 
 
Data collectors, 
Outcome adjudicators, 
Data analysts 
by colds/URTI (ie symptoms of flu) 
 
11222 MCRN153 
(NN1250-3561) 
Parallel Outpatient clinic No  Yes  
11587 MCRN164 
(PRI01C) 
Parallel Other- 
Participants' homes 
 
No  No Laboratory samples 
 
11860 MCRN171 
(TRA115450) 
Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
Yes  
2258 MENDS Parallel Outpatient clinic, 
paediatric ward, 
community clinic 
Yes All involved in the trial 
(patients, parents/carers, 
researchers, pharmacists 
etc...) 
No Sleep diaries and actigraphy 
(designed and used specifically for 
the study) 
6739 MIGS Parallel Paediatric ward, 
Neonatal Intensive 
Care Unit 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No Laboratory analysis 
 
10727 NCRN308 - 
Aprepitant in 
paediatric CINV 
Parallel Outpatient clinic, 
Paediatric ward 
Yes Patients, 
Health care providers, 
Data collectors 
Yes  
2522 NEPHROTIC 
SYNDROME 
Parallel Outpatient clinic, 
Paediatric ward 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
Yes  
3776 NEST Parallel Paediatric Intensive 
Care Unit, Neonatal 
Intensive Care Unit 
No  No Individual assessment 
 
2502 P3MC Parallel Outpatient clinic Yes Patients, No Patient diaries designed for the trial 
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Health care providers  
2313 POP Study Parallel Outpatient clinic, 
Paediatric ward 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No DEXA scans 
8483 Salford Bright 
Smiles Baby Study 
Parallel General practice, 
community clinic, 
Sure Start 
Children's Centres 
and other relevant 
community venues 
No  No Dental Assessment at 3 years of age 
 
6906 SCAMP Information on study characteristics not available, no response from CI 
4168 StePS Parallel Paediatric Intensive 
Care Unit 
No  No electronic CRF 
 
4050 SWET Parallel Outpatient clinic 
 
Yes Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No Blinded nurse assessment using 
eczema score 
 
13601 The first BCVC 
nasal flu vaccine 
study 
Other- RCT Other-nurseries Yes Data analysts No Lab analysis of samples collected in 
the study 
 
3838 TIPIT Parallel Neonatal Intensive 
Care Unit 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No Width of subarachnoid space 
measured by cranial ultrasound 
 
4417 Treatments for 
Childhood Crohn's 
Disease 
Parallel Outpatient clinic 
 
No  Yes  
8869 Wheeze and 
Intermittent 
Treatment: WAIT 
Parallel Outpatient clinic, 
Paediatric Ward 
Children's Accident 
& Emergency, 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Yes  
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Accident & 
Emergency 
Department, 
Paediatric Intensive 
Care Unit, general 
practice 
Data analysts 
6625 A Pilot Study to 
Explore the 
Feasibility of 
Computerised CBT 
for Children 
Parallel Community clinic Yes Patients, Data collectors, 
Data analysts 
No Assessment interview with one of the 
research staff 
 
6525 AIRS Parallel General practice No  No Otosocopy and tympanometry 
performed by the pratice nurse. 
6030 Atomoxetine HSEN Parallel Outpatient clinic 
 
No  Yes  
7861 Baby wipes trial Parallel Postnatal Ward 
 
Yes Data collectors, Data 
analysts 
No Primary outcome was skin hydration, 
measured using a non-invasive 
Corneometer on skin surface of 
buttocks.  Baseline measurement in 
hospital, follow-up measurement in 
the home. 
 
11874 CHAFFINCH Trial 
Pilot 
Factorial Paediatric Ward 
 
No  Yes  
10428 CLICK-EAST: The 
Edinburgh Autism 
Social-attention 
Trial 
Other- 
Wait-list 
control 
 
Outpatient clinic, 
Community clinic 
 
 
Yes Data collectors, 
Outcome adjudicators, 
Data analysts 
No Video recording and coding of 
observation of parent-child free play 
session in assessment lab 
 
9348 Dolphin Study 1 Parallel Neonatal Intensive 
Care Unit, 
Community clinic 
 
Yes Patients, 
Health care providers, 
Data collectors 
No Performance on the cognitive scale of 
the Bayley Scales of Infant and 
Toddler Development III at 24 
months 
6797 Dolphin Study 2 
 
Parallel Community clinic Yes Patients, 
Health care providers, 
No Performance on the cognitive scale of 
the Bayley Scales of Infant and 
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Data collectors Toddler Development III at 24 
months 
5286 Evaluation of 
Telephone 
Administered CBT 
for Young People 
with OCD 
Factorial Outpatient clinic 
 
Yes Outcome adjudicators 
 
No clinician interview 
 
9666 i-BASIS Parallel Outpatient clinic, 
Community clinic 
 
 
Yes Data collectors, 
Outcome adjudicators, 
Data analysts 
No videotape analysis 
 
5863 IMPACT Information on study characteristics not available, no response from CI 
8624 Intervention for 
Parents with Young 
Asthmatic Children 
 
4227 Kneeblock Study Parallel Other- 
wheelchair services 
No  No Radiograph every 12 months 
 
5823 LEAP Study Parallel Paediatric Ward No  No Double-blind, placebo-controlled 
food challenge (DBPCFC), Skin 
Prick Test (SPT) and specific IgE at 
final study visit 
6532 NIRS Crossover Neonatal Intensive 
Care Unit 
No  No Direct observation of FiO2 required 
to maintain SaO2 92%+ 
6251 Nitric Oxide Levels Parallel Outpatient clinic Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators 
No CRF 
8163 Optigrow Infant 
Feeding Study 
Parallel Other- 
The trial was 
largely conducted 
via home visits. 
 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators, 
Data analysts 
No Nurses conducted anthropometry at 
home 
 
2165 PACT Parallel Outpatient clinic, Yes Data collectors, No Research assessments 
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Community clinic, 
The National 
Autistic Society 
Self(parent)-referral 
 
 
 
Outcome adjudicators, 
Data analysts 
(interviews/questionnaires with 
parents and assessments/ 
observations with children) 
 
9967 Pilot RCT 
comparing Surgery 
to Observation for 
Intermittent 
Exotropia 
Other- Pilot Outpatient clinic 
 
Yes Outcome adjudicators 
 
No 
 
CRFs input into symphony database 
 
11078 Preventing asthma 
exacerbations by 
avoiding mite 
allergen 
Parallel Paediatric Ward 
Children's Accident 
& Emergency 
Accident & 
Emergency 
Department 
Yes Patients, 
Health care providers, 
Data collectors, 
Outcome adjudicators 
No Parental recall 
 
6817 STATbiTR Parallel School Yes Data collectors, 
Data analysts 
No A paediatric physiotherapist blinded 
to the allocation of groups performed 
the assessments in the schools. 
 
7993 Study of Tolerance 
to Oral Peanut 
Crossover Outpatient clinic 
 
No  No Paper CRF of double-blinded food 
challenge 
8133 Telephone 
consultations for 
children with 
inflammatory 
bowel disease 
Information on study characteristics not available, no response from CI 
10090 Use of sensory 
blankets for 
children with 
autistic spectrum 
disorder 
Crossover Outpatient clinic, 
School, 
Contacting help 
groups 
 
Yes Patients, Outcome 
adjudicators 
 
No 
 
Actigraphy 
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Appendix 16: Classification of studies included in the NIHR portfolio review   
Study ID Study Title Intervention IMP/non-
IMP 
Disease/condition under study Acute/Chronic/H
ealthy 
2312 ADEPT Timing of enteral feeding, day 2 vs. 
day 6 
non IMP Necrotising Enterocoloitis (NEC) Acute 
3217 Amitriptyline in EB Pain Amitriptyline IMP Epidermolysis Bullosa Chronic 
12221 An alternative booster 
vaccine against meningitis 
and ear infections 
Vaccine IMP Healthy infants Healthy 
2231 BOOST II UK Level of arterial oxygen saturation 
levels 
non IMP Prematurity Chronic 
11354 Bronchiolitis of Infancy 
Discharge Study (BIDS) 
 
 
 
 
Level of arterial oxygen saturation 
for stopping therapeutic oxygen  
Non IMP Bronchiolitis Acute 
8976 Can we Reduce the Number 
of Vaccine Injections for 
Children? 
Vaccine IMP Healthy infants Healthy 
5799 CASG112 Valganciclovir IMP Congenital Cytomegalovirus (CMV) Chronic 
7976 CATCH Heparin bonded or antibiotic 
impregnated central venous 
catheters (CVCs) 
IMP  Paediatric Intensive Care Unit 
admissions needing central venous 
catheters for at least three days 
Acute 
3218 CHIP Trial Tight Glucose control  non IMP Intensive care treatment with an arterial 
line in-situ and receiving both 
mechanical ventilation and vasoactive 
support drugs following injury, major 
surgery or in association with critical 
illness in whom it is anticipated such 
treatment will be required to continue 
Acute 
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for at least 12 hours. 
9111 Cognative GA Study - TIVA 
versus volatile anaesthesia in 
children: cognitive effects 
Anaesthesia: intravenous vs. 
volatile 
IMP Day stay general anaesthetic (GA) for 
multiple dental extractions and 
restorations 
Acute 
4171 DECIDE Diabetes treatment started at home 
vs. hospital 
non IMP Type I Diabetes Chronic 
3777 DRN067 (FACTS) Enhanced family communication non IMP Type I Diabetes Chronic 
7464 H1N1 Vaccine IMP Healthy infants Healthy 
7552 I2S2 Iodine supplementation vs. Placebo IMP Extreme prematurity Chronic 
8814 INDIGO - Pump versus 
MDI insulin and 
hypoglycaemia in children. 
Multiple injections versus pump 
insulin therapy 
IMP Diabetes Chronic 
7553 KONCERT (PENTA18) Lopinavir/Ritonavir IMP HIV Chronic 
2276 MAGNETIC Magnesium IMP Acute exacerbation asthma Acute 
3774 MASCOT Salmetrol/Monteleukast IMP Asthma Chronic 
2736 MCRN000 (MEE103219) Mepolizumab IMP Eosinophilic esophagitis Chronic 
3297 MCRN002 (6096A1-007) 13-valent pneumococcal conjugate 
(13vPnC) vaccine 
IMP Healthy infants Healthy 
3826 MCRN003 (MK0954-326) Losartan IMP Proteinuria in paediatric patients with 
or without hematuria 
Chronic 
4108 MCRN008 (A6281287) genotropin IMP children born SGA Chronic 
4497 MCRN011 (WA18221) tocilizumab IMP s JIA Chronic 
4615 MCRN014 (M06-806) Adalimumab IMP Crohns Disease Chronic 
5716 MCRN017 (A6111137) latanoprost opthalmic solution IMP paediatric glaucoma Chronic 
4739 MCRN018 (E2090-E044-
312) 
zonisamide IMP partial onset seizures Chronic 
5788 MCRN020 (MI-CP178) vaccine IMP healthy infants Healthy 
5831 MCRN023 (V72P12) vaccines IMP Healthy infants Healthy 
5858 MCRN024 (SPD489-325) Lisdexamfetamine Dimesylate IMP ADHD Chronic 
5906 MCRN026 (0954_337-01) MK-0954/Losartan Potassium IMP Hypertension Chronic 
6308 MCRN033 (111709) vaccine IMP healthy infants Healthy 
6310 MCRN042 (SCO/BIA-2093-
305) 
Eslicarbazepine acetate IMP refractory partial seizures Chronic 
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7050 MCRN049 (WA19977A) Tocilizumab IMP Active Polyarticular-Course Juvenile 
Idiopathic Arthritis 
Chronic 
7122 MCRN052 (MAB-N007) Pagibaximab Injection IMP Staphylococcal Sepsis Acute 
7357 MCRN057 (GT-21) Grazax IMP grass pollen allergy Chronic 
7768 MCRN067 
(CACZ885G2301) 
Canakinumab IMP Systemic Juvenile Idiopathic Arthritis Chronic 
7816 MCRN071 (082-00) Rizatriptan IMP Acute Treatment of Migraine Acute 
7985 MCRN076 (NN8630-1824) Pegylated GH IMP Growth Hormone deficiency Chronic 
8309 MCRN084 (VX08-770-103) VX-770 IMP CF Chronic 
8526 MCRN089 (111763) vaccine IMP healthy infants Healthy 
9513 MCRN105 (AI463-189) Entecavir IMP Chronic Hepatitis B virus infection Chronic 
10290 MCRN112 (SPD503-315) Guanfacine Hydrochloride IMP ADHD Chronic 
9998 MCRN119 (HGT-HIT-045) Idursulfase IMP Hunter Syndrome Chronic 
10291 MCRN128 (CL2-16257-
090) 
Ivabradine IMP Dilated cardiomyopathy and chronic 
heart failure 
Chronic 
10292 MCRN129 (M0001-C303) Prucalopride IMP functional constipation Chronic 
10907 MCRN142 
(CNTO1275PSO3006) 
Ustekinumab IMP psoriasis Chronic 
10909 MCRN144 (115345) Influenza vaccine IMP Healthy infants Healthy 
11222 MCRN153 (NN1250-3561) Insulin degludec IMP Type I DM Chronic 
11587 MCRN164 (PRI01C) vaccine IMP healthy infants Healthy 
11860 MCRN171 (TRA115450) Eltrombopag IMP Chronic ITP Chronic 
2258 MENDS melatonin IMP children with neurodevelopmental 
disorders and impaired sleep 
Chronic 
6739 MIGS Glutamine IMP Infants requiring PN and surgery for 
congenital or acquired gastrointestinal 
anomalies- gastroschisis, NEC, bowel 
atresia or intestinal surgery for other 
reasons 
 Acute 
10727 NCRN308 - Aprepitant in 
paediatric CINV 
Aprepitant IMP Chemotherapy induced nausea and 
vomiting 
Chronic 
2522 NEPHROTIC SYNDROME Prednisolone IMP childhood nephrotic syndrome Chronic 
3776 NEST cooling non IMP neonates with cardiorespiratory failure Acute 
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2502 P3MC Propanolol and pizotifen IMP Migraine Chronic 
2313 POP Study Risedronate IMP Rheumatic disease Chronic 
8483 Salford Bright Smiles Baby 
Study 
flouride varnish and behavioural 
intervention 
IMP healthy children Healthy 
6906 SCAMP scNPNmax IMP Prematurity Acute 
4168 StePS corticosteroids IMP severe sepsis Acute 
4050 SWET ion-exchange water softener NonIMP eczema Chronic 
13601 The first BCVC nasal flu 
vaccine study 
vaccine IMP healthy infants Healthy 
3838 TIPIT Thyroxine IMP Prematurity Chronic 
4417 Treatments for Childhood 
Crohn's Disease 
Liquid diet therapy vs. 
corticosteroids 
IMP Crohns Disease Chronic 
8869 Wheeze and Intermittent 
Treatment: WAIT 
monteleukast IMP wheeze Acute 
6625 A Pilot Study to Explore the 
Feasibility of Computerised 
CBT for Children 
cognitive behaviour therapy 
 
nonIMP 
 
Emotional disorders 
 
Chronic 
 
6525 AIRS autoinflation nonIMP Otitis media with effusion Chronic 
6030 Atomoxetine HSEN Atomoxetine IMP ADHD Chronic 
7861 Baby wipes trial Cleansing system in baby wipes: 
non-ionic sugar derived surfactants- 
coco-glucoside, lauryl glucoside; 
emollients- glycerine and glyceryl 
oleate, citric acid in a rayon viscose 
and polyester nonwoven fibre blend IMP Atopic eczema/atopic dermatitis Chronic 
11874 CHAFFINCH Trial Pilot fresh fruit non-IMP asthma Chronic 
10428 CLICK-EAST: The 
Edinburgh Autism Social-
attention Trial 
computer-based learning 
programme 
non-IMP autistic spectrum disorder Chronic 
9348 Dolphin Study 1 neurotrophic supplement containing 
docosahexanoic acid (DHA), 
uridine monophosphate (ump) and 
choline along with supportive IMP neurodisabilities in neonates Chronic 
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minerals and vitamins 
6797 Dolphin Study 2 
 
 
 
neurotrophic supplement containing 
docosahexanoic acid (DHA), 
uridine monophosphate (ump) and 
choline along with supportive 
minerals and vitamins IMP CP Chronic 
5286 Evaluation of Telephone 
Administered CBT for 
Young People with OCD 
telephonic vs. face to face cognitive 
behaviour therapy non IMP OCD Chronic 
9666 i-BASIS structured psychosocial parent-
mediated intervention 
nonIMP Autistic spectrum disorder (ASD) Chronic 
5863 IMPACT Brief psychodynamic therapy 
(BPP), cognitive behavioural 
therapy (CBT) and active clinical 
care (ACC)  
non IMP Moderate to severe depression  
8624 Intervention for Parents with 
Young Asthmatic Children 
Group delivered Triple P parenting 
seminars and telephone support 
nonIMP Asthma Chronic 
4227 Kneeblock Study kneeblock and sacral pad non IMP Cerebral Palsy Chronic 
5823 LEAP Study Peanut non IMP Peanut allergy/food hypersensitivity Chronic 
6532 NIRS 
CPAP vs. SiPAP non IMP 
preterm neonates with lung disease 
needing respiratory support Acute 
6251 Nitric Oxide Levels monitoring exhaled Nitric oxide 
levels non IMP Asthma Chronic 
8163 Optigrow Infant Feeding 
Study milk formula non IMP healthy infants Healthy 
2165 PACT trial communication intervention non IMP autistic spectrum disorder Chronic 
9967 Pilot RCT comparing 
Surgery to Observation for 
Intermittent Exotropia surgery vs. active monitoring non IMP Intermittent exotropia Chronic 
11078 Preventing asthma 
exacerbations by avoiding 
mite allergen 
Mite proof bedding nonIMP Asthma Chronic 
6817 STATbiTR exercise programs non IMP CP Chronic 
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7993 Study of Tolerance to Oral 
Peanut 
peanut oral immunotherapy with 
peanut protein IMP peanut allergy Chronic 
8133 Telephone consultations for 
children with inflammatory 
bowel disease 
telephonic vs. face to face 
consultation non IMP IBD Chronic 
10090 Use of sensory blankets for 
children with autistic 
spectrum disorder sensory weighted blankets non IMP ASD Chronic 
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Appendix 17: Recruitment survey questionnaire tool (Chapter 4) 
1. Please enter your ID number 
____________________________________________  
 
2. Please indicate your role with regards to recruitment to the trial 
[ ] Site lead/PI 
[ ] Medical practitioner 
[ ] Research nurse 
[ ] Other 
 
Please describe your role in relation to recruitment to the trial 
____________________________________________  
 
3. Which site/hospital were you recruiting from? 
____________________________________________  
 
4. Have you been involved for the whole trial period? 
[ ] Yes 
[ ] No 
 
Was this during 
[ ] setup/early recruitment period 
[ ] once trial established at site 
 
How long were you involved in recruiting for the trial? (approximately, in months) 
 
 
5. Trial level factors affecting recruitment 
Listed below are trial level factors that commonly affect recruitment. Please indicate whether 
a listed factor was a facilitator or barrier to recruitment to the trial and rate them from -3 to 
+3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
Factors -3 -2 -1 0 +1 +2 +3 
Funding        
Trial design        
Patient inclusion criteria        
Being a drug trial        
Study protocol compared to clinical 
practice 
       
Clinical equipoise        
Previous feasibility assessment        
Previous pilot trial        
Publicity by the trial team        
External publicity        
Trial management        
Protocol amendments        
Seasonal variation        
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6. Site level factors affecting recruitment 
Listed below are site level factors that commonly affect recruitment. Please indicate whether 
a listed factor was a facilitator or barrier to recruitment to the trial and rate them from -3 to 
+3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
Factors -3 -2 -1 0 +1 +2 +3 
Time to open up site        
Recruitment target        
Time to complete administrative work 
related to the trial 
       
Number of trained staff        
Local clinical arrangements        
Choice of recruitment setting        
GCP training        
Data collection process        
Competing local research projects        
Local research culture        
 
7. Patient level factors affecting recruitment 
Listed below are patient level factors that commonly affect recruitment. Please indicate 
whether a listed factor was a facilitator or barrier to recruitment to the trial and rate them 
from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
Factors -3 -2 -1 0 +1 +2 +3 
Consent rate        
Familiarity with experimental treatment        
Patients’/parents’ attitude towards their 
taking experimental medicine or placebo 
       
Patients’/parents’ preference for a particular 
treatment 
       
Patients’/parents’ concerns about side effects 
of new drug 
       
Duration of trial and follow up        
Treatment choice by random allocation        
Additional trial investigations        
Additional travel and extra costs        
Intervention available only in the trial        
Communication between research team and 
patient/parents 
       
Clinician influence        
Language or cultural barriers        
 
8. Clinical Team factors affecting recruitment 
Listed below are clinical team factors that commonly affect recruitment. Please indicate 
whether a listed factor was a facilitator or barrier to recruitment to the trial and rate them 
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from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
Factors -3 -2 -1 0 +1 +2 +3 
Research experience of clinical team        
Presence of designated research 
nurse/practitioner 
       
Availability of designated research team        
Availability of research staff out of hours        
Shift patterns of work        
Motivation of clinical team        
Clinical workload        
Perceived importance of research 
generally in clinical practice 
       
Perceived importance of the particular 
research question 
       
Communication skills of clinical team        
Clinician preference for particular 
treatment 
       
Clinician attitude to involving patients in 
research 
       
Difficulty in approaching patients for 
consent 
       
 
9. Information and consent related factors affecting recruitment  
Listed below are information ad consent related factors that commonly affect recruitment. 
Please indicate whether a listed factor was a facilitator or barrier to recruitment to the trial 
and rate them from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
Factors -3 -2 -1 0 +1 +2 +3 
Amount and complexity of trial 
information provided 
       
Clarity in presentation of trial 
information 
       
Social and emotional dynamics of 
trial discussion 
       
Time and setting of consent seeking        
Senior doctors and nurses seeking 
consent 
       
Experience and training of clinical 
team seeking consent 
       
 
10. Study team factors affecting recruitment 
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Listed below are study team factors that commonly affect recruitment. Please indicate 
whether a listed factor was a facilitator or barrier to recruitment to the trial and rate them 
from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
Factors -3 -2 -1 0 +1 +2 +3 
Motivation of the study team at site        
Communication and coordination 
between study team members at site 
       
Communication and coordination 
between study team at site and CTU 
       
Research experience of PI and study 
team members at site 
       
 
11. What interventions or strategies were applied to overcome any hurdles identified in 
previous questions and how effective were these? 
 
 
 
 
 
12. How would you organise the trial differently to improve recruitment? Please include 
additional comments, if any 
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Appendix 18: MAGNETIC trial sites (Chapter 5) 
SN Hospital sites 
 Sites that recruited 
1 St Thomas Hospital 
2 Royal Devon and Exeter Hospital 
3 Derbyshire Children’s Hospital 
4 Tameside General Hospital 
5 Leicester Royal Infirmary 
6 Royal Albert Edward Infirmary, Wigan 
7 Queens Hospital, Burton 
8 University Hospital of Wales 
9 Royal London Hospital 
10 Countess of Chester Hospital 
11 Macclesfield District General Hospital 
12 Royal Hospital for Sick Children, Glasgow 
13 Sheffield Children’s Hospital 
14 Preston Royal Infirmary 
15 Bristol Royal Children’s Hospital 
16 QMC Nottingham 
17 Victoria Hospital Blackpool 
18 Ormskirk and District Hospital 
19 Wythenshawe Hospital 
20 Birmingham Children’s Hospital 
21 University Hospital of North Staffordshire 
22 Craigavon Area Hospital 
23 Birmingham Heartlands Hospital 
24 Royal Aberdeen Children’s Hospital 
25 University Hospital North Tees 
26 University Hospital Lewisham 
27 Altnagelvin Area Hospital 
28 Southampton General Hospital 
29 Royal Manchester Children’s Hospital 
30 Royal Cornwall Hospital 
 Sites that opened up but could not recruit 
1 Leighton Hospital Crewe 
2 Whiston Hospital 
3 Royal Alexandra Children’s Hospital Brighton 
 Sites that did not open up 
1 Royal Belfast Hospital for Sick Children 
2 Antrim Hospital 
3 Morriston Hospital, Swansea 
4 Fairfield General Hospital 
 
  
324 
 
Appendix 19: MAGNETIC recruitment survey 
1) Please enter your ID number 
 
 
2) Please indicate your role with regards to recruitment to MAGNETIC 
Site lead/PI 
Medical practitioner 
Research nurse 
Other 
 
Please describe your role in relation to recruitment to MAGNETIC 
 
 
3) Which site/hospital were you recruiting from? 
 
 
4) Have you been involved with MAGNETIC for the whole trial period? 
Yes 
No 
 
Was this during 
setup/early recruitment period 
once trial established at site 
 
How long were you involved in recruiting for MAGNETIC? (approximately, in months) 
 
 
 
5) Listed below are trial specific factors that commonly affect recruitment. Please indicate 
whether a listed factor was a facilitator or barrier to recruitment to MAGNETIC and rate 
them from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
-3  -2  -1  0  +1  +2  +3  
Funding 
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Trial design 
       
Patient inclusion 
criteria        
MAGNETIC being a 
drug trial        
Study protocol 
compared to clinical 
practice 
       
Clinical equipoise 
       
Previous feasibility 
assessment        
Previous pilot trial 
       
Publicity by the trial 
team        
External publicity 
       
Trial management 
       
Protocol amendments 
       
Seasonal variation 
       
 
 
 
6) Listed below are site specific factors that commonly affect recruitment. Please indicate 
whether a listed factor was a facilitator or barrier to recruitment to MAGNETIC and rate 
them from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
-3  -2  -1  0  +1  +2  +3  
Time to open up site 
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Recruitment target 
       
Time to complete 
administrative work 
related to the trial 
       
Number of trained staff 
       
Local clinical 
arrangements        
Choice of recruitment 
setting        
GCP training 
       
Data collection process 
       
Competing local 
research projects        
Local research culture 
       
 
 
7) Listed below are patient specific factors that commonly affect recruitment. Please indicate 
whether a listed factor was a facilitator or barrier to recruitment to MAGNETIC and rate 
them from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
-3  -2  -1  0  +1 +2  +3  
Consent rate 
       
Familiarity with 
experimental treatment        
Parent's attitude 
towards their taking 
experimental medicine 
or placebo 
       
327 
 
Parent's preference for 
a particular treatment        
Parent's concerns about 
side effects of new 
drug 
       
Duration of trial and 
follow up        
Treatment choice by 
random allocation        
Additional trial 
investigations        
Additional travel and 
extra costs        
Intervention available 
only in the trial        
Communication 
between research team 
and parents 
       
Clinician influence 
       
Language or cultural 
barriers        
 
 
8) Listed below are clinical team factors that commonly affect recruitment. Please indicate 
whether a listed factor was a facilitator or barrier to recruitment to MAGNETIC and rate 
them from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
-3  -2  -1  0  +1  +2 +3 
Research experience of 
clinical team        
Presence of designated 
research 
nurse/practitioner 
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Availability of 
designated research 
team 
       
Availability of research 
staff out of hours        
Shift patterns of work 
       
Motivation of clinical 
team        
Clinical workload 
       
Perceived importance 
of research generally in 
clinical practice 
       
Perceived importance 
of the particular 
research question 
       
Communication skills 
of clinical team        
Clinician preference 
for particular treatment        
Clinician attitude to 
involving patients in 
research 
       
Difficulty in 
approaching patients 
for consent 
       
 
 
9) Listed below are Information and consent related factors that commonly affect 
recruitment. Please indicate whether a listed factor was a facilitator or barrier to 
recruitment to MAGNETIC and rate them from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
-3  -2  -1  0  +1  +2  
+
3
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Amount and 
complexity of trial 
information provided 
       
Clarity in presentation 
of trial information        
Social and emotional 
dynamics of trial 
discussion 
       
Time and setting of 
consent seeking        
Senior doctors and 
nurses seeking consent        
Experience and 
training of clinical 
team seeking consent 
       
 
10) Listed below are study team factors that commonly affect recruitment. Please indicate 
whether a listed factor was a facilitator or barrier to recruitment to MAGNETIC and rate 
them from -3 to +3 as below:  
-3 strong barrier  
-2 intermediate barrier 
-1 weak barrier  
0 not applicable  
+1 weak facilitator  
+2 intermediate facilitator  
+3 strong facilitator 
 
-3  -2  -1  0  +1  +2  +3  
Motivation of MAGNETIC 
study team at site        
Communication and 
coordination between study 
team members at site 
       
Communication and 
coordination between study 
team at site and CTU 
       
Research experience of PI 
and study team members at 
site 
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11) What interventions or strategies were applied to overcome any hurdles identified in 
previous questions and how effective were these? 
 
 
12) How would you organise MAGNETIC differently to improve recruitment? Please 
include additional comments, if any 
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Appendix 20: Email sent to NRES Queries Line (queries@nres.nhs.uk) on 
18/07/2011 
 
Dear NRES team 
I am a Clinical PhD student in the North West Hub for Trials Methodology Research. 
Could I please request for advice on the following: 
 
MAGNETIC is a randomised, multi-center, placebo controlled study of nebulised 
magnesium in acute severe asthma in children which has been completed in April 2011. 
The Chief Investigator of MAGNETIC and project team from NWHTMR wish to explore 
the recruitment experience of MAGNETIC study teams at sites by conducting an online 
survey collating views of study team members on facilitators and barriers to recruitment, 
effect of various recruitment strategies applied and suggestions for change in organisation 
of future trials such as MAGNETIC. I have attached a project summary for your 
consideration. 
 
Please advise if we would require ethical clearance for this project. Having read your 
‘Defining Research’ guidance it would seem that this survey may not be designated as 
research but as service evaluation of NHS RCTs, however I would be very grateful for 
your advice regarding my interpretation of the guidance in this regard. 
 
I look forward to hearing from you. 
 
Many Thanks 
Geetinder 
 
Dr Geetinder Kaur 
Clinical Research Fellow 
Institute of Child Health 
Alder Hey Hospital 
Liverpool 
 
Response received from NRES Query line on 20/07/2011 
 
Thank you for your further email enquiry.  As you are aware, our leaflet “Defining 
Research”, explains how we differentiate research from other activities, and is published 
at: http://www.nres.npsa.nhs.uk/applications/is-your-project-research/.  
Based on the information you provided, our advice is that the project is not considered to 
be research according to this guidance. It would appear to be Service Evaluation and 
therefore it does not require ethical review by a NHS Research Ethics Committee.  
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If you are undertaking the project within the NHS, you should check with the relevant 
NHS care organisation(s) what other review arrangements or sources of advice apply to 
projects of this type.  Guidance may also be available from the clinical governance office.  
Although ethical review by an NHS REC is not necessary in this case, all types of study 
involving human participants should be conducted in accordance with basic ethical 
principles, such as informed consent and respect for the confidentiality of 
participants.  Also, in processing identifiable data there are legal requirements under the 
Data Protection Act 2000.  When undertaking an audit or service/therapy evaluation, the 
investigator and his/her team are responsible for considering the ethics of their project 
with advice from within their organisation.  University projects may require approval by 
the university ethics committee.   Please refer to our guidance on student research at: 
http://www.nres.npsa.nhs.uk/applications/guidance/research-
guidance/?esctl1654606_entryid62=83668. 
This response should not be interpreted as giving a form of ethical approval or any 
endorsement to your project, but it may be provided to a journal or other body as 
evidence that ethical approval is not required under NHS research governance 
arrangements. 
However, if you, your sponsor/funder or any NHS organisation feel that the project 
should be managed as research, and/or that ethical review by an NHS REC is essential, 
then please write setting out your reasons and we will be pleased to consider your request 
further.   
Where NHS organisations have clarified that a project is not to be managed as research, 
the Research Governance Framework states that it should not be presented as research 
within the NHS. 
 
If you have received advice on the same or a similar matter from a different source (for 
example directly from a Research Ethics Committee (REC) or from an NHS R&D 
department), it would be helpful if you could share the initial query and response received 
if then seeking additional advice through the NRES Queries service. 
 
However, if you have been asked to follow a particular course of action by a REC as part 
of a provisional or conditional opinion, then the REC requirements are mandatory to the 
opinion, unless specifically revised by that REC.  Should you wish to query the REC 
requirements, this should either be through contacting the REC direct or, alternatively, 
the relevant local operational manager. 
 
Regards  
 
Queries Line 
National Research Ethics Service 
National Patient Safety Agency 
4-8 Maple Street 
London 
W1T 5HD  
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Appendix 21: Covering letter for survey questionnaire (Chapter 5) 
Dear  
Thank you for being involved in MAGNETIC.  There has been a huge effort form all 
those involved and, as I am sure you know, we have been successful in recruiting over 
500 children. Some centres managed to recruit well and other had many difficulties, some 
overcome and others not. We are trying to understand what went well and what didn’t go 
so well.   
We are contacting you to gather information on factors which acted as facilitators/barriers 
for recruitment to MAGNETIC and would be grateful if you could share your experiences 
with us. This information will be very useful in designing future trials and will be a part 
of a PhD project for Dr Geetinder Kaur who is a clinical PhD student in the North West 
Hub for Trials Methodology Research under the supervision of Professor Rosalind Smyth 
and Professor Paula Williamson.  
The survey is short and will only take a few minutes to complete via the following link: 
http://edu.surveygizmo.com/s3/583910/MAGNETIC-recruitment-survey 
The survey questionnaire has a list of some commonly reported factors affecting 
recruitment and questions with free text space for additional comments. Please answer all 
the questions and order the factors from -3 to +3 depending on whether you think the 
factor acted as a facilitator (+1 to +3) or a barrier (-1 to -3) or did not affect recruitment at 
your site (0).   
All information provided will be strictly confidential. Your personal details are not 
required for this survey and a unique identification number will be used instead of your 
name when collating responses. Please note that whilst we need to know site details for 
data management purposes, no site will be identified in any publication and the data will 
be treated in strictest confidence within the research team listed in this letter. 
Many thanks  
Kind Regards, 
Dr Colin Powell (Chief Investigator) 
John Lowe (Trial Coordinator) 
Dr Geetinder Kaur (Clinical PhD student) 
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Appendix 22: Scatterplots: Calibrated site recruitment and PI response for 
factors 
Trial level factors 
Fig. I: Relationship between funding and calibrated site recruitment 
 
 
 
Fig. II: Relationship between trial design and calibrated site recruitment 
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Fig. III: Relationship between patient inclusion criteria and calibrated site recruitment 
 
 
 
Fig. IV: Relationship between MAGNETIC being a drug trial and calibrated site 
recruitment  
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Fig. V: Relationship between study protocol compared to clinical practice and calibrated site 
recruitment 
 
 
Fig. VI: Relationship between clinical equipoise and calibrated site recruitment 
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Fig. VII: Relationship between previous feasibility assessment and calibrated site 
recruitment 
 
 
 
Fig. VIII: Relationship between previous pilot trial and calibrated site recruitment  
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Fig. IX: Relationship between publicity by trial team and calibrated site recruitment 
 
 
 
Fig. X: Relationship between external publicity and calibrated site recruitment 
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Fig. XI Relationship between trial management and calibrated site recruitment 
 
 
 
Fig. XII Relationship between trial management and calibrated site recruitment 
 
 
  
340 
 
Fig. XIII Relationship between seasonal variation and calibrated site recruitment 
 
 
Site level factors 
Fig. XIV Relationship between time to open up site and calibrated site recruitment 
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Fig. XV: Relationship between recruitment target and calibrated site recruitment 
 
 
 
Fig. XVI: Relationship between time taken to complete trial related administrative work and 
calibrated site recruitment 
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Fig. XVII: Relationship between number of trained staff and calibrated site recruitment 
 
 
Fig. XVIII: Relationship between time taken to complete trial related administrative work 
and calibrated site recruitment 
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Fig. IXX: Relationship between choice of recruitment setting and calibrated site recruitment 
 
 
 
Fig. XX: Relationship between GCP training and calibrated site recruitment 
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Fig. XXI: Relationship between data collection process and calibrated site recruitment 
 
 
 
Fig. XXII: Relationship between competing local research projects and calibrated site 
recruitment 
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Fig. XXIII: Relationship between local research culture and calibrated site recruitment 
 
 
 
Patient related factors 
Fig. XXIV: Relationship between consent rate and calibrated site recruitment 
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Fig. XXV: Relationship between familiarity with experimental treatment and calibrated site 
recruitment 
 
 
 
Fig. XXVI: Relationship between parents’ attitude towards taking experimental medicine 
and calibrated site recruitment 
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Fig. XXVII: Relationship between parents’ preference for a particular treatment and 
calibrated site recruitment 
 
 
 
Fig. XXVIII: Relationship between parents’ concerns about side effects of new drug and 
calibrated site recruitment 
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Fig.XXIX: Relationship between duration of trial and follow up and calibrated site 
recruitment 
 
 
 
 
Fig. XXX: Relationship between treatment choice by random allocation and calibrated site 
recruitment 
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Fig. XXXI: Relationship between additional trial investigations and calibrated site 
recruitment 
 
 
 
 
Fig. XXXII: Relationship between additional travel and extra costs and calibrated site 
recruitment 
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Fig. XXXIII: Relationship between intervention available only in the trial and calibrated site 
recruitment 
 
 
 
Fig. XXXIV: Relationship between communication between research team and parents and 
calibrated site recruitment 
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Fig. XXXV: Relationship between language and cultural barriers and calibrated site 
recruitment 
 
 
 
Clinical team related factors 
Fig. XXXVI: Relationship between language and cultural barriers and calibrated site 
recruitment 
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Fig. XXXVII: Relationship between presence of designated research nurse/practitioner and 
calibrated site recruitment 
 
 
 
Fig. XXXVIII: Relationship between language and cultural barriers and calibrated site 
recruitment 
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Fig. XXXIX: Relationship between availability of research staff out of hours and calibrated 
site recruitment 
 
 
 
 
Fig. XL: Relationship between shift patterns of work and calibrated site recruitment 
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Fig. XLI: Relationship between motivation of clinical team and calibrated site recruitment 
 
 
 
Fig. XLII: Relationship between clinical workload and calibrated site recruitment 
 
 
 
  
355 
 
Fig. XLIII: Relationship between language and cultural barriers and calibrated site 
recruitment 
 
 
 
Fig. XLIV: Relationship between perceived importance of research question and calibrated 
site recruitment 
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Fig. XLV: Relationship between communication skills of clinical team and calibrated site 
recruitment 
 
 
 
Fig. XLVI: Relationship between clinician preference for particular treatment and 
calibrated site recruitment 
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Fig. XLVII: Relationship between clinician attitude to involving patients in research and 
calibrated site recruitment 
 
 
 
Fig. XLVIII: Relationship between difficulty in approaching patients for consent and 
calibrated site recruitment 
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Fig. XLIX: Relationship between amount and complexity of trial information provided and 
calibrated site recruitment 
 
 
 
Fig. L: Relationship between clarity in presentation of trial information and calibrated site 
recruitment 
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Fig. LI: Relationship between social and emotional dynamics of trial discussion and 
calibrated site recruitment 
 
 
 
Fig. LII: Relationship between time and setting of consent seeking and calibrated site 
recruitment 
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Fig. LIII: Relationship between senior doctors and nurses seeking consent and calibrated site 
recruitment 
 
 
 
Fig. LIV: Relationship between experience and training of clinical team seeking consent and 
calibrated site recruitment 
 
 
  
361 
 
Study Team factors 
Fig. LV: Relationship between motivation of MAGNETIC team at site and calibrated site 
recruitment 
 
 
 
Fig. LVI: Relationship between communication and coordination between study team 
members at site and calibrated site recruitment 
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Fig. LVII: Relationship between communication and coordination between study team at site 
and CTU and calibrated site recruitment 
 
 
 
Fig. LVIII: Relationship between research experience of PI and study team at site and 
calibrated site recruitment 
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Appendix 23: Histogram showing the distribution of calibrated recruitment 
at sites 
 
CR2- Calibrated recruitment at sites 
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Appendix 24: Correlation of calibrated site recruitment with PI responses  
Spearman’s rank correlation 
 Correlation 
co-efficient 
p-value 
Trial level factors   
Funding  .336 0.126 
Trial design .462 0.031 
Patient Inclusion Criteria .212 0.356 
MAGNETIC being a drug trial .488 0.021 
Study protocol compared to clinical practice .184 0.413 
Clinical equipoise .335 0.138 
Previous feasibility assessment .270 0.224 
Previous pilot trial .039 0.867 
Publicity by the trial team .132 0.559 
External publicity .225 0.313 
Trial management .460 0.031 
Protocol amendments .098 0.666 
Seasonal variation .238 0.286 
Site level factors   
Time to open up site .035 0.877 
Recruitment target .131 0.561 
Time to complete administrative work related 
to the trial 
-.073 0.746 
Number of trained staff .155 0.490 
Local clinical arrangements .402 0.071 
Choice of recruitment setting .504 0.017 
GCP training .198 0.378 
Data collection process -.254 0.255 
Competing local research projects -.473 0.026 
Local research culture .007 0.974 
Patient related factors   
Consent rate .553 0.008 
Familiarity with experimental treatment .262 0.239 
Parent's attitude towards their child taking 
experimental medicine or placebo 
.639 0.001 
Parent's preference for a particular treatment .402 0.064 
Parent's concerns about side effects of new 
drug 
.308 0.163 
Duration of trial and follow up .031 0.891 
Treatment choice by random allocation .035 0.876 
Additional trial investigations .110 0.627 
Additional travel and extra costs -.048 0.834 
Intervention available only in the trial -.220 0.326 
Communication between research team and 
parents 
.343 0.118 
Clinician influence .282 0.204 
Language or cultural barriers .426 0.048 
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Clinical team related factors   
Research experience of clinical team .428 0.047 
Presence of designated research 
nurse/practitioner 
.442 0.040 
Availability of designated research team .407 0.060 
Availability of research staff out of hours .396 0.068 
Shift patterns of work .117 0.605 
Motivation of clinical team .330 0.133 
Clinical workload .288 0.193 
Perceived importance of research generally in 
clinical practice 
-.022 0.921 
Perceived importance of the particular 
research question 
.362 0.098 
Communication skills of clinical team .310 0.161 
Clinician preference for particular treatment -.129 0.567 
Clinician attitude to involving patients in 
research 
.266 0.231 
Difficulty in approaching patients for consent .582 0.004 
Information and consent related factors   
Amount and complexity of trial information 
provided 
.507 0.016 
Clarity in presentation of trial information .410 0.058 
Social and emotional dynamics of trial 
discussion 
.250 0.262 
Time and setting of consent seeking .354 0.106 
Senior doctors and nurses seeking consent .364 0.105 
Experience and training of clinical team 
seeking consent 
.217 0.333 
Study team factors   
Motivation of MAGNETIC study team at site .396 0.076 
Communication and coordination between 
study team members at site 
.385 0.085 
Communication and coordination between 
study team at site and CTU 
.507 0.019 
Research experience of PI and study team 
members at site 
.292 0.199 
 
  
366 
 
Linear Regression 
 R R-squared p-value 
Trial level factors    
Funding  0.328 0.108 0.136 
Trial design 0.416 0.173 0.054 
Patient Inclusion Criteria 0.209 0.044 0.363 
MAGNETIC being a drug trial 0.447 0.200 0.037 
Study protocol compared to clinical practice 0.114 0.013 0.612 
Clinical equipoise 0.196 0.038 0.395 
Previous feasibility assessment 0.281 0.079 0.205 
Previous pilot trial 0.071 0.005 0.761 
Publicity by the trial team 0.186 0.035 0.407 
External publicity 0.275 0.076 0.215 
Trial management 0.421 0.177 0.051 
Protocol amendments 0.067 0.005 0.766 
Seasonal variation 0.285 0.081 0.199 
Site level factors    
Time to open up site 0.040 0.002 0.861 
Recruitment target 0.096 0.009 0.670 
Time to complete administrative work related 
to the trial 
0.035 0.001 0.876 
Number of trained staff 0.034 0.001 0.879 
Local clinical arrangements 0.335 0.112 0.138 
Choice of recruitment setting 0.474 0.225 0.026 
GCP training 0.178 0.032 0.427 
Data collection process 0.206 0.042 0.358 
Competing local research projects 0.437 0.191 0.042 
Local research culture 0.017 0.000 0.940 
Patient related factors    
Consent rate 0.534 0.286 0.010 
Familiarity with experimental treatment 0.274 0.075 0.218 
Parent's attitude towards their child taking 
experimental medicine or placebo 
0.639 0.409 0.001 
Parent's preference for a particular treatment 0.377 0.142 0.084 
Parent's concerns about side effects of new 
drug 
0.382 0.146 0.079 
Duration of trial and follow up 0.062 0.004 0.784 
Treatment choice by random allocation 0.005 0.000 0.983 
Additional trial investigations 0.143 0.020 0.526 
Additional travel and extra costs 0.066 0.004 0.772 
Intervention available only in the trial 0.200 0.040 0.371 
Communication between research team and 
parents 
0.223 0.050 0.319 
Clinician influence 0.236 0.056 0.291 
Language or cultural barriers 0.461 0.213 0.031 
Clinical team related factors    
Research experience of clinical team 0.416 0.173 0.054 
Presence of designated research 
nurse/practitioner 
0.406 0.165 0.06 
Availability of designated research team 0.412 0.170 0.057 
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Availability of research staff out of hours 0.279 0.078 0.208 
Shift patterns of work 0.071 0.005 0.754 
Motivation of clinical team 0.290 0.084 0.191 
Clinical workload 0.196 0.038 0.382 
Perceived importance of research generally in 
clinical practice 
0.023 0.001 0.921 
Perceived importance of the particular 
research question 
0.365 0.133 0.095 
Communication skills of clinical team 0.235 0.055 0.293 
Clinician preference for particular treatment 0.011 0.000 0.960 
Clinician attitude to involving patients in 
research 
0.214 0.046 0.339 
Difficulty in approaching patients for consent 0.520 0.271 0.013 
Information and consent related factors    
Amount and complexity of trial information 
provided 
0.425 0.181 0.049 
Clarity in presentation of trial information 0.403 0.162 0.063 
Social and emotional dynamics of trial 
discussion 
0.295 0.087 0.183 
Time and setting of consent seeking 0.287 0.082 0.195 
Senior doctors and nurses seeking consent 0.153 0.024 0.507 
Experience and training of clinical team 
seeking consent 
0.057 0.003 0.801 
Study team factors    
Motivation of MAGNETIC study team at site 0.381 0.146 0.088 
Communication and coordination between 
study team members at site 
0.356 0.126 0.114 
Communication and coordination between 
study team at site and CTU 
0.499 0.249 0.021 
Research experience of PI and study team 
members at site 
0.291 0.085 0.201 
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Appendix 25: Papers citing the recruitment survey tool described in Chapter 4 
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Appendix 26: Requests for permission to use the recruitment survey tool described 
in Chapter 4 
03/05/2015 
 
I would like to start my email by introducing myself. I am Rula Museli, a MSc student-Clinical 
Research at the University of Liverpool. And I am at the final stage- the dissertation- to graduate. I 
choose "Clinical Trials in Jordan: A Survey on Cancer Adult Patients to Determine Factors 
Affecting Patients’ Recruitment into Clinical Trials" as a topic for my dissertation.  
Now, I am trying to prepare the survey and I found the one your honor and your colleagues had 
already developed and was published in a paper under a title: "Developing a survey of barriers and 
facilitators to recruitment in randomized controlled trials" in Trials, 2012, 13: 218. 
I am interested in the "Recruitment Survey" and would like to ask if your kindness allow me to use 
part of it for the survey for my MSc degree.  
I appreciate your consideration.   
Best Regards, 
Rula Museli 
 
 
05/03/2015 
 
Dear Ms. Kaur 
I am writing to seek your permission in using the survey you designed and published. I am doing 
my Masters dissertation in clinical research, and I work in paediatric palliative care at Great 
Ormond Street Hospital. To give you a bit of background, there have been no clinical trials within 
paediatric palliative care, which is an area that is growing in terms of qualitative research, but very 
little in seeking to establish an evidence base in clinical practice. I would be most grateful if you 
permit me to use your questionnaire, which will be used within Great Ormond Street surveying the 
view of clinicians and senior nurses. 
 
Once again thank you for your time, and I look forward to hearing from you. 
 
Maggie Comac 
 
 
 
19/01/2015 
 
Dear Dr Kaur 
I have recently read your paper about the web based survey you developed to assess professionals 
experience in recruiting to trials.  I am currently working with colleagues at the University of 
Leeds in the Leeds Institute of Health Science and the Institute of Clinical Trials on a feasibility 
study which is reliant on adequate recruitment to the trial.  I was wondering if you would be able 
to share a copy of your survey with us for us to consider how we could use it to assess the 
experience of teams in future trials.  Is it available more widely for sharing yet? I look forward to 
hearing from you. 
Best wishes 
Janine 
 
Dr Janine Bestall 
Senior Research Fellow 
Academic Unit of Psychiatry and Behavioural Sciences; Room 2.02 Leeds Institute of Health 
Sciences 101, Clarendon Road, Leeds 
LS2 9LJ 
Phone: 0113 343 5114; e-mail:J.bestall@leeds.ac.uk 
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14/10/2015 
 
Hi Geetinder 
I have just read Kaur et al.: Developing a survey of barriers and facilitators to recruitment in 
randomized controlled trials. Trials 2012 13:218.  I wondered if your questionnaire would be 
helpful for our study and so wish to know if it is publicly available?   We currently have 3 sites 
involved in our pilot study and plan to conduct a larger effectiveness trial.  It is funded by NIHR 
HS-DR. 
Best Wishes 
Gill  
   
Dr Gill Hubbard 
Reader & Co-Director 
Cancer Care Research Centre 
School of Health Sciences 
University of Stirling 
Highland Campus 
Centre for Health Science 
Old Perth Road 
INVERNESS 
IV2 3JH 
  
Tel: + 44 (0) 1463 255649 
Tel direct line: + 44 (0) 1463 255646 
Email: gill.hubbard@stir.ac.uk 
Web: https://sites.google.com/site/gillhubbardstirling/home 
University Web: http://rms.stir.ac.uk/converis-stirling/person/11927 
 
 
20/01/14 
 
Hello Dr. Kaur, 
I read your "Developing a survey pf barriers..." paper and I am wondering if you have a paper in 
progress or completed on the results of your survey that you would be willing to share? We are 
considering using your survey and would like to know the results of your study. Thank you, Janice 
Sabin 
Janice A. Sabin, PhD, MSW 
 Research Assistant Professor, University of Washington Department of Biomedical Informatics 
and Medical Education Box 357240 Seattle, WA 98195 206-616-9421, (c) 206-851-7938 
http://faculty.washington.edu/sabinja/index.html 
 
08/08/2013 
 
I just read your article in trialsjournal and am very interested.  Is it possible for you to send me the 
actual survey? I am a patient advocate who is involved with the development of clinical trials, and 
I think this might be of interest to our research group. 
  
Thank you for considering my request. 
  
Nancy 
  
Nancy Roach 
www.FightColorectalCancer.org 
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Appendix 27: Copy of publications arising from work in this thesis 
